<SEC-DOCUMENT>0001628280-22-014372.txt : 20220513
<SEC-HEADER>0001628280-22-014372.hdr.sgml : 20220513
<ACCEPTANCE-DATETIME>20220513170635
ACCESSION NUMBER:		0001628280-22-014372
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220513
DATE AS OF CHANGE:		20220513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		22923865

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cpix-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:71f09af2-eb91-4470-8350-f575ad603b6a,g:f5c1e857-adec-4283-ba91-4579f8814480,d:a1d36fc2a31344efa67485eba5f161bf--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:cpix="http://www.cumberlandpharma.com/20220331" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80L2ZyYWc6MjM2NzAwZThmYWU0NDY2NGEzY2YwNjAxMzg4MGYwY2MvdGFibGU6MTE2NTk0ZDE5NjY2NGQwYTkxOGU1NTkzMWQzMGE3MTkvdGFibGVyYW5nZToxMTY1OTRkMTk2NjY0ZDBhOTE4ZTU1OTMxZDMwYTcxOV81LTEtMS0xLTIzMzcy_5fd9c0a6-5b6c-4ef0-98ef-73da2529a40f">2022</ix:nonNumeric><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80L2ZyYWc6MjM2NzAwZThmYWU0NDY2NGEzY2YwNjAxMzg4MGYwY2MvdGFibGU6MTE2NTk0ZDE5NjY2NGQwYTkxOGU1NTkzMWQzMGE3MTkvdGFibGVyYW5nZToxMTY1OTRkMTk2NjY0ZDBhOTE4ZTU1OTMxZDMwYTcxOV82LTEtMS0xLTIzMzcy_975a576e-1498-4904-b21d-48bfd55a83c4">Q1</ix:nonNumeric><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80L2ZyYWc6MjM2NzAwZThmYWU0NDY2NGEzY2YwNjAxMzg4MGYwY2MvdGFibGU6MTE2NTk0ZDE5NjY2NGQwYTkxOGU1NTkzMWQzMGE3MTkvdGFibGVyYW5nZToxMTY1OTRkMTk2NjY0ZDBhOTE4ZTU1OTMxZDMwYTcxOV83LTEtMS0xLTIzMzcy_c4e5f167-ef54-4cc7-83f9-c88094fa193d">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80L2ZyYWc6MjM2NzAwZThmYWU0NDY2NGEzY2YwNjAxMzg4MGYwY2MvdGV4dHJlZ2lvbjoyMzY3MDBlOGZhZTQ0NjY0YTNjZjA2MDEzODgwZjBjY183OA_c76ca47f-b7c2-41b5-85f5-fbea1597e3ff">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80L2ZyYWc6MjM2NzAwZThmYWU0NDY2NGEzY2YwNjAxMzg4MGYwY2MvdGV4dHJlZ2lvbjoyMzY3MDBlOGZhZTQ0NjY0YTNjZjA2MDEzODgwZjBjY183OQ_d8cf48e6-7d1c-4c91-88a0-060e926717f5">0001087294</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if17ad389803849e8845be7075058d029_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if88ebbbeffcb449c948e6a903954c826_I20220509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i8f233a458221495a93adac84dff7b497_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644ff4fff14b4f54ad5cdf6cc770dece_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c89fbd5ff1649de916ca18e3a139199_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibedb5ab4be9f4828b6ff4f2b9053cd4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idff02794c5744302a7a96ca85b2b2f66_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb20159ba2734e579f3392f2e79daeab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1d0083118644bf1b61cd8ab51f0651c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie296e6d816494ea481965188b1bfd3f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17901c1bb2d74608877a7c878cad3111_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56165262ecf84c87b423cb5447374724_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id350bef77d574d008a405bc73ebfe1fe_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if554e0ab48004252b12642dddb138333_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i446d1255167148e999d79f66391e2f66_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97cd8436b20f43fca8ed1adbd8f5dc98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i429817e1a880442a9a593ae8851d641d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09d5c2c85fad488185d55a2c1dacd727_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i315c01ee2f6d43d9856f494cb2c0a31d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i715fd504c0c84828baacf0d421460e91_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if31eafab8bfe4d1b94fb61717226d991_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cde581e0d7e4fa0be8fb69e2e2b1b22_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf07c0fa3a084e55ab5d2d0e826c062b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:Segment</xbrli:measure></xbrli:unit><xbrli:context id="ie877302447534894b2d5513d38b31fbb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b5c64a6e224a7291d17215b8e20cac_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice443517d3bd4eacb0f21f2731ff3c9a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29eb8f904a99423e9e75afb35fc798bb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f7afb68d83b46cf9e1efc1a40f6f60d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d669dc1bc564b61a9673076b557bba0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7edbe25bc59c416088d0b62c3c7ba86d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i200c0ccbad3548a4ab7da1ea2e3a57f0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc6fa5f3f3948bab15a2a93c882cb38_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e515d306ed64aeb9f21e8890cae9d55_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4604540a3e34ae8969cd1ce548e7c56_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7faae5cf158490da1a4081a5c49115b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id911eaa5894443c2a98fbc046aa0ba09_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia78b359fdf784449a00e7aa9d754ce29_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdccc9e2bb3149a6a0c56fbbbec9dd0b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i796c57f0f1b3412d8d803b33df824490_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bd2dd746ac5484bada9868db377c71a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c714cbee7e14e928534563714a191c7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b835511e1b4d32814daf525c7b851d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad57998d50b42e28e43f57e0458042e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0daea624eb8d4452969618186921bc8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i098351aedd7d43fe971148fc9b861a98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae86c13d2edd4a3bb59c24847ec261c4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84c1a7a949634b2ca9c4f2cac3729504_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2325bc53765d4db18477773f3a908aeb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f1903407422459a9d2afe8a574e9574_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i8c5daecc32784c3b84e2034c8b84fb28_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i9e9d6ba88f264e658e866ce6a611c696_I20211115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e0ddb33c8e14da08e5d4bf80bbf83c4_I20211115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cpix:BroadwestLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewalterm"><xbrli:measure>cpix:renewalTerm</xbrli:measure></xbrli:unit><xbrli:context id="i6f9bbd3fc1b64e3aaff098e2d4118248_I20100513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08bc631bb3a84b3e911db80c62f763aa_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i289b83d4e5d54057a0a8a4e6c2f1c792_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61780641954246b1a1327370732b7ffa_D20211227-20211227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-27</xbrli:startDate><xbrli:endDate>2021-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i252b48b488b0434e85d14e8d2b0c2868_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91438a451f684b24a2fca503fc14d053_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i393e64896f1e48d1a056d5ef7f775821_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if18a26b0f0ee4feca8ce62bae76cfdec_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75376963bb5c44dd95c8a7c842962c8d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30c0769f6c3c4e2da21df888867dc1bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:FifthAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1994f4e6e7b4be9b7830b35c2aac539_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a86b88298df427db4bc3b73b915632f_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27af9c4796d34881a155e56ca9fd7685_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8197f941295d4acd903690460d5fb886_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic80f9798db0747c1acdd1be19fd4f610_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47ad0a97e0314f8eba21273d51757cd8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42ffe35d0bb445bca3edfba518ae51db_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99eb7be3baca40ca8e4e084c3136775c_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65fbb43d257d44b79182efae8d2e0fd5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ef7c1987e104296b100805721e7adc8_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93eb9b844c7244b59e4acf2535ce2a3d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bf6dd4ac05d40108e2514911c613b85_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic73781ab99bd43f2bb632a84368ba389_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a90c1c0e8b64d6ebbf750ff29642e7a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38e26d699b094a1ca3994c9d4c08e244_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4192a5594914fce8a1e18207ab24bd1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i390596c6353c4e4383db5ca0102868d7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33b531a22e104cd8907be7f1309ea431_I20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i411fb7851cc645fda84082a006d9aae8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8840d2d783664d03833988394492a1b2_I20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90ce8664b55e4a05a9829ae3b930adff_I20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i636282a040df4f679c7f36b32d67a813_D20220103-20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10cdce073f8047ab9cded3432889dbae_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i882c40446970433c9806df95c94da0c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad75b7bb8c1f44d99624874d167e93a3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i973592a5bcc6433aaf22a683d9a22dd5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>cpix:installment</xbrli:measure></xbrli:unit><xbrli:context id="i9c0e77e71ede43e88dd6fd578f76e2e6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i703c37c87b3b4ae1a94069c964a3f5b7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia1d36fc2a31344efa67485eba5f161bf_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTc4_3a910e92-a874-4374-9a24-f45b30069e82">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6MGFlNDljYjUwYzNiNDM3ZGE4YmNjYzU1ZTgwYjFjYTUvdGFibGVyYW5nZTowYWU0OWNiNTBjM2I0MzdkYThiY2NjNTVlODBiMWNhNV8wLTAtMS0xLTIzMzcy_6881eee8-6cde-42d6-8682-08c716de00c3">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xMzA_47765a2c-15d9-40c8-bcaf-90379a0ff953">March 31, 2022</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6M2MzZTIwNWVkMzI3NGIwZDlhOWUwZWZjOTQ2NTE2ZDcvdGFibGVyYW5nZTozYzNlMjA1ZWQzMjc0YjBkOWE5ZTBlZmM5NDY1MTZkN18wLTAtMS0xLTIzMzcy_b681a900-ac96-4b3c-aac2-822b75c9877d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTc0_08d4e48a-ca70-4ede-82c2-ec62f5944618">001-33637</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTgx_34b89e78-6ac3-4bfc-a63a-a271623b3bdb">Cumberland Pharmaceuticals Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified In Its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8wLTAtMS0xLTIzMzcy_e313a7a9-5343-4a5e-bf01-87e49e3a57e6">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8wLTItMS0xLTIzMzcy_6d660aaa-1a2c-425d-b3f5-9d77029fbe1a">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8zLTAtMS0xLTIzMzcyL3RleHRyZWdpb246YTE0MWZjOGJmYmEzNDNhMWJmMTBlNTg2MmIzMmE3NTlfNQ_b18ec93d-9809-4ab2-ab85-88f67d278d3e">2525 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8zLTAtMS0xLTIzMzcyL3RleHRyZWdpb246YTE0MWZjOGJmYmEzNDNhMWJmMTBlNTg2MmIzMmE3NTlfOQ_5acee415-b07f-4c93-9b3a-9f15ee96a64a">Suite 950</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8zLTAtMS0xLTIzMzcyL3RleHRyZWdpb246YTE0MWZjOGJmYmEzNDNhMWJmMTBlNTg2MmIzMmE3NTlfMTM_dcb516dd-e90e-48ab-a7af-090c2480abb2">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8zLTAtMS0xLTIzMzcyL3RleHRyZWdpb246YTE0MWZjOGJmYmEzNDNhMWJmMTBlNTg2MmIzMmE3NTlfMTc_f3d1e39e-dd15-4109-88f5-ebc09a07fd83">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8zLTItMS0xLTIzMzcy_ee342a80-3acc-4b3c-a4c3-eb9b9facc6c6">37203</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTc1_cc162360-b798-42f7-9235-773e5d3d572d">615</ix:nonNumeric>) <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTc2_493c73d5-030b-4d82-83eb-186777d77266">255-0068</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"></td><td style="width:31.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6NzEzNTg4NjRiNWI5NDEyYzk5Yzg4YjdjZGQ2NGIxZDQvdGFibGVyYW5nZTo3MTM1ODg2NGI1Yjk0MTJjOTljODhiN2NkZDY0YjFkNF8yLTAtMS0xLTIzMzcy_12fbdf17-d3f1-43e1-9493-604e604ba828">Common stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6NzEzNTg4NjRiNWI5NDEyYzk5Yzg4YjdjZGQ2NGIxZDQvdGFibGVyYW5nZTo3MTM1ODg2NGI1Yjk0MTJjOTljODhiN2NkZDY0YjFkNF8yLTItMS0xLTIzMzcy_dbfe46a3-549b-4f4b-9049-81aeac4809a4">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6NzEzNTg4NjRiNWI5NDEyYzk5Yzg4YjdjZGQ2NGIxZDQvdGFibGVyYW5nZTo3MTM1ODg2NGI1Yjk0MTJjOTljODhiN2NkZDY0YjFkNF8yLTQtMS0xLTIzMzcy_af582e1b-741b-4069-808a-701a58954e09">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTc3_07268e6e-23dc-48bb-8165-c67ae3c30f97">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTcx_7a250d74-e21f-4f6c-bf0b-9818d550e893">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6NDQxMzYzZmUyNDIyNGIxNGJkZjkyZjdhNmMzODQwOTkvdGFibGVyYW5nZTo0NDEzNjNmZTI0MjI0YjE0YmRmOTJmN2E2YzM4NDA5OV8xLTAtMS0xLTIzMzcy_3ceb769b-9917-447b-a5a3-2c442a761cff">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6NDQxMzYzZmUyNDIyNGIxNGJkZjkyZjdhNmMzODQwOTkvdGFibGVyYW5nZTo0NDEzNjNmZTI0MjI0YjE0YmRmOTJmN2E2YzM4NDA5OV8xLTUtMS0xLTIzMzcy_b66de79c-49a7-4137-bfba-8166164d81b7">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6NDQxMzYzZmUyNDIyNGIxNGJkZjkyZjdhNmMzODQwOTkvdGFibGVyYW5nZTo0NDEzNjNmZTI0MjI0YjE0YmRmOTJmN2E2YzM4NDA5OV8yLTItMS0xLTIzMzcy_8dee71ec-c8e0-458f-bd21-9450da136724">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to&#160;Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTcy_b91918ea-867e-46dd-b329-b9c530e59677">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <ix:nonFraction unitRef="shares" contextRef="if88ebbbeffcb449c948e6a903954c826_I20220509" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTM2_6b4e095a-1479-4475-b3c1-db84c78458ed">14,766,492</ix:nonFraction> shares of common stock as of May&#160;9, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:9pt"><span><br/></span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.469%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_10">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;padding-right:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_13">Item&#160;1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_13">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_16">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_19">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_22">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_22">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_25">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_25">4</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_28">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_28">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_58">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_58">16</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_79">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_79">27</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_82">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_82">27</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_85">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_85">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_88">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_88">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_91">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_91">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_94">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_94">28</a></span></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_97">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_97">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_100">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia1d36fc2a31344efa67485eba5f161bf_100">30</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ia1d36fc2a31344efa67485eba5f161bf_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_13"></div><div style="-sec-extract:summary;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements (Unaudited)</span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_16"></div><div style="-sec-extract:summary;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMy0xLTEtMS0yMzM3Mg_8cca0f5e-30bd-4a68-9122-8e6a9c9998f0">17,266,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMy0zLTEtMS0yMzM3Mg_58bd1f3d-a928-4d9e-b2a8-7275fbf71428">27,040,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfNS0xLTEtMS0yMzM3Mg_3959dabd-3c92-4e2a-b428-275036d78899">14,635,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfNS0zLTEtMS0yMzM3Mg_67c17f33-6ad1-4928-8f0c-f4b398d8b458">6,877,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfNi0xLTEtMS0yMzM3Mg_05b27725-bc49-42fa-ba7f-2d13e6a9992c">9,878,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfNi0zLTEtMS0yMzM3Mg_e7178dca-924b-47cc-9898-1d45dbab0182">8,429,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfNy0xLTEtMS0yMzM3Mg_3cfc146b-a73a-46ed-9fe3-ab1c2a575b64">3,561,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfNy0zLTEtMS0yMzM3Mg_0844e8e7-0a99-48c6-8492-a3e1b66d9197">3,339,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfOC0xLTEtMS0yMzM3Mg_cc4e6165-18ce-44fb-991e-2908bab2738d">45,341,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfOC0zLTEtMS0yMzM3Mg_13cb60be-2ba3-4084-b50d-c19d02ca55a5">45,688,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfOS0xLTEtMS0yMzM3Mg_e0975b68-b678-486e-84af-520244a1cddb">10,593,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfOS0zLTEtMS0yMzM3Mg_6f5a6075-59b5-466f-a5f0-e0eb6dafdf48">9,048,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTAtMS0xLTEtMjMzNzI_9fd8c862-977c-45f3-ae3f-a568ac31b5a9">409,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTAtMy0xLTEtMjMzNzI_5482f006-9daf-4e6c-93e8-7eae63db9fd1">442,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTEtMS0xLTEtMjMzNzI_7a1cbeb0-ebc8-4bd6-a3ca-5c68b765996b">34,479,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTEtMy0xLTEtMjMzNzI_a0099788-a762-4f22-8018-e6dc0d0d14fa">23,954,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTItMS0xLTEtMjMzNzI_40dc8eee-5637-4a8d-b085-8eb4906b3400">1,932,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTItMy0xLTEtMjMzNzI_d00e4fba-f530-44af-b823-78938a93863b">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTMtMS0xLTEtMjMzNzI_544a9768-6e8f-4f0e-bb03-2237d301c2c2">761,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTMtMy0xLTEtMjMzNzI_5fdef202-dfc1-4d8e-a473-000a7281df65"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTMtMy0xLTEtMjMzNzI_8a50daf5-f64a-4c9f-8246-e2bfaf5dbbd8">1,024,200</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTQtMS0xLTEtMjMzNzI_28410087-5507-42d6-a35f-73f483c89861">3,178,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTQtMy0xLTEtMjMzNzI_3dcda24a-267f-4022-8d97-e37cbaf8089f">3,419,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTUtMS0xLTEtMjMzNzI_1bd19d27-f7e4-42ea-9914-4d1f2c31c112">96,697,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTUtMy0xLTEtMjMzNzI_d95b8f85-9173-4f82-ae66-f35f1d19c0ea">84,459,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTgtMS0xLTEtMjMzNzI_34d3000e-6541-4cbf-ae22-c66baa167356">11,447,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTgtMy0xLTEtMjMzNzI_848b81b3-ebb4-4494-8b04-cf9d0b16ce27">9,640,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTktMS0xLTEtMjMzNzI_11a58c38-7098-4cf9-8477-e10f513335b9">766,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTktMy0xLTEtMjMzNzI_47dcec09-9bcd-4d06-abb6-359b2949c82e"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTktMy0xLTEtMjMzNzI_ceccbe19-e4da-4ad8-9d53-bbd7b8f1b82b">969,677</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjAtMS0xLTEtMjMzNzI_d0203267-adb3-41c0-bf51-97fde7e41b1e">12,343,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjAtMy0xLTEtMjMzNzI_6ee7ebd1-d74c-4719-a47d-cb457614b9e2">8,668,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjEtMS0xLTEtMjMzNzI_e9c7fb67-b6e2-4fa0-906f-461fd50946bd">24,557,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjEtMy0xLTEtMjMzNzI_6fdfe7fa-50c5-4642-81c6-b868554859f7">19,278,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjItMS0xLTEtMjMzNzI_7f88d0a8-b5f7-47af-bec2-b495ee348a17">20,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjItMy0xLTEtMjMzNzI_e40c1958-8cfa-4876-bcad-166f3c0e7ef2">15,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjMtMS0xLTEtMjMzNzI_b97cc6d4-42fa-4fdc-a454-29257c133fec">22,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjMtMy0xLTEtMjMzNzI_4418b772-efef-4aee-b316-006e5dc37f97"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjMtMy0xLTEtMjMzNzI_b3e1eb15-f394-468a-bdf8-0aae1ef1e270">90,016</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjQtMS0xLTEtMjMzNzI_9e9fe7bd-3d2b-4cc3-9e66-314fbe5cc55b">11,323,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjQtMy0xLTEtMjMzNzI_6b82a70e-3720-49b1-96f0-d48bc0c91ff2">7,488,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjUtMS0xLTEtMjMzNzI_f16126b2-b47c-4d7d-88c4-7771c4a8923d">55,903,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjUtMy0xLTEtMjMzNzI_56c73add-7811-48bd-bcfe-7be178ba0f4b">41,857,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjYtMS0xLTEtMjMzNzI_de5907b2-f242-483b-8050-be25bb014d5b"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjYtMy0xLTEtMjMzNzI_3f665f4b-9253-441d-ada8-ab67aed7400c"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;<ix:nonFraction unitRef="usdPerShare" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="INF" name="us-gaap:CommonStockNoParValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY18xNw_d83304e6-7c01-4966-abb0-293f332ca896"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="INF" name="us-gaap:CommonStockNoParValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY18xNw_ec70afa5-0f1c-4523-ab4a-ad8e23ccebe3">no</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY18zMQ_bf4657bb-7d96-48ba-840a-26b6c719a205"><ix:nonFraction unitRef="shares" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY18zMQ_c1d32118-0bbf-4c49-97b0-30b7cde60fc2">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY181Mw_210106f1-4ea6-47e7-8c78-c84950ac7f68"><ix:nonFraction unitRef="shares" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY181Mw_4050a7e4-55e3-48cd-ac58-a5a665b079cf">14,730,760</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY182MA_82650b84-f2ba-4684-9c7b-763f04c848b9"><ix:nonFraction unitRef="shares" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY182MA_f12c0592-7354-43fa-9a3c-91c5a12c1824">14,742,754</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2022 and December 31, 2021 , respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMS0xLTEtMjMzNzI_d2dcab0a-303f-4add-81e0-440a9a287da8">48,046,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMy0xLTEtMjMzNzI_5f7a433c-678e-4402-8fdb-6a0acc54d39b">48,452,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzAtMS0xLTEtMjMzNzI_2ceee3c7-bf88-42b8-8406-d2a1aff95474">7,023,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzAtMy0xLTEtMjMzNzI_f9d9fb2e-4f01-469a-908e-db6a079749a9">5,638,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzEtMS0xLTEtMjMzNzI_9ef8a504-dd45-4467-b0fb-ca472d2b7fbc">41,022,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzEtMy0xLTEtMjMzNzI_29b8fc8c-2560-4375-af6d-97315e35593f">42,814,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzItMS0xLTEtMjMzNzI_cdea89cf-4c3c-4a06-82eb-798f5dd980a8">229,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzItMy0xLTEtMjMzNzI_94c68ae5-bbc3-4ea7-b4b5-0149f16476d5">212,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzMtMS0xLTEtMjMzNzI_671956bc-8c40-47e9-8037-e9b48f4f5a9d">40,793,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzMtMy0xLTEtMjMzNzI_6e4149b7-3b5d-455e-85ac-10e5b6016510">42,601,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzQtMS0xLTEtMjMzNzI_d06983f6-8449-484b-a019-7952a87dc6b8">96,697,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzQtMy0xLTEtMjMzNzI_63cc0b19-31d4-4ae6-a22e-ada19b8d2340">84,459,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ia1d36fc2a31344efa67485eba5f161bf_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMi01LTEtMS0yMzM3Mg_6e275429-c3df-4b27-985c-794d29917aea">11,175,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMi03LTEtMS0yMzM3Mg_cbfce169-1185-414a-9c34-971e102e72bb">10,537,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNC01LTEtMS0yMzM3Mg_c0440576-cd7a-4389-b0cc-ac9e782138da">2,211,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNC03LTEtMS0yMzM3Mg_6b36a5d3-1674-4dae-aec4-cd193803b27d">2,417,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNS01LTEtMS0yMzM3Mg_165e1b6d-e9cd-4313-93c4-a3b717f95dd8">4,614,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNS03LTEtMS0yMzM3Mg_de6feec4-e964-4591-a4a7-7be741a2749c">3,787,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNi01LTEtMS0yMzM3Mg_5aa5d2af-d775-46c5-b420-57ec230ff2d3">1,745,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNi03LTEtMS0yMzM3Mg_9056a6a8-4808-4b67-8d39-6c77d75ce251">1,257,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNy01LTEtMS0yMzM3Mg_a5d5dc53-d207-47e2-a08c-01ec2b4b9193">2,302,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNy03LTEtMS0yMzM3Mg_780de144-8953-477c-a9b0-dd749356a42b">2,230,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfOC01LTEtMS0yMzM3Mg_4a644832-59ba-41fe-837c-f6f9639bac42">1,593,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfOC03LTEtMS0yMzM3Mg_fa38d890-7c78-487e-939a-cb78a79be9bc">1,168,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfOS01LTEtMS0yMzM3Mg_f384f70d-fea6-40b0-8391-62d9f655d7ad">12,467,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfOS03LTEtMS0yMzM3Mg_ed45f087-0d91-4d7b-95fc-aeb420ed3fbc">10,861,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTAtNS0xLTEtMjMzNzI_8aaa5fed-ffa3-4fe8-9aec-fb9b7503bef2">1,291,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTAtNy0xLTEtMjMzNzI_7f7c85c8-b276-432c-b377-6a32ca260f6b">324,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTEtNS0xLTEtMjMzNzI_e5b2096f-cab0-42a9-ac6a-ce52317a345a">16,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTEtNy0xLTEtMjMzNzI_9d64e3f4-faa7-4b88-af67-44dcae1d9fa6">5,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTMtNS0xLTEtMjMzNzI_2bf3158b-e67f-4152-859d-efa885edde4f">119,575</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTMtNy0xLTEtMjMzNzI_26089730-fe8c-45bb-acf1-62fdb5432629">24,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTQtNS0xLTEtMjMzNzI_f3623599-fe2c-4032-a828-8414aceee476">1,395,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTQtNy0xLTEtMjMzNzI_383b2977-95e8-4468-b004-9bca4b196fdd">343,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTUtNS0xLTEtMjMzNzI_44400ef6-0bd8-4c9d-ab19-096b9ad02b19">6,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTUtNy0xLTEtMjMzNzI_ff12372a-6095-4233-a43e-ccf58e148a30">7,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTYtNS0xLTEtMjMzNzI_e16771ea-1f72-40f2-9cbb-b700bb4beeb9">1,402,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTYtNy0xLTEtMjMzNzI_d538414a-a6eb-40bb-a03c-58c11776bdf2">350,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644ff4fff14b4f54ad5cdf6cc770dece_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTctNS0xLTEtMjMzNzI_37660da1-e720-440b-b27a-0d3f909bae4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c89fbd5ff1649de916ca18e3a139199_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTctNy0xLTEtMjMzNzI_47f6dff7-ea4a-4e0f-9347-01f1570319b1">495,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTgtNS0xLTEtMjMzNzI_f9cafc37-cd39-476f-8e48-097f96023c4e">1,402,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTgtNy0xLTEtMjMzNzI_629108db-6a72-494f-acc0-9dc48131b227">144,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTktNS0xLTEtMjMzNzI_ee9111ca-f780-466a-8b74-497ec5cbbba9">17,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTktNy0xLTEtMjMzNzI_b5f2aa2c-3bcd-45f5-a778-7f77d4ee4561">22,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjAtNS0xLTEtMjMzNzI_d47ce715-7315-416e-9f2b-346787b1d82f">1,385,253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjAtNy0xLTEtMjMzNzI_f9f2e69f-f791-4990-b09b-74273cfec55c">166,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjItNS0xLTEtMjMzNzI_91900bb6-ac37-449e-9488-d06c389d3e5e">0.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjItNy0xLTEtMjMzNzI_6e9a0ba7-cb19-41da-b3cb-f2a47a7bb021">0.02</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjMtNS0xLTEtMjMzNzI_5bb7b451-48ff-48e7-9e1d-0ac17c168ff1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjMtNy0xLTEtMjMzNzI_41a8ba4e-5efa-4140-9532-5091f0a11d90">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjQtNS0xLTEtMjMzNzI_2745c57b-9566-4e89-a7b5-1f8c8092058d">0.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjQtNy0xLTEtMjMzNzI_2f2b9fe5-29af-45b6-ad88-19ef178bc238">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjYtNS0xLTEtMjMzNzI_38ad84c0-b180-4d07-b009-b3c817bb1d51">0.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjYtNy0xLTEtMjMzNzI_76486850-ef77-4fa1-abed-e5315d817309">0.02</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjctNS0xLTEtMjMzNzI_a66eaeb2-3810-4ff6-b631-6843d83fa93c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjctNy0xLTEtMjMzNzI_fafaa495-3117-41d2-8a9a-21a442603508">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjgtNS0xLTEtMjMzNzI_d02c4391-ac77-4318-85da-15415fce9750">0.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjgtNy0xLTEtMjMzNzI_678d83db-a7f5-4ea5-b6d2-2c7ce1aef86f">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMzAtNS0xLTEtMjMzNzI_03c21247-7439-4fc0-8c40-8c657597cfa6">14,691,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMzAtNy0xLTEtMjMzNzI_a7d7824d-e641-4a2e-84d3-0a37e4253a0d">14,974,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMzEtNS0xLTEtMjMzNzI_62d62e1e-5d57-4b99-9eb6-adc2215f3c4d">14,691,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMzEtNy0xLTEtMjMzNzI_5994851d-a842-4f3d-b9ef-0ca12abf9025">15,244,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ia1d36fc2a31344efa67485eba5f161bf_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMy0xLTEtMS0yMzM3Mg_648c4565-9eb3-492c-a4e0-f401c4fd29b8">1,402,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMy0zLTEtMS0yMzM3Mg_46c818fc-17c4-4744-abf7-6233a3a3f307">144,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfNC0xLTEtMS0yMzM3Mg_9aafd138-4e05-4979-a8ab-be9670dcad98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfNC0zLTEtMS0yMzM3Mg_07ab9ef4-a926-480b-bf6c-b7607c45e752">495,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfNS0xLTEtMS0yMzM3Mg_4a6042cb-6f47-484e-a07b-3e042744c5f7">1,402,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfNS0zLTEtMS0yMzM3Mg_7dbc6b58-3065-4f53-96ed-2d90afbace99">350,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfNy0xLTEtMS0yMzM3Mg_620ef460-0237-4b63-8366-e74d97c2c7e5">1,653,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfNy0zLTEtMS0yMzM3Mg_b82c4b75-e228-4ed1-b013-e0128520f72f">1,227,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfOC0xLTEtMS0yMzM3Mg_ceda5a50-b9e6-4a47-b620-40fd63b3e3e6">159,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfOC0zLTEtMS0yMzM3Mg_6807f60d-d15d-4138-9c23-3f55bac33cd0">162,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in non-cash contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfOS0xLTEtMS0yMzM3Mg_d48c8b94-9e3d-4cbf-ac07-361763529e8e">370,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfOS0zLTEtMS0yMzM3Mg_88b2cd55-ae01-4531-a81f-72bc2081dda6">280,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTAtMS0xLTEtMjMzNzI_23173c42-4d80-45e3-9c03-053453baaee7">222,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTAtMy0xLTEtMjMzNzI_cec9896f-cd4f-4f64-a362-c2a1ec13d86d">76,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in noncash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTEtMS0xLTEtMjMzNzI_122248ba-b8b9-414f-9a8a-00685e725e90">2,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTEtMy0xLTEtMjMzNzI_c5d49518-714d-4981-8194-3b1141a4b791">13,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTQtMS0xLTEtMjMzNzI_2cbeeb01-9444-49bc-94a9-7055677c8f36">7,758,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTQtMy0xLTEtMjMzNzI_fd68a66c-12f0-45f3-8a5d-e471b83cbc9c">171,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTUtMS0xLTEtMjMzNzI_1bc70e14-c1ba-4798-ae17-9916852f6d04">2,271,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTUtMy0xLTEtMjMzNzI_f7f39ce3-e4a4-4701-ad2a-16ec65c10796">1,868,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTYtMS0xLTEtMjMzNzI_2f83c137-18a3-423f-866f-c28bc56eb0df">239,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTYtMy0xLTEtMjMzNzI_d1e6777b-d143-41fc-9f62-444e8618f46a">507,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTctMS0xLTEtMjMzNzI_34bceb5a-91f4-4336-812b-7334cb115cf4">4,461,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" sign="-" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTctMy0xLTEtMjMzNzI_7a20c812-6c08-4a6f-a71b-89ef6d211f5d">1,311,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTgtMS0xLTEtMjMzNzI_000893ee-bc76-43e1-b5db-a5582ed55964">371,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTgtMy0xLTEtMjMzNzI_fdb638f4-e11a-4d59-ad53-d5216e2f9012">299,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTktMS0xLTEtMjMzNzI_91fe0995-ce1d-47f2-9860-1c84d6475ca7">150,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTktMy0xLTEtMjMzNzI_4701f449-31c7-4cef-91ba-b3552a5d935e">1,290,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjAtMS0xLTEtMjMzNzI_b66f5944-e413-4bf9-8125-701e42e6f2f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjAtMy0xLTEtMjMzNzI_a97a5810-fe26-4db4-8c2e-91db95b462ff">495,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjEtMS0xLTEtMjMzNzI_872bb16c-4a38-4128-87d2-cca00daa7a1b">150,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjEtMy0xLTEtMjMzNzI_7a779cdc-b2cd-4475-9ec7-bb114b92437d">1,785,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjMtMS0xLTEtMjMzNzI_dbf34d5c-f897-473a-b4e4-54057c9a7abc">26,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjMtMy0xLTEtMjMzNzI_3fd72162-7877-4ed3-aaaa-6bfdca0a73d2">19,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note receivable investment funding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjUtMS0xLTEtMjMzNzI_401872ee-878b-4564-af54-361fefee0afd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjUtMy0xLTEtMjMzNzI_04c4246e-2f4d-440a-9b0b-60241c1fe4bd">200,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjYtMS0xLTEtMjQ5NzU_21cc3fc2-ba03-4b90-9a01-e6a09c5b2893">13,500,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjYtMy0xLTEtMjQ5NzU_3754baa3-2f41-41f0-a628-3833d98d3a13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjYtMS0xLTEtMjMzNzI_08c0812b-5a41-4d55-b62a-70e20f9b480a">14,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjYtMy0xLTEtMjMzNzI_62ae80a6-3363-48e2-b4c4-af2857762649">98,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjctMS0xLTEtMjMzNzI_e05db191-20b9-4d2d-a750-8f5eb3d6945f">13,541,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjctMy0xLTEtMjMzNzI_1d60514a-0571-4279-8f79-2a89788df9de">318,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzAtMS0xLTEtMjMzNzI_740a0f1a-4eac-4f7e-920f-eb8d89aef4c1">20,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzAtMy0xLTEtMjMzNzI_5f3c19fe-9d18-46f3-b7e7-d23ac28f5232">15,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments on line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzEtMS0xLTEtMjMzNzI_116ab87c-8e18-4d47-af37-068b681be286">15,000,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzEtMy0xLTEtMjMzNzI_c63a4fce-f5f4-4b11-8b54-519f64d8d110">15,000,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzItMS0xLTEtMjMzNzI_63956c06-41c3-4289-83b2-d596c4d282b8">501,505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzItMy0xLTEtMjMzNzI_8b3df205-fdc3-452b-a6b8-153de2d73d14">995,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzQtMS0xLTEtMjMzNzI_a0b3da1f-3d1d-4849-9774-a68758f03440">580,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzQtMy0xLTEtMjMzNzI_791eb824-1999-40e7-8cfb-d159af39f353">302,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzUtMS0xLTEtMjMzNzI_cf212e92-4f35-4338-a8f4-c0f676a29f87">3,918,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzUtMy0xLTEtMjMzNzI_6ed57a59-21a7-478b-b9c4-e6261fc308a6">1,298,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzYtMS0xLTEtMjMzNzI_29153ff5-2ccc-4aca-955b-40652107123b">9,774,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzYtMy0xLTEtMjMzNzI_5f342f0b-2d9f-459e-aacc-efbab5501250">169,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzctMS0xLTEtMjMzNzI_62a0d9b4-af3d-4ef2-8464-95f1166af76f">27,040,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedb5ab4be9f4828b6ff4f2b9053cd4b_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzctMy0xLTEtMjMzNzI_7fa4ced9-2b93-493d-be77-7f21957e867f">24,753,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzgtMS0xLTEtMjMzNzI_93c04fac-3b88-46be-a0ce-9c43f3f0246e">17,266,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idff02794c5744302a7a96ca85b2b2f66_I20210331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzgtMy0xLTEtMjMzNzI_8e6df392-7aed-433c-a4f8-539db300e058">24,922,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ia1d36fc2a31344efa67485eba5f161bf_25"></div><hr style="page-break-after:always"/><div style="min-height:33.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb20159ba2734e579f3392f2e79daeab_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMi0xLTEtMS0yMzM3Mg_1b68654f-e8b7-439f-8574-d07430792094">14,988,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb20159ba2734e579f3392f2e79daeab_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMi0zLTEtMS0yMzM3Mg_6894126e-8489-49ec-990c-f9f51e79a443">49,121,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1d0083118644bf1b61cd8ab51f0651c_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMi01LTEtMS0yMzM3Mg_7dacbae6-3289-4db2-b4c3-b000a78999e3">2,131,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie296e6d816494ea481965188b1bfd3f5_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMi03LTEtMS0yMzM3Mg_8e1d19d9-2cda-4c9b-865b-77071d303043">117,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedb5ab4be9f4828b6ff4f2b9053cd4b_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMi05LTEtMS0yMzM3Mg_72585d0b-8f40-47b4-ba93-9ec9795d1962">46,873,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMy0xLTEtMS0yMzM3Mg_d783e853-de85-4413-ad82-3bb670fb0996">187,759</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMy0zLTEtMS0yMzM3Mg_ab24f539-5076-49d3-acfe-c54ab42a59ea">162,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMy05LTEtMS0yMzM3Mg_808347cf-007e-4854-a1f4-ccb5f51d3efe">162,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNC0xLTEtMS0yMzM3Mg_deeeb198-4d64-493f-a03d-69a9c0036276">91,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNC0zLTEtMS0yMzM3Mg_146ab648-4887-46a0-8554-1c8711b989f7">303,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNC05LTEtMS0yMzM3Mg_183d411e-5d24-491b-943e-f5d2d4724399">303,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17901c1bb2d74608877a7c878cad3111_D20210101-20210331" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNS01LTEtMS0yMzM3Mg_cb2199d8-9202-4c70-861f-59fb83ccaa15">166,828</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56165262ecf84c87b423cb5447374724_D20210101-20210331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNS03LTEtMS0yMzM3Mg_6b926014-75f0-4598-a80f-d5e5cc28aa43">22,167</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNS05LTEtMS0yMzM3Mg_1f28a636-8240-4eec-9db1-3e78ef1ea7ac">144,661</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id350bef77d574d008a405bc73ebfe1fe_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNi0xLTEtMS0yMzM3Mg_66a79d98-45cd-4b79-80d4-8b5c7d43ee11">15,084,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id350bef77d574d008a405bc73ebfe1fe_I20210331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNi0zLTEtMS0yMzM3Mg_2806c0b5-a282-40b6-8a39-c03b54928b2d">48,981,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if554e0ab48004252b12642dddb138333_I20210331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNi01LTEtMS0yMzM3Mg_0f9b190d-a79d-4cc7-839e-118b96953da8">1,964,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i446d1255167148e999d79f66391e2f66_I20210331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNi03LTEtMS0yMzM3Mg_d3bcd8fb-cdc6-4dcc-8bc1-b3631e14cd52">139,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idff02794c5744302a7a96ca85b2b2f66_I20210331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNi05LTEtMS0yMzM3Mg_0f859525-1119-4960-990d-7b9e1db30a40">46,877,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97cd8436b20f43fca8ed1adbd8f5dc98_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMi0xLTEtMS0yMzM3Mg_5c94cf90-9ec3-4ceb-a6b6-99faaff79b70">14,742,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97cd8436b20f43fca8ed1adbd8f5dc98_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMi0zLTEtMS0yMzM3Mg_8f4f02cb-d466-4580-9769-e3a5ebd0f672">48,452,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i429817e1a880442a9a593ae8851d641d_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMi01LTEtMS0yMzM3Mg_78ffa789-faa7-418f-aec4-ff1b8ff67ada">5,638,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09d5c2c85fad488185d55a2c1dacd727_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMi03LTEtMS0yMzM3Mg_fde019a4-beab-4680-901e-0c138533c1e5">212,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMi05LTEtMS0yMzM3Mg_6845a75f-018c-4f8e-90a4-4b0ea46399bd">42,601,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMy0xLTEtMS0yMzM3Mg_5e3a2ce9-025d-4c97-9c9e-fed0b7ac214a">162,155</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMy0zLTEtMS0yMzM3Mg_0b629f99-7b8a-4b57-b41b-1f9e0f0ef124">159,901</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMy05LTEtMS0yMzM3Mg_735a38c2-8817-432c-9469-c4c1a145b2d8">159,901</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNC0xLTEtMS0yMzM3Mg_1e874a68-856a-4474-a646-41a5ccac7081">174,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNC0zLTEtMS0yMzM3Mg_39c6c449-2be6-442f-9961-a9e6d06bc44d">566,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNC05LTEtMS0yMzM3Mg_78ecf884-61e8-48ec-902b-9fa994144d3e">566,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i315c01ee2f6d43d9856f494cb2c0a31d_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNS01LTEtMS0yMzM3Mg_e16d10d2-6b9e-40a0-8bd1-62ca8e709520">1,385,253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i715fd504c0c84828baacf0d421460e91_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNS03LTEtMS0yMzM3Mg_c56ecbfc-2ecf-4167-86d9-b897dc08292b">17,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNS05LTEtMS0yMzM3Mg_c51a560f-a456-4ffe-82c9-af99d9535966">1,402,433</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if31eafab8bfe4d1b94fb61717226d991_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNi0xLTEtMS0yMzM3Mg_821bf56e-11e5-4ed7-baa4-21463fca6d54">14,730,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31eafab8bfe4d1b94fb61717226d991_I20220331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNi0zLTEtMS0yMzM3Mg_88a66238-d961-4193-aa71-f607047ee6d8">48,046,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cde581e0d7e4fa0be8fb69e2e2b1b22_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNi01LTEtMS0yMzM3Mg_42ff4642-0be0-4b5e-83be-a584354cd937">7,023,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf07c0fa3a084e55ab5d2d0e826c062b_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNi03LTEtMS0yMzM3Mg_73dcf55c-2da2-4bf8-94b3-6f9a825570ba">229,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNi05LTEtMS0yMzM3Mg_6dc170f9-de1a-49b3-ba9c-30290ffa7daa">40,793,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ia1d36fc2a31344efa67485eba5f161bf_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_31"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zMS9mcmFnOjFkNWQ0ZmY1MjNjZDRjMTk5Nzc0N2ZkNTBhYzU5ZDQ0L3RleHRyZWdpb246MWQ1ZDRmZjUyM2NkNGMxOTk3NzQ3ZmQ1MGFjNTlkNDRfMTAwMzM_6736a951-fb36-4417-a411-48170dc2e7af" continuedAt="i50bc8c38dcce477bb77345c617248b9e" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i50bc8c38dcce477bb77345c617248b9e" continuedAt="i3ce973300e01462b939fb77427a3d30f"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products.  The Company's primary target markets are hospital acute care, oncology, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be served effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital, oncology and field sales forces in the United States.  We are continuing to build a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2021, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 (the &#8220;2021 Annual Report on Form 10-K&#8221;). The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland has faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our clinical studies were impacted as fewer patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020, 2021 and the three months ended March 31, 2022,  we carefully monitored our supply chain, including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance during the pandemic.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i3ce973300e01462b939fb77427a3d30f" continuedAt="idb42c83d7bde4a2d931c903976b12642"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zMS9mcmFnOjFkNWQ0ZmY1MjNjZDRjMTk5Nzc0N2ZkNTBhYzU5ZDQ0L3RleHRyZWdpb246MWQ1ZDRmZjUyM2NkNGMxOTk3NzQ3ZmQ1MGFjNTlkNDRfMTAwMzU_8e5bf0eb-d5b3-49fc-9d8a-246a2a256a9a" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zMS9mcmFnOjFkNWQ0ZmY1MjNjZDRjMTk5Nzc0N2ZkNTBhYzU5ZDQ0L3RleHRyZWdpb246MWQ1ZDRmZjUyM2NkNGMxOTk3NzQ3ZmQ1MGFjNTlkNDRfMTAwMzY_96da59db-d802-4bf1-b00b-91ef0092b1d9" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zMS9mcmFnOjFkNWQ0ZmY1MjNjZDRjMTk5Nzc0N2ZkNTBhYzU5ZDQ0L3RleHRyZWdpb246MWQ1ZDRmZjUyM2NkNGMxOTk3NzQ3ZmQ1MGFjNTlkNDRfMTAwMzE_4a8e3fdf-416d-488f-a208-18907162335e" continuedAt="i8b76698cfd2d4ec890f70d7c556f7c33" escape="true">Operating Segments</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idb42c83d7bde4a2d931c903976b12642"><ix:continuation id="i8b76698cfd2d4ec890f70d7c556f7c33">The Company has <ix:nonFraction unitRef="segment" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zMS9mcmFnOjFkNWQ0ZmY1MjNjZDRjMTk5Nzc0N2ZkNTBhYzU5ZDQ0L3RleHRyZWdpb246MWQ1ZDRmZjUyM2NkNGMxOTk3NzQ3ZmQ1MGFjNTlkNDRfOTIyNQ_a200cfca-fad7-4f58-af3a-19d8a7455340">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation></ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_34"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RleHRyZWdpb246NGViMGQ3YzdlYWU4NDUwOTkzYWEwNTI1ODExZTA0NTdfNDI0_5b960598-3c1f-4731-aec1-720d07df8693" continuedAt="i12b3ff0102fc4023be2ee952015fc27c" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i12b3ff0102fc4023be2ee952015fc27c"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RleHRyZWdpb246NGViMGQ3YzdlYWU4NDUwOTkzYWEwNTI1ODExZTA0NTdfNDI2_9aecfe8a-8d98-4c9f-99c8-6b18bd6e65f2" continuedAt="i60c697c7063b4d4494f737b5eeab8325" escape="true">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2022 and 2021:</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><ix:continuation id="i60c697c7063b4d4494f737b5eeab8325"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNC0xLTEtMS0yMzM3Mg_e16771ea-1f72-40f2-9cbb-b700bb4beeb9">1,402,433</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNC0zLTEtMS0yMzM3Mg_d538414a-a6eb-40bb-a03c-58c11776bdf2">350,749</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644ff4fff14b4f54ad5cdf6cc770dece_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNS0xLTEtMS0yMzM3Mg_37660da1-e720-440b-b27a-0d3f909bae4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c89fbd5ff1649de916ca18e3a139199_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNS0zLTEtMS0yMzM3Mg_47f6dff7-ea4a-4e0f-9347-01f1570319b1">495,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNi0xLTEtMS0yMzM3Mg_0dfd9f6f-15c5-4b29-b65f-ca3769a327ad">1,402,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNi0zLTEtMS0yMzM3Mg_a9fc1e9f-1769-4516-8200-123616e1d1d7">144,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNy0xLTEtMS0yMzM3Mg_ee9111ca-f780-466a-8b74-497ec5cbbba9">17,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNy0zLTEtMS0yMzM3Mg_b5f2aa2c-3bcd-45f5-a778-7f77d4ee4561">22,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfOC0xLTEtMS0yMzM3Mg_d47ce715-7315-416e-9f2b-346787b1d82f">1,385,253</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfOC0zLTEtMS0yMzM3Mg_f9f2e69f-f791-4990-b09b-74273cfec55c">166,828</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfMTAtMS0xLTEtMjMzNzI_03c21247-7439-4fc0-8c40-8c657597cfa6">14,691,623</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfMTAtMy0xLTEtMjMzNzI_a7d7824d-e641-4a2e-84d3-0a37e4253a0d">14,974,663</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfMTEtMS0xLTEtMjMzNzI_d3ed46d0-cd4b-49bb-b67b-4def6e4d1b46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfMTEtMy0xLTEtMjMzNzI_480670ed-d9e6-4570-9e93-5de77c7dd586">269,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfMTItMS0xLTEtMjMzNzI_62d62e1e-5d57-4b99-9eb6-adc2215f3c4d">14,691,623</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfMTItMy0xLTEtMjMzNzI_5994851d-a842-4f3d-b9ef-0ca12abf9025">15,244,146</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and 2021, restricted stock awards and options to purchase <ix:nonFraction unitRef="shares" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RleHRyZWdpb246NGViMGQ3YzdlYWU4NDUwOTkzYWEwNTI1ODExZTA0NTdfMjQ4_e6c8de21-5d51-4dc1-a06d-8443880edfde">131,225</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RleHRyZWdpb246NGViMGQ3YzdlYWU4NDUwOTkzYWEwNTI1ODExZTA0NTdfMjU1_239aa2e5-4cd6-40ba-9e27-8e3f87e8775c">215,600</ix:nonFraction> shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div></ix:continuation><div id="ia1d36fc2a31344efa67485eba5f161bf_37"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RleHRyZWdpb246ODRkODlkMzgyM2VhNGRkNjhhM2U0ZjQxZWY1MDg3OTFfMjY5OA_d12dcaa1-e78d-4487-9ce2-d3c67175895d" continuedAt="i13ff777197024e3288844660e9d67b89" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i13ff777197024e3288844660e9d67b89"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. </span></div><div style="margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RleHRyZWdpb246ODRkODlkMzgyM2VhNGRkNjhhM2U0ZjQxZWY1MDg3OTFfMjY5OQ_ac3aaae9-ef6d-4f3d-be34-8976945c15b1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.806%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie877302447534894b2d5513d38b31fbb_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfMy01LTEtMS0yMzM3Mg_3c5e52c7-e967-4103-8181-92a83018f2ca">3,945,097</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b5c64a6e224a7291d17215b8e20cac_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfMy03LTEtMS0yMzM3Mg_169027b9-9b9c-4766-8f48-529df28ed99e">2,994,378</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice443517d3bd4eacb0f21f2731ff3c9a_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNC01LTEtMS0yNTAxMA_3446f4b3-e0b6-46c8-966b-d7a3a7d9d398">3,397,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29eb8f904a99423e9e75afb35fc798bb_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNC03LTEtMS0yNTAxMA_e30105a7-20e0-4519-8eb0-be52e7ce21d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f7afb68d83b46cf9e1efc1a40f6f60d_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNC01LTEtMS0yMzM3Mg_3d9db5e7-499f-4ce4-96b7-05ed116eb0c8">2,501,434</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d669dc1bc564b61a9673076b557bba0_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNC03LTEtMS0yMzM3Mg_5e26fb59-307d-4c9f-849e-83e0bbc6c049">5,052,243</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7edbe25bc59c416088d0b62c3c7ba86d_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNS01LTEtMS0yMzM3Mg_1667540c-6548-41f0-83f0-be3f8ba9a07c">959,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i200c0ccbad3548a4ab7da1ea2e3a57f0_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNS03LTEtMS0yMzM3Mg_b5fcea1b-ff3c-4669-b847-1ecb0a7ae953">1,539,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1dc6fa5f3f3948bab15a2a93c882cb38_D20220101-20220331" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNi01LTEtMS0yMzM3Mg_6d53e13f-ce01-4792-ab75-71253823d4c6">117,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e515d306ed64aeb9f21e8890cae9d55_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNi03LTEtMS0yMzM3Mg_cc9e1969-570a-4209-bbd2-61b6510859b2">1,134,264</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4604540a3e34ae8969cd1ce548e7c56_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNy01LTEtMS0yMzM3Mg_5fdfca3a-7090-4ccb-a0d4-f7c52aab15e8">111,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7faae5cf158490da1a4081a5c49115b_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNy03LTEtMS0yMzM3Mg_40fcda26-bb51-47c6-a22e-649c7403d452">117,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id911eaa5894443c2a98fbc046aa0ba09_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfOC01LTEtMS0yMzM3Mg_fad626d7-456e-4409-9a80-85a810210f5a">22,737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia78b359fdf784449a00e7aa9d754ce29_D20210101-20210331" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfOC03LTEtMS0yMzM3Mg_7fafdd7d-3ae4-4e17-8b44-e3188490acc9">450,263</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdccc9e2bb3149a6a0c56fbbbec9dd0b_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfOS01LTEtMS0yMzM3Mg_a162c339-7ae7-4842-8ebf-7745592f6dd1">59,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i796c57f0f1b3412d8d803b33df824490_D20210101-20210331" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfOS03LTEtMS0yMzM3Mg_c6f506cb-b837-4b04-a45e-7023b2100020">32,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd2dd746ac5484bada9868db377c71a_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfMTAtNS0xLTEtMjMzNzI_38930a09-c254-4c7b-a52a-ef35e480c1ad">295,618</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c714cbee7e14e928534563714a191c7_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfMTAtNy0xLTEtMjMzNzI_6fb43b11-2616-4bba-a745-54a2c4fdcb94">182,102</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfMTEtNS0xLTEtMjMzNzI_328c3285-00e8-49d6-857a-c04990b42e33">11,175,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfMTEtNy0xLTEtMjMzNzI_ab54795f-72e9-4e5f-a52a-c12208d2d907">10,537,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omeclamox-Pak revenue for the first quarter of 2022 and 2021 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  In the first quarter of 2022, the amounts noted were normal adjustments by channel partners.  Net revenue was impacted by product return adjustments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to Vaprisol, we are in the process of transitioning to a new manufacturer and expect FDA approval later this year.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i52b835511e1b4d32814daf525c7b851d_D20220101-20220331" decimals="-4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RleHRyZWdpb246ODRkODlkMzgyM2VhNGRkNjhhM2U0ZjQxZWY1MDg3OTFfMjYwMg_e9a155ed-50b1-469d-9d0d-91a6fec0986f">0.04</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibad57998d50b42e28e43f57e0458042e_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RleHRyZWdpb246ODRkODlkMzgyM2VhNGRkNjhhM2U0ZjQxZWY1MDg3OTFfMjYwOQ_46ab326c-c3af-4452-b93c-884129de879d">0.1</ix:nonFraction> million for the three months ended March 31, 2022 and 2021, respectively.</span></div></ix:continuation><div id="ia1d36fc2a31344efa67485eba5f161bf_40"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4) <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMjE2NA_51bd96c2-96b6-473b-a231-7f2175a7de70" continuedAt="i91f90453fb3d4c73a058a1a4b16005b3" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="i91f90453fb3d4c73a058a1a4b16005b3"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2022 and December 31, 2021, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $<ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTAzOQ_a37739e9-2cd9-49f6-9cd2-285e724f2789">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTA0Ng_f5ac7df4-c458-46ea-9578-f3eb1691406b">1.4</ix:nonFraction> million, respectively.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at March 31, 2022 and December 31, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consigned inventory represents Authorized Generic inventory stored with our partner until shipment.   </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $<ix:nonFraction unitRef="usd" contextRef="i0daea624eb8d4452969618186921bc8f_I20211231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTYzNQ_f8963c04-4e12-4e23-823e-578ddeb7b3fd">15.6</ix:nonFraction> million that were all initially classified as non-current inventories at the date of acquisition.  For the Sancuso acquisition, Cumberland acquired $<ix:nonFraction unitRef="usd" contextRef="i098351aedd7d43fe971148fc9b861a98_I20211231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMjE5OTAyMzI1OTA4Nw_09410ee7-1851-48c6-8433-7892479bc5ed">3.0</ix:nonFraction> million of work in progress non-current inventory.  At March 31, 2022 and December 31, 2021, total non-current inventory, including Vibativ, Sancuso and our clinical trial drug ifetroban, was $<ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTgwOQ_e33dd526-5d85-41ff-9346-79d64d9dc368">10.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTgxNg_298f2828-a475-48d0-aefd-7d8e936df6d7">9.0</ix:nonFraction> million, respectively. The Company had $<ix:nonFraction unitRef="usd" contextRef="iae86c13d2edd4a3bb59c24847ec261c4_I20220331" decimals="-5" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTg1MA_ff46b76c-bce3-465d-a321-8324ee4000eb">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0daea624eb8d4452969618186921bc8f_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTg1Nw_24bd3273-ca3c-47d3-9b7f-b84da85efa72">0.5</ix:nonFraction> million of Vibativ finished goods included in non-current inventory at March 31, 2022 and December 31, 2021, respectively.  The Company also has obtained $<ix:nonFraction unitRef="usd" contextRef="i84c1a7a949634b2ca9c4f2cac3729504_I20220331" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMjE5OTAyMzI1OTE4Mw_40f5ac44-f633-4d04-a42a-f8f16cd7510e">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2325bc53765d4db18477773f3a908aeb_I20211231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTk3OQ_2ca93532-112f-4a9b-ac13-9aadf57b6893">0.4</ix:nonFraction>&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at March 31, 2022 and December 31, 2021, respectively. </span></div><div style="margin-top:8pt"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMjE2Nw_3cade9f6-631a-4140-a32c-b69adb1d3301" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022 and December 31, 2021 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:57.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfMi0yLTEtMS0yMzM3Mg_192991da-23a2-4eb5-a2bb-2bd2f8794d2d">15,004,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfMi00LTEtMS0yMzM3Mg_ba65153b-a1f1-408a-8b3d-282b50d2706b"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfMi00LTEtMS0yMzM3Mg_bec3db18-6b4e-45ad-9515-8ed6332fbbaf">12,374,983</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfMy0yLTEtMS0yMzM3Mg_0c80250d-fe73-43c5-adfd-a54848e790ab">129,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfMy00LTEtMS0yMzM3Mg_8c4e84d2-ed9b-46f8-a2eb-2878197ae00f"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfMy00LTEtMS0yMzM3Mg_eec3829d-0b90-46fb-a04a-81a1798a89d7">164,378</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNC0yLTEtMS0yMzM3Mg_494dc18f-4186-44b7-a78f-8b6245be7166">5,338,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNC00LTEtMS0yMzM3Mg_0e0c9367-eeb0-418f-a317-84592d7d62ec"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNC00LTEtMS0yMzM3Mg_a935b94b-f48b-43ba-a4c8-a113af9de855">4,939,088</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNS0yLTEtMS0yMzM3Mg_91e79dff-d75b-4f68-a673-159dfd441716">20,472,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNS00LTEtMS0yMzM3Mg_f2c88b57-80c0-48dd-b564-27c0e07005bd">17,478,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNi0yLTEtMS0yMzM3Mg_63a0f892-ccbd-497c-a116-4091f1201908">10,593,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNi00LTEtMS0yMzM3Mg_a47740c9-dacb-4086-8702-9a58737394b3">9,048,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNy0yLTEtMS0yMzM3Mg_7430fca0-73c4-44da-8c3c-5152ef260c38">9,878,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNy00LTEtMS0yMzM3Mg_8f7e70e3-486e-4b6d-8d73-2672feb1beb8">8,429,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="ia1d36fc2a31344efa67485eba5f161bf_43"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5) <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTk4MA_46120881-db5b-42aa-9cbb-865bfb806a8f" continuedAt="ic7e7e07609cd467f932959618d89eaed" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="ic7e7e07609cd467f932959618d89eaed"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s significant operating leases include the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="i2f1903407422459a9d2afe8a574e9574_I20220331" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfOTQ_b656207f-f0cd-4aa1-bd30-7fb774ea4399">25,500</ix:nonFraction> square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The Company's operating leases also include the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="i8c5daecc32784c3b84e2034c8b84fb28_I20220331" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMzAw_0a1c1ee2-27de-4a32-83c2-6f0dd09e5066">14,200</ix:nonFraction> square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is <ix:nonFraction unitRef="number" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTI0OA_c21f3341-147d-4231-becd-f1f5365a0898">7.42</ix:nonFraction>%. The weighted-average remaining lease term at March 31, 2022 is <ix:nonNumeric contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTMwMw_594a24b5-b992-46fa-ae58-eb99653002b4">0.8</ix:nonNumeric> years.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company will lease approximately <ix:nonFraction unitRef="sqft" contextRef="i9e9d6ba88f264e658e866ce6a611c696_I20211115" decimals="0" name="cpix:LesseeOperatingLeaseLeasedArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMzg0ODI5MDY5OTk4NA_50f581aa-4181-43da-98a7-1b0a3dd2fbde">16,631</ix:nonFraction> rentable square feet of space (the &#8220;Leased Premise&#8221;) at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise will serve as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (<ix:nonNumeric contextRef="i9e9d6ba88f264e658e866ce6a611c696_I20211115" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMzg0ODI5MDY5OTk5Mw_e51c1949-94b3-4239-a2c2-0e4a4e782534">157</ix:nonNumeric>) months, with <ix:nonFraction unitRef="renewalterm" contextRef="i7e0ddb33c8e14da08e5d4bf80bbf83c4_I20211115" decimals="INF" name="cpix:LesseeOperatingLeaseNumberOfRenewalTerms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMzg0ODI5MDY5OTk5MQ_9b793344-5a27-4005-ba3c-44598919c2ab">two</ix:nonFraction> consecutive options to renew for a period of <ix:nonNumeric contextRef="i7e0ddb33c8e14da08e5d4bf80bbf83c4_I20211115" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMzg0ODI5MDcwMDAwNA_0997d34c-9284-479f-821e-c3706ef7a7c4">five years</ix:nonNumeric> each, and will commence on the earlier of November 1, 2022, the date on which Cumberland takes occupancy of the Leased Premise, or the date which Cumberland receives a temporary or permanent certificate of occupancy for the Leased Premise.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTk4MQ_98e31e05-3450-4c44-84ae-6c517deb8458" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYzMWVhYTkzZjk4ZTRmOTViYmVjMzJkODc2ZTY1NjE0L3RhYmxlcmFuZ2U6NjMxZWFhOTNmOThlNGY5NWJiZWMzMmQ4NzZlNjU2MTRfMS0yLTEtMS0yMzM3Mg_544a9768-6e8f-4f0e-bb03-2237d301c2c2">761,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYzMWVhYTkzZjk4ZTRmOTViYmVjMzJkODc2ZTY1NjE0L3RhYmxlcmFuZ2U6NjMxZWFhOTNmOThlNGY5NWJiZWMzMmQ4NzZlNjU2MTRfMS00LTEtMS0yMzM3Mg_5fdef202-dfc1-4d8e-a473-000a7281df65"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYzMWVhYTkzZjk4ZTRmOTViYmVjMzJkODc2ZTY1NjE0L3RhYmxlcmFuZ2U6NjMxZWFhOTNmOThlNGY5NWJiZWMzMmQ4NzZlNjU2MTRfMS00LTEtMS0yMzM3Mg_8a50daf5-f64a-4c9f-8246-e2bfaf5dbbd8">1,024,200</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfMS0yLTEtMS0yMzM3Mg_11a58c38-7098-4cf9-8477-e10f513335b9">766,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfMS00LTEtMS0yMzM3Mg_47dcec09-9bcd-4d06-abb6-359b2949c82e"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfMS00LTEtMS0yMzM3Mg_ceccbe19-e4da-4ad8-9d53-bbd7b8f1b82b">969,677</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfMy0yLTEtMS0yMzM3Mg_b97cc6d4-42fa-4fdc-a454-29257c133fec">22,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfMy00LTEtMS0yMzM3Mg_4418b772-efef-4aee-b316-006e5dc37f97"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfMy00LTEtMS0yMzM3Mg_b3e1eb15-f394-468a-bdf8-0aae1ef1e270">90,016</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="cpix:LeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfNC0yLTEtMS0yMzM3Mg_f5b25531-2d23-49bf-83bc-c942878952f6">789,200</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="cpix:LeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfNC00LTEtMS0yMzM3Mg_871361d3-191a-413a-87b1-5358a965dcf9">1,059,693</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the Broadwest agreement, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $<ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTUxMA_8b6ffaa8-4300-4d8c-a099-d88585b64c7f">0.1</ix:nonFraction> million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div></ix:nonNumeric><div><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTk3OA_6b836a50-f8d4-4af6-adaa-874261851c07" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at March 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOmNkNmQ5NzVjOTEzNzQxM2Q5YjAyMDFmMmUwNjNjOWY2L3RhYmxlcmFuZ2U6Y2Q2ZDk3NWM5MTM3NDEzZDliMDIwMWYyZTA2M2M5ZjZfMi0yLTEtMS0yMzM3Mg_5e53f39f-e550-4b31-8747-d0e822200c97">730,829</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOmNkNmQ5NzVjOTEzNzQxM2Q5YjAyMDFmMmUwNjNjOWY2L3RhYmxlcmFuZ2U6Y2Q2ZDk3NWM5MTM3NDEzZDliMDIwMWYyZTA2M2M5ZjZfMy0yLTEtMS0yMzM3Mg_228ac672-454d-4592-bd03-50f408c454b3">92,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOmNkNmQ5NzVjOTEzNzQxM2Q5YjAyMDFmMmUwNjNjOWY2L3RhYmxlcmFuZ2U6Y2Q2ZDk3NWM5MTM3NDEzZDliMDIwMWYyZTA2M2M5ZjZfNS0yLTEtMS0yMzM3Mg_b3d0c460-c1bb-468c-8c2f-ac891496af75">823,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOmNkNmQ5NzVjOTEzNzQxM2Q5YjAyMDFmMmUwNjNjOWY2L3RhYmxlcmFuZ2U6Y2Q2ZDk3NWM5MTM3NDEzZDliMDIwMWYyZTA2M2M5ZjZfNi0yLTEtMS0yMzM3Mg_03e52a9c-15df-439a-8aa3-3ed804a03067">34,106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOmNkNmQ5NzVjOTEzNzQxM2Q5YjAyMDFmMmUwNjNjOWY2L3RhYmxlcmFuZ2U6Y2Q2ZDk3NWM5MTM3NDEzZDliMDIwMWYyZTA2M2M5ZjZfNy0yLTEtMS0yMzM3Mg_9d28f7a9-8c12-48c3-aa0c-f76bb53aff43">789,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTk3OQ_fe0d18e3-edcf-4d41-8bdd-d30cd64adc59" continuedAt="i3a2cefabfc924cdf878759f8bc027f03" escape="true">Rent expense and sublease income were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="i3a2cefabfc924cdf878759f8bc027f03"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYwYThhYWRkMmZiYjQ4ZTU4NjA2YzJkZTI2NWUwMDUxL3RhYmxlcmFuZ2U6NjBhOGFhZGQyZmJiNDhlNTg2MDZjMmRlMjY1ZTAwNTFfMi0yLTEtMS0yMzM3Mg_de928ce5-f246-4516-ad68-17c0cdc2301a">285,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYwYThhYWRkMmZiYjQ4ZTU4NjA2YzJkZTI2NWUwMDUxL3RhYmxlcmFuZ2U6NjBhOGFhZGQyZmJiNDhlNTg2MDZjMmRlMjY1ZTAwNTFfMi00LTEtMS0yMzM3Mg_35051850-e98e-48b4-8140-feb2cc73f9ce">227,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" decimals="0" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYwYThhYWRkMmZiYjQ4ZTU4NjA2YzJkZTI2NWUwMDUxL3RhYmxlcmFuZ2U6NjBhOGFhZGQyZmJiNDhlNTg2MDZjMmRlMjY1ZTAwNTFfNC0yLTEtMS0yMzM3Mg_c09ea5a6-e951-4f99-b919-74eb2a6ed344">161,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331" decimals="0" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYwYThhYWRkMmZiYjQ4ZTU4NjA2YzJkZTI2NWUwMDUxL3RhYmxlcmFuZ2U6NjBhOGFhZGQyZmJiNDhlNTg2MDZjMmRlMjY1ZTAwNTFfNC00LTEtMS0yMzM3Mg_421782da-6ddc-42ec-bc20-67e47c2cf3ef">178,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ia1d36fc2a31344efa67485eba5f161bf_46"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6) <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzg0ODI5MDcxMDA5Mw_6f74fec7-e3df-4e0b-9ea4-a68bbad1d88d" continuedAt="ia422809153084468928933c32acefea4" escape="true">SHAREHOLDERS&#8217; EQUITY AND DEBT</ix:nonNumeric></span></div><ix:continuation id="ia422809153084468928933c32acefea4" continuedAt="ifbbf995b3c844ebda1a847d1e3ef9d53"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i6f9bbd3fc1b64e3aaff098e2d4118248_I20100513" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMTMz_937cf292-900e-4b03-b8ab-7a86ebe754cb">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="i08bc631bb3a84b3e911db80c62f763aa_I20160131" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMjk0_bf4b6cd2-00da-4c4a-a450-87505deaeecb">10</ix:nonFraction> million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2022 and March 31, 2021, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNDAw_3ee178c5-a7e1-4f31-853d-74d9eb89070f">174,149</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNDE0_6d11f282-2308-4992-bb83-ef3dd7f6b9a5">91,724</ix:nonFraction> shares of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNDcz_81fe3749-155b-455f-82ac-8c4a78b2b9f8">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNDgw_0662ec59-d165-417d-afed-981c818b73f1">0.3</ix:nonFraction> million, respectively.  At March 31, 2022, approximately $<ix:nonFraction unitRef="usd" contextRef="if31eafab8bfe4d1b94fb61717226d991_I20220331" decimals="0" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNTIw_bd0c55d6-445a-4f17-be38-07103c487f98">4.2</ix:nonFraction> million of common shares was left to repurchase under this program.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's March 2022 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  These purchases began in April 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="i289b83d4e5d54057a0a8a4e6c2f1c792_D20171101-20171130" decimals="-6" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMTA1OA_ffee0f2f-581a-4154-8302-b7c6428140c7">100</ix:nonFraction> million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021.  On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $<ix:nonFraction unitRef="usd" contextRef="i61780641954246b1a1327370732b7ffa_D20211227-20211227" decimals="-6" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMjE5OTAyMzI2MzQxMw_09e31d4b-b301-471f-8ed2-2237810a10a4">19</ix:nonFraction> million.  The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. The Company did not issue any shares under an ATM during the three months ended March 31, 2022 or March 31, 2021.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants and Incentive Stock Options</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and March 31, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i252b48b488b0434e85d14e8d2b0c2868_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMTk0NA_bb4675ae-91f5-4d7b-a2ff-45f70cfb5e44">65,225</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i91438a451f684b24a2fca503fc14d053_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMTk1OA_a6477777-a5c4-44ee-9802-2e7b28b61529">35,850</ix:nonFraction> shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <ix:nonNumeric contextRef="i393e64896f1e48d1a056d5ef7f775821_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNzI2Nw_3f14adc6-5212-469f-aa8d-ad206b6ddb38">one-year</ix:nonNumeric> anniversary of the date of grant.  During the three months ended March 31, 2022 and 2021, the Company also issued <ix:nonFraction unitRef="shares" contextRef="if18a26b0f0ee4feca8ce62bae76cfdec_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMjI0Mw_4610bcc7-7418-4438-b965-469a77f4ab16">166,350</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i75376963bb5c44dd95c8a7c842962c8d_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMjE5OTAyMzI2ODMwMQ_7f55bc64-f733-4d36-9584-e740333d7de0">172,350</ix:nonFraction> incentive stock options, respectively, to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March 2032 and 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement (the "Pinnacle Agreement") to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $<ix:nonFraction unitRef="usd" contextRef="i30c0769f6c3c4e2da21df888867dc1bb_I20211231" decimals="-6" name="cpix:LineOfCreditFacilityAdditionalBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzg0ODI5MDcxMDA4MQ_14a3be68-886e-457c-9436-e6405a74f47b">15</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i30c0769f6c3c4e2da21df888867dc1bb_I20211231" decimals="-6" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzg0ODI5MDcxMDA2OA_01798f09-182f-4f70-9723-cb1610c9f932">20</ix:nonFraction>&#160;million. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment ("Fifth Amendment") to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Pinnacle Agreement was dated July 2017.  Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement.  The Fifth Amendment extends the maturity date three years through October 1, 2024.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="ie1994f4e6e7b4be9b7830b35c2aac539_D20200814-20200814" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzgyMg_ff2a25b6-2f05-4d92-97fa-9435228863dd">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i2a86b88298df427db4bc3b73b915632f_D20200814-20200814" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzgyOA_b75d8ef1-6f49-44f1-bd0a-8a16e05d0728">2.75</ix:nonFraction>% above LIBOR with a minimum LIBOR of <ix:nonFraction unitRef="number" contextRef="i27af9c4796d34881a155e56ca9fd7685_D20200814-20200814" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzg2Nw_f9578051-07f7-4d9d-994e-8effa39caec5">0.90</ix:nonFraction>%. The applicable interest rate under the Pinnacle Agreement was <ix:nonFraction unitRef="number" contextRef="i8197f941295d4acd903690460d5fb886_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzkzMw_326edca5-073b-4f6b-a73f-0e8d18f10b33">3.65</ix:nonFraction>% at March 31, 2022.  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="ic80f9798db0747c1acdd1be19fd4f610_D20220101-20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzk2Ng_3e045b49-7eaf-4c2b-a5d4-0544d7c745f0">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  The parties have agreed on a process to determine a new interest rate benchmark at the point the LIBOR rate is expected to be discontinued over the next 12  to 24 months.    </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="ifbbf995b3c844ebda1a847d1e3ef9d53" continuedAt="ib7a65485bc674ffc89b0823e6183c852"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i47ad0a97e0314f8eba21273d51757cd8_I20220331" decimals="-5" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNDExMQ_ff359313-f5fa-4ac9-b9d8-a0ab3a8cc2f8">20.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8f233a458221495a93adac84dff7b497_I20211231" decimals="0" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMjE5OTAyMzI2ODM2OA_e40c1958-8cfa-4876-bcad-166f3c0e7ef2">15.0</ix:nonFraction> million, respectively, in borrowings outstanding under its revolving credit facility.  The Company was in compliance with the Maximum Funded Debt Ratio financial covenant as of March 31, 2022.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the line of credit are collateralized by substantially all of our assets.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><ix:continuation id="ib7a65485bc674ffc89b0823e6183c852" continuedAt="ib355e4ec63134d46bb65b82fc8e05ba2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib355e4ec63134d46bb65b82fc8e05ba2">. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $<ix:nonFraction unitRef="usd" contextRef="i42ffe35d0bb445bca3edfba518ae51db_I20200831" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNjg2OQ_e6fee356-bcf0-4d0f-83c4-7e081607e223">0.2</ix:nonFraction>&#160;million equity contribution and an initial investment from Cumberland in the form of a $<ix:nonFraction unitRef="usd" contextRef="i99eb7be3baca40ca8e4e084c3136775c_I20200831" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNjk1MQ_5fe8db77-78cc-4bac-86bc-f3d6b41cf186">0.2</ix:nonFraction>&#160;million convertible note, which was funded during the first quarter of 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license product candidates from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies Inc.</ix:continuation>   </span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_49"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7) <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80OS9mcmFnOjJhNjVlOTc0MmYyNzQwYzY5MmUyN2MyODQwNzI1ODUxL3RleHRyZWdpb246MmE2NWU5NzQyZjI3NDBjNjkyZTI3YzI4NDA3MjU4NTFfNjM1_5413ba6d-ab6b-4597-9637-7e2ecb843756" continuedAt="i5ef588a1311840d4810a4bf454e6166c" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5ef588a1311840d4810a4bf454e6166c" continuedAt="if4aeb3183ca44d569cfd9d11d9cc1648">As of March 31, 2022, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="i65fbb43d257d44b79182efae8d2e0fd5_I20220331" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80OS9mcmFnOjJhNjVlOTc0MmYyNzQwYzY5MmUyN2MyODQwNzI1ODUxL3RleHRyZWdpb246MmE2NWU5NzQyZjI3NDBjNjkyZTI3YzI4NDA3MjU4NTFfNjI_6877a3bf-72a7-463a-b5ef-4bd39522ec68">56.6</ix:nonFraction> million in federal net operating loss carryforwards including approximately $<ix:nonFraction unitRef="usd" contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80OS9mcmFnOjJhNjVlOTc0MmYyNzQwYzY5MmUyN2MyODQwNzI1ODUxL3RleHRyZWdpb246MmE2NWU5NzQyZjI3NDBjNjkyZTI3YzI4NDA3MjU4NTFfMTMz_d12c878b-c46e-43fd-a442-964ad1131ab0">44.1</ix:nonFraction> million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2022 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </ix:continuation></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if4aeb3183ca44d569cfd9d11d9cc1648">The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</ix:continuation> </span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_52"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8) <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81Mi9mcmFnOjI5OWIyMDY0ZDg5ODQwZWJhZDRjYjJiNjc4ZDU2Zjc2L3RleHRyZWdpb246Mjk5YjIwNjRkODk4NDBlYmFkNGNiMmI2NzhkNTZmNzZfMTAyNw_15c58536-054e-4f6f-af69-3b8091228b11" continuedAt="i25911f3c7b064b2f8fbe6fed5ba804d9" escape="true">COLLABORATIVE AGREEMENTS</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><ix:continuation id="i25911f3c7b064b2f8fbe6fed5ba804d9"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span></ix:continuation></div><div id="ia1d36fc2a31344efa67485eba5f161bf_55"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9) <ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNTg0Mw_32c94e88-8f2b-469b-9fa4-76d301972ad0" continuedAt="i60cb19e3bcb84f62b2b69392d559fa21" escape="true">ADDITIONS AND RETURN OF PRODUCT RIGHTS</ix:nonNumeric></span></div><ix:continuation id="i60cb19e3bcb84f62b2b69392d559fa21" continuedAt="i29c35c65a5a5482b8f69382ae11a1455"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i4ef7c1987e104296b100805721e7adc8_D20181101-20181130" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfOTcx_81b58010-04c5-45d1-987f-7d26b54b0451">20.0</ix:nonFraction>&#160;million at the closing of the transaction and a $<ix:nonFraction unitRef="usd" contextRef="i4ef7c1987e104296b100805721e7adc8_D20181101-20181130" decimals="-5" name="us-gaap:OtherPaymentsToAcquireBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMTAxNA_46a86c56-9b4c-4ac7-81d6-cd7432d70c06">5.0</ix:nonFraction>&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="i4ef7c1987e104296b100805721e7adc8_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMTExNw_0a59ff18-c72e-45ca-8993-8e63f27ecaa8">20</ix:nonFraction>% of on-going net sales of the product after the $<ix:nonFraction unitRef="usd" contextRef="i4ef7c1987e104296b100805721e7adc8_D20181101-20181130" decimals="-5" name="cpix:TieredRoyaltyPaymentsThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDgwNQ_d24cd94c-55dc-4d97-805a-ed59a6de375d">2.5</ix:nonFraction>&#160;million threshold is met. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNTg0MQ_cdcc8e36-31db-4889-b1d5-e67597a74a40" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0daea624eb8d4452969618186921bc8f_I20211231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjc0ODFkODNmOWIyNTRlMjg5MDg0YzI0ZjVmYTViYjVmL3RhYmxlcmFuZ2U6NzQ4MWQ4M2Y5YjI1NGUyODkwODRjMjRmNWZhNWJiNWZfOS0xLTEtMS0yMzM3Mg_590efa4f-9a27-4551-8d78-3878133a6106">6,515,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93eb9b844c7244b59e4acf2535ce2a3d_D20220101-20220331" decimals="0" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjc0ODFkODNmOWIyNTRlMjg5MDg0YzI0ZjVmYTViYjVmL3RhYmxlcmFuZ2U6NzQ4MWQ4M2Y5YjI1NGUyODkwODRjMjRmNWZhNWJiNWZfMTAtMS0xLTEtMjMzNzI_ecc27e4f-f03a-46c4-acb7-50d7569afd9a">501,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93eb9b844c7244b59e4acf2535ce2a3d_D20220101-20220331" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjc0ODFkODNmOWIyNTRlMjg5MDg0YzI0ZjVmYTViYjVmL3RhYmxlcmFuZ2U6NzQ4MWQ4M2Y5YjI1NGUyODkwODRjMjRmNWZhNWJiNWZfMTEtMS0xLTEtMjMzNzI_8fedbcb4-2612-4889-b278-ef3f73104c05">370,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93eb9b844c7244b59e4acf2535ce2a3d_D20220101-20220331" decimals="0" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjc0ODFkODNmOWIyNTRlMjg5MDg0YzI0ZjVmYTViYjVmL3RhYmxlcmFuZ2U6NzQ4MWQ4M2Y5YjI1NGUyODkwODRjMjRmNWZhNWJiNWZfMTItMS0xLTEtMjMzNzI_b4297138-f8be-41f7-ba93-8a28280310e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae86c13d2edd4a3bb59c24847ec261c4_I20220331" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjc0ODFkODNmOWIyNTRlMjg5MDg0YzI0ZjVmYTViYjVmL3RhYmxlcmFuZ2U6NzQ4MWQ4M2Y5YjI1NGUyODkwODRjMjRmNWZhNWJiNWZfMTMtMS0xLTEtMjMzNzI_34fc124a-5f00-41fe-aabf-9e6aa57d4ac9">6,384,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="iae86c13d2edd4a3bb59c24847ec261c4_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMjE5OTAyMzI2MTM5OA_ddba7c18-c1d9-454c-b8ab-5211302a2b18">6.4</ix:nonFraction> million was accounted for as $<ix:nonFraction unitRef="usd" contextRef="iae86c13d2edd4a3bb59c24847ec261c4_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNDk0NzgwMjMzNTkwMQ_3da4c273-4863-409b-9dbc-e3abc2d7f9f2">2.3</ix:nonFraction> million of other current liabilities and $<ix:nonFraction unitRef="usd" contextRef="iae86c13d2edd4a3bb59c24847ec261c4_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNDk0NzgwMjMzNTk0Mg_d0ac1316-46f4-4690-b4de-50ec5e268462">4.1</ix:nonFraction> million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2022.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $<ix:nonFraction unitRef="usd" contextRef="i1bf6dd4ac05d40108e2514911c613b85_D20161101-20161130" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMjQxMQ_241edaff-8277-4407-ba73-4f06b34081e9">100,000</ix:nonFraction> at closing.  The Company provided $<ix:nonFraction unitRef="usd" contextRef="i1bf6dd4ac05d40108e2514911c613b85_D20161101-20161130" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMjQ0OA_aef21c2b-4b80-4a19-b4a8-c7ddcbb4866e">0.9</ix:nonFraction>&#160;million in consideration through a grant of <ix:nonFraction unitRef="shares" contextRef="ic73781ab99bd43f2bb632a84368ba389_D20161101-20161130" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMjQ4Nw_80e3deed-a524-4946-8730-6c3aa31563ca">180,000</ix:nonFraction> restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The <ix:nonFraction unitRef="shares" contextRef="ic73781ab99bd43f2bb632a84368ba389_D20161101-20161130" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzA5OA_ccff8dd8-79a6-41a0-a399-e459cf0ea9a6">180,000</ix:nonFraction> shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $<ix:nonFraction unitRef="usd" contextRef="i9a90c1c0e8b64d6ebbf750ff29642e7a_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzIxNg_221e015b-1449-4784-8792-259e6f96e9a2">0.9</ix:nonFraction>&#160;million on the vesting date. The FDA approval also resulted in a $<ix:nonFraction unitRef="usd" contextRef="i38e26d699b094a1ca3994c9d4c08e244_I20200731" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzI3Ng_1dbbff5b-7491-4529-8516-832d1e4aaf26">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that took place in late 2021 will result in a $<ix:nonFraction unitRef="usd" contextRef="if4192a5594914fce8a1e18207ab24bd1_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzQzMg_2219a51e-ef44-4ca2-aa1a-529b9449b0bf">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  This milestone payment is payable during 2022 and is included as a current liability at March 31, 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has approximately $<ix:nonFraction unitRef="usd" contextRef="i390596c6353c4e4383db5ca0102868d7_I20220331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzU5Mg_424c4bbe-c594-424b-bdaf-ce444c616c7d">2.6</ix:nonFraction>&#160;million in net intangible assets related to RediTrex at March 31, 2022.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i29c35c65a5a5482b8f69382ae11a1455" continuedAt="i1d766b42140c4eb6a4cfeeedcce505b1"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso Acquisition</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2022, Cumberland acquired the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i33b531a22e104cd8907be7f1309ea431_I20220103" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDgxOQ_a5a40de3-9921-45b8-bf8b-1eec8761dcbe">13.5</ix:nonFraction>&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i33b531a22e104cd8907be7f1309ea431_I20220103" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDgzNA_c3d63a95-30d4-40d4-b109-f4a43af6a061">3.5</ix:nonFraction>&#160;million based on the attainment of various approvals and sales performance. The Company believes that $<ix:nonFraction unitRef="usd" contextRef="i411fb7851cc645fda84082a006d9aae8_D20220101-20220331" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDg0OA_8ecc3e01-a958-43d6-9c05-e27561a4d142">1.5</ix:nonFraction>&#160;million of the milestone payments will be earned and paid.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="i8840d2d783664d03833988394492a1b2_I20220103" decimals="2" name="cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDg2Mg_b580aacd-cfbf-4efc-a573-bf1d960407b2">10</ix:nonFraction>% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a preliminary valuation of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was funded by cash and the Company's revolving credit facility.  The Company is working with an outside consultant firm to finalize the Sancuso valuation of the transaction which will be completed later this year.  The estimates of fair value for the more significant assets and liabilities assumed were prepaid expenses $<ix:nonFraction unitRef="usd" contextRef="i90ce8664b55e4a05a9829ae3b930adff_I20220103" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDg2Nw_9e1b3607-b46e-42e2-a3e6-6f004a68a7fa">0.3</ix:nonFraction>&#160;million, inventory $<ix:nonFraction unitRef="usd" contextRef="i90ce8664b55e4a05a9829ae3b930adff_I20220103" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDg4MQ_2521a590-4b40-4c8c-9d79-373ed210da73">5.2</ix:nonFraction>&#160;million, goodwill $<ix:nonFraction unitRef="usd" contextRef="i90ce8664b55e4a05a9829ae3b930adff_I20220103" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDkwOQ_1f0f0258-c009-4bc4-b696-42df154b3e00">1.0</ix:nonFraction>&#160;million, intangible assets $<ix:nonFraction unitRef="usd" contextRef="i90ce8664b55e4a05a9829ae3b930adff_I20220103" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDkyMw_98edcd09-9f49-457a-8188-effe8c2afe0e">12.1</ix:nonFraction>&#160;million, milestone payable $<ix:nonFraction unitRef="usd" contextRef="i636282a040df4f679c7f36b32d67a813_D20220103-20220103" decimals="-5" name="us-gaap:OtherPaymentsToAcquireBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDkzOA_596359fa-e24a-4d51-a187-9c84b2a94718">1.2</ix:nonFraction>&#160;million and contingent liability $<ix:nonFraction unitRef="usd" contextRef="i90ce8664b55e4a05a9829ae3b930adff_I20220103" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDg5NQ_d42eb2ca-565a-4e8c-ba1b-b699925212f4">3.9</ix:nonFraction>&#160;million.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability earned and accrued in operating expenses is paid to Kyowa Kirin quarterly.  The contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="i10cdce073f8047ab9cded3432889dbae_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDk1Mg_5c081507-b0aa-4217-8937-01767825cf83">3.9</ix:nonFraction>&#160;million was accounted for as $<ix:nonFraction unitRef="usd" contextRef="i10cdce073f8047ab9cded3432889dbae_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDk2Ng_dfa00e60-4ff9-4101-8711-f16b89543d5f">1.3</ix:nonFraction>&#160;million of current liabilities and $<ix:nonFraction unitRef="usd" contextRef="i10cdce073f8047ab9cded3432889dbae_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDk4MA_9affe093-ffd0-4eb5-88f6-8e014298756e">2.6</ix:nonFraction>&#160;million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2022.  </span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i1d766b42140c4eb6a4cfeeedcce505b1"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ethyol and Totect </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland received $<ix:nonFraction unitRef="usd" contextRef="i882c40446970433c9806df95c94da0c4_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNDgwNA_493372a8-659e-4b6e-991f-8bbc484bd7b5">5</ix:nonFraction>&#160;million in financial consideration paid in quarterly installments over the <ix:nonNumeric contextRef="iad75b7bb8c1f44d99624874d167e93a3_D20190101-20191231" name="cpix:FinancialConsiderationPaymentPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMTAxMQ_fcab91da-af88-4086-a883-1703a97994b1">two-years</ix:nonNumeric> following the transition date. Cumberland recorded the first <ix:nonFraction unitRef="installment" contextRef="i973592a5bcc6433aaf22a683d9a22dd5_D20200101-20201231" decimals="INF" name="cpix:FinancialConsiderationNumberOfInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDk5NA_1ec1f0c0-0089-4fb0-989b-49794eb8002d">four</ix:nonFraction> quarterly installments totaling $<ix:nonFraction unitRef="usd" contextRef="i973592a5bcc6433aaf22a683d9a22dd5_D20200101-20201231" decimals="-5" name="cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNDk4Mg_1aad7f7e-3d44-43a2-85f5-7f4e7ffc8f6a">3.0</ix:nonFraction> million during 2020 and the final <ix:nonFraction unitRef="installment" contextRef="i9c0e77e71ede43e88dd6fd578f76e2e6_D20210101-20211231" decimals="INF" name="cpix:FinancialConsiderationNumberOfInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMTAxMg_fdce952e-4482-43d4-b9bd-413876deadb9">four</ix:nonFraction> installments totaling $<ix:nonFraction unitRef="usd" contextRef="i703c37c87b3b4ae1a94069c964a3f5b7_D20210101-20211231" decimals="-5" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNTAzOA_341b176c-3716-427e-a020-a4d6fbfd3f4c">2.0</ix:nonFraction> million during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discontinued operations.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from Ethyol and Totect met the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><ix:nonNumeric contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNTg0Mg_3659e092-0f92-4d67-ae7b-df0c3ac44f8a" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company did not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.829%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644ff4fff14b4f54ad5cdf6cc770dece_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjllYTY4NGEyNDc0MzQwZDg4ODQwNjExMTUwOTcxMzBhL3RhYmxlcmFuZ2U6OWVhNjg0YTI0NzQzNDBkODg4NDA2MTExNTA5NzEzMGFfMy01LTEtMS0yMzM3Mg_37660da1-e720-440b-b27a-0d3f909bae4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c89fbd5ff1649de916ca18e3a139199_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjllYTY4NGEyNDc0MzQwZDg4ODQwNjExMTUwOTcxMzBhL3RhYmxlcmFuZ2U6OWVhNjg0YTI0NzQzNDBkODg4NDA2MTExNTA5NzEzMGFfMy03LTEtMS0yMzM3Mg_47f6dff7-ea4a-4e0f-9347-01f1570319b1">495,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644ff4fff14b4f54ad5cdf6cc770dece_D20220101-20220331" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjllYTY4NGEyNDc0MzQwZDg4ODQwNjExMTUwOTcxMzBhL3RhYmxlcmFuZ2U6OWVhNjg0YTI0NzQzNDBkODg4NDA2MTExNTA5NzEzMGFfNi01LTEtMS0yMzM3Mg_1911ffd5-908c-4afc-b1ce-26adfadbf75a">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c89fbd5ff1649de916ca18e3a139199_D20210101-20210331" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjllYTY4NGEyNDc0MzQwZDg4ODQwNjExMTUwOTcxMzBhL3RhYmxlcmFuZ2U6OWVhNjg0YTI0NzQzNDBkODg4NDA2MTExNTA5NzEzMGFfNi03LTEtMS0yMzM3Mg_aac22bd8-32a6-41f9-9317-bb53b8533c24">495,410</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ia1d36fc2a31344efa67485eba5f161bf_58"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure regarding forward-looking statements</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains certain forward-looking statements which reflect management&#8217;s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ significantly from the results discussed in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; management of our growth and integration of our acquisitions and impacts on our business as well as national and international markets and economies resulting from the COVID-19 pandemic. While forward-looking statements reflect our beliefs and best judgment based upon current information, they are not guarantees of future performance. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2021, and our other filings with the SEC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management&#8217;s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div><span><br/></span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_61"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. We are dedicated to providing innovative products that improve the quality of care for patients and address poorly met medical needs. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary target sectors are hospital acute care, oncology, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote our approved products through our hospital, oncology and field sales forces in the United States.  We have also established partnerships in Puerto Rico and the Middle East for our Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product  and are continuing to build a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of FDA approved brands includes:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of acetaminophen poisoning; </span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caldolor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of pain and fever;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lactulose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) oral, a prescription laxative, for the treatment of constipation;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Omeclamox</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Pak</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, amoxicillin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) oral, for the treatment of Helicobacter pylori (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease;</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">RediTrex</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">methotrexate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis;</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">granisetron) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vibativ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these commercial brands, we have Phase II clinical programs underway evaluating our ifetroban product candidates for patients with cardiomyopathy associated with 1) Duchenne Muscular Dystrophy (&#8220;DMD&#8221;), a fatal, genetic neuromuscular disease; 2) Systemic Sclerosis (&#8220;SSc&#8221;) or scleroderma, a debilitating autoimmune disorder characterized by fibrosis of the skin and internal organs; and 3)  Aspirin-Exacerbated Respiratory Disease (&#8220;AERD&#8221;), a severe form of asthma. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has built core competencies in the acquisition, development and commercialization of pharmaceutical products in the U.S. - and we believe we can leverage this existing infrastructure to support our continued growth both domestically and internationally. Our management team consists of pharmaceutical industry veterans with experience in business development, product development, regulatory, manufacturing, sales, marketing and finance. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business development team identifies, evaluates, and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary formulations, manages our clinical studies, prepares our FDA submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacturing, release and shipment of our products. Our marketing and sales organization is responsible for our commercial activities, and we work closely with our distribution partners to ensure the availability and delivery of our products.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GROWTH STRATEGY</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s growth strategy involves maximizing the success of our existing brands while continuing to build a portfolio of differentiated products. We currently feature eight FDA products approved for sale in the United States. We are also continuing to explore international partnerships to bring our medicines to patients in other countries. Additionally, we look for opportunities to expand our products into additional patient populations through clinical trials, new presentations and our support of select, investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products, as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates largely to address poorly met medical needs.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are supplementing these activities with the earlier-stage drug development at Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary. CET partners with academic research institutions to identify and support the progress of promising new product candidates, which Cumberland could further develop and commercialize.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we are seeking long-term sustainable growth by:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Supporting and expanding the use of our marketed products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use. For example, we have secured pediatric approval of Acetadote and Caldolor and are expanding the labeling for both brands accordingly. We also recently further expanded the labeling for Caldolor to allow its use prior to surgery. We will continue to explore such opportunities to bring our products to new patient populations.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Selectively adding complementary brands. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA-approved drugs as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. Our acquisition of Vibativ and Sancuso are examples of this strategy.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Progressing our clinical pipeline and incubating future product opportunities at CET.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe it is important to build a pipeline of innovative new product opportunities, as we are doing though our ifetroban Phase II development programs. We are also supplementing our acquisitions and late-stage development activities with early-stage drug development activities with CET. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Leveraging our infrastructure through co-promotion partnerships. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic partners that can complement our capabilities and enhance opportunities for our brands. For example, our co-promotion partnerships have allowed us to expand the support for Kristalose and Sancuso across the U.S.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Building an international contribution to our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established our own commercial capabilities, including three sales divisions, to cover the U.S. market for our products. We are also building a network of select international partners to register our products and make them available to patients in their countries. We will continue to develop and expand our network of international partners while supporting our partners&#8217; registration and commercialization efforts in their respective territories. The acquisition of Vibativ resulted in several new international partners and market opportunities.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Managing our operations with financial discipline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continually work to manage our expenses in line with our revenues to deliver cash flow from operations. We remain in a strong financial position, with favorable gross margins and a strong balance sheet.</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT DEVELOPMENTS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2020, the U.S. declared a health care emergency following the outbreak of SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness. Cumberland managed through the resulting pandemic, continuing to operate our business &#8211; keeping facilities open and our organization intact. We moved quickly to ensure the health and safety of our team. We also maintained our ongoing compliance with the many laws and regulations that apply to us as a publicly traded pharmaceutical company.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, we faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our clinical studies were also impacted, as fewer patients sought elective surgeries and our access to medical facilities was substantially limited. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carefully monitored our supply chain, including the flow of raw materials and the batches of finished products emerging from the facilities that manufacture our products. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio that includes brands that have delivered a strong performance during the pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the challenges of operating during a pandemic, Cumberland has remained committed to our mission of providing innovative products that improve the quality of care for patients and address poorly met medical needs. We have continued to build our portfolio of innovative and differentiated products through a multifaceted strategy that includes the development of new candidates and acquisition of established brands. Our resulting, diversified product line has enabled us to weather external challenges, while our team has remained responsive to the evolving medical market. We are prepared for and look forward to future opportunities to carry out our mission. Overall, we have been able to continue the delivery of our products while addressing the interests of our shareholders, employees, partners and community.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sancuso Acquisition</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We started off the first quarter of 2022 with an exciting announcement &#8211; Cumberland acquired the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sancuso Promotion</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To support Sancuso, we have established an oncology sales division, which is initially comprised of two former Kyowa Kirin employees and their five contracted inside sales individuals.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 19, 2022, we also entered into an agreement with Verity Pharmaceuticals International Limited (&#8220;Verity&#8221;) for the national co-promotion of Sancuso. Verity is a specialty pharmaceutical company that will utilize its established oncology commercial organization and customer network to co-promote Sancuso throughout the United States. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Verity will cover a majority of the U.S. market for an initial three-year term, with an option to extend for an additional two years. Verity and Cumberland will share in the incremental contribution margin resulting from Verity&#8217;s efforts.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Vibativ Agreements</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">In March 2022, we announced the launch of our Vibativ product in Puerto Rico. The announcement followed an August 2021 agreement with Verity to license and commercialize our Vibativ product in that territory. Verity has a particular strength and experience in the Puerto Rican market. Vibativ can serve as a potentially life-saving treatment in patients with hospital-acquired and ventilator-associated pneumonia resulting from infections, including the flu and COVID-19.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Also in March 2022, we announced that we have entered into an agreement with Tabuk Pharmaceutical Manufacturing Company (&#8220;Tabuk&#8221;), a fully owned subsidiary of Saudi Arabia&#8217;s publicly traded Astra Industrial Group. Under the terms of the agreement, Tabuk received an exclusive license to distribute Vibativ in Saudi Arabi and Jordan, with an option to expand into other countries in the region. Cumberland has recognized an upfront payment from Tabuk.  In addition, the agreement calls for milestone payments as well as an agreed transfer price on supplies of the product for that territory.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Omeclamox-Pak Supply Update</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The packager for our Omeclamox-Pak product has been unable to provide us with supplies of the product, having encountered difficulties and therefore suspending operations during the pandemic. We are currently awaiting the facility&#8217;s packaging to resume, while also exploring other alternatives to restart the product&#8217;s packaging, before we build new inventory and resupply the market.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vaprisol Supply Update</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are transitioning to a new manufacturer for our Vaprisol product. During 2021, we shipped all remaining inventory of the product and notified the FDA that supplies of the product were then not currently available. We have transferred manufacturing to a new facility, and await the submission and FDA approval for that plant before resuming shipments. That company plans to provide an interim supply of compounded product to the market while awaiting the needed facility approval.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ifetroban Clinical Studies</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been evaluating our ifetroban product candidate, a selective thromboxane-prostanoid receptor (&#8220;TPr&#8221;) antagonist, in a series of clinical studies. It has been dosed in nearly 1,400 subjects and was found to be safe and well tolerated in healthy volunteers and various patient populations. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is currently sponsoring three Phase II clinical programs to evaluate ifetroban in 1) Aspirin-Exacerbated Respiratory Disease, a severe form of asthma; 2) Systemic Sclerosis or scleroderma; a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs; and 3) patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, a genetic neuromuscular disease that results in deterioration of the skeletal, heart and lung muscles.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After being interrupted by the pandemic, enrollment in these studies has resumed as many of our clinical study sites have reopened and begun screening patients for potential participation. We are awaiting results from the studies underway before deciding on the best development path for the registration of ifetroban.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also designing a Phase II study to evaluate the use of ifetroban to treat patients with Progressive Fibrosing Interstitial Lung Diseases. We are preparing an application to the FDA to support the new program.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our company-sponsored studies, an NIH-funded, Harvard-clinical-investigator-led trial has closed enrollment of patients with Aspirin Exacerbated Respiratory Disease. This Phase II, placebo-controlled study, complements our programs and we will announce top-line results following a completion of the data analysis.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland remains committed to our mission of providing innovative products that improve the quality of care for patients and address poorly met medical needs. We are working to fulfill this mission by building a portfolio of innovative and differentiated products through a multifaceted strategy that includes the development of new candidates as well as the acquisition of established brands. Our resulting, diversified product line has enabled us to weather external challenges amid the pandemic, while our team remains responsive to the evolving medical market. We are prepared for and look forward to future opportunities to carry out our mission throughout the remainder of the year.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ia1d36fc2a31344efa67485eba5f161bf_64"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see a discussion of our critical accounting policies and significant judgments and estimates in Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report and the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2021 Annual Report on Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Judgments</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, inventories, fair value of contingent consideration liabilities associated with business combinations, share-based compensation and intangible assets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="ia1d36fc2a31344efa67485eba5f161bf_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended March 31, 2022 compared to the three months ended March 31, 2021 </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited interim statements of operations for continuing operations for the three months ended March 31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,537,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,211,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,417,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205,444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,614,429&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787,340&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,089&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,745,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302,349&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,230,509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,593,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,467,044&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,861,459&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605,585&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,291,999)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324,300)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(967,699)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,041&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,426&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,395,533)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343,291)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,052,242)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350,749)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,051,684)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues by product for the periods presented: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,550,809)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(579,862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,251,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,537,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,886&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the three months ended March 31, 2022, were $11.2 million compared to $10.5 million for the three months ended March 31, 2021.  As detailed in the table above, net revenue increased for two of our marketed products: Kristalose and RediTrex during the quarter, as well as the addition of Sancuso.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue increased by 31.8% during the first quarter of 2022 to $3.9 million, when compared to the prior year period.  The increase was primarily the result of growth in shipments of the product to our wholesale customers.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the quarter, there was a slight decrease in the product's revenue when compared to the prior year period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue was $(0.1) million for the first quarter of 2022, a decrease of $1.3 million compared to the same period last year. This decrease of net sales compared to the first quarter of 2021 is primarily due to a stock shortage as we await pending FDA approval on a new manufacturer. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue was $1.0 million for the first quarter of 2022, a decrease of $0.6 million compared to the same period last year. The decrease was the result of lower international shipments of the product, due to order timing.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue was $2.5 million for the three months ended March 31, 2022, compared to $5.1 million for the same period last year.  The decrease was a result of increased purchases in 2021 due in part to a new packaging change.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso revenue was $3.4 million for the first quarter of 2022, which was $0.3 million higher than the first quarter of 2021 U.S. results reported by Kyowa Kirin, from whom Cumberland acquired the U.S. rights to Sancuso on January 3, 2022.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak had no sales for the first quarter of 2022, as Cumberland is currently out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties, and currently is under new management and a reorganization. We are in discussions about the resumption of packaging the product.  Net revenue for the first quarter of 2022 was positively impacted by various revenue adjustments.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">st of products sold for the first quarter of 2022 and 2021 were $2.2 million and $2.4 million, respectively. Cost of products sold, as a percentage of net revenues, were 19.8% during the three months ended March 31, 2022, compared to 22.9% during the three months ended March 31, 2021.  This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix.  </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the first quarter of 2022 increased $0.8 million compared to the prior year period.  This increase is primarily attributable to an increase in marketing spending for Sancuso as well as royalty costs, direct promotional spending, meeting costs and travel expenses for all of our existing brands including our new oncology sales force. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs for the first quarter of 2022 and 2021 were $1.7 million and $1.3 million, respectively.  A portion of our research and development costs is variable based on the number of trials, study sites, number of patients and the cost per patient in each of our clinical programs. We continue to fund our ongoing clinical initiatives associated with our pipeline products.     </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense for the first quarter of 2022 was $2.3 million, which was  $0.1 million higher than the first quarter of 2021. The increase was primarily attributable to increases in compensation expense.</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,651,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,816&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042,957&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,193,075&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 2022 net revenue includes a $150,000 payment to Cumberland required under the terms of a new licensee agreement.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Since Acquisition</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,772,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,116,416&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,135,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,520,679&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 2022 net revenue includes a $150,000 payment to Cumberland required under the terms of a new licensee agreement.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Sancuso:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Sancuso</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,264&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,098,845&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Sancuso inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2022.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the three months ended March 31, 2022, and three months ended March 31, 2021, totaled approximately $1.6 million and $1.2 million, respectively.  The increase in amortization expense is due to the acquisition of Sancuso.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax expense for the three months ended March 31, 2022, was comparable to the income tax expense for the three months ended March 31, 2021.  </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, we had approximately $56.6 million in federal net operating loss carryforwards including approximately  $44 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations.  We expect to continue to pay minimal income taxes during 2022 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_73"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash equivalents, cash flows from operations and the amounts borrowed under our line of credit. We believe that our internally generated cash flows, existing working capital and our line of credit will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our liquidity and working capital as of March 31, 2022 and December 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,266,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,040,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (current assets less current liabilities)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,784,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,409,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit availability</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net changes in cash and cash equivalents for the three months ended March 31, 2022 and March 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,498)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785,549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,541,898)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,298,079)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,774,031)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $9.8 million decrease in cash and cash equivalents for the three months ended March 31, 2022, was primarily attributable to cash used in investing and partially offset by cash provided by financing activities.  Cash used in operating activities of $0.2 million was primarily the result of accounts receivable increasing by $7.8 million mainly from Sancuso sales, positively impacted by decreases in inventory of $2.3 million and increases in accounts payable and other liabilities of $4.1 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $1.8 million.  Cash used in investing activities was the result of the acquisition of Sancuso.  Our financing activities included the increase in our line of credit of $5.0 million partially offset by the $0.6 million in cash used to repurchase shares of our common stock as well as the $0.5 million used for the payment of royalties for sales of Vibativ and Sancuso.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $0.2 million increase in cash and cash equivalents for the three months ended March 31, 2021, was primarily attributable to cash provided by operating activities, partially offset by cash used in investing and financing activities.  Cash provided by operating activities of $1.8 million was positively impacted by decreases in inventory of $1.9 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $1.4 million.  Cash used in investing activities was the result of additions to intangibles of $0.1 million and the payment of $0.2 million to the WHC JV.  Our financing activities included the $0.3 million in cash used to repurchase shares of our common stock as well as the $1.0 million used for the payment of royalties to Theravance for sales of Vibativ. </span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement (the "Pinnacle Agreement") to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $15 million to $20 million. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment ("Fifth Amendment") to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Pinnacle Agreement was dated July 2017.  Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement. The Fifth Amendment extends the maturity date three years through October 1, 2024.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at March 31, 2022.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  The parties have agreed on a process to determine a new interest rate benchmark at the point the LIBOR rate is expected to be discontinued over the next 12  to 24 months.    </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the Company had $20.0 million and $15.0 million, respectively, in borrowings outstanding under its revolving credit facility.  The Company was in compliance with the Maximum Funded Debt Ratio financial covenant as of March 31, 2022. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland used the PPP loan funds for such qualifying expenses. Due to assistance from our PPP loan, the Company did not lay off or furlough any employees as a result of the COVID-19 pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Cumberland submitted a request for the loan&#8217;s forgiveness. On June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven. </span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_76"></div><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, we did not engage in any off-balance sheet arrangements.</span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_79"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and our revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts at March 31, 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread.  The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at March 31, 2022.   As of March 31, 2022, we had $20.0 million in borrowings outstanding under our revolving credit facility. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Rate Risk</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we operate primarily in the United States, we are exposed to foreign currency risk.  Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations.  We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice.  Foreign currency exchange gains and losses were immaterial for the three months ended March 31, 2022 and 2021.  Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.</span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_82"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management, with the participation of the Company&#8217;s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, the Company&#8217;s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company&#8217;s disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and is accumulated and communicated to the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, there has not been any change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="ia1d36fc2a31344efa67485eba5f161bf_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_88"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material developments with regard to the legal proceedings previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_91"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information set forth in this quarterly report, an investor should consider the risk factors included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div id="ia1d36fc2a31344efa67485eba5f161bf_94"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity, by month, during the three months ended March 31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:37.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares or Units</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased, which were also Part of the Publicly Announced Plans or Programs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price&#160;Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;Share</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Unit)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Approximate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Value) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;(or&#160;Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">that May Yet Be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased&#160;Under</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">the Plans or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Programs</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,642</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,595,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,910</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,465,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,597</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,213,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,149</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Of this amount, 50,874 shares were repurchased directly through private purchases at the then-current fair market value of common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ia1d36fc2a31344efa67485eba5f161bf_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ajkazimi-2022.htm">Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between A.J. Kazimi and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.11 of the Company&#8217;s Annual Report on Form 10-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 11, 2022).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="leopavliv-2022.htm">Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between Leo B. Pavliv and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.13 of the Company&#8217;s Annual Report on Form 10-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 11, 2022).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="johnhamm-2022.htm">Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between John M. Hamm and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.14 of the Company&#8217;s Annual Report on Form 10-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 11, 2022).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="jamesherman-2022.htm">Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between James L. Herman and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.15 of the Company&#8217;s Annual Report on Form 10-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 11, 2022).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="pinnaclebank-cpiamend7tolo.htm">Seventh</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="pinnaclebank-cpiamend7tolo.htm"> Amendment to Revolving Credit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="pinnaclebank-cpiamend7tolo.htm"> Loan Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="pinnaclebank-cpiamend7tolo.htm">, dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="pinnaclebank-cpiamend7tolo.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="pinnaclebank-cpiamend7tolo.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="pinnaclebank-cpiamend7tolo.htm">31</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="pinnaclebank-cpiamend7tolo.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="pinnaclebank-cpiamend7tolo.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="pinnaclebank-cpiamend7tolo.htm">, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q1-exhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q1-exhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q1-exhibit321.htm">Certification of Chief Executive and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVER PAGE INTERACTIVE DATA FILE (FORMATTED AS INLINE XBRL AND CONTAINED IN EXHIBIT 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ia1d36fc2a31344efa67485eba5f161bf_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:8.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.416%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Duly Authorized Officer</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ajkazimi-2022.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3d04a729a8db4a27a73095f5c963e0ba_1"></div><div style="min-height:153.36pt;width:100%"><div style="text-align:center"><img alt="image_2.jpg" src="image_2.jpg" style="height:90px;margin-bottom:5pt;vertical-align:text-bottom;width:394px"></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 7, 2022</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mr. AJ Kazimi </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2525 West End Avenue, Suite 950</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nashville, TN  37203</font></div><div style="text-align:justify"><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of AJ Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear AJ, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2022, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Chief Executive Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of six hundred thirty-five thousand dollars ($635,000.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2022.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:153.36pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain </font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:153.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret </font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:153.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.&#160; The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:153.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i3d04a729a8db4a27a73095f5c963e0ba_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><img alt="image_2.jpg" src="image_2.jpg" style="height:90px;margin-bottom:5pt;vertical-align:text-bottom;width:394px"></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Standards of Business Conduct and Ethics.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:108pt;padding-right:108pt;text-align:center"><img alt="image_1.jpg" src="image_1.jpg" style="height:92px;margin-bottom:5pt;vertical-align:text-bottom;width:216px"></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;Stephanie Smith, MBA, HRM</font></div><div style="padding-left:108pt;padding-right:108pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HR Manager</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of March 2022&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________________________________</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.J. Kazimi </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>leopavliv-2022.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7f3de3444f2b4a418d75b7ec37a0b275_1"></div><div style="min-height:100.08pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 7, 2022</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mr. Leo Pavliv </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2525 West End Avenue, Suite 950</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nashville, TN  37203</font></div><div style="text-align:justify"><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of Leo Pavliv as Executive Vice President, Chief Development &#38; Operations Officer by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Leo, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2022, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Executive Vice President, Chief Development &#38; Operations Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of four hundred and fifty-five thousand dollars ($455,000.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2022.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.&#160; The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7f3de3444f2b4a418d75b7ec37a0b275_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Standards of Business Conduct and Ethics.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:108pt;padding-right:108pt;text-align:center"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of March 2022&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________________________________</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leo Pavliv </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>johnhamm-2022.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1cba605d41dc46e680f2632b7335b0f3_1"></div><div style="min-height:149.76pt;width:100%"><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:85px;margin-bottom:5pt;vertical-align:text-bottom;width:371px"></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 7, 2022</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mr. John Hamm </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2525 West End Avenue, Suite 950</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nashville, TN  37203</font></div><div style="text-align:justify"><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of John Hamm as Senior Director of Finance &#38; Accounting &#38; Chief Financial Officer Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear John, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2022, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Senior Director of Finance &#38; Accounting &#38; Chief Financial Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of one hundred and ninety-two thousand dollars ($192,000.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2022.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in </font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:149.76pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, </font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:149.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall </font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:149.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.&#160; The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable </font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:149.76pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1cba605d41dc46e680f2632b7335b0f3_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:85px;margin-bottom:5pt;vertical-align:text-bottom;width:371px"></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Standards of Business Conduct and Ethics.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:108pt;padding-right:108pt;text-align:center"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of March 2022&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________________________________</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">John Hamm </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>jamesherman-2022.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6e442e2be8644261aa1ce3e9ec66eacb_1"></div><div style="min-height:100.08pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 7, 2022</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mr. James Herman </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2525 West End Avenue, Suite 950</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nashville, TN  37203</font></div><div style="text-align:justify"><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of James Herman as Executive Vice President, National Accounts and Chief Compliance Officer Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear John, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2022, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Executive Vice President, National Accounts and Chief Compliance Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of two hundred and ninety-two thousand dollars ($292,000.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2022.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.&#160; The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6e442e2be8644261aa1ce3e9ec66eacb_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Standards of Business Conduct and Ethics.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:108pt;padding-right:108pt;text-align:center"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of March 2022&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________________________________</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James Herman </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>pinnaclebank-cpiamend7tolo.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8ecb277e1c0a410c8f8853c4c34c4181_1"></div><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:51.95pt;padding-right:51.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SEVENTH AMENDMENT  TO REVOLVING  CREDIT LOAN AGREEMENT</font></div><div><font><br></font></div><div style="margin-top:5.85pt;padding-left:40.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">THIS SEVENTH AMENDMENT  TO REVOLVING  CREDIT LOAN AGREEMENT  (this</font></div><div style="margin-top:0.1pt;padding-left:6.2pt;padding-right:4.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:116%">&#34;Amendment&#34;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:116%">is entered into as of March 31, 2022 by and between CUMBERLAND PHARMACEUTICALS INC., a Tennessee corporation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:116%">(&#34;Borrower&#34;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:116%">and PINNACLE BANK, a Tennessee banking corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:116%">&#34;Lender&#34;).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:51.92pt;padding-right:51.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RECITALS&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.5pt;padding-right:5.3pt;text-align:justify;text-indent:24.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:116%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:116%;padding-left:31.6pt">Borrower and the Lender entered into that certain Revolving Credit Loan Agreement dated as of July 31, 2017, as amended by that certain First Amendment to Revolving Credit Loan Agreement dated August 14, 2018, as amended by that ce1iain First Amendment to Revolving Credit Note and Second Amendment to Revolving Credit Loan Agreement dated October 17, 2018, as amended by that certain Second Amendment to Revolving Credit Note and Third Amendment to Revolving Credit Loan Agreement dated May 10, 2019, as amended by that certain Third Amendment to Revolving Credit Note and Fourth Amendment to Revolving Credit Loan Agreement dated October 7, 2020, as amended by that certain Fourth Amendment to Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement dated as of October 28, 2021, and as amended by that certain Fifth Amendment to Revolving Credit Note and Sixth Amendment to Revolving Credit Loan Agreement dated as of December 31, 2021 (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:116%">&#34;Loan Agreement&#34;). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:116%">Capitalized terms not otherwise defined therein have the same meaning as set fo1ih in the Loan Agreement.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:74.65pt;text-indent:-43.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:34.33pt">Borrower and the Lender desire to amend the Loan Agreement as provided herein.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.7pt;padding-right:5.65pt;text-align:justify;text-indent:33.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.9pt;text-indent:-33.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:26.25pt;text-decoration:underline">Section 6.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">of the Loan Agreement is hereby amended and restated as follows&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:40.2pt;padding-right:5.4pt;text-align:justify;text-indent:34.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">6.7       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">Maximum  Funded  Debt  R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">atio. Permit the Funded Debt Ratio of Borrower  as calculated for Borrower and its Subsidiaries at the end of each fiscal quarter on a rolling  four quaiier basis to exceed 2.50 to 1.00.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.9pt;text-indent:34.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:24.18pt">In connection with item  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">above, any and all provisions or definitions related  to the</font></div><div style="margin-top:0.1pt;padding-left:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Funded Debt to Tangible Capital Ratio&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">set forth in the Loan Agreement ai&#183;e hereby deleted.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.781%"><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">follows&#58;</font></div><div style="margin-top:3.65pt;padding-left:33.1pt;text-indent:-34.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">3.</font></div></div><div style="display:inline-block;max-width:0.437%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.782%"><div style="padding-left:33.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:31.03pt">The definition of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;EBITDA&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">is hereby amended and restated as</font></div></div></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:3.65pt;padding-left:39.45pt;padding-right:5.4pt;text-align:justify;text-indent:35.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;EBITDA&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">means (a) Net Income Attributable to Borrower's Shareholders, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">plus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(b) to the extent deducted in determining Net Income Attributable to Borrower's Shareholders, and without duplication, the sum of (i) Interest Expense, (ii) income tax expense, (iii) depreciation expense, (iv) amortization expense, (v) Non-Cash Compensation Expense, (vi) cost of products sold associated with the Vibativ Acquisition provided that (x) the inventory was acquired on the acquisition date, and (y) the aggregate amount of such cost of products sold shall not exceed 30% of EBITDA in any measurement period, (vii) the one-time write down of Vibativ inventory recognized in the quarter ending December 31, 2021 in the amount of $1,100,000, and, as reasonably agreed to by Lender, any additional one-time non-cash adjustments as reported by the Borrower on the  Borrower's quarterly &#34;Reconciliation of Net Income (loss) Attributable to Common Shareholders to Adjusted Earnings (loss) ...&#34;, and (viii) cost of products sold associated</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">105639-301010</font></div><div style="height:35.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i8ecb277e1c0a410c8f8853c4c34c4181_4"></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3.65pt;padding-left:40.7pt;padding-right:5.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:116%">with the Sancuso Acquisition provided that (x) the work in process and finished goods inventory was acquired on the acquisition date, and (y) the aggregate amount of such cost of products sold shall not exceed 30% of EBITDA in any measurement period. For purposes of calculating EBITDA, EBITDA shall only include EBITDA arising from a permitted Acquisition if Lender is provided with a quality of earnings report related to any such Acquisition reasonably acceptable to Lender. Notwithstanding the foregoing, EBITDA shall include the following amounts for the specified periods related to the Sancuso Acquisition&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:106.45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.309%"><tr><td style="width:1.0%"></td><td style="width:55.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.35pt;padding-left:1.07pt;padding-right:1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Period</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 34.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Amount</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:7.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">3 months ending 6&#47;30&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 29.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">$2,001,365</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:7.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">3 months ending 9&#47;30&#47;2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 29.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">$2,001,365</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">3 months ending 12&#47;31&#47;2021</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 29.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">$2,001,365</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:5.6pt;text-align:justify;text-indent:34.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%;padding-left:23.43pt">The following is hereby added as a new definition under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%;text-decoration:underline">Section 9.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:119%">of the Loan Agreement&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:40.7pt;padding-right:5.55pt;text-align:justify;text-indent:34.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:117%">&#34;Sancuso Acquisition&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:117%">means Borrower's purchase of certain assets related to the manufacture, marketing and sale of the proprietary oncology-supportive care medicine, Sancuso, from Kyowa Kirin, Inc.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:75.25pt;text-indent:-34.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:26.43pt">The Loan Agreement are not amended in any other respect.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.7pt;padding-right:5.55pt;text-align:justify;text-indent:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:117%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:117%;padding-left:23.43pt">Borrower reaffirms the terms and provisions of the Loan Documents and agrees that such terms and provisions are valid and binding, enforceable in accordance with its terms and provisions, subject to no defense, counterclaim, or objection.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:141.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#91;signatures commence on following page&#93;</font></div><div style="height:35.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i8ecb277e1c0a410c8f8853c4c34c4181_7"></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:3.7pt;padding-left:32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENTERED INTO as of the date first written above.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:168.6pt;padding-right:168.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">BORROWER&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:205.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.773%"><div style="margin-top:0.5pt"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:100%">--</font></div><div style="margin-top:0.25pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.453%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.774%"><div><font><br></font></div><div style="padding-left:72.6pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:58px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:100%">Digitally </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">signed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:100%">by AJ. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">Kazimi</font></div><div style="margin-top:0.8pt;padding-left:72.35pt;padding-right:48.4pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:18px;margin-bottom:5pt;vertical-align:text-bottom;width:21px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.5pt;font-weight:400;line-height:130%">DN&#58; cn&#61;A.J.  Kazimi, o&#61;Cumberland </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.5pt;font-weight:400;line-height:130%">Pharmaceuticals Inc., ou&#61;CPI, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:130%">email&#61;tmajor&#64;cumberlandpharma.</font></div></div></div><div style="margin-top:0.35pt;padding-left:254.65pt;text-indent:-15.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:5.38pt">. Kazimi, Chief.&#160;&#160;&#160;&#160;'eootv.e&#61;iicer</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:158.82pt;padding-right:158.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">LENDER&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:177.22pt;padding-right:177.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PINNACLE  BANK</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:203.9pt"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:53px;margin-bottom:5pt;vertical-align:text-bottom;width:303px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:56.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Seventh Amendment to Revolving Credit Loan Agreement&#93;</font></div><div style="height:35.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>a2022q1-exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i674390f227504a65a39d028b2ce6d979_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, A.J. Kazimi, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>a2022q1-exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7076f9d0efa940f090cc458300e7780f_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Hamm, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>a2022q1-exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2c30800bf879443da72cfcb608138d66_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form&#160;10-Q for the fiscal quarter ended March 31, 2022 of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer and John Hamm, Chief Financial Officer of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:38.888%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A. J. Kazimi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2022</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Hamm</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2022</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>cpix-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:71f09af2-eb91-4470-8350-f575ad603b6a,g:f5c1e857-adec-4283-ba91-4579f8814480-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquity" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationOrganizationDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails">
        <link:definition>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>2104102 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>2305301 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails">
        <link:definition>2406402 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual">
        <link:definition>2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>2108103 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>2309302 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails">
        <link:definition>2410404 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>2111104 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>2312303 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>2413405 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>2414406 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>2115105 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>2316304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>2417407 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>2418408 - Disclosure - Leases - Lease Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails">
        <link:definition>2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1">
        <link:definition>2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRentExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails">
        <link:definition>2420410 - Disclosure - Leases - Rent Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebt" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt">
        <link:definition>2121106 - Disclosure - Shareholders' Equity and Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtShareholdersEquityDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails">
        <link:definition>2422411 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtDebtDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails">
        <link:definition>2423412 - Disclosure - Shareholders' Equity and Debt - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>2124107 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2425413 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements">
        <link:definition>2126108 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRights" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights">
        <link:definition>2127109 - Disclosure - Additions and Returns of Product Rights</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsTables" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables">
        <link:definition>2328305 - Disclosure - Additions and Returns of Product Rights (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails">
        <link:definition>2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsChangeinConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
        <link:definition>2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails">
        <link:definition>2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OtherLongTermObligationsExcludingCurrentPortion" abstract="false" name="OtherLongTermObligationsExcludingCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_FifthAmendmentMember" abstract="true" name="FifthAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseNumberOfRenewalTerms" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalTerms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_ClinigenHealthcareLimitedMember" abstract="true" name="ClinigenHealthcareLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ShareholdersEquityTextualAbstract" abstract="true" name="ShareholdersEquityTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_MethotrexateMember" abstract="true" name="MethotrexateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_IfetrobanClinicalMember" abstract="true" name="IfetrobanClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_IncentiveStockOptionsMember" abstract="true" name="IncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_EquityAndDebtAbstract" abstract="true" name="EquityAndDebtAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_BroadwestLeaseFiveYearRenewalOptionMember" abstract="true" name="BroadwestLeaseFiveYearRenewalOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" abstract="false" name="IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_WinHealthInvestmentSingaporeLtdMember" abstract="true" name="WinHealthInvestmentSingaporeLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_FinancialConsiderationPaymentPeriod" abstract="false" name="FinancialConsiderationPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" abstract="false" name="ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SancusoMember" abstract="true" name="SancusoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_RediTrexMember" abstract="true" name="RediTrexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInCurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseLeasedArea" abstract="false" name="LesseeOperatingLeaseLeasedArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="cpix_KyowaKirinMember" abstract="true" name="KyowaKirinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_FinancialConsiderationNumberOfInstallments" abstract="false" name="FinancialConsiderationNumberOfInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_ProductsAbstract" abstract="true" name="ProductsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsThreshold" abstract="false" name="TieredRoyaltyPaymentsThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" abstract="false" name="ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>cpix-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:71f09af2-eb91-4470-8350-f575ad603b6a,g:f5c1e857-adec-4283-ba91-4579f8814480-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6728e7e1-940a-4d04-ac0c-d1e81712f109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1a08195-46ee-42de-93d6-265765581566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6728e7e1-940a-4d04-ac0c-d1e81712f109" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1a08195-46ee-42de-93d6-265765581566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c287e882-f62b-4838-975f-99b057342c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6728e7e1-940a-4d04-ac0c-d1e81712f109" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c287e882-f62b-4838-975f-99b057342c8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_4978c07b-102f-4cbe-8db5-07c6b28213ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6728e7e1-940a-4d04-ac0c-d1e81712f109" xlink:to="loc_us-gaap_OtherAssetsCurrent_4978c07b-102f-4cbe-8db5-07c6b28213ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d486a944-f989-4b95-837e-248ec47f2231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6728e7e1-940a-4d04-ac0c-d1e81712f109" xlink:to="loc_us-gaap_InventoryNet_d486a944-f989-4b95-837e-248ec47f2231" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f290e880-e21f-47c8-ab82-fe062d550915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_3a1ffdf7-300d-4a95-be66-22cd53767309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f290e880-e21f-47c8-ab82-fe062d550915" xlink:to="loc_us-gaap_LongTermLineOfCredit_3a1ffdf7-300d-4a95-be66-22cd53767309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8d3cf236-5194-4cc1-8496-3fc7edf4ea14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f290e880-e21f-47c8-ab82-fe062d550915" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8d3cf236-5194-4cc1-8496-3fc7edf4ea14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dae3f58c-5afd-40e3-a85f-cbbc92bdf792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f290e880-e21f-47c8-ab82-fe062d550915" xlink:to="loc_us-gaap_LiabilitiesCurrent_dae3f58c-5afd-40e3-a85f-cbbc92bdf792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_00dd0327-f5a3-445f-b064-64ebf26b46fa" xlink:href="cpix-20220331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f290e880-e21f-47c8-ab82-fe062d550915" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_00dd0327-f5a3-445f-b064-64ebf26b46fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8492db08-7dae-466d-9595-ad39d924124d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_df92bc9f-bb02-41ab-b0d0-4c76b1317af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8492db08-7dae-466d-9595-ad39d924124d" xlink:to="loc_us-gaap_CommonStockValue_df92bc9f-bb02-41ab-b0d0-4c76b1317af4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df542db8-3931-4f46-8f34-a37030b16669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8492db08-7dae-466d-9595-ad39d924124d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df542db8-3931-4f46-8f34-a37030b16669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_af07b706-9013-4528-abde-3318eb17e274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36f82743-fb15-48d4-8b9c-5a39b892f673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_af07b706-9013-4528-abde-3318eb17e274" xlink:to="loc_us-gaap_StockholdersEquity_36f82743-fb15-48d4-8b9c-5a39b892f673" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e3a150a3-aad9-4fae-acdf-e212a1fb51e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_af07b706-9013-4528-abde-3318eb17e274" xlink:to="loc_us-gaap_MinorityInterest_e3a150a3-aad9-4fae-acdf-e212a1fb51e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4b0b6209-5e5f-4a65-812c-4140f13aace4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1c9b5087-61e0-4560-89a8-22c35ec9555f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4b0b6209-5e5f-4a65-812c-4140f13aace4" xlink:to="loc_us-gaap_Liabilities_1c9b5087-61e0-4560-89a8-22c35ec9555f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0b1c824a-42cc-4af8-b822-085d87ae0c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4b0b6209-5e5f-4a65-812c-4140f13aace4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0b1c824a-42cc-4af8-b822-085d87ae0c36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_91305c79-2082-4d52-b57e-7c1afc9432c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4b0b6209-5e5f-4a65-812c-4140f13aace4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_91305c79-2082-4d52-b57e-7c1afc9432c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_53ed84ef-50be-4e6c-af04-91ef49bcf7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_da655d09-31f1-47ed-9874-24a5b9876197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53ed84ef-50be-4e6c-af04-91ef49bcf7f5" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_da655d09-31f1-47ed-9874-24a5b9876197" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f2e9c14b-2c1c-4bba-af0a-1e5aa4f4ee45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53ed84ef-50be-4e6c-af04-91ef49bcf7f5" xlink:to="loc_us-gaap_AccountsPayableCurrent_f2e9c14b-2c1c-4bba-af0a-1e5aa4f4ee45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8dbb578d-e199-405d-adfe-805d55d6ef34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53ed84ef-50be-4e6c-af04-91ef49bcf7f5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8dbb578d-e199-405d-adfe-805d55d6ef34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d5f697fa-7a95-4170-86b5-f4c27d9b7df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_98b6358d-5b76-4dcc-ad2f-371a4b64d2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d5f697fa-7a95-4170-86b5-f4c27d9b7df1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_98b6358d-5b76-4dcc-ad2f-371a4b64d2e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a364acdf-21f7-437f-8557-538ba1548baf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d5f697fa-7a95-4170-86b5-f4c27d9b7df1" xlink:to="loc_us-gaap_Goodwill_a364acdf-21f7-437f-8557-538ba1548baf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_edf0d6dd-496c-4ce0-9ccc-05ea1fdf6f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d5f697fa-7a95-4170-86b5-f4c27d9b7df1" xlink:to="loc_us-gaap_InventoryNoncurrent_edf0d6dd-496c-4ce0-9ccc-05ea1fdf6f36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ecb82bbe-b58f-42dc-a0ee-5632acc8edcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d5f697fa-7a95-4170-86b5-f4c27d9b7df1" xlink:to="loc_us-gaap_AssetsCurrent_ecb82bbe-b58f-42dc-a0ee-5632acc8edcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fad5b0a6-8270-4c1d-a376-8348159a793c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d5f697fa-7a95-4170-86b5-f4c27d9b7df1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fad5b0a6-8270-4c1d-a376-8348159a793c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5d714f78-90bf-4a71-bebe-0283ee44d66d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d5f697fa-7a95-4170-86b5-f4c27d9b7df1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5d714f78-90bf-4a71-bebe-0283ee44d66d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d4571fb8-fd0d-4692-8676-5108e6a3b1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d5f697fa-7a95-4170-86b5-f4c27d9b7df1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d4571fb8-fd0d-4692-8676-5108e6a3b1b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20220331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d09f96d0-834f-4bed-a380-54bf63deb0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d4994de2-2613-491a-bc4b-eb836644345e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d09f96d0-834f-4bed-a380-54bf63deb0b4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d4994de2-2613-491a-bc4b-eb836644345e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_30790d12-9d47-458d-a2fb-c512ca79212c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d09f96d0-834f-4bed-a380-54bf63deb0b4" xlink:to="loc_us-gaap_CostsAndExpenses_30790d12-9d47-458d-a2fb-c512ca79212c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0ec77702-e4d3-4720-811c-d74f7ec6dc94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8e403312-9347-4d6e-b1b7-d4c1bd75dca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0ec77702-e4d3-4720-811c-d74f7ec6dc94" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8e403312-9347-4d6e-b1b7-d4c1bd75dca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_89bd05ed-54e1-4f51-97ed-80939d940ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0ec77702-e4d3-4720-811c-d74f7ec6dc94" xlink:to="loc_us-gaap_SellingAndMarketingExpense_89bd05ed-54e1-4f51-97ed-80939d940ea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_44bdb32c-00c6-4b28-add4-ea3f9ef0bf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0ec77702-e4d3-4720-811c-d74f7ec6dc94" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_44bdb32c-00c6-4b28-add4-ea3f9ef0bf4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_60c33f01-3864-40ba-838f-c3ae96c794ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0ec77702-e4d3-4720-811c-d74f7ec6dc94" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_60c33f01-3864-40ba-838f-c3ae96c794ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d73bd002-38c5-4c27-a11e-b14b51f23e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0ec77702-e4d3-4720-811c-d74f7ec6dc94" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d73bd002-38c5-4c27-a11e-b14b51f23e41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e66941a3-a752-4dbc-a45b-022de035f086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d8f5609-dc51-4614-8d4b-285a9b7a525b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e66941a3-a752-4dbc-a45b-022de035f086" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d8f5609-dc51-4614-8d4b-285a9b7a525b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f4fd161b-6f9b-4dd4-a391-ed7a569608bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e66941a3-a752-4dbc-a45b-022de035f086" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f4fd161b-6f9b-4dd4-a391-ed7a569608bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5bf080a9-4ca7-4872-af5d-a19e5e3f016c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_27b794a6-e35b-44cf-b991-203bc423bb66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5bf080a9-4ca7-4872-af5d-a19e5e3f016c" xlink:to="loc_us-gaap_ProfitLoss_27b794a6-e35b-44cf-b991-203bc423bb66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4451df28-72e4-4344-85b7-23f414e0334d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5bf080a9-4ca7-4872-af5d-a19e5e3f016c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4451df28-72e4-4344-85b7-23f414e0334d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e6cd370a-f740-401c-8e01-138acf57903d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_63e41caa-8844-4825-b33f-b69b021eabf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_e6cd370a-f740-401c-8e01-138acf57903d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_63e41caa-8844-4825-b33f-b69b021eabf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a1cf9b60-615c-4877-940b-0c76338e7554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_e6cd370a-f740-401c-8e01-138acf57903d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a1cf9b60-615c-4877-940b-0c76338e7554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_abd5d1bd-0d9a-4cbd-a0a9-7219c3f89d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6c1f2e61-71a4-4ecb-9633-b9c0b4b4a4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_abd5d1bd-0d9a-4cbd-a0a9-7219c3f89d22" xlink:to="loc_us-gaap_OperatingIncomeLoss_6c1f2e61-71a4-4ecb-9633-b9c0b4b4a4ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5b17e7c9-83fc-47b5-bb98-1cb95ebeb7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_abd5d1bd-0d9a-4cbd-a0a9-7219c3f89d22" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5b17e7c9-83fc-47b5-bb98-1cb95ebeb7c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_78410599-1ffd-4c08-bd47-3a9f6d8ae80a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_abd5d1bd-0d9a-4cbd-a0a9-7219c3f89d22" xlink:to="loc_us-gaap_InterestExpense_78410599-1ffd-4c08-bd47-3a9f6d8ae80a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20220331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_944092fb-79b3-4226-92a8-a79e30f29be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_a9870173-9324-4ab6-81aa-04aae60e4760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_944092fb-79b3-4226-92a8-a79e30f29be3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_a9870173-9324-4ab6-81aa-04aae60e4760" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_56bc1a28-1a5d-4cce-88eb-b1fefb6a5cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_944092fb-79b3-4226-92a8-a79e30f29be3" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_56bc1a28-1a5d-4cce-88eb-b1fefb6a5cbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_19f58226-48af-4d3d-be4c-62a42518ecba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_41dc5f04-0002-4c32-ab1d-730aad1913cf" xlink:href="cpix-20220331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_19f58226-48af-4d3d-be4c-62a42518ecba" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_41dc5f04-0002-4c32-ab1d-730aad1913cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_dd3a7924-050c-414c-8baa-5966dcddec62" xlink:href="cpix-20220331.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_19f58226-48af-4d3d-be4c-62a42518ecba" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_dd3a7924-050c-414c-8baa-5966dcddec62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_db9325d6-b89e-44d6-92a7-b106f073acf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_19f58226-48af-4d3d-be4c-62a42518ecba" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_db9325d6-b89e-44d6-92a7-b106f073acf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_118c75e1-9759-4f67-ad8e-ce2d050e4f47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_19f58226-48af-4d3d-be4c-62a42518ecba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_118c75e1-9759-4f67-ad8e-ce2d050e4f47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_48ca2f43-d79a-40d1-b858-de7401fb0cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_19f58226-48af-4d3d-be4c-62a42518ecba" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_48ca2f43-d79a-40d1-b858-de7401fb0cb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b44f3d39-dbca-4290-b4f2-2d4c99edbf07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_19f58226-48af-4d3d-be4c-62a42518ecba" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b44f3d39-dbca-4290-b4f2-2d4c99edbf07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1a49b374-48ec-4ebb-b93d-192970ff8cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_19f58226-48af-4d3d-be4c-62a42518ecba" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1a49b374-48ec-4ebb-b93d-192970ff8cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e4b1034f-09f2-42da-a6af-b2b9dc5714a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_19f58226-48af-4d3d-be4c-62a42518ecba" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e4b1034f-09f2-42da-a6af-b2b9dc5714a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_fbe0acc4-ed23-4df9-9467-24e7aef0bc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_19f58226-48af-4d3d-be4c-62a42518ecba" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_fbe0acc4-ed23-4df9-9467-24e7aef0bc2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2f6aa414-14d9-40c7-8391-aa048b876f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_19f58226-48af-4d3d-be4c-62a42518ecba" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2f6aa414-14d9-40c7-8391-aa048b876f3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d26fd837-520a-4213-90d5-9e2f2b0cc747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_19f58226-48af-4d3d-be4c-62a42518ecba" xlink:to="loc_us-gaap_ShareBasedCompensation_d26fd837-520a-4213-90d5-9e2f2b0cc747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_feda3f87-35c1-4617-a51f-c6355c700b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d001828b-7513-4831-833e-f12dafb42432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_feda3f87-35c1-4617-a51f-c6355c700b7e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d001828b-7513-4831-833e-f12dafb42432" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3cc1975e-db7b-4afe-adea-8d56a699cdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_feda3f87-35c1-4617-a51f-c6355c700b7e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3cc1975e-db7b-4afe-adea-8d56a699cdb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_5dbb6c3c-e81e-409e-ba2f-63501b1f3c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_feda3f87-35c1-4617-a51f-c6355c700b7e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_5dbb6c3c-e81e-409e-ba2f-63501b1f3c2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_18368a99-644f-4bbd-be5c-2e245c43505a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_feda3f87-35c1-4617-a51f-c6355c700b7e" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_18368a99-644f-4bbd-be5c-2e245c43505a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9849078-571d-418c-8a8c-f988db1fd0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_8ce22f9b-eb55-436e-8848-8632783630a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9849078-571d-418c-8a8c-f988db1fd0d0" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_8ce22f9b-eb55-436e-8848-8632783630a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8d0109e5-e9b3-439d-8c4d-06e3c5c54079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9849078-571d-418c-8a8c-f988db1fd0d0" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8d0109e5-e9b3-439d-8c4d-06e3c5c54079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_52a7c9d5-d38e-4c65-bd37-6a5bc14dd39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9849078-571d-418c-8a8c-f988db1fd0d0" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_52a7c9d5-d38e-4c65-bd37-6a5bc14dd39c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9de412a9-09a6-4542-9285-46baba62b2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9849078-571d-418c-8a8c-f988db1fd0d0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9de412a9-09a6-4542-9285-46baba62b2d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15980023-1aa0-4538-8ecf-03b003aca157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5977ff07-9747-4fd7-8d68-2891dbe72466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15980023-1aa0-4538-8ecf-03b003aca157" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5977ff07-9747-4fd7-8d68-2891dbe72466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28f91402-1d6e-4651-94ca-16aca54535b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15980023-1aa0-4538-8ecf-03b003aca157" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28f91402-1d6e-4651-94ca-16aca54535b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45a6a90f-7fab-446e-bf24-bd8d1bd15f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15980023-1aa0-4538-8ecf-03b003aca157" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45a6a90f-7fab-446e-bf24-bd8d1bd15f1c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b629f44c-66ee-4d06-8101-6219f1d6a59c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ad28f35d-7998-4178-9dc8-673700ab6811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b629f44c-66ee-4d06-8101-6219f1d6a59c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ad28f35d-7998-4178-9dc8-673700ab6811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_060f0617-de76-4321-9af6-a3146dc3059e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b629f44c-66ee-4d06-8101-6219f1d6a59c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_060f0617-de76-4321-9af6-a3146dc3059e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_2a62cf58-6041-4895-9285-3a66983db136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_bb863bed-dccb-4977-85e2-e8d7056e2708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2a62cf58-6041-4895-9285-3a66983db136" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_bb863bed-dccb-4977-85e2-e8d7056e2708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_1cd051c8-d1c1-4dd7-ae5b-f7d46cdee2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2a62cf58-6041-4895-9285-3a66983db136" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_1cd051c8-d1c1-4dd7-ae5b-f7d46cdee2ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_04571085-e7de-485c-8f35-451f325db302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2a62cf58-6041-4895-9285-3a66983db136" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_04571085-e7de-485c-8f35-451f325db302" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a06f2c68-86c2-421e-b30e-094cebb84e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e09007fe-4500-4bdd-8166-50a1d27d8af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a06f2c68-86c2-421e-b30e-094cebb84e5b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e09007fe-4500-4bdd-8166-50a1d27d8af1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7befe914-b5e4-435c-9f0d-e112af51acb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a06f2c68-86c2-421e-b30e-094cebb84e5b" xlink:to="loc_us-gaap_OperatingLeaseLiability_7befe914-b5e4-435c-9f0d-e112af51acb9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20220331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31b2729e-f416-4681-b05f-8dc9eb035735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_185bc719-8bad-4c9c-806d-6a94cc89b5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31b2729e-f416-4681-b05f-8dc9eb035735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_185bc719-8bad-4c9c-806d-6a94cc89b5b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3f36ddf6-18d7-4847-b681-2681284a8840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31b2729e-f416-4681-b05f-8dc9eb035735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3f36ddf6-18d7-4847-b681-2681284a8840" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>cpix-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:71f09af2-eb91-4470-8350-f575ad603b6a,g:f5c1e857-adec-4283-ba91-4579f8814480-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20220331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended" id="i2ef4afa0f80c41039b5603908f744b69_CondensedConsolidatedStatementofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3059006c-d5c5-4463-a834-351bafa5bede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3059006c-d5c5-4463-a834-351bafa5bede" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fac8024c-8f5e-4271-a2eb-20edf171bcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fac8024c-8f5e-4271-a2eb-20edf171bcbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bd329711-aa5d-4e0c-9a5f-01eec6820e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bd329711-aa5d-4e0c-9a5f-01eec6820e27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a09fdaaf-5765-4f3d-b1a6-643513e0c1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a09fdaaf-5765-4f3d-b1a6-643513e0c1b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_59930284-9ce1-4895-83f0-d7301d31050a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_59930284-9ce1-4895-83f0-d7301d31050a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_0ff25dde-6a05-4847-8903-a0bc2df11397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_0ff25dde-6a05-4847-8903-a0bc2df11397" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_156a6679-3f0b-4d5e-8c3c-86cb0b47fb25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_156a6679-3f0b-4d5e-8c3c-86cb0b47fb25" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9c796f94-40ba-4d55-b7be-3aacb9472c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_ProfitLoss_9c796f94-40ba-4d55-b7be-3aacb9472c8e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4b48b93e-c1c0-4d5f-bdb2-8a68e0512f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7d3b57bb-bc03-46c1-8acb-31be419ed3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0db3a097-bf37-400b-9773-61a5f6ca39ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3059006c-d5c5-4463-a834-351bafa5bede" xlink:to="loc_us-gaap_StatementTable_0db3a097-bf37-400b-9773-61a5f6ca39ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e58b6b45-dd44-4715-bcd1-0ae706c99aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0db3a097-bf37-400b-9773-61a5f6ca39ea" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e58b6b45-dd44-4715-bcd1-0ae706c99aee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e58b6b45-dd44-4715-bcd1-0ae706c99aee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e58b6b45-dd44-4715-bcd1-0ae706c99aee" xlink:to="loc_us-gaap_EquityComponentDomain_e58b6b45-dd44-4715-bcd1-0ae706c99aee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_877031c6-0565-492a-ae37-f657657af0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e58b6b45-dd44-4715-bcd1-0ae706c99aee" xlink:to="loc_us-gaap_EquityComponentDomain_877031c6-0565-492a-ae37-f657657af0c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4f52d79d-5e46-463e-8077-02d3ff84575a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_877031c6-0565-492a-ae37-f657657af0c2" xlink:to="loc_us-gaap_CommonStockMember_4f52d79d-5e46-463e-8077-02d3ff84575a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9b337c01-c946-4cc3-ba66-232e8878ddc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_877031c6-0565-492a-ae37-f657657af0c2" xlink:to="loc_us-gaap_RetainedEarningsMember_9b337c01-c946-4cc3-ba66-232e8878ddc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_55310f07-3ae4-42f2-b525-51ba9c4a3dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_877031c6-0565-492a-ae37-f657657af0c2" xlink:to="loc_us-gaap_NoncontrollingInterestMember_55310f07-3ae4-42f2-b525-51ba9c4a3dec" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#RevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended" id="i2716ae4e88f14cfa85411de1ba57a7ef_RevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_00c75d56-c017-47c8-9b67-ba862a7a2d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ec9f3135-220f-4027-ae41-ea071f53a6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_00c75d56-c017-47c8-9b67-ba862a7a2d93" xlink:to="loc_us-gaap_RevenuesAbstract_ec9f3135-220f-4027-ae41-ea071f53a6a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_6700b1f3-7dc4-4e2f-955f-37b03651433f" xlink:href="cpix-20220331.xsd#cpix_ProductsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_ec9f3135-220f-4027-ae41-ea071f53a6a7" xlink:to="loc_cpix_ProductsAbstract_6700b1f3-7dc4-4e2f-955f-37b03651433f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_015e7360-4869-4ecb-bb19-2b95af9eefe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductsAbstract_6700b1f3-7dc4-4e2f-955f-37b03651433f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_015e7360-4869-4ecb-bb19-2b95af9eefe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4316c940-9420-40ae-a294-276b8ab75490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_00c75d56-c017-47c8-9b67-ba862a7a2d93" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4316c940-9420-40ae-a294-276b8ab75490" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_480150e9-100c-4828-9916-a71ee764bbdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4316c940-9420-40ae-a294-276b8ab75490" xlink:to="loc_srt_ProductOrServiceAxis_480150e9-100c-4828-9916-a71ee764bbdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_480150e9-100c-4828-9916-a71ee764bbdf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_480150e9-100c-4828-9916-a71ee764bbdf" xlink:to="loc_srt_ProductsAndServicesDomain_480150e9-100c-4828-9916-a71ee764bbdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_480150e9-100c-4828-9916-a71ee764bbdf" xlink:to="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_d47a710a-5b87-4247-af93-fa3819128c50" xlink:href="cpix-20220331.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_KristaloseMember_d47a710a-5b87-4247-af93-fa3819128c50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_28a8e248-f9ad-4fb2-a0cf-58b8679cdb53" xlink:href="cpix-20220331.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_SancusoMember_28a8e248-f9ad-4fb2-a0cf-58b8679cdb53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_08578d5f-80bd-42c7-9d94-2c0b99b64348" xlink:href="cpix-20220331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_VIBATIVMember_08578d5f-80bd-42c7-9d94-2c0b99b64348" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_808cca5e-5d96-4e87-b819-5610998dcb6e" xlink:href="cpix-20220331.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_CaldolorMember_808cca5e-5d96-4e87-b819-5610998dcb6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_141961f8-85c6-4715-9e6b-8b1b480c6cbb" xlink:href="cpix-20220331.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_VaprisolMember_141961f8-85c6-4715-9e6b-8b1b480c6cbb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_72f97b30-a52a-4576-862f-472212f0dff9" xlink:href="cpix-20220331.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_AcetadoteMember_72f97b30-a52a-4576-862f-472212f0dff9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_3ed01386-5219-42e5-88ce-f2c466de817d" xlink:href="cpix-20220331.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_OmeclamoxPakMember_3ed01386-5219-42e5-88ce-f2c466de817d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_48796a85-2f55-4193-b310-132602fa1a68" xlink:href="cpix-20220331.xsd#cpix_RediTrexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_RediTrexMember_48796a85-2f55-4193-b310-132602fa1a68" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_ea6ef95e-4706-4880-b378-331dd3397011" xlink:href="cpix-20220331.xsd#cpix_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_OtherProductsMember_ea6ef95e-4706-4880-b378-331dd3397011" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_52791d45-5944-4564-b1cb-106ce4f71b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_us-gaap_GrantMember_52791d45-5944-4564-b1cb-106ce4f71b08" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i05a0bd684a2b4f03b7cee488453babb5_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_b04ca22a-40c7-4667-a315-d1cbf28d18e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_346d7021-80de-4110-abfe-4dc0905a8e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_b04ca22a-40c7-4667-a315-d1cbf28d18e4" xlink:to="loc_us-gaap_InventoryValuationReserves_346d7021-80de-4110-abfe-4dc0905a8e5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c1c4b955-e1ee-4a39-8ede-1cc2d6944b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_b04ca22a-40c7-4667-a315-d1cbf28d18e4" xlink:to="loc_us-gaap_InventoryNoncurrent_c1c4b955-e1ee-4a39-8ede-1cc2d6944b10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_1029f68a-65a6-4915-8a93-6bb1a12264c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_b04ca22a-40c7-4667-a315-d1cbf28d18e4" xlink:to="loc_us-gaap_InventoryFinishedGoods_1029f68a-65a6-4915-8a93-6bb1a12264c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1628299a-bd0a-4afa-82fd-2d23ca0f8d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_b04ca22a-40c7-4667-a315-d1cbf28d18e4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1628299a-bd0a-4afa-82fd-2d23ca0f8d34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_41907653-30fb-46f8-8b29-c281cb42eac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_b04ca22a-40c7-4667-a315-d1cbf28d18e4" xlink:to="loc_us-gaap_InventoryCurrentTable_41907653-30fb-46f8-8b29-c281cb42eac4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_125fdaeb-a7ae-4fe1-8dc9-9f62c871b3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_41907653-30fb-46f8-8b29-c281cb42eac4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_125fdaeb-a7ae-4fe1-8dc9-9f62c871b3d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_125fdaeb-a7ae-4fe1-8dc9-9f62c871b3d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_125fdaeb-a7ae-4fe1-8dc9-9f62c871b3d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_125fdaeb-a7ae-4fe1-8dc9-9f62c871b3d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_347ce80c-052d-4e3c-97e6-d1ff08778f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_125fdaeb-a7ae-4fe1-8dc9-9f62c871b3d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_347ce80c-052d-4e3c-97e6-d1ff08778f08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_7617fdb9-f167-4c00-be77-27e149334fc2" xlink:href="cpix-20220331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_347ce80c-052d-4e3c-97e6-d1ff08778f08" xlink:to="loc_cpix_IfetrobanClinicalMember_7617fdb9-f167-4c00-be77-27e149334fc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_d17841f5-4812-4242-94c8-338785aab5bd" xlink:href="cpix-20220331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_347ce80c-052d-4e3c-97e6-d1ff08778f08" xlink:to="loc_cpix_VIBATIVMember_d17841f5-4812-4242-94c8-338785aab5bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_40448919-8d0a-40d1-adee-c148d5e774bb" xlink:href="cpix-20220331.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_347ce80c-052d-4e3c-97e6-d1ff08778f08" xlink:to="loc_cpix_SancusoMember_40448919-8d0a-40d1-adee-c148d5e774bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_5c4a3cbf-e409-40cf-a766-926b6cbb9277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_41907653-30fb-46f8-8b29-c281cb42eac4" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_5c4a3cbf-e409-40cf-a766-926b6cbb9277" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_5c4a3cbf-e409-40cf-a766-926b6cbb9277_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_5c4a3cbf-e409-40cf-a766-926b6cbb9277" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_5c4a3cbf-e409-40cf-a766-926b6cbb9277_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_382f6282-17ab-4b11-8072-5c7bb27dbdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_5c4a3cbf-e409-40cf-a766-926b6cbb9277" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_382f6282-17ab-4b11-8072-5c7bb27dbdbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_0ecedb5a-30a1-464e-990a-1a1529dc404c" xlink:href="cpix-20220331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_382f6282-17ab-4b11-8072-5c7bb27dbdbc" xlink:to="loc_cpix_IfetrobanClinicalMember_0ecedb5a-30a1-464e-990a-1a1529dc404c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i089409827a004c8b920def0835d25bad_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_9c30a253-6d43-429f-9aac-3e9c8c54be09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_9c30a253-6d43-429f-9aac-3e9c8c54be09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2df4a296-e336-4209-97e3-73278685c476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2df4a296-e336-4209-97e3-73278685c476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6e49409b-6eb2-42cc-b991-d9738472be32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6e49409b-6eb2-42cc-b991-d9738472be32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea_69cfee07-c6bf-42f8-bbdc-1eeb51c2e37a" xlink:href="cpix-20220331.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_cpix_LesseeOperatingLeaseLeasedArea_69cfee07-c6bf-42f8-bbdc-1eeb51c2e37a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4d405c18-7082-4ec8-86e0-f4193863e13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4d405c18-7082-4ec8-86e0-f4193863e13d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_b93dea2d-478b-492d-bfc8-f26daae56ea2" xlink:href="cpix-20220331.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_b93dea2d-478b-492d-bfc8-f26daae56ea2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d6d438ba-7e90-4f24-8cc6-3b2a270a815d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d6d438ba-7e90-4f24-8cc6-3b2a270a815d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4948eca3-b042-420b-aece-e8a1bb57e4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4948eca3-b042-420b-aece-e8a1bb57e4ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_c74536be-dbce-4e19-b9e6-9204ba377b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_c74536be-dbce-4e19-b9e6-9204ba377b2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f38adc6-f1ce-48df-ae22-87d5a71a9de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c74536be-dbce-4e19-b9e6-9204ba377b2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f38adc6-f1ce-48df-ae22-87d5a71a9de4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f38adc6-f1ce-48df-ae22-87d5a71a9de4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f38adc6-f1ce-48df-ae22-87d5a71a9de4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f38adc6-f1ce-48df-ae22-87d5a71a9de4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fd744b45-bb7f-4b86-b0e1-e2861b4f7b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f38adc6-f1ce-48df-ae22-87d5a71a9de4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fd744b45-bb7f-4b86-b0e1-e2861b4f7b10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f2c9b013-8d97-4f8a-9683-2e927cac67d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fd744b45-bb7f-4b86-b0e1-e2861b4f7b10" xlink:to="loc_us-gaap_BuildingMember_f2c9b013-8d97-4f8a-9683-2e927cac67d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_4500e21f-1854-4d58-8b2b-bb159c1d4b52" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fd744b45-bb7f-4b86-b0e1-e2861b4f7b10" xlink:to="loc_srt_OfficeBuildingMember_4500e21f-1854-4d58-8b2b-bb159c1d4b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_7b909f1f-2890-4426-82a3-216e5ad194a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c74536be-dbce-4e19-b9e6-9204ba377b2f" xlink:to="loc_us-gaap_LeaseContractualTermAxis_7b909f1f-2890-4426-82a3-216e5ad194a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_7b909f1f-2890-4426-82a3-216e5ad194a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_7b909f1f-2890-4426-82a3-216e5ad194a6" xlink:to="loc_us-gaap_LeaseContractualTermDomain_7b909f1f-2890-4426-82a3-216e5ad194a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_7b291451-a21c-44de-b9ea-1a893a24656e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_7b909f1f-2890-4426-82a3-216e5ad194a6" xlink:to="loc_us-gaap_LeaseContractualTermDomain_7b291451-a21c-44de-b9ea-1a893a24656e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_27eca7f3-5f86-4b9c-9714-98ee519ba65a" xlink:href="cpix-20220331.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_7b291451-a21c-44de-b9ea-1a893a24656e" xlink:to="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_27eca7f3-5f86-4b9c-9714-98ee519ba65a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended" id="i551510d9771e4a6bb0e44de358e9942b_ShareholdersEquityandDebtShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40acd8c9-075e-4674-bb37-684586c9504d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:href="cpix-20220331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40acd8c9-075e-4674-bb37-684586c9504d" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8e95c472-9d7b-4a6a-bc08-a048f6e9ed6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8e95c472-9d7b-4a6a-bc08-a048f6e9ed6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_e765e828-f8f2-4ce4-8703-8e0bf221b23c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_e765e828-f8f2-4ce4-8703-8e0bf221b23c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_6b647743-8096-40b7-a68e-14d506fd875e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_6b647743-8096-40b7-a68e-14d506fd875e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9f8c2520-0ea9-470b-95e9-0a85f0faac86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9f8c2520-0ea9-470b-95e9-0a85f0faac86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_e3239653-c327-4647-820c-f3a98a0f3b56" xlink:href="cpix-20220331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_e3239653-c327-4647-820c-f3a98a0f3b56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4e8db747-7159-4a58-966e-1cfc9c2dd935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4e8db747-7159-4a58-966e-1cfc9c2dd935" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8f62d730-9feb-42e3-a048-dc6e42f707c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8f62d730-9feb-42e3-a048-dc6e42f707c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73e3ab8f-9cb3-4b2b-9e77-149cd0961956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40acd8c9-075e-4674-bb37-684586c9504d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73e3ab8f-9cb3-4b2b-9e77-149cd0961956" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_04cb9a24-9f69-4304-a6d6-ab59c2db184d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73e3ab8f-9cb3-4b2b-9e77-149cd0961956" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_04cb9a24-9f69-4304-a6d6-ab59c2db184d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_04cb9a24-9f69-4304-a6d6-ab59c2db184d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04cb9a24-9f69-4304-a6d6-ab59c2db184d" xlink:to="loc_us-gaap_EquityComponentDomain_04cb9a24-9f69-4304-a6d6-ab59c2db184d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7ce3d174-302e-4140-b517-ce22f94fb6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04cb9a24-9f69-4304-a6d6-ab59c2db184d" xlink:to="loc_us-gaap_EquityComponentDomain_7ce3d174-302e-4140-b517-ce22f94fb6c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_70ab8e7f-20d5-4211-b1f6-16f1143b2ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7ce3d174-302e-4140-b517-ce22f94fb6c6" xlink:to="loc_us-gaap_CommonStockMember_70ab8e7f-20d5-4211-b1f6-16f1143b2ca3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_25d43c12-7875-413c-b98e-a64dae65c6ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73e3ab8f-9cb3-4b2b-9e77-149cd0961956" xlink:to="loc_srt_TitleOfIndividualAxis_25d43c12-7875-413c-b98e-a64dae65c6ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_25d43c12-7875-413c-b98e-a64dae65c6ce_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_25d43c12-7875-413c-b98e-a64dae65c6ce" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_25d43c12-7875-413c-b98e-a64dae65c6ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4318a0f8-0f8e-43b4-a0af-3a405f3bc08a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_25d43c12-7875-413c-b98e-a64dae65c6ce" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4318a0f8-0f8e-43b4-a0af-3a405f3bc08a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_f7655a94-ce56-4836-91c1-c324100bbadb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4318a0f8-0f8e-43b4-a0af-3a405f3bc08a" xlink:to="loc_srt_DirectorMember_f7655a94-ce56-4836-91c1-c324100bbadb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc97bca0-14af-4ba0-99fa-df8f5b7ea1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73e3ab8f-9cb3-4b2b-9e77-149cd0961956" xlink:to="loc_us-gaap_AwardTypeAxis_dc97bca0-14af-4ba0-99fa-df8f5b7ea1a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc97bca0-14af-4ba0-99fa-df8f5b7ea1a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dc97bca0-14af-4ba0-99fa-df8f5b7ea1a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc97bca0-14af-4ba0-99fa-df8f5b7ea1a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a110371c-973e-424a-8f74-73ab2afa041a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dc97bca0-14af-4ba0-99fa-df8f5b7ea1a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a110371c-973e-424a-8f74-73ab2afa041a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d06ac7ce-bd15-4d2e-a42c-59e0f390a523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a110371c-973e-424a-8f74-73ab2afa041a" xlink:to="loc_us-gaap_RestrictedStockMember_d06ac7ce-bd15-4d2e-a42c-59e0f390a523" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember_bf9a020d-efd8-45e3-a11a-f0a3181bcfa8" xlink:href="cpix-20220331.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a110371c-973e-424a-8f74-73ab2afa041a" xlink:to="loc_cpix_IncentiveStockOptionsMember_bf9a020d-efd8-45e3-a11a-f0a3181bcfa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_8388988b-3ca6-4943-b13d-c34b24ef71a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73e3ab8f-9cb3-4b2b-9e77-149cd0961956" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_8388988b-3ca6-4943-b13d-c34b24ef71a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8388988b-3ca6-4943-b13d-c34b24ef71a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_8388988b-3ca6-4943-b13d-c34b24ef71a2" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8388988b-3ca6-4943-b13d-c34b24ef71a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_dc6363a7-39f5-471e-b56e-4d7c63a7390d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_8388988b-3ca6-4943-b13d-c34b24ef71a2" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_dc6363a7-39f5-471e-b56e-4d7c63a7390d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_d583bd20-6290-459c-8865-6ec51fe9b460" xlink:href="cpix-20220331.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_dc6363a7-39f5-471e-b56e-4d7c63a7390d" xlink:to="loc_cpix_PinnacleBankMember_d583bd20-6290-459c-8865-6ec51fe9b460" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended" id="i51f41ec95cd94e9aabe53e58b5c75a59_ShareholdersEquityandDebtDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_374593eb-9150-411a-821a-22cfaaeb9946" xlink:href="cpix-20220331.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_374593eb-9150-411a-821a-22cfaaeb9946" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_d6d37e8a-9a82-4c9b-a069-2b95781239a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_d6d37e8a-9a82-4c9b-a069-2b95781239a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7353925a-0a32-47ec-9ae3-cd6c83516823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7353925a-0a32-47ec-9ae3-cd6c83516823" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e472a13-9747-4784-9e70-f0f20395286e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e472a13-9747-4784-9e70-f0f20395286e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_1931fe47-e5ce-40a4-9806-77ee7865b6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_1931fe47-e5ce-40a4-9806-77ee7865b6cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_aa6f4c34-a18c-4d55-89aa-88522a7c3eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_LongTermLineOfCredit_aa6f4c34-a18c-4d55-89aa-88522a7c3eb2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_7b4ae229-286f-4bd7-bf9e-58f6901f41f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_7b4ae229-286f-4bd7-bf9e-58f6901f41f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8a46e0d2-8f51-47e4-be80-9c4c26296b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8a46e0d2-8f51-47e4-be80-9c4c26296b9d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_0039730b-fc33-4149-9607-90010e7bac92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_0039730b-fc33-4149-9607-90010e7bac92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_0039730b-fc33-4149-9607-90010e7bac92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_0039730b-fc33-4149-9607-90010e7bac92" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_0039730b-fc33-4149-9607-90010e7bac92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_7154ea4b-8699-4908-b8fa-0589cec184d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_0039730b-fc33-4149-9607-90010e7bac92" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_7154ea4b-8699-4908-b8fa-0589cec184d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_91fe21ce-4567-4085-b426-73fa0cfa2218" xlink:href="cpix-20220331.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7154ea4b-8699-4908-b8fa-0589cec184d4" xlink:to="loc_cpix_PinnacleBankMember_91fe21ce-4567-4085-b426-73fa0cfa2218" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b00de137-a882-4137-b78d-87d3ad1f5fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_us-gaap_DebtInstrumentAxis_b00de137-a882-4137-b78d-87d3ad1f5fa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b00de137-a882-4137-b78d-87d3ad1f5fa8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b00de137-a882-4137-b78d-87d3ad1f5fa8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b00de137-a882-4137-b78d-87d3ad1f5fa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4aaad100-14e5-44f3-b8db-1291fc17474d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b00de137-a882-4137-b78d-87d3ad1f5fa8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4aaad100-14e5-44f3-b8db-1291fc17474d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1c61e1c2-8341-4cea-b48f-88dcbc887933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4aaad100-14e5-44f3-b8db-1291fc17474d" xlink:to="loc_us-gaap_LineOfCreditMember_1c61e1c2-8341-4cea-b48f-88dcbc887933" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FifthAmendmentMember_2ac97fde-3a80-4cba-a3d4-1701d73b0c87" xlink:href="cpix-20220331.xsd#cpix_FifthAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4aaad100-14e5-44f3-b8db-1291fc17474d" xlink:to="loc_cpix_FifthAmendmentMember_2ac97fde-3a80-4cba-a3d4-1701d73b0c87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4431fc02-f3b9-4b5a-8e57-5acb53614828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_us-gaap_CreditFacilityAxis_4431fc02-f3b9-4b5a-8e57-5acb53614828" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4431fc02-f3b9-4b5a-8e57-5acb53614828_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_4431fc02-f3b9-4b5a-8e57-5acb53614828" xlink:to="loc_us-gaap_CreditFacilityDomain_4431fc02-f3b9-4b5a-8e57-5acb53614828_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7fa2213e-8228-45d1-807f-c1d4ac2a07e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_4431fc02-f3b9-4b5a-8e57-5acb53614828" xlink:to="loc_us-gaap_CreditFacilityDomain_7fa2213e-8228-45d1-807f-c1d4ac2a07e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_85c265db-aca0-4e50-8466-fb7f0234f829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7fa2213e-8228-45d1-807f-c1d4ac2a07e9" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_85c265db-aca0-4e50-8466-fb7f0234f829" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1c537c37-c6a1-4802-b513-7d4ce266e6ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_srt_RangeAxis_1c537c37-c6a1-4802-b513-7d4ce266e6ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c537c37-c6a1-4802-b513-7d4ce266e6ac_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1c537c37-c6a1-4802-b513-7d4ce266e6ac" xlink:to="loc_srt_RangeMember_1c537c37-c6a1-4802-b513-7d4ce266e6ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_554377bc-4c64-482c-bc9e-e3bf0f7f3073" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1c537c37-c6a1-4802-b513-7d4ce266e6ac" xlink:to="loc_srt_RangeMember_554377bc-4c64-482c-bc9e-e3bf0f7f3073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1ead5683-0a6f-40ac-9cfa-c6c08a3cb012" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_554377bc-4c64-482c-bc9e-e3bf0f7f3073" xlink:to="loc_srt_MinimumMember_1ead5683-0a6f-40ac-9cfa-c6c08a3cb012" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c043dc79-47ef-42db-8f19-2f5cb4409660" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_554377bc-4c64-482c-bc9e-e3bf0f7f3073" xlink:to="loc_srt_MaximumMember_c043dc79-47ef-42db-8f19-2f5cb4409660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f95845b4-7c99-4389-a5a6-77b8a5b1cba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_us-gaap_VariableRateAxis_f95845b4-7c99-4389-a5a6-77b8a5b1cba9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f95845b4-7c99-4389-a5a6-77b8a5b1cba9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_f95845b4-7c99-4389-a5a6-77b8a5b1cba9" xlink:to="loc_us-gaap_VariableRateDomain_f95845b4-7c99-4389-a5a6-77b8a5b1cba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c77b5720-3934-4190-a0d9-00cfe5e09262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_f95845b4-7c99-4389-a5a6-77b8a5b1cba9" xlink:to="loc_us-gaap_VariableRateDomain_c77b5720-3934-4190-a0d9-00cfe5e09262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f6eff7c9-728d-4368-8646-f7d3e28bb46b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_c77b5720-3934-4190-a0d9-00cfe5e09262" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f6eff7c9-728d-4368-8646-f7d3e28bb46b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5d57b063-f0b9-4a63-ab84-64519c63241b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5d57b063-f0b9-4a63-ab84-64519c63241b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5d57b063-f0b9-4a63-ab84-64519c63241b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5d57b063-f0b9-4a63-ab84-64519c63241b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5d57b063-f0b9-4a63-ab84-64519c63241b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6be373a7-c0c8-4faa-9852-606592175ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5d57b063-f0b9-4a63-ab84-64519c63241b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6be373a7-c0c8-4faa-9852-606592175ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_6eeb604f-9bb1-487b-8de2-9dffbcccf1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6be373a7-c0c8-4faa-9852-606592175ecd" xlink:to="loc_us-gaap_ConvertibleDebtMember_6eeb604f-9bb1-487b-8de2-9dffbcccf1dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7e45d909-9da6-4ce3-8128-71dc2edf705d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_srt_CounterpartyNameAxis_7e45d909-9da6-4ce3-8128-71dc2edf705d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7e45d909-9da6-4ce3-8128-71dc2edf705d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7e45d909-9da6-4ce3-8128-71dc2edf705d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7e45d909-9da6-4ce3-8128-71dc2edf705d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6272847-6c67-4dd2-afaa-5eab3557dd4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7e45d909-9da6-4ce3-8128-71dc2edf705d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6272847-6c67-4dd2-afaa-5eab3557dd4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember_d54c6eef-d7d6-40db-af48-70a7a38f34d1" xlink:href="cpix-20220331.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6272847-6c67-4dd2-afaa-5eab3557dd4e" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdMember_d54c6eef-d7d6-40db-af48-70a7a38f34d1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20220331.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="i30abb1cc51764ac8bdf87b674bc547e5_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_cc84651b-2505-4886-8074-787bf9609b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_49e0912b-5dfd-4b2f-93d5-efb7fb6ba236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cc84651b-2505-4886-8074-787bf9609b6e" xlink:to="loc_us-gaap_OperatingLossCarryforwards_49e0912b-5dfd-4b2f-93d5-efb7fb6ba236" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_16e90639-dcf9-4bdc-84d0-e4e386ccee21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cc84651b-2505-4886-8074-787bf9609b6e" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_16e90639-dcf9-4bdc-84d0-e4e386ccee21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4e6f0917-882d-4d1a-90b3-749775cb6342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_16e90639-dcf9-4bdc-84d0-e4e386ccee21" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4e6f0917-882d-4d1a-90b3-749775cb6342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4e6f0917-882d-4d1a-90b3-749775cb6342_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4e6f0917-882d-4d1a-90b3-749775cb6342" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4e6f0917-882d-4d1a-90b3-749775cb6342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e911e6a7-2529-472c-8227-51f7c370e5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4e6f0917-882d-4d1a-90b3-749775cb6342" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e911e6a7-2529-472c-8227-51f7c370e5e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_495b0e64-c4d7-41d6-9a9f-ece9474e3c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e911e6a7-2529-472c-8227-51f7c370e5e3" xlink:to="loc_us-gaap_DomesticCountryMember_495b0e64-c4d7-41d6-9a9f-ece9474e3c9b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended" id="i1b14c9b751b54a26a929bf9fddc3fe70_AdditionsandReturnsofProductRightsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8cc8ff1f-4c0b-4f82-b740-1c2cadf4f2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8cc8ff1f-4c0b-4f82-b740-1c2cadf4f2b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_36cb9d8f-3c9c-4c63-960d-4f8b9b134dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_36cb9d8f-3c9c-4c63-960d-4f8b9b134dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_f140d39c-233b-4c84-8168-b1c63cdb44c0" xlink:href="cpix-20220331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_f140d39c-233b-4c84-8168-b1c63cdb44c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsThreshold_568ac77c-9887-43ba-96a1-9ecbb460f62c" xlink:href="cpix-20220331.xsd#cpix_TieredRoyaltyPaymentsThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_TieredRoyaltyPaymentsThreshold_568ac77c-9887-43ba-96a1-9ecbb460f62c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_da59ee16-dfa6-4d33-be01-b23284c6e979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_da59ee16-dfa6-4d33-be01-b23284c6e979" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_bcc208f6-212e-4ee0-ad18-32b9fe291dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_bcc208f6-212e-4ee0-ad18-32b9fe291dce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7cbc9254-ee8d-4ebd-becf-e332c0d232f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7cbc9254-ee8d-4ebd-becf-e332c0d232f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a72a3fbf-4a3e-4108-851f-f3990147bcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a72a3fbf-4a3e-4108-851f-f3990147bcf4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ef83b48c-7e52-4245-b4ff-e032cde9779e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ef83b48c-7e52-4245-b4ff-e032cde9779e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_f71cee9e-66b3-4859-b76b-c1dce0f2daae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_f71cee9e-66b3-4859-b76b-c1dce0f2daae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_eac2a4c4-eb52-43ea-a8e5-6e959d8fd1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_eac2a4c4-eb52-43ea-a8e5-6e959d8fd1a4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_9e908a25-ff8a-4510-82fa-6ae5b1f6f664" xlink:href="cpix-20220331.xsd#cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_9e908a25-ff8a-4510-82fa-6ae5b1f6f664" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_edb53fb0-a5a4-495b-a880-8fc39a6c5de4" xlink:href="cpix-20220331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_edb53fb0-a5a4-495b-a880-8fc39a6c5de4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_32cb1cb6-6f97-40ab-a08c-835ebb6b8420" xlink:href="cpix-20220331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_32cb1cb6-6f97-40ab-a08c-835ebb6b8420" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_716e3b0f-300b-4ef1-a959-3973f9024075" xlink:href="cpix-20220331.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_716e3b0f-300b-4ef1-a959-3973f9024075" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_505c578d-4752-4803-be78-7287bf75acd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_505c578d-4752-4803-be78-7287bf75acd6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_201eba71-d03f-46f3-bada-b02dfdd091b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_201eba71-d03f-46f3-bada-b02dfdd091b3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_48ff346c-a024-4465-b46e-250a108e6285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_Goodwill_48ff346c-a024-4465-b46e-250a108e6285" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7ca0f1a4-9717-4e05-98f5-24b095eaade3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7ca0f1a4-9717-4e05-98f5-24b095eaade3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_1447bf30-ecca-44ff-aac6-a54907a1d4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_1447bf30-ecca-44ff-aac6-a54907a1d4f0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationPaymentPeriod_88731633-ce53-4d82-a011-55743bae559d" xlink:href="cpix-20220331.xsd#cpix_FinancialConsiderationPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_FinancialConsiderationPaymentPeriod_88731633-ce53-4d82-a011-55743bae559d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationNumberOfInstallments_fbeaf646-5b95-4d46-b872-9131e09eda47" xlink:href="cpix-20220331.xsd#cpix_FinancialConsiderationNumberOfInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_FinancialConsiderationNumberOfInstallments_fbeaf646-5b95-4d46-b872-9131e09eda47" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_d84c457d-b1e7-4659-a0ec-ce2ac63374f5" xlink:href="cpix-20220331.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_d84c457d-b1e7-4659-a0ec-ce2ac63374f5" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7ee17478-e248-4924-aba0-645e1e31c1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7ee17478-e248-4924-aba0-645e1e31c1b2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6e6d8c25-76b2-46e9-a45a-b9b7b0714e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6e6d8c25-76b2-46e9-a45a-b9b7b0714e35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e6d8c25-76b2-46e9-a45a-b9b7b0714e35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6e6d8c25-76b2-46e9-a45a-b9b7b0714e35" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e6d8c25-76b2-46e9-a45a-b9b7b0714e35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a32eddc7-aa38-49e1-9e09-5ca53c518f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6e6d8c25-76b2-46e9-a45a-b9b7b0714e35" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a32eddc7-aa38-49e1-9e09-5ca53c518f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_e7c71264-9113-460f-93d4-2060e2a8e38a" xlink:href="cpix-20220331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a32eddc7-aa38-49e1-9e09-5ca53c518f86" xlink:to="loc_cpix_VIBATIVMember_e7c71264-9113-460f-93d4-2060e2a8e38a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_93563ecf-7af6-45c4-95b6-e07ab6136dc8" xlink:href="cpix-20220331.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a32eddc7-aa38-49e1-9e09-5ca53c518f86" xlink:to="loc_cpix_MethotrexateMember_93563ecf-7af6-45c4-95b6-e07ab6136dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_528c3333-6107-42ad-a113-a12203519cc3" xlink:href="cpix-20220331.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a32eddc7-aa38-49e1-9e09-5ca53c518f86" xlink:to="loc_cpix_SancusoMember_528c3333-6107-42ad-a113-a12203519cc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_82570244-07cc-4f07-8821-3f9b0ac5b6e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:to="loc_srt_CounterpartyNameAxis_82570244-07cc-4f07-8821-3f9b0ac5b6e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82570244-07cc-4f07-8821-3f9b0ac5b6e2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_82570244-07cc-4f07-8821-3f9b0ac5b6e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82570244-07cc-4f07-8821-3f9b0ac5b6e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8965666-0ce7-4c90-8607-ff930b7bb1e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_82570244-07cc-4f07-8821-3f9b0ac5b6e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8965666-0ce7-4c90-8607-ff930b7bb1e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_e010ae08-8bb9-4817-9810-89118d07239d" xlink:href="cpix-20220331.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8965666-0ce7-4c90-8607-ff930b7bb1e8" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_e010ae08-8bb9-4817-9810-89118d07239d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember_f342e59c-81f3-4599-a1b0-2fdc831db98f" xlink:href="cpix-20220331.xsd#cpix_KyowaKirinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8965666-0ce7-4c90-8607-ff930b7bb1e8" xlink:to="loc_cpix_KyowaKirinMember_f342e59c-81f3-4599-a1b0-2fdc831db98f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_03f7c917-799d-4e51-a5bf-5eb6296160f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:to="loc_us-gaap_AwardTypeAxis_03f7c917-799d-4e51-a5bf-5eb6296160f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f7c917-799d-4e51-a5bf-5eb6296160f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_03f7c917-799d-4e51-a5bf-5eb6296160f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03f7c917-799d-4e51-a5bf-5eb6296160f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9b5ca9b-e070-4014-8793-8fca03fd3ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_03f7c917-799d-4e51-a5bf-5eb6296160f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9b5ca9b-e070-4014-8793-8fca03fd3ea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e88a79ff-838d-469b-abba-859019b92334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9b5ca9b-e070-4014-8793-8fca03fd3ea1" xlink:to="loc_us-gaap_RestrictedStockMember_e88a79ff-838d-469b-abba-859019b92334" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6bfb72e6-d3c7-49af-ba65-48487500a17a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6bfb72e6-d3c7-49af-ba65-48487500a17a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bfb72e6-d3c7-49af-ba65-48487500a17a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6bfb72e6-d3c7-49af-ba65-48487500a17a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bfb72e6-d3c7-49af-ba65-48487500a17a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_718e4484-f10d-47af-ba82-17d793896c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6bfb72e6-d3c7-49af-ba65-48487500a17a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_718e4484-f10d-47af-ba82-17d793896c6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_03bd2325-3627-4df2-b14c-6ab9d677f6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_718e4484-f10d-47af-ba82-17d793896c6c" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_03bd2325-3627-4df2-b14c-6ab9d677f6eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_19741a9f-55bb-4eba-953a-0837ecced466" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:to="loc_srt_RangeAxis_19741a9f-55bb-4eba-953a-0837ecced466" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_19741a9f-55bb-4eba-953a-0837ecced466_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_19741a9f-55bb-4eba-953a-0837ecced466" xlink:to="loc_srt_RangeMember_19741a9f-55bb-4eba-953a-0837ecced466_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd3b109e-b55e-4f88-aba7-053f836e7762" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_19741a9f-55bb-4eba-953a-0837ecced466" xlink:to="loc_srt_RangeMember_dd3b109e-b55e-4f88-aba7-053f836e7762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c791286-98d9-4548-ae5e-c19f023400c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dd3b109e-b55e-4f88-aba7-053f836e7762" xlink:to="loc_srt_MaximumMember_9c791286-98d9-4548-ae5e-c19f023400c5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended" id="i5f704b6c34704d5da048c518b58f4497_AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8aa2136a-6192-4313-bb89-2f6bcdbfa56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_733372c3-7d7f-48d5-a930-d0b278517a93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8aa2136a-6192-4313-bb89-2f6bcdbfa56c" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_733372c3-7d7f-48d5-a930-d0b278517a93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_17d7b808-8b2a-4aa7-a3be-2d721c15bbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_733372c3-7d7f-48d5-a930-d0b278517a93" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_17d7b808-8b2a-4aa7-a3be-2d721c15bbb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_15469ef9-6935-4d7c-8039-8ba6d9358d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_733372c3-7d7f-48d5-a930-d0b278517a93" xlink:to="loc_us-gaap_PaymentsForRoyalties_15469ef9-6935-4d7c-8039-8ba6d9358d88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76d3a43e-1f4a-4d67-b3ea-ccee0bdc8c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_733372c3-7d7f-48d5-a930-d0b278517a93" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76d3a43e-1f4a-4d67-b3ea-ccee0bdc8c58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_c5f95d80-83a4-443d-ae51-03d5079a1f0f" xlink:href="cpix-20220331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_733372c3-7d7f-48d5-a930-d0b278517a93" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_c5f95d80-83a4-443d-ae51-03d5079a1f0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c66e9ef2-1f1c-4f9f-b2f8-a714c3f79c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_652074f3-c680-4beb-8225-314886b2c759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8aa2136a-6192-4313-bb89-2f6bcdbfa56c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_652074f3-c680-4beb-8225-314886b2c759" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_89998546-da4f-4311-8744-db567b2298fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_652074f3-c680-4beb-8225-314886b2c759" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_89998546-da4f-4311-8744-db567b2298fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89998546-da4f-4311-8744-db567b2298fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89998546-da4f-4311-8744-db567b2298fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89998546-da4f-4311-8744-db567b2298fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_985429d7-ec01-41e5-99a5-97120d15a295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89998546-da4f-4311-8744-db567b2298fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_985429d7-ec01-41e5-99a5-97120d15a295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_6b2ac75d-7ec2-47ec-a6fd-e03697a7fedf" xlink:href="cpix-20220331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_985429d7-ec01-41e5-99a5-97120d15a295" xlink:to="loc_cpix_VIBATIVMember_6b2ac75d-7ec2-47ec-a6fd-e03697a7fedf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="extended" id="i8fd92ed8ed664e7ea034fd0ddc62608e_AdditionsandReturnsofProductRightsDissolutionPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d1c894ab-83da-4ff2-83e9-6f81f1a8faec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27bcb5f6-45ba-41a2-a47d-c8ac324029fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d1c894ab-83da-4ff2-83e9-6f81f1a8faec" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27bcb5f6-45ba-41a2-a47d-c8ac324029fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_015f73db-04c8-4278-b360-d69f2d4c3d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d1c894ab-83da-4ff2-83e9-6f81f1a8faec" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_015f73db-04c8-4278-b360-d69f2d4c3d90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a35f3e9-2541-4a86-bdf3-a619ecd17719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d1c894ab-83da-4ff2-83e9-6f81f1a8faec" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a35f3e9-2541-4a86-bdf3-a619ecd17719" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_de167165-510c-4bf3-87b7-95b9dc24e262" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a35f3e9-2541-4a86-bdf3-a619ecd17719" xlink:to="loc_srt_CounterpartyNameAxis_de167165-510c-4bf3-87b7-95b9dc24e262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_de167165-510c-4bf3-87b7-95b9dc24e262_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_de167165-510c-4bf3-87b7-95b9dc24e262" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_de167165-510c-4bf3-87b7-95b9dc24e262_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6b0cd0f-b7cc-49c0-96cc-7fcaa44cb7e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_de167165-510c-4bf3-87b7-95b9dc24e262" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6b0cd0f-b7cc-49c0-96cc-7fcaa44cb7e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_f4d839ee-881b-450b-ad5b-8d9bf402b37e" xlink:href="cpix-20220331.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6b0cd0f-b7cc-49c0-96cc-7fcaa44cb7e5" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_f4d839ee-881b-450b-ad5b-8d9bf402b37e" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>cpix-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:71f09af2-eb91-4470-8350-f575ad603b6a,g:f5c1e857-adec-4283-ba91-4579f8814480-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8f1a6157-05e0-48f4-9e65-ec75058674bb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase outstanding common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IfetrobanClinicalMember_79550f2a-c0f2-40e6-8495-f1c90f876b42_terseLabel_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_label_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical [Member]</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_documentation_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember" xlink:href="cpix-20220331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IfetrobanClinicalMember" xlink:to="lab_cpix_IfetrobanClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_47b53873-5602-4a96-a0b4-523f7eec87db_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_e58ba428-ace7-4c44-8acf-5b1b0892158d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_e4179968-ac1a-4352-bd78-7be5fa4895ee_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_0bd6c2c1-c115-4eb4-8668-7027ea087494_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e56743c8-e7e0-4d9a-b46f-bce4834cdbc5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2a27620c-5fcb-4a1c-9b9e-23fa47915a79_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5f509106-c014-4896-b327-09f8d9152ba6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_9b4ea188-0eb6-44d4-a40d-f607602153e5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_bbfa4d5d-431f-4cc4-be47-84d61e2545e0_negatedTerseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_documentation_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:href="cpix-20220331.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:to="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a9a23795-c590-4a1d-aaa7-2266e2b98f82_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_228c1303-9782-4a88-af2e-2d0ed6e58dc2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_65a5984d-a65b-4926-927c-5c4753447a15_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b0c11f1a-e8c1-43e5-9318-71205a3e0ae4_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_51c4d3f0-7134-4e56-bf09-0c550ce92584_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_eb81cfcf-0ea8-404b-974d-2353e38b13b7_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20220331.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_3b5bf855-26f4-428e-bfb3-8bdc7138f2b5_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_7c85388c-c128-4408-8c65-4c80feddfadd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b82255c7-0b2a-498d-96c1-860babcce31c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_93301524-9102-4a7e-9e8e-47fddc55e0af_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20220331.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_01645897-d848-4a09-afa9-981fe319ad65_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3c271896-e929-4004-8407-68b6c6c82386_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f6f66174-85d0-4efb-9c1d-7a0e2838f831_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_23942772-50b8-4d00-84be-17d6df59546f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c2612b88-d768-4162-a031-72cfc122c51d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_74203217-89fa-4153-b653-46ab954f290f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5ed40bc7-f88b-4c19-b39a-57f2aa3b566d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_c83b3604-d28c-4261-bb3c-484ba470f7b4_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional borrowing capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="cpix-20220331.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c283a2dd-bd94-4ce9-86db-756af4bdce7c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_08a15d20-e522-4ba1-9f5d-c5ee634180f7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_135851d5-71b6-4ed0-b767-c487616bc4ad_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_371e7b9d-5c96-46d9-a02c-cc08569f747e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_980f2f62-7b9d-44a7-b926-95143f974258_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_149c2018-4116-46e3-82a5-8c5dc7566a59_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ffe5e85f-418c-4997-ace7-4f62361b8d6b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_59dc4bc7-d3e8-46b0-90b1-643186adc915_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_bc18d20c-6dd9-4008-a52b-1b0c35428081_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductsAbstract_55ee697c-faaf-443a-9dbb-a85b81e40b2b_verboseLabel_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products:</link:label>
    <link:label id="lab_cpix_ProductsAbstract_label_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_documentation_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract" xlink:href="cpix-20220331.xsd#cpix_ProductsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductsAbstract" xlink:to="lab_cpix_ProductsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_35a9130a-bf1c-4ff7-8d58-b798a7f7c866_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_209e4910-d14c-4165-a9d7-4f7809638a42_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63ecd1a8-01e0-4a10-a46e-49c26ebfee72_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_e2faf9e6-b550-44b6-8759-730c8313a74e_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_e3227b2a-e1dc-4770-8adc-60ff46892262_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories classified as current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_ad9ef1ba-b1f3-45f0-a62a-1fd3b8a35391_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_c9ae2859-90ba-4726-aed6-0941217dfe77_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_866cad97-ba09-459f-a5f3-d222780fcd1e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_965c2f4b-29a6-4d0d-8746-cda613d83c47_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_022be013-548e-474a-a70a-2b02ec10a732_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_33d74a96-e09b-4463-86c2-2c99cc506781_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares left to repurchase</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsThreshold_416bc6f9-a979-4674-8cc1-d0c6b9170d7e_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty payment, threshold</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsThreshold_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Threshold</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsThreshold_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsThreshold" xlink:href="cpix-20220331.xsd#cpix_TieredRoyaltyPaymentsThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsThreshold" xlink:to="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_28ac12ce-e5e2-4fa5-a5e1-ec36b4aa5a2a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent portion of the contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6b5e8eb4-138d-4a88-87d5-d9c5f3592211_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1b93413e-d383-429e-85c2-ebe1906ab2fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_55854bd6-2917-430e-8f7b-81ca3ed33df8_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for purchase through restricted stock awards and options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b1b3c7c3-c705-42f8-a83e-db738b3c9859_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_5769fd91-4b95-4faf-81cb-534b4c2b7cf1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_6af802a8-c742-4487-9361-d5ddd059bb02_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20220331.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_6cc27a6e-e984-4afc-aadf-814ba662ea06_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights, installment payments</link:label>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_label_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets, Installment Payment</link:label>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_documentation_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets, Installment Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:href="cpix-20220331.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:to="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_7cf73c4b-7e6b-482e-98ae-58d8327be1bb_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_a62f7d10-f209-4be1-839a-1987cfc32a7a_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20220331.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FifthAmendmentMember_3932bc87-3818-413b-bfcd-81a70d5273ab_terseLabel_en-US" xlink:label="lab_cpix_FifthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifth Amendment</link:label>
    <link:label id="lab_cpix_FifthAmendmentMember_label_en-US" xlink:label="lab_cpix_FifthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifth Amendment [Member]</link:label>
    <link:label id="lab_cpix_FifthAmendmentMember_documentation_en-US" xlink:label="lab_cpix_FifthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifth Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FifthAmendmentMember" xlink:href="cpix-20220331.xsd#cpix_FifthAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FifthAmendmentMember" xlink:to="lab_cpix_FifthAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_aa803799-e437-47f4-bfbc-f562f062851e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_fc8dab49-3e77-46fe-9fef-8cfaa1447327_terseLabel_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_label_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited [Member]</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_documentation_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember" xlink:href="cpix-20220331.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ClinigenHealthcareLimitedMember" xlink:to="lab_cpix_ClinigenHealthcareLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_cbe7c344-e6e2-4b10-9878-40de461267b0_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_dfdae54b-1724-4ae6-950b-7ee3c6453ab0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_eb45b8ed-ac62-45e3-ab57-e08b63a9c513_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8d7acb52-d782-4ce0-a7a6-48fc73cbe5d1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_74c023e2-55cc-43b1-890f-091fb6ea8b88_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_11a20c50-29c3-4c0a-b757-c3f62e9c6065_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_c7e4c52c-00dc-476e-9a39-20d5f029b32f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_2c276ef6-1cc2-4503-9221-644628bf8545_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2548f10-ff59-4317-a023-d4b50d2ed706_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0529153b-fd8b-440c-9006-27dba4e94d9b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_48b61912-e754-46d3-8dd5-81da144fcd96_terseLabel_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration, payment period</link:label>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_label_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Payment Period</link:label>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_documentation_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationPaymentPeriod" xlink:href="cpix-20220331.xsd#cpix_FinancialConsiderationPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FinancialConsiderationPaymentPeriod" xlink:to="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_0245cb5f-4ab2-466a-b6b6-65304b0574b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_c925ab76-6470-4a81-910a-5118695e9f3d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e680a4b1-3352-4806-aef0-6e3338b6905f_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6cc24a92-c0f8-49c1-b34d-d8fed5b74ace_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_57816c18-d08f-4ba4-a8e0-f23ed9606ea9_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_117a4942-26da-4079-9b3d-7d71688481d5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f7984f2d-2569-4667-9b4b-f9a91994e0ec_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_502a349e-9c91-48d5-aa41-52649fd08b09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted in period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_af0291fd-852b-4dd9-aeb0-558a07dbc594_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable investment funding</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7e9d29b9-aa84-4730-b7a6-d5a872ea50ed_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_517b0cb1-5120-48b7-b8bd-19c2a7327731_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty, percent</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:href="cpix-20220331.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_e00767fc-7ad1-4fe5-a3a4-7379beba7d7a_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ffbe5170-45db-46ee-b208-2e20485d8e1c_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_cb77e9e2-7e5f-404b-b7be-c832615aac2b_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_40dfca90-7ed8-479b-b5ce-d7af8ebf5502_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_77dfe998-6a38-42c1-b40b-a451ff453083_terseLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20220331.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_183e2ee0-b426-488f-b280-d31d959b2751_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square feet of office space</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_75647d55-26a1-4141-ad39-2473e9965a2b_terseLabel_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option</link:label>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_label_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option [Member]</link:label>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_documentation_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:href="cpix-20220331.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:to="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherProductsMember_2a826f28-4a08-43ed-8fe4-008a751cce99_terseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_cpix_OtherProductsMember_label_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember" xlink:href="cpix-20220331.xsd#cpix_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember" xlink:to="lab_cpix_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0cdd2e85-bc0b-497f-aacb-7a047a0508cc_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84883cb9-430c-4374-b4c0-eff3bda09395_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_06fe6c99-62dc-4e62-a0f6-06d9250ea80a_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20220331.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e7c9cfa5-2d01-49ba-ab1a-b54f0a39dc4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_f225f820-b1c7-4705-a487-08635dbc6ac0_verboseLabel_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_label_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_documentation_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract" xlink:href="cpix-20220331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract" xlink:to="lab_cpix_ShareholdersEquityTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_695d7cb0-c4b6-4d46-a102-b29274de0d64_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9eecb04c-3843-4057-9ed5-4cbb1a222c83_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9cf0b727-daa8-4df3-9d0d-d14141a8d1d8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1878b149-96fb-42d8-8182-c41b1c2b4b2a_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6fa01c24-9cf6-4a44-88c6-e6f0aee6ebb0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_40646dfb-6109-41be-b40d-1552db256c38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a9a0ec98-2f7d-4729-9690-8463947941c8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_fd5ada13-fb6a-47fa-b7e6-5b75622a7cdd_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_42d71805-62a9-414d-9889-4ff053f5cc7d_terseLabel_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_label_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember" xlink:href="cpix-20220331.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncentiveStockOptionsMember" xlink:to="lab_cpix_IncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_d04b5990-3179-45a9-81e2-394de44d01ad_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7f1d9923-aec6-4ec0-9c8f-9423dd1fb926_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_bb93e0c2-9b8c-478d-b681-89554be7680c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_be8aa1ff-8493-4a62-85bb-886b98917de6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of the contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d334f5fc-e47d-47d7-a42d-5d58c2bbc511_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_95136c81-11d9-429f-a590-9f1623b36c4d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_9881865b-41c7-4156-bddc-290cbbf42abe_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_48145a26-6564-49b9-9298-7a76b9b554bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e2da78bb-a63e-4c8e-b1b0-a1a8b686c4db_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_085b3c8e-2a2e-4d60-a37d-7b9a992943ab_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_8a86c1b9-e5f3-4422-b89c-35fb2c97d8ae_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20220331.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ddb4a13b-c18e-471d-8a12-3bbf6a70b8df_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_b81973f8-8736-4b8a-85a7-93cdaadb4a4a_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c8288792-7ce3-4997-addb-4f6921f87146_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7418888a-124a-47d8-9124-ab75716e79f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_352a5939-02c5-4ce4-b446-2f77ad57d7a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d3ceb4fd-2f31-4da3-be76-baa4f05b2f25_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (income) loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_916fcb59-678b-4087-9692-b232ef2571fa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0b99185b-a60b-470c-b663-5a37cf01691c_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_269e2444-808c-403d-af79-120cf2fd61c0_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_768091ce-8892-4d1a-a318-12fb2c8d234f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_ebc1dbb6-886c-4e0b-946c-8ff3e4dc9f0b_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_c087f109-13b3-4217-b87e-01a11d1b28c4_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward" xlink:to="lab_us-gaap_LossContingencyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_77be0ff8-a763-47fd-95da-9b29e279e5ee_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c4b4e99-4cad-4a12-b3bf-9341417b3dd2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_66ece0e8-ab98-4c2e-85b1-d55adff05449_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4ddd9ea9-6f44-40e3-b5e1-8a34eaea6e13_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9cd923d0-d171-4d4f-aaf3-1e8a313f1126_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1d83fffc-9055-4541-a302-770b2401baad_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_dce401ee-ec30-461e-8a0b-b0f5dc5b2b8c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of other securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RediTrexMember_18f757ca-8c06-4175-93e2-b69bf136c8f7_terseLabel_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:label id="lab_cpix_RediTrexMember_label_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex [Member]</link:label>
    <link:label id="lab_cpix_RediTrexMember_documentation_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember" xlink:href="cpix-20220331.xsd#cpix_RediTrexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RediTrexMember" xlink:to="lab_cpix_RediTrexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_2e5ed1c4-ec54-40d4-b40b-876ff7868ef2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial investment in joint ventures</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_18760dc6-9cbc-49fd-8056-5f7a3dc3a3aa_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal terms</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:href="cpix-20220331.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:to="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_60b62bbc-0a45-4cd0-9c4f-936b395b8d0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a765e21c-a001-4826-ac47-6f1fbe65d507_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a7a73be-c642-4f1d-a811-5954dbcd5550_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7a986f2b-12f8-4e30-a308-1603087a4abd_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6a43ec5e-699b-43d3-890b-cfa64225d606_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_ebd5b7ff-1dff-48b4-ae6d-026a3d800ab0_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of tiered royalty payments (up to)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20220331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ff9c565-d7fd-4dab-bece-8a622eba864f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Lease Liabilities at March 31, 2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f71b68af-adce-492f-a2ae-cb548e76f4b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0569d77e-3e85-4333-b62e-58e281afc401_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ad94173c-6f49-479a-b230-cfbbb1d47a85_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9c54fae6-1bd8-47ff-9c94-b2d34ac40c44_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c1a93e88-f296-46a2-876e-9c6c58d74a56_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_27cf33de-4a9e-4574-9c1d-ed24ca1c3b51_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_6da5c8de-5f0b-4c3d-bb2c-b211e676c734_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum sublease income under noncancelable operating subleases</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FinancialConsiderationNumberOfInstallments_ca18aee9-b377-463f-bdec-06ba21786f31_terseLabel_en-US" xlink:label="lab_cpix_FinancialConsiderationNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration, number of installments</link:label>
    <link:label id="lab_cpix_FinancialConsiderationNumberOfInstallments_label_en-US" xlink:label="lab_cpix_FinancialConsiderationNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Number of Installments</link:label>
    <link:label id="lab_cpix_FinancialConsiderationNumberOfInstallments_documentation_en-US" xlink:label="lab_cpix_FinancialConsiderationNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Number of Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationNumberOfInstallments" xlink:href="cpix-20220331.xsd#cpix_FinancialConsiderationNumberOfInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FinancialConsiderationNumberOfInstallments" xlink:to="lab_cpix_FinancialConsiderationNumberOfInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_fb7d456e-f6e0-4224-ad34-168333b3f6aa_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1dd4c27d-7028-4617-8a72-4e5173b303c0_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_af9f6005-cf73-4954-8642-7ed8a0bd5bf0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_1076e789-c6f9-41c8-8322-8da6ad6fbf1f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_c2993bc5-e779-4334-9ba5-a8b162b82448_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20220331.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_d376820c-b70a-4114-8bce-8d7a70148b97_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_ade459c2-8a78-410b-ab3c-b512c43b1794_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="cpix-20220331.xsd#cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ee0a4421-fb11-4aee-9cac-791a4d0508e6_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_28b5b504-a9e0-43cd-a683-4ca0e4b3f5a7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_9125df02-81a1-40d4-9edd-0d18cb5e4f38_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b81976f0-4ab8-4562-b533-c381bc306c84_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_242b00c0-62cb-479a-bad7-0216fe0216b0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5b2db428-30c8-4c73-893e-70ac2771cbb3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5111867b-1ecc-4592-a250-51119e33958c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_9aa61098-151c-4baa-a68d-cebcfc1fb0b8_verboseLabel_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_label_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_documentation_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:href="cpix-20220331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:to="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e8cc8574-d861-4d31-bfb9-8d2b7ba739b1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_15eb5f40-cebc-4c11-923d-60e03264b135_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_edd9d895-ffa6-4f52-95c4-84236a86130e_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20220331.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_772c2a4d-2425-4043-a309-10f0e0b06f12_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_0041781a-7f8f-4b3a-b382-4bbb00b4bbdc_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_15b86fbe-66db-45bf-8522-a2dca1b08050_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5e373af7-5a30-4762-b157-5f12c8205c51_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_30e39d6e-2ecb-4d25-b709-4dad13e381c1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f6b2706a-75d6-4586-8e64-a556fb0cedd1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration included in operating expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_c3af8d2e-9022-4401-a2dd-e04cc40eef1d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8becb161-47e3-4f81-8701-3ce967e573fe_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_067b906a-47eb-4283-b871-37443ae99ce4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_3ddbbaff-f472-4f2e-a6bf-dcb4711c8f55_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_b1c47e33-1209-418b-b083-d4a6a614cb51_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net, Items Net of Reserve Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:to="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_16e612e5-3237-413d-97d7-0041a2a879ec_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Position</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20220331.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_ddf0d698-80da-484d-8f21-d8fe51c612c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c55798d3-0344-450b-a651-786f0874291f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c9447468-550c-4ec8-878e-1a386f20b986_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d585cb26-0db6-42c3-8e18-144ce5136903_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8b54e05a-a0cd-4358-ae3b-2fcc38ffa073_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_657a1bd6-2407-4d1b-a6b1-344714eef1a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested common stock, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_46d9c05c-4852-45d1-8534-105a70eee719_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_73c6bcd9-44c3-4061-931a-6f5a5d53e937_terseLabel_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_label_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd [Member]</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_documentation_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:href="cpix-20220331.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:to="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_24b10bff-0d99-47a1-85d2-dfb7762a4668_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_7198a90f-a21d-423b-b077-dfa713852abd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3f157391-cd58-4d3c-ba9d-901231cddd00_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1ae76958-14c8-4ad5-a6c4-0bf40d06f847_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_1f8408a9-1148-4b1e-b71c-e794fb48c6b8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_7987bcd1-2533-46f4-868a-af2dc0bbd942_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_72b4b1c1-b1e7-462a-ab0a-d09d573cc01b_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:href="cpix-20220331.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:to="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_0ee0f45e-e516-41ed-a67f-98cf06c2c12d_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_345411e9-5c40-40be-a547-28d8f6b27ee4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_5beaac4d-93ec-427e-ab2a-3f2be20da5db_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_89a76433-1b7a-4d87-b577-76cf4acdc37a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_b0417cc9-5a5c-4080-b3a5-28709548b80f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_80e03ba0-9028-4b17-b2e1-4825157d2e73_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_4ddca9a2-89bc-45b5-863b-91b2882d770c_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased area</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Leased Area</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Leased Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea" xlink:href="cpix-20220331.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseLeasedArea" xlink:to="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_c4d6b1c9-0221-4123-b257-f955196c3bc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f937c76c-cabb-4fce-b867-2d332ba5d641_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1071bfa3-84c2-42bb-b603-ef75d6042945_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_22e2704b-b836-412d-ae6a-7bb64579b5bc_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2bc48d81-8f74-4459-8f7a-3cf3a8a587fd_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ef350983-1c9e-47c8-bf85-92982e5bd8dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_0cdbd2e3-494b-47d2-ab6b-54e1d0e171e6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f8bdb6d3-9dd9-40ef-82c1-39e44ba872f1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_bad5482f-34e9-4176-b67c-3f033b10423d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_3f424fc0-bc2b-4145-95ea-60698824d013_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_58c11094-c61a-44d4-9eb1-d4e46a84d543_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_f7a69ef3-13d9-4fdf-b73a-f975c2bb42a7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONS AND RETURN OF PRODUCT RIGHTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SancusoMember_971b058f-8097-432e-b7e6-18976a42a576_terseLabel_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sancuso</link:label>
    <link:label id="lab_cpix_SancusoMember_label_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sancuso [Member]</link:label>
    <link:label id="lab_cpix_SancusoMember_documentation_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sancuso</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember" xlink:href="cpix-20220331.xsd#cpix_SancusoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SancusoMember" xlink:to="lab_cpix_SancusoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_eff1768e-580a-43ec-b2ee-e10e59554a7b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_30adae45-67a5-4601-831c-e04dc7cdbfb7_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_69ed566e-b1f0-495a-972e-acb032d08f4d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_8eac90d8-885e-4ada-a6d5-1b91621e847e_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_f5fe3562-1e32-4d60-8d42-b855da995c4c_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_133cf57f-3a73-49f1-8333-7319f896d215_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_d0575e55-eed9-45fb-9932-f5a2c65fa404_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obsolescence and discontinuance losses</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ae466db-c43f-4cc4-9790-ff8e69f8affd_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eff872cb-e58f-43f4-8cd2-cb6e9f1c89b4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_e19932e2-99a1-453f-a7c2-7669067a2d90_negatedLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_3947adbc-5453-463e-b369-7e2f27cb1a5c_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_6b819783-5bf5-4c14-a206-5996a839237f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3296ffdd-e784-492c-898a-e010f0905844_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_404b8b59-3a77-4768-878b-44da4e0e21a9_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_6ce4dbce-26d6-40d1-956f-41dc46afc38a_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_4934ea69-2edc-43c6-b2a4-2e25db48ae59_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_908b1e1d-7091-4358-9640-b81a7d8ef43f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_7016fc63-5aac-425a-846c-662acb134ebd_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_32e9342e-5813-4b71-9ecf-587b3728033d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e256aad8-57c7-4571-a879-31bc40448469_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_3d2130e8-d30a-42ae-a82d-577dd90f7c22_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_8b4986e2-7376-4e1c-a5ad-b945ffd0f741_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a66c742c-c27b-43e2-adde-ae8e75475588_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f3025e8c-2336-46a8-9d10-3c2d98d08bab_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KyowaKirinMember_8a180073-bc36-4194-86f5-d8c0128a0285_terseLabel_en-US" xlink:label="lab_cpix_KyowaKirinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin</link:label>
    <link:label id="lab_cpix_KyowaKirinMember_label_en-US" xlink:label="lab_cpix_KyowaKirinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin [Member]</link:label>
    <link:label id="lab_cpix_KyowaKirinMember_documentation_en-US" xlink:label="lab_cpix_KyowaKirinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember" xlink:href="cpix-20220331.xsd#cpix_KyowaKirinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KyowaKirinMember" xlink:to="lab_cpix_KyowaKirinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_886cf350-f552-4590-95f6-66e960245808_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27daebf9-d8e3-459d-a6cf-ce4dd7a1175f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_5d0a5604-b922-4f13-986d-7fbaf075ad37_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_cef970e5-c8ec-44cc-b305-66a25170410a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_442dafc9-068c-42e4-9dcc-a3b22e2d9fce_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued in operating expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20220331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_79e9727a-98bb-4bf7-8dca-726a174a8957_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_3ce2df51-28f1-40d7-908d-6db672498a71_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3d912d26-76ca-4933-835f-3c8e45c8619b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MethotrexateMember_9377e772-793e-4934-a007-b5316014d5fb_terseLabel_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate</link:label>
    <link:label id="lab_cpix_MethotrexateMember_label_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:label id="lab_cpix_MethotrexateMember_documentation_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember" xlink:href="cpix-20220331.xsd#cpix_MethotrexateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MethotrexateMember" xlink:to="lab_cpix_MethotrexateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_74e4433f-8ac0-4421-b585-bcb2f70c4d4d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY AND DEBT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_ec200d1a-2030-4306-b948-12a90065cf36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Dissolution Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_f2813e2d-abee-49a5-970d-3efc82995fb3_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_2258c9db-7344-4c7b-8f28-d121c2e4381d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0529a2b5-5e75-4c03-97d7-159c87b652ea_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_3091ebd3-b2e8-4531-8a8e-0bcf38feb4ea_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5c8dd2a1-ee11-41b8-811a-9cff5eb6b501_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_96de705a-6f75-40b4-baab-9c3e2b19cd6d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0c5bc2a-16fe-491a-a86d-13de601f4b71_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_194eef61-8d31-4d24-95f5-7595e94cca69_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b6cd4591-b7e1-4db4-89c4-bdbe6c1fcfcf_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_c0250144-faa1-465e-91c3-4d48f3ba0995_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d8d6dbfd-4b12-4370-bd0e-23863dcca103_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_89072f6b-3f8d-40d4-b504-544ce1591b9b_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments, expected</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:href="cpix-20220331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_14054df6-e238-4a25-b78b-4f6606656997_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c7da7b4c-6bb7-43d5-ab83-3b79d68dd270_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_81b4fb27-8f66-4302-b5b7-e41488c39ea9_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments, maximum</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:href="cpix-20220331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fe5fb2bc-b604-4969-9e2d-1b4038725e78_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9b1db3b8-4747-4c4e-b424-bdf2006d8ae4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_a63dcec8-2337-4d00-9c8f-518ddd4e88e4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATIVE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_add53f97-c24a-471f-a31f-a191a31fe6e7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ad2cd5-19fe-4bc3-9039-1a7438cb91ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b5cc1d86-aac5-4adb-b810-e68a17d2b203_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_dab9d6c8-903e-423a-b1f6-0eed8110ebc4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_79c710d8-47ed-43eb-b612-325cbc708936_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f372ea4c-a9dd-466c-9a54-e8657845ea45_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_371ee8ab-e965-49fb-a2aa-b66cddf5cca8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_16a5c8c0-9ef0-4d9b-a860-ccd9b450199f_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d3c467f1-b483-49ac-9f04-f0712e33b083_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_9e79e2ff-7703-4f68-90bb-d9641f0efb87_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_84282da4-bcd7-4eac-a586-2730f20061a6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EquityAndDebtAbstract_label_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:label id="lab_cpix_EquityAndDebtAbstract_documentation_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract" xlink:href="cpix-20220331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EquityAndDebtAbstract" xlink:to="lab_cpix_EquityAndDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficeBuildingMember_b7e693e0-56e2-46dc-bca3-49892cb39e24_terseLabel_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wet Laboratory and Office Space</link:label>
    <link:label id="lab_srt_OfficeBuildingMember_label_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficeBuildingMember" xlink:to="lab_srt_OfficeBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5bc2631d-8319-4240-9d08-9dd4aef710ff_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2823a46e-f5e5-4a00-8f6b-fecd8bc82f79_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_358e81e2-3323-41e1-85f8-4a268fae997a_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_b7c7e154-3b8e-4cde-993f-56d71028584d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_368a1812-c408-40b4-ae90-dfd8ba35cd30_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_3c25a092-c4a2-4efb-aed5-6a79f6603ff0_verboseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseInCurrentOperatingLiabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:href="cpix-20220331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:to="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3f839860-342c-4239-b1f9-3282112d724c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_863f8e36-15c5-4075-8b0f-e20deab27cf4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2efec5a1-e329-478f-9e7f-fc364e0e38e6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2d138643-8807-411b-93da-b74aedb290f6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_8a59f347-c18a-4485-92f2-7d6ae808392b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4ced5335-bdd2-4b0a-b6c9-5baa3ee2c5ad_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_2458f7bd-6dd8-4a34-88ed-39a81c04715b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e090ffea-46a7-4d69-bf15-61ce9b9edacd_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_fb2c62d0-3f1a-49e4-aca3-23b5eafe57bc_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_62fb975a-5daa-49ba-a088-d7308370a5eb_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations income</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_3bb290c1-1d52-4026-935e-5754547d27ee_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eaec6082-89f1-44f3-b919-408e00b60f08_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_56af68c7-b3e2-4669-8008-01a975b4fedb_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_722ace7a-b1ea-4c18-9efa-6458385f506f_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0ae595c3-9fb4-4131-91d4-6d9c2918819a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_110553eb-aa1c-462c-b047-34dc8e4b8944_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5b14bd7d-2ca5-4d94-85e3-00db9dd4a694_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_cee01f40-35e4-4e32-9579-ccce2ea1c744_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_12126409-7404-4ba1-998f-4228c15cb19b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b1ad2890-22cc-4c93-9212-82419a195ad4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_850e2d50-cf16-49ef-b321-500e1ee6c061_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_d67f06a4-40c9-414b-b59e-c8b71c482c70_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20220331.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f5a9c376-c602-47dd-81b2-9ca3b19d7f72_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_81d285e8-9736-4704-ae38-5124c99b3d13_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_58a78aa3-040c-432a-a00e-2be59849b9fc_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb5f6ed9-7337-4592-96d2-9bb7be21e2cb_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e10debf3-99e5-4979-8ae2-1da5f70d952a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_f42b4496-5073-48b6-be86-7d936e2822d4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_7ffde033-a893-4bf2-be6d-e3412563f4e3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_8a99b954-d157-44e1-bac2-1accd4b6623d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_023d86ab-ae1a-487c-8a6f-1e5085ce7bbd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_a2e17d5b-b08f-47a9-8821-03c67baddcde_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_1d07c43a-9247-44eb-8a05-fe38ea4e39f2_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20220331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_50c9778d-d0b5-47f2-b108-4697bcbd7250_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>cpix-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:71f09af2-eb91-4470-8350-f575ad603b6a,g:f5c1e857-adec-4283-ba91-4579f8814480-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_93f41dda-07e0-4989-bc0f-d8c595caff83" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_DocumentType_93f41dda-07e0-4989-bc0f-d8c595caff83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_449c65a5-c989-4f81-a775-2c70c8b78ddc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_DocumentQuarterlyReport_449c65a5-c989-4f81-a775-2c70c8b78ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_13f6c1ea-6641-426c-a081-daedb556b1a8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_DocumentPeriodEndDate_13f6c1ea-6641-426c-a081-daedb556b1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_65980a17-e92b-4571-897c-a9a906e628c9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_DocumentTransitionReport_65980a17-e92b-4571-897c-a9a906e628c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_65798d6b-a39c-4c38-8279-b33a317e7024" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityFileNumber_65798d6b-a39c-4c38-8279-b33a317e7024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cc766ea7-9144-4929-b8d6-9fba92e6bf2d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityRegistrantName_cc766ea7-9144-4929-b8d6-9fba92e6bf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_533d356a-47d6-452b-8e56-07c0c2578b09" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityIncorporationStateCountryCode_533d356a-47d6-452b-8e56-07c0c2578b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ed2b8cdf-32d9-4a19-8506-ca7d350cd47c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityTaxIdentificationNumber_ed2b8cdf-32d9-4a19-8506-ca7d350cd47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d870bd74-f70e-4305-878f-a992efafa0d4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityAddressAddressLine1_d870bd74-f70e-4305-878f-a992efafa0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_73d72f7c-e523-463d-bf3b-e7903d2ab77d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityAddressAddressLine2_73d72f7c-e523-463d-bf3b-e7903d2ab77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e0fabcd6-b6c9-4888-9206-d9ec93e80ef8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityAddressCityOrTown_e0fabcd6-b6c9-4888-9206-d9ec93e80ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ffd18aa1-3840-47e8-bb3f-8f53209ce5d8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityAddressStateOrProvince_ffd18aa1-3840-47e8-bb3f-8f53209ce5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4177ba98-99b0-407f-ab0b-b1645be2e18d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityAddressPostalZipCode_4177ba98-99b0-407f-ab0b-b1645be2e18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4b468b0b-d46b-4d42-9c64-4623b691fb89" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_CityAreaCode_4b468b0b-d46b-4d42-9c64-4623b691fb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_24f9885f-0677-46c7-86fa-fe8cfea34511" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_LocalPhoneNumber_24f9885f-0677-46c7-86fa-fe8cfea34511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b4c14121-426e-4084-92e3-ce5bcd8272c3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_Security12bTitle_b4c14121-426e-4084-92e3-ce5bcd8272c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e1673d67-dde2-4cda-9d3f-69ac2cddcc1f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_TradingSymbol_e1673d67-dde2-4cda-9d3f-69ac2cddcc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b343913e-c0f0-4784-aac8-ccd0860e97ff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_SecurityExchangeName_b343913e-c0f0-4784-aac8-ccd0860e97ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8c99e6f3-8af6-4ee2-8ea6-cba2fd4660c4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityCurrentReportingStatus_8c99e6f3-8af6-4ee2-8ea6-cba2fd4660c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f00ee198-8ee5-4097-b59c-44662ab6146a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityInteractiveDataCurrent_f00ee198-8ee5-4097-b59c-44662ab6146a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_655331c9-b640-44b0-9734-4c75620a5d88" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityFilerCategory_655331c9-b640-44b0-9734-4c75620a5d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_23b2bdca-b160-4c44-91e0-79aadf695635" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntitySmallBusiness_23b2bdca-b160-4c44-91e0-79aadf695635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7f837ad8-2f40-42ca-a532-2a0f3b186a08" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityEmergingGrowthCompany_7f837ad8-2f40-42ca-a532-2a0f3b186a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c8530abf-e4c6-4691-b01a-f55802e9672e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityShellCompany_c8530abf-e4c6-4691-b01a-f55802e9672e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f870f98b-f50e-404d-bf45-ca5761966f70" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f870f98b-f50e-404d-bf45-ca5761966f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6d7866fc-7b06-48d6-965d-07a802c7e357" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_DocumentFiscalYearFocus_6d7866fc-7b06-48d6-965d-07a802c7e357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_28d524c4-d92c-4faf-998f-1f1692f74b2c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_DocumentFiscalPeriodFocus_28d524c4-d92c-4faf-998f-1f1692f74b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d4e18cc6-dcdc-48f5-9c08-1d32ac15346c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_AmendmentFlag_d4e18cc6-dcdc-48f5-9c08-1d32ac15346c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_be2c4cc5-160b-467e-bb1b-bfee8c8817a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_EntityCentralIndexKey_be2c4cc5-160b-467e-bb1b-bfee8c8817a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_44a2a86b-385a-4ea9-b79a-dafd759582fe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e30cb6e2-b8fa-4772-94b7-6cd5a45a0124" xlink:to="loc_dei_CurrentFiscalYearEndDate_44a2a86b-385a-4ea9-b79a-dafd759582fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c5aa2741-191b-4861-9fba-bd807352109c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e117f0e1-ae62-4a2d-8886-53b8d1c8771f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c5aa2741-191b-4861-9fba-bd807352109c" xlink:to="loc_us-gaap_AssetsAbstract_e117f0e1-ae62-4a2d-8886-53b8d1c8771f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_76218813-7d91-45d1-8d92-26e6e685cc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e117f0e1-ae62-4a2d-8886-53b8d1c8771f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_76218813-7d91-45d1-8d92-26e6e685cc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b95f0548-3fae-4e33-94a2-3301a53e95d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76218813-7d91-45d1-8d92-26e6e685cc0b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b95f0548-3fae-4e33-94a2-3301a53e95d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7a985143-e288-4c04-9964-64d778bcdde9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76218813-7d91-45d1-8d92-26e6e685cc0b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7a985143-e288-4c04-9964-64d778bcdde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_57ba0667-9d26-438d-8377-6d043f773e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76218813-7d91-45d1-8d92-26e6e685cc0b" xlink:to="loc_us-gaap_InventoryNet_57ba0667-9d26-438d-8377-6d043f773e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_622b9dee-86ee-450a-89cf-195aad4baab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76218813-7d91-45d1-8d92-26e6e685cc0b" xlink:to="loc_us-gaap_OtherAssetsCurrent_622b9dee-86ee-450a-89cf-195aad4baab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_45a348d8-1739-401e-96e9-7e01f7eff140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76218813-7d91-45d1-8d92-26e6e685cc0b" xlink:to="loc_us-gaap_AssetsCurrent_45a348d8-1739-401e-96e9-7e01f7eff140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_ac4bdbb8-8b82-49b4-93b0-5e2f84ad3801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e117f0e1-ae62-4a2d-8886-53b8d1c8771f" xlink:to="loc_us-gaap_InventoryNoncurrent_ac4bdbb8-8b82-49b4-93b0-5e2f84ad3801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f52bfc04-b1c1-4c7d-8b26-e9bbf3271f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e117f0e1-ae62-4a2d-8886-53b8d1c8771f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f52bfc04-b1c1-4c7d-8b26-e9bbf3271f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66c4609d-5c34-4c81-9c5f-ed2f481f8e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e117f0e1-ae62-4a2d-8886-53b8d1c8771f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66c4609d-5c34-4c81-9c5f-ed2f481f8e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a7210869-5d2d-42d3-a94c-92edb9f2a04b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e117f0e1-ae62-4a2d-8886-53b8d1c8771f" xlink:to="loc_us-gaap_Goodwill_a7210869-5d2d-42d3-a94c-92edb9f2a04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b17caf8-1c18-453b-adc7-606bc0e38fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e117f0e1-ae62-4a2d-8886-53b8d1c8771f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b17caf8-1c18-453b-adc7-606bc0e38fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c458ad79-1ac0-4c43-84c1-bd140ebfa188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e117f0e1-ae62-4a2d-8886-53b8d1c8771f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c458ad79-1ac0-4c43-84c1-bd140ebfa188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8f1c2b87-1a39-4d94-a194-ab44d0c5a0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e117f0e1-ae62-4a2d-8886-53b8d1c8771f" xlink:to="loc_us-gaap_Assets_8f1c2b87-1a39-4d94-a194-ab44d0c5a0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ff2fc45a-c95b-41b2-8751-fb95dfe806cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c5aa2741-191b-4861-9fba-bd807352109c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ff2fc45a-c95b-41b2-8751-fb95dfe806cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_59a58de6-ebc2-4a3a-9ce5-d0eb8c2165bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ff2fc45a-c95b-41b2-8751-fb95dfe806cd" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_59a58de6-ebc2-4a3a-9ce5-d0eb8c2165bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fb70aae6-bb07-487d-88e2-7e2478b1c807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_59a58de6-ebc2-4a3a-9ce5-d0eb8c2165bb" xlink:to="loc_us-gaap_AccountsPayableCurrent_fb70aae6-bb07-487d-88e2-7e2478b1c807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_31c07fb5-d9e8-4afc-b522-7a5bf7f74cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_59a58de6-ebc2-4a3a-9ce5-d0eb8c2165bb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_31c07fb5-d9e8-4afc-b522-7a5bf7f74cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_098ce6fa-f7ab-449b-b749-1277ac727674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_59a58de6-ebc2-4a3a-9ce5-d0eb8c2165bb" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_098ce6fa-f7ab-449b-b749-1277ac727674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cbab71a3-7172-4d9b-95e8-72565d4735af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_59a58de6-ebc2-4a3a-9ce5-d0eb8c2165bb" xlink:to="loc_us-gaap_LiabilitiesCurrent_cbab71a3-7172-4d9b-95e8-72565d4735af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_2edc572f-c7bb-410f-aa35-154bf41c2e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ff2fc45a-c95b-41b2-8751-fb95dfe806cd" xlink:to="loc_us-gaap_LongTermLineOfCredit_2edc572f-c7bb-410f-aa35-154bf41c2e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_088df13c-4bef-4ff5-9e35-f65e1022a30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ff2fc45a-c95b-41b2-8751-fb95dfe806cd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_088df13c-4bef-4ff5-9e35-f65e1022a30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_00605337-4aa3-4744-85fe-846c4f487b9a" xlink:href="cpix-20220331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ff2fc45a-c95b-41b2-8751-fb95dfe806cd" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_00605337-4aa3-4744-85fe-846c4f487b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6d62d843-5b14-4ee3-872d-8f25cde3c7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ff2fc45a-c95b-41b2-8751-fb95dfe806cd" xlink:to="loc_us-gaap_Liabilities_6d62d843-5b14-4ee3-872d-8f25cde3c7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_435c7efe-336a-4bd7-8dba-7fa5b7cbdbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ff2fc45a-c95b-41b2-8751-fb95dfe806cd" xlink:to="loc_us-gaap_CommitmentsAndContingencies_435c7efe-336a-4bd7-8dba-7fa5b7cbdbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_290c8219-6b42-4604-821a-3d7f678be417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ff2fc45a-c95b-41b2-8751-fb95dfe806cd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_290c8219-6b42-4604-821a-3d7f678be417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0d193879-2226-42ff-9f8a-881c74250589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_290c8219-6b42-4604-821a-3d7f678be417" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0d193879-2226-42ff-9f8a-881c74250589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f83a6a03-4cf5-46bb-ae87-b27ae563c884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0d193879-2226-42ff-9f8a-881c74250589" xlink:to="loc_us-gaap_CommonStockValue_f83a6a03-4cf5-46bb-ae87-b27ae563c884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e2070cd0-6add-44f3-9c5d-cced9e67dd2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0d193879-2226-42ff-9f8a-881c74250589" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e2070cd0-6add-44f3-9c5d-cced9e67dd2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f198dd50-4165-4119-884b-715ded19175b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0d193879-2226-42ff-9f8a-881c74250589" xlink:to="loc_us-gaap_StockholdersEquity_f198dd50-4165-4119-884b-715ded19175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_91eff195-d0e0-4a52-98c8-97b0ac642792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_290c8219-6b42-4604-821a-3d7f678be417" xlink:to="loc_us-gaap_MinorityInterest_91eff195-d0e0-4a52-98c8-97b0ac642792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_282e7f6c-20c9-4274-a239-57e5a89f6cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_290c8219-6b42-4604-821a-3d7f678be417" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_282e7f6c-20c9-4274-a239-57e5a89f6cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b0085937-a4ac-4378-b796-4d838fcba046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ff2fc45a-c95b-41b2-8751-fb95dfe806cd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b0085937-a4ac-4378-b796-4d838fcba046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20220331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_89e6f058-2e4a-4f06-b594-3bd6b78cc08d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_c42611c4-6bf4-4df0-8dd8-bcf4a130f492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89e6f058-2e4a-4f06-b594-3bd6b78cc08d" xlink:to="loc_us-gaap_CommonStockNoParValue_c42611c4-6bf4-4df0-8dd8-bcf4a130f492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a3f2af9c-a6dc-46c1-af5f-9321172130b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89e6f058-2e4a-4f06-b594-3bd6b78cc08d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a3f2af9c-a6dc-46c1-af5f-9321172130b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c72a0191-3e39-48d3-bcab-eb429832af68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89e6f058-2e4a-4f06-b594-3bd6b78cc08d" xlink:to="loc_us-gaap_CommonStockSharesIssued_c72a0191-3e39-48d3-bcab-eb429832af68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_55f5e1f0-583d-4e23-9d6a-48df7a65bcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89e6f058-2e4a-4f06-b594-3bd6b78cc08d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_55f5e1f0-583d-4e23-9d6a-48df7a65bcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20220331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ccb21af2-3964-4b02-b420-0c3c6088ef8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ccb21af2-3964-4b02-b420-0c3c6088ef8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_46a933c8-3128-4497-a35f-431184660d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_46a933c8-3128-4497-a35f-431184660d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9f413321-49e0-4044-bc04-93295166ecc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_46a933c8-3128-4497-a35f-431184660d74" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9f413321-49e0-4044-bc04-93295166ecc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_1c23b512-9ff8-4d5a-ad53-4891ac8361d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_46a933c8-3128-4497-a35f-431184660d74" xlink:to="loc_us-gaap_SellingAndMarketingExpense_1c23b512-9ff8-4d5a-ad53-4891ac8361d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9caeb690-958a-437f-8174-342818dfbe8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_46a933c8-3128-4497-a35f-431184660d74" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9caeb690-958a-437f-8174-342818dfbe8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_708dbe2b-111c-4570-84ce-de532533c818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_46a933c8-3128-4497-a35f-431184660d74" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_708dbe2b-111c-4570-84ce-de532533c818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_cf34d3b1-e662-4dfb-9d43-022149886c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_46a933c8-3128-4497-a35f-431184660d74" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_cf34d3b1-e662-4dfb-9d43-022149886c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d440922a-62f4-43d7-81a6-5111e24c1ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_46a933c8-3128-4497-a35f-431184660d74" xlink:to="loc_us-gaap_CostsAndExpenses_d440922a-62f4-43d7-81a6-5111e24c1ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_60bce427-bee0-40d5-ac0c-7ecef80368f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_46a933c8-3128-4497-a35f-431184660d74" xlink:to="loc_us-gaap_OperatingIncomeLoss_60bce427-bee0-40d5-ac0c-7ecef80368f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b3d6fa38-945b-40ba-80db-0955c15de8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b3d6fa38-945b-40ba-80db-0955c15de8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_01ac3a31-e282-4169-a365-1e4fea8e471e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:to="loc_us-gaap_InterestExpense_01ac3a31-e282-4169-a365-1e4fea8e471e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7bb9ee3d-afc9-4d7c-a8d3-a6e1cbf0fbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7bb9ee3d-afc9-4d7c-a8d3-a6e1cbf0fbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_703ca1b3-a66d-4c0b-90d7-aa1627aa0b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_703ca1b3-a66d-4c0b-90d7-aa1627aa0b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b55faa73-ec2b-4657-b82e-f14cb693df7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b55faa73-ec2b-4657-b82e-f14cb693df7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_45e24c2e-7cec-4b19-94d6-1153d1d8d83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_45e24c2e-7cec-4b19-94d6-1153d1d8d83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7f4033fc-3c60-43d4-907b-185592a65179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:to="loc_us-gaap_ProfitLoss_7f4033fc-3c60-43d4-907b-185592a65179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4f65aff0-a967-42d8-892b-abc919d82071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4f65aff0-a967-42d8-892b-abc919d82071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_931adc4d-c017-499c-9360-788acca3035a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:to="loc_us-gaap_NetIncomeLoss_931adc4d-c017-499c-9360-788acca3035a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8ee12dfd-adca-4612-a716-dca6918f487e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:to="loc_us-gaap_EarningsPerShareAbstract_8ee12dfd-adca-4612-a716-dca6918f487e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_65afac3c-2460-4515-b5df-73894b83ab4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8ee12dfd-adca-4612-a716-dca6918f487e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_65afac3c-2460-4515-b5df-73894b83ab4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_84089db6-4714-40b5-a65e-ce874050a240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8ee12dfd-adca-4612-a716-dca6918f487e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_84089db6-4714-40b5-a65e-ce874050a240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4716e708-0d68-4398-9d83-07e1869d2236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8ee12dfd-adca-4612-a716-dca6918f487e" xlink:to="loc_us-gaap_EarningsPerShareBasic_4716e708-0d68-4398-9d83-07e1869d2236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_15458e8b-c9da-47e7-abc3-2f6ffff3e96c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8ee12dfd-adca-4612-a716-dca6918f487e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_15458e8b-c9da-47e7-abc3-2f6ffff3e96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3668c264-a658-4e19-b09e-32dd32bbb2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8ee12dfd-adca-4612-a716-dca6918f487e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3668c264-a658-4e19-b09e-32dd32bbb2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_34e9973c-3f43-4b1f-855e-7bd7b2360086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8ee12dfd-adca-4612-a716-dca6918f487e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_34e9973c-3f43-4b1f-855e-7bd7b2360086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b1637540-e5e1-4405-b34c-7475eecbaf28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_244c527f-5896-4dab-bf1f-975b984079d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b1637540-e5e1-4405-b34c-7475eecbaf28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1d3fa409-fee7-4c56-80ad-a4beeb0b0746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b1637540-e5e1-4405-b34c-7475eecbaf28" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1d3fa409-fee7-4c56-80ad-a4beeb0b0746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5db41ff0-bac1-40ef-a3d8-3ca41c694e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b1637540-e5e1-4405-b34c-7475eecbaf28" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5db41ff0-bac1-40ef-a3d8-3ca41c694e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20220331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_68cb0779-fe06-43cf-b2ed-39a7461ca698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_57ed6641-4dd7-40a6-8212-8ad06ad6d8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_68cb0779-fe06-43cf-b2ed-39a7461ca698" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_57ed6641-4dd7-40a6-8212-8ad06ad6d8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_946fecf6-731f-4bb7-928d-acdce499410a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_57ed6641-4dd7-40a6-8212-8ad06ad6d8f9" xlink:to="loc_us-gaap_ProfitLoss_946fecf6-731f-4bb7-928d-acdce499410a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9fd38516-c033-4bbe-a277-8b2a5dd2333b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_57ed6641-4dd7-40a6-8212-8ad06ad6d8f9" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9fd38516-c033-4bbe-a277-8b2a5dd2333b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c71cb76c-a714-4f35-a2be-578dd9210201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_57ed6641-4dd7-40a6-8212-8ad06ad6d8f9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c71cb76c-a714-4f35-a2be-578dd9210201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7926c2bb-2777-4e63-ab37-558d1e05e5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_57ed6641-4dd7-40a6-8212-8ad06ad6d8f9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7926c2bb-2777-4e63-ab37-558d1e05e5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_48cd040c-72f7-41f6-af8f-9914258c229c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7926c2bb-2777-4e63-ab37-558d1e05e5b6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_48cd040c-72f7-41f6-af8f-9914258c229c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2e0abd52-8174-4187-ae73-b2b15179376e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7926c2bb-2777-4e63-ab37-558d1e05e5b6" xlink:to="loc_us-gaap_ShareBasedCompensation_2e0abd52-8174-4187-ae73-b2b15179376e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_d5bd9831-8c21-4035-97e0-65f0bdf0ca08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7926c2bb-2777-4e63-ab37-558d1e05e5b6" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_d5bd9831-8c21-4035-97e0-65f0bdf0ca08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_bd729e8f-2e55-4df1-a552-a208421704fb" xlink:href="cpix-20220331.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7926c2bb-2777-4e63-ab37-558d1e05e5b6" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_bd729e8f-2e55-4df1-a552-a208421704fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_abc75009-1c54-4954-9e88-eee7dc58fe0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7926c2bb-2777-4e63-ab37-558d1e05e5b6" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_abc75009-1c54-4954-9e88-eee7dc58fe0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2a49599b-6b9a-42e3-b883-77c12087cb77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7926c2bb-2777-4e63-ab37-558d1e05e5b6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2a49599b-6b9a-42e3-b883-77c12087cb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_410f3b2a-7c4b-4b13-9aab-81d966636bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2a49599b-6b9a-42e3-b883-77c12087cb77" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_410f3b2a-7c4b-4b13-9aab-81d966636bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e3f11831-ac42-4a55-8422-c05ef59a178f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2a49599b-6b9a-42e3-b883-77c12087cb77" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e3f11831-ac42-4a55-8422-c05ef59a178f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5d7f3c12-0679-4245-91f5-ccde0327ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2a49599b-6b9a-42e3-b883-77c12087cb77" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5d7f3c12-0679-4245-91f5-ccde0327ceca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_767a8d01-db74-4a9c-9c1b-c05022be97fd" xlink:href="cpix-20220331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2a49599b-6b9a-42e3-b883-77c12087cb77" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_767a8d01-db74-4a9c-9c1b-c05022be97fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_a2298b98-3146-4dfc-9a4a-ddaee88126fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2a49599b-6b9a-42e3-b883-77c12087cb77" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_a2298b98-3146-4dfc-9a4a-ddaee88126fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1e3b2614-af2f-45e0-950b-13a6f6133ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_57ed6641-4dd7-40a6-8212-8ad06ad6d8f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1e3b2614-af2f-45e0-950b-13a6f6133ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_54694776-2672-4f77-a6d3-beb720109f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_57ed6641-4dd7-40a6-8212-8ad06ad6d8f9" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_54694776-2672-4f77-a6d3-beb720109f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b554f7c7-47ae-4cd6-a432-ae9ea89e903c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_57ed6641-4dd7-40a6-8212-8ad06ad6d8f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b554f7c7-47ae-4cd6-a432-ae9ea89e903c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c292a55-ab92-409c-8d90-a4057bfe1013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_68cb0779-fe06-43cf-b2ed-39a7461ca698" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c292a55-ab92-409c-8d90-a4057bfe1013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bc451467-1971-41f8-9a5d-9503f54cfeda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c292a55-ab92-409c-8d90-a4057bfe1013" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bc451467-1971-41f8-9a5d-9503f54cfeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_8261f97b-d8e8-4cb1-93f7-65c594c22aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c292a55-ab92-409c-8d90-a4057bfe1013" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_8261f97b-d8e8-4cb1-93f7-65c594c22aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_d71798dd-5d4b-4bda-bf9d-f12a65bdc87d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c292a55-ab92-409c-8d90-a4057bfe1013" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_d71798dd-5d4b-4bda-bf9d-f12a65bdc87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_c662f185-57cf-4265-8481-9bc0afd3a099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c292a55-ab92-409c-8d90-a4057bfe1013" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_c662f185-57cf-4265-8481-9bc0afd3a099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5279638a-d54f-4f8e-a42c-e920efca2352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c292a55-ab92-409c-8d90-a4057bfe1013" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5279638a-d54f-4f8e-a42c-e920efca2352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f47cbea-a9b6-4565-9d82-a2ec8b00ab05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_68cb0779-fe06-43cf-b2ed-39a7461ca698" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f47cbea-a9b6-4565-9d82-a2ec8b00ab05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_76dbd4f3-5d0b-44ac-89d6-fcbc62b8daf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f47cbea-a9b6-4565-9d82-a2ec8b00ab05" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_76dbd4f3-5d0b-44ac-89d6-fcbc62b8daf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_c210260f-c7e3-482c-b15f-d3de8db1ffe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f47cbea-a9b6-4565-9d82-a2ec8b00ab05" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_c210260f-c7e3-482c-b15f-d3de8db1ffe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e1f370be-6d89-42d6-b296-2b31270a5af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f47cbea-a9b6-4565-9d82-a2ec8b00ab05" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e1f370be-6d89-42d6-b296-2b31270a5af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_678bb917-57ef-41ee-a47d-e319b69e21f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f47cbea-a9b6-4565-9d82-a2ec8b00ab05" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_678bb917-57ef-41ee-a47d-e319b69e21f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55c7506c-6baa-4b41-8720-b8148c9c9d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f47cbea-a9b6-4565-9d82-a2ec8b00ab05" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55c7506c-6baa-4b41-8720-b8148c9c9d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87b7ce60-4b1f-452e-bcce-f74b0e90ca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f47cbea-a9b6-4565-9d82-a2ec8b00ab05" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87b7ce60-4b1f-452e-bcce-f74b0e90ca9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f7b30449-d285-4cae-bfd0-aac67cef7a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f47cbea-a9b6-4565-9d82-a2ec8b00ab05" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f7b30449-d285-4cae-bfd0-aac67cef7a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ff8aee1b-b19b-46c1-8738-ad70211153bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f47cbea-a9b6-4565-9d82-a2ec8b00ab05" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ff8aee1b-b19b-46c1-8738-ad70211153bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20220331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_225353ac-6890-4447-8a21-1027e3f1375c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0db3a097-bf37-400b-9773-61a5f6ca39ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_225353ac-6890-4447-8a21-1027e3f1375c" xlink:to="loc_us-gaap_StatementTable_0db3a097-bf37-400b-9773-61a5f6ca39ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e58b6b45-dd44-4715-bcd1-0ae706c99aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0db3a097-bf37-400b-9773-61a5f6ca39ea" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e58b6b45-dd44-4715-bcd1-0ae706c99aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_877031c6-0565-492a-ae37-f657657af0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e58b6b45-dd44-4715-bcd1-0ae706c99aee" xlink:to="loc_us-gaap_EquityComponentDomain_877031c6-0565-492a-ae37-f657657af0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4f52d79d-5e46-463e-8077-02d3ff84575a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_877031c6-0565-492a-ae37-f657657af0c2" xlink:to="loc_us-gaap_CommonStockMember_4f52d79d-5e46-463e-8077-02d3ff84575a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9b337c01-c946-4cc3-ba66-232e8878ddc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_877031c6-0565-492a-ae37-f657657af0c2" xlink:to="loc_us-gaap_RetainedEarningsMember_9b337c01-c946-4cc3-ba66-232e8878ddc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_55310f07-3ae4-42f2-b525-51ba9c4a3dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_877031c6-0565-492a-ae37-f657657af0c2" xlink:to="loc_us-gaap_NoncontrollingInterestMember_55310f07-3ae4-42f2-b525-51ba9c4a3dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3059006c-d5c5-4463-a834-351bafa5bede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0db3a097-bf37-400b-9773-61a5f6ca39ea" xlink:to="loc_us-gaap_StatementLineItems_3059006c-d5c5-4463-a834-351bafa5bede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3059006c-d5c5-4463-a834-351bafa5bede" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fac8024c-8f5e-4271-a2eb-20edf171bcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fac8024c-8f5e-4271-a2eb-20edf171bcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bd329711-aa5d-4e0c-9a5f-01eec6820e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bd329711-aa5d-4e0c-9a5f-01eec6820e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a09fdaaf-5765-4f3d-b1a6-643513e0c1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a09fdaaf-5765-4f3d-b1a6-643513e0c1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_59930284-9ce1-4895-83f0-d7301d31050a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_59930284-9ce1-4895-83f0-d7301d31050a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_0ff25dde-6a05-4847-8903-a0bc2df11397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_0ff25dde-6a05-4847-8903-a0bc2df11397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_156a6679-3f0b-4d5e-8c3c-86cb0b47fb25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_156a6679-3f0b-4d5e-8c3c-86cb0b47fb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9c796f94-40ba-4d55-b7be-3aacb9472c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_ProfitLoss_9c796f94-40ba-4d55-b7be-3aacb9472c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4b48b93e-c1c0-4d5f-bdb2-8a68e0512f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4b48b93e-c1c0-4d5f-bdb2-8a68e0512f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7d3b57bb-bc03-46c1-8acb-31be419ed3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0125ae9d-ad74-4541-a820-68e722d8581d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7d3b57bb-bc03-46c1-8acb-31be419ed3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20220331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_71fcdd0d-21e9-476f-9d6c-4dc5d9fc8042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1c2acd2d-1c00-4238-ba84-f87166604553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_71fcdd0d-21e9-476f-9d6c-4dc5d9fc8042" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1c2acd2d-1c00-4238-ba84-f87166604553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20220331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acce5da4-1970-4750-9965-e20b3eaae615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_000a0268-ecc8-48e1-8368-301ec41e5db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acce5da4-1970-4750-9965-e20b3eaae615" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_000a0268-ecc8-48e1-8368-301ec41e5db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_456a557d-b5f2-49b4-bc86-04416003b8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acce5da4-1970-4750-9965-e20b3eaae615" xlink:to="loc_us-gaap_UseOfEstimates_456a557d-b5f2-49b4-bc86-04416003b8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8e127f60-eac1-4067-ad3b-b7f2cbd661b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_acce5da4-1970-4750-9965-e20b3eaae615" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8e127f60-eac1-4067-ad3b-b7f2cbd661b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df7816b6-d64f-40ef-8ab9-cdeea2485436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2ba83b7b-6201-44cf-933a-8f03e7a91850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df7816b6-d64f-40ef-8ab9-cdeea2485436" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2ba83b7b-6201-44cf-933a-8f03e7a91850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20220331.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_22fd392a-a841-4fa4-8997-23bc4444c95c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_242bd977-f7fd-464c-8ece-c0313863a3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_22fd392a-a841-4fa4-8997-23bc4444c95c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_242bd977-f7fd-464c-8ece-c0313863a3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20220331.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f6f7860c-1eed-414c-b01c-821fc7386c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9ac999c7-ae9b-4120-87b3-450087252cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f6f7860c-1eed-414c-b01c-821fc7386c4a" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9ac999c7-ae9b-4120-87b3-450087252cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#EarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6456b9bf-2c61-47c4-9b06-38a142417628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_1daf0112-ab4f-418e-bc96-dcaf293fd13e" xlink:href="cpix-20220331.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6456b9bf-2c61-47c4-9b06-38a142417628" xlink:to="loc_cpix_NumeratorAbstract_1daf0112-ab4f-418e-bc96-dcaf293fd13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f70adbcf-c852-43de-8d10-1a5b2816df7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_1daf0112-ab4f-418e-bc96-dcaf293fd13e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f70adbcf-c852-43de-8d10-1a5b2816df7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_33cb5df9-057c-4436-9f61-4e18d54cff37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_1daf0112-ab4f-418e-bc96-dcaf293fd13e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_33cb5df9-057c-4436-9f61-4e18d54cff37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4e60f1ab-2721-450d-a5b8-1e977bad186a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_1daf0112-ab4f-418e-bc96-dcaf293fd13e" xlink:to="loc_us-gaap_ProfitLoss_4e60f1ab-2721-450d-a5b8-1e977bad186a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e28ff9df-1eec-4365-b660-7352fdfef714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_1daf0112-ab4f-418e-bc96-dcaf293fd13e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e28ff9df-1eec-4365-b660-7352fdfef714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e4045860-f58e-41f0-bd09-212861199b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_1daf0112-ab4f-418e-bc96-dcaf293fd13e" xlink:to="loc_us-gaap_NetIncomeLoss_e4045860-f58e-41f0-bd09-212861199b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_841fb38c-8d82-4dff-9337-d52fa2f0f460" xlink:href="cpix-20220331.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6456b9bf-2c61-47c4-9b06-38a142417628" xlink:to="loc_cpix_DenominatorAbstract_841fb38c-8d82-4dff-9337-d52fa2f0f460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5ebf87fa-8a5f-47b1-820f-9d57c44c368c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_841fb38c-8d82-4dff-9337-d52fa2f0f460" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5ebf87fa-8a5f-47b1-820f-9d57c44c368c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_70c54832-0b70-4196-a744-98261dbac72b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_841fb38c-8d82-4dff-9337-d52fa2f0f460" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_70c54832-0b70-4196-a744-98261dbac72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f2b20007-c6df-4f55-acab-bbc65f3c0941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_841fb38c-8d82-4dff-9337-d52fa2f0f460" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f2b20007-c6df-4f55-acab-bbc65f3c0941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20220331.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c5a81378-0ca6-40af-9aba-3213baf9c2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9c492078-68cd-4031-9c8e-b19e209f4024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c5a81378-0ca6-40af-9aba-3213baf9c2db" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9c492078-68cd-4031-9c8e-b19e209f4024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20220331.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4f494ac4-4a9a-4572-ad31-1a350ad9d8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_a74da3f9-7661-4b03-956b-41589d67f8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4f494ac4-4a9a-4572-ad31-1a350ad9d8cc" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_a74da3f9-7661-4b03-956b-41589d67f8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20220331.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_eda2883c-d459-4d55-a023-b5ae92086ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4e961014-40de-4d81-a006-16fe72663a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_eda2883c-d459-4d55-a023-b5ae92086ced" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4e961014-40de-4d81-a006-16fe72663a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#RevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8ea3bed4-c04d-4fd6-aed3-08c2d37a84c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4316c940-9420-40ae-a294-276b8ab75490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8ea3bed4-c04d-4fd6-aed3-08c2d37a84c5" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4316c940-9420-40ae-a294-276b8ab75490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_480150e9-100c-4828-9916-a71ee764bbdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4316c940-9420-40ae-a294-276b8ab75490" xlink:to="loc_srt_ProductOrServiceAxis_480150e9-100c-4828-9916-a71ee764bbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_480150e9-100c-4828-9916-a71ee764bbdf" xlink:to="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_d47a710a-5b87-4247-af93-fa3819128c50" xlink:href="cpix-20220331.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_KristaloseMember_d47a710a-5b87-4247-af93-fa3819128c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_28a8e248-f9ad-4fb2-a0cf-58b8679cdb53" xlink:href="cpix-20220331.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_SancusoMember_28a8e248-f9ad-4fb2-a0cf-58b8679cdb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_08578d5f-80bd-42c7-9d94-2c0b99b64348" xlink:href="cpix-20220331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_VIBATIVMember_08578d5f-80bd-42c7-9d94-2c0b99b64348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_808cca5e-5d96-4e87-b819-5610998dcb6e" xlink:href="cpix-20220331.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_CaldolorMember_808cca5e-5d96-4e87-b819-5610998dcb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_141961f8-85c6-4715-9e6b-8b1b480c6cbb" xlink:href="cpix-20220331.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_VaprisolMember_141961f8-85c6-4715-9e6b-8b1b480c6cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_72f97b30-a52a-4576-862f-472212f0dff9" xlink:href="cpix-20220331.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_AcetadoteMember_72f97b30-a52a-4576-862f-472212f0dff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_3ed01386-5219-42e5-88ce-f2c466de817d" xlink:href="cpix-20220331.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_OmeclamoxPakMember_3ed01386-5219-42e5-88ce-f2c466de817d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_48796a85-2f55-4193-b310-132602fa1a68" xlink:href="cpix-20220331.xsd#cpix_RediTrexMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_RediTrexMember_48796a85-2f55-4193-b310-132602fa1a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_ea6ef95e-4706-4880-b378-331dd3397011" xlink:href="cpix-20220331.xsd#cpix_OtherProductsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_cpix_OtherProductsMember_ea6ef95e-4706-4880-b378-331dd3397011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_52791d45-5944-4564-b1cb-106ce4f71b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53366a36-a983-48f9-8f5b-f786f575fabd" xlink:to="loc_us-gaap_GrantMember_52791d45-5944-4564-b1cb-106ce4f71b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_00c75d56-c017-47c8-9b67-ba862a7a2d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4316c940-9420-40ae-a294-276b8ab75490" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_00c75d56-c017-47c8-9b67-ba862a7a2d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ec9f3135-220f-4027-ae41-ea071f53a6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_00c75d56-c017-47c8-9b67-ba862a7a2d93" xlink:to="loc_us-gaap_RevenuesAbstract_ec9f3135-220f-4027-ae41-ea071f53a6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_6700b1f3-7dc4-4e2f-955f-37b03651433f" xlink:href="cpix-20220331.xsd#cpix_ProductsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_ec9f3135-220f-4027-ae41-ea071f53a6a7" xlink:to="loc_cpix_ProductsAbstract_6700b1f3-7dc4-4e2f-955f-37b03651433f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_015e7360-4869-4ecb-bb19-2b95af9eefe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductsAbstract_6700b1f3-7dc4-4e2f-955f-37b03651433f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_015e7360-4869-4ecb-bb19-2b95af9eefe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20220331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_377a8d04-9552-4767-a3a0-630ec38b7d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_33f78cc1-b7a4-4bb3-b9ca-938318ea49ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_377a8d04-9552-4767-a3a0-630ec38b7d20" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_33f78cc1-b7a4-4bb3-b9ca-938318ea49ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20220331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ec92176f-108e-4d0f-960b-cfba9d5406cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d545237e-f704-43a4-a49a-85da5e2bfc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ec92176f-108e-4d0f-960b-cfba9d5406cb" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d545237e-f704-43a4-a49a-85da5e2bfc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_32703f62-3189-471d-bca6-aec22f4afd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_41907653-30fb-46f8-8b29-c281cb42eac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_32703f62-3189-471d-bca6-aec22f4afd4d" xlink:to="loc_us-gaap_InventoryCurrentTable_41907653-30fb-46f8-8b29-c281cb42eac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_125fdaeb-a7ae-4fe1-8dc9-9f62c871b3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_41907653-30fb-46f8-8b29-c281cb42eac4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_125fdaeb-a7ae-4fe1-8dc9-9f62c871b3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_347ce80c-052d-4e3c-97e6-d1ff08778f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_125fdaeb-a7ae-4fe1-8dc9-9f62c871b3d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_347ce80c-052d-4e3c-97e6-d1ff08778f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_7617fdb9-f167-4c00-be77-27e149334fc2" xlink:href="cpix-20220331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_347ce80c-052d-4e3c-97e6-d1ff08778f08" xlink:to="loc_cpix_IfetrobanClinicalMember_7617fdb9-f167-4c00-be77-27e149334fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_d17841f5-4812-4242-94c8-338785aab5bd" xlink:href="cpix-20220331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_347ce80c-052d-4e3c-97e6-d1ff08778f08" xlink:to="loc_cpix_VIBATIVMember_d17841f5-4812-4242-94c8-338785aab5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_40448919-8d0a-40d1-adee-c148d5e774bb" xlink:href="cpix-20220331.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_347ce80c-052d-4e3c-97e6-d1ff08778f08" xlink:to="loc_cpix_SancusoMember_40448919-8d0a-40d1-adee-c148d5e774bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_5c4a3cbf-e409-40cf-a766-926b6cbb9277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_41907653-30fb-46f8-8b29-c281cb42eac4" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_5c4a3cbf-e409-40cf-a766-926b6cbb9277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_382f6282-17ab-4b11-8072-5c7bb27dbdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_5c4a3cbf-e409-40cf-a766-926b6cbb9277" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_382f6282-17ab-4b11-8072-5c7bb27dbdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_0ecedb5a-30a1-464e-990a-1a1529dc404c" xlink:href="cpix-20220331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_382f6282-17ab-4b11-8072-5c7bb27dbdbc" xlink:to="loc_cpix_IfetrobanClinicalMember_0ecedb5a-30a1-464e-990a-1a1529dc404c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_b04ca22a-40c7-4667-a315-d1cbf28d18e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_41907653-30fb-46f8-8b29-c281cb42eac4" xlink:to="loc_us-gaap_InventoryLineItems_b04ca22a-40c7-4667-a315-d1cbf28d18e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_346d7021-80de-4110-abfe-4dc0905a8e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_b04ca22a-40c7-4667-a315-d1cbf28d18e4" xlink:to="loc_us-gaap_InventoryValuationReserves_346d7021-80de-4110-abfe-4dc0905a8e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c1c4b955-e1ee-4a39-8ede-1cc2d6944b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_b04ca22a-40c7-4667-a315-d1cbf28d18e4" xlink:to="loc_us-gaap_InventoryNoncurrent_c1c4b955-e1ee-4a39-8ede-1cc2d6944b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_1029f68a-65a6-4915-8a93-6bb1a12264c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_b04ca22a-40c7-4667-a315-d1cbf28d18e4" xlink:to="loc_us-gaap_InventoryFinishedGoods_1029f68a-65a6-4915-8a93-6bb1a12264c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1628299a-bd0a-4afa-82fd-2d23ca0f8d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_b04ca22a-40c7-4667-a315-d1cbf28d18e4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1628299a-bd0a-4afa-82fd-2d23ca0f8d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_150ddfd9-c07f-4707-bdf7-b37c8c053ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_31a7c2f0-0d8b-4292-bc6a-d3ea14c56b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_150ddfd9-c07f-4707-bdf7-b37c8c053ed4" xlink:to="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_31a7c2f0-0d8b-4292-bc6a-d3ea14c56b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_87f9c76b-d23f-4327-81f4-8c3794844fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_31a7c2f0-0d8b-4292-bc6a-d3ea14c56b59" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_87f9c76b-d23f-4327-81f4-8c3794844fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_743a67e5-2d15-44c0-a2ce-55a0e601adff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_31a7c2f0-0d8b-4292-bc6a-d3ea14c56b59" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_743a67e5-2d15-44c0-a2ce-55a0e601adff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ec541175-bb57-49db-86ad-e8879fcf753f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_31a7c2f0-0d8b-4292-bc6a-d3ea14c56b59" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ec541175-bb57-49db-86ad-e8879fcf753f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d2008a38-3ad7-4179-a0ac-256de89204c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_31a7c2f0-0d8b-4292-bc6a-d3ea14c56b59" xlink:to="loc_us-gaap_InventoryGross_d2008a38-3ad7-4179-a0ac-256de89204c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_43295bf5-a62c-4ea2-beca-210398f9e434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_31a7c2f0-0d8b-4292-bc6a-d3ea14c56b59" xlink:to="loc_us-gaap_InventoryNoncurrent_43295bf5-a62c-4ea2-beca-210398f9e434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7a2a0713-b2c9-42a0-a8db-8033f8e8f17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_31a7c2f0-0d8b-4292-bc6a-d3ea14c56b59" xlink:to="loc_us-gaap_InventoryNet_7a2a0713-b2c9-42a0-a8db-8033f8e8f17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20220331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_207339b4-6107-4057-a65e-378be23098f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_8161891d-c839-46f5-9d14-ab1a64c72639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_207339b4-6107-4057-a65e-378be23098f7" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_8161891d-c839-46f5-9d14-ab1a64c72639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20220331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_373acc5c-10eb-4242-a74a-a136ec67d85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_2fd9f4bb-087b-4655-afe1-6abf160a51aa" xlink:href="cpix-20220331.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_373acc5c-10eb-4242-a74a-a136ec67d85a" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_2fd9f4bb-087b-4655-afe1-6abf160a51aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d102cc78-3236-4c96-b67c-311f614a46bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_373acc5c-10eb-4242-a74a-a136ec67d85a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d102cc78-3236-4c96-b67c-311f614a46bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_b7575b7b-2013-48b7-ad41-f08347296262" xlink:href="cpix-20220331.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_373acc5c-10eb-4242-a74a-a136ec67d85a" xlink:to="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_b7575b7b-2013-48b7-ad41-f08347296262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_df223710-1fdf-4cb0-91a0-b7cc75ebac5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_c74536be-dbce-4e19-b9e6-9204ba377b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_df223710-1fdf-4cb0-91a0-b7cc75ebac5f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_c74536be-dbce-4e19-b9e6-9204ba377b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f38adc6-f1ce-48df-ae22-87d5a71a9de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c74536be-dbce-4e19-b9e6-9204ba377b2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f38adc6-f1ce-48df-ae22-87d5a71a9de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fd744b45-bb7f-4b86-b0e1-e2861b4f7b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f38adc6-f1ce-48df-ae22-87d5a71a9de4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fd744b45-bb7f-4b86-b0e1-e2861b4f7b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f2c9b013-8d97-4f8a-9683-2e927cac67d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fd744b45-bb7f-4b86-b0e1-e2861b4f7b10" xlink:to="loc_us-gaap_BuildingMember_f2c9b013-8d97-4f8a-9683-2e927cac67d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_4500e21f-1854-4d58-8b2b-bb159c1d4b52" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fd744b45-bb7f-4b86-b0e1-e2861b4f7b10" xlink:to="loc_srt_OfficeBuildingMember_4500e21f-1854-4d58-8b2b-bb159c1d4b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_7b909f1f-2890-4426-82a3-216e5ad194a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c74536be-dbce-4e19-b9e6-9204ba377b2f" xlink:to="loc_us-gaap_LeaseContractualTermAxis_7b909f1f-2890-4426-82a3-216e5ad194a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_7b291451-a21c-44de-b9ea-1a893a24656e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_7b909f1f-2890-4426-82a3-216e5ad194a6" xlink:to="loc_us-gaap_LeaseContractualTermDomain_7b291451-a21c-44de-b9ea-1a893a24656e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_27eca7f3-5f86-4b9c-9714-98ee519ba65a" xlink:href="cpix-20220331.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_7b291451-a21c-44de-b9ea-1a893a24656e" xlink:to="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_27eca7f3-5f86-4b9c-9714-98ee519ba65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c74536be-dbce-4e19-b9e6-9204ba377b2f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_9c30a253-6d43-429f-9aac-3e9c8c54be09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_9c30a253-6d43-429f-9aac-3e9c8c54be09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2df4a296-e336-4209-97e3-73278685c476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2df4a296-e336-4209-97e3-73278685c476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6e49409b-6eb2-42cc-b991-d9738472be32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6e49409b-6eb2-42cc-b991-d9738472be32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea_69cfee07-c6bf-42f8-bbdc-1eeb51c2e37a" xlink:href="cpix-20220331.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_cpix_LesseeOperatingLeaseLeasedArea_69cfee07-c6bf-42f8-bbdc-1eeb51c2e37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4d405c18-7082-4ec8-86e0-f4193863e13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4d405c18-7082-4ec8-86e0-f4193863e13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_b93dea2d-478b-492d-bfc8-f26daae56ea2" xlink:href="cpix-20220331.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_b93dea2d-478b-492d-bfc8-f26daae56ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d6d438ba-7e90-4f24-8cc6-3b2a270a815d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d6d438ba-7e90-4f24-8cc6-3b2a270a815d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4948eca3-b042-420b-aece-e8a1bb57e4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f328ea88-5aa1-4748-86f4-a3d7a4033265" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4948eca3-b042-420b-aece-e8a1bb57e4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_61850c9f-3e58-4fcb-8681-b10bf77e1df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8180b4ea-aa13-4be6-91c7-193e5dabdd75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61850c9f-3e58-4fcb-8681-b10bf77e1df5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8180b4ea-aa13-4be6-91c7-193e5dabdd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b7716048-1fb1-4cf1-b5cc-9bf1b5708318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61850c9f-3e58-4fcb-8681-b10bf77e1df5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b7716048-1fb1-4cf1-b5cc-9bf1b5708318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_06b46f78-3ed3-4efe-a84a-e62430a5ea1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61850c9f-3e58-4fcb-8681-b10bf77e1df5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_06b46f78-3ed3-4efe-a84a-e62430a5ea1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_c057a728-3038-4ed9-b79b-8efb937a7578" xlink:href="cpix-20220331.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_61850c9f-3e58-4fcb-8681-b10bf77e1df5" xlink:to="loc_cpix_LeaseLiability_c057a728-3038-4ed9-b79b-8efb937a7578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ebbe2936-2cc7-41ef-adaa-b1ff29949b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ca955520-7c99-43ff-85cd-3341ecf451d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ebbe2936-2cc7-41ef-adaa-b1ff29949b07" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ca955520-7c99-43ff-85cd-3341ecf451d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7102d413-3105-4597-a297-aedf81e4fe65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ca955520-7c99-43ff-85cd-3341ecf451d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7102d413-3105-4597-a297-aedf81e4fe65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2e9bcab7-61b6-47b3-98e4-36b004964615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ca955520-7c99-43ff-85cd-3341ecf451d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2e9bcab7-61b6-47b3-98e4-36b004964615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f7f6cc68-ad40-4014-a3eb-f68d190b2ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ca955520-7c99-43ff-85cd-3341ecf451d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f7f6cc68-ad40-4014-a3eb-f68d190b2ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8009ad44-44af-40f0-86aa-00b6618defdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ca955520-7c99-43ff-85cd-3341ecf451d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8009ad44-44af-40f0-86aa-00b6618defdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9761d29d-979c-4064-8b4a-04d0cf9ec9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ca955520-7c99-43ff-85cd-3341ecf451d7" xlink:to="loc_us-gaap_OperatingLeaseLiability_9761d29d-979c-4064-8b4a-04d0cf9ec9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20220331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#LeasesRentExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_68898d89-e47b-4c1b-9869-1c414902d363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_f36144ff-c292-4b94-8b30-d6d148d2bed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_68898d89-e47b-4c1b-9869-1c414902d363" xlink:to="loc_us-gaap_OperatingLeaseExpense_f36144ff-c292-4b94-8b30-d6d148d2bed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_86e7d870-04b3-45ae-a43a-00a3fc74664f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_68898d89-e47b-4c1b-9869-1c414902d363" xlink:to="loc_us-gaap_SubleaseIncome_86e7d870-04b3-45ae-a43a-00a3fc74664f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20220331.xsd#ShareholdersEquityandDebt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_d0e5e4b4-a2ae-4a65-b221-56d01b457160" xlink:href="cpix-20220331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_37a7f3c5-437e-44a9-9919-07201d9363de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_d0e5e4b4-a2ae-4a65-b221-56d01b457160" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_37a7f3c5-437e-44a9-9919-07201d9363de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_e5e336fa-a247-461a-8023-a47bec90311e" xlink:href="cpix-20220331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73e3ab8f-9cb3-4b2b-9e77-149cd0961956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_e5e336fa-a247-461a-8023-a47bec90311e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73e3ab8f-9cb3-4b2b-9e77-149cd0961956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_04cb9a24-9f69-4304-a6d6-ab59c2db184d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73e3ab8f-9cb3-4b2b-9e77-149cd0961956" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_04cb9a24-9f69-4304-a6d6-ab59c2db184d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7ce3d174-302e-4140-b517-ce22f94fb6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04cb9a24-9f69-4304-a6d6-ab59c2db184d" xlink:to="loc_us-gaap_EquityComponentDomain_7ce3d174-302e-4140-b517-ce22f94fb6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_70ab8e7f-20d5-4211-b1f6-16f1143b2ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7ce3d174-302e-4140-b517-ce22f94fb6c6" xlink:to="loc_us-gaap_CommonStockMember_70ab8e7f-20d5-4211-b1f6-16f1143b2ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_25d43c12-7875-413c-b98e-a64dae65c6ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73e3ab8f-9cb3-4b2b-9e77-149cd0961956" xlink:to="loc_srt_TitleOfIndividualAxis_25d43c12-7875-413c-b98e-a64dae65c6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4318a0f8-0f8e-43b4-a0af-3a405f3bc08a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_25d43c12-7875-413c-b98e-a64dae65c6ce" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4318a0f8-0f8e-43b4-a0af-3a405f3bc08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_f7655a94-ce56-4836-91c1-c324100bbadb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4318a0f8-0f8e-43b4-a0af-3a405f3bc08a" xlink:to="loc_srt_DirectorMember_f7655a94-ce56-4836-91c1-c324100bbadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc97bca0-14af-4ba0-99fa-df8f5b7ea1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73e3ab8f-9cb3-4b2b-9e77-149cd0961956" xlink:to="loc_us-gaap_AwardTypeAxis_dc97bca0-14af-4ba0-99fa-df8f5b7ea1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a110371c-973e-424a-8f74-73ab2afa041a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dc97bca0-14af-4ba0-99fa-df8f5b7ea1a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a110371c-973e-424a-8f74-73ab2afa041a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d06ac7ce-bd15-4d2e-a42c-59e0f390a523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a110371c-973e-424a-8f74-73ab2afa041a" xlink:to="loc_us-gaap_RestrictedStockMember_d06ac7ce-bd15-4d2e-a42c-59e0f390a523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember_bf9a020d-efd8-45e3-a11a-f0a3181bcfa8" xlink:href="cpix-20220331.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a110371c-973e-424a-8f74-73ab2afa041a" xlink:to="loc_cpix_IncentiveStockOptionsMember_bf9a020d-efd8-45e3-a11a-f0a3181bcfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_8388988b-3ca6-4943-b13d-c34b24ef71a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73e3ab8f-9cb3-4b2b-9e77-149cd0961956" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_8388988b-3ca6-4943-b13d-c34b24ef71a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_dc6363a7-39f5-471e-b56e-4d7c63a7390d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_8388988b-3ca6-4943-b13d-c34b24ef71a2" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_dc6363a7-39f5-471e-b56e-4d7c63a7390d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_d583bd20-6290-459c-8865-6ec51fe9b460" xlink:href="cpix-20220331.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_dc6363a7-39f5-471e-b56e-4d7c63a7390d" xlink:to="loc_cpix_PinnacleBankMember_d583bd20-6290-459c-8865-6ec51fe9b460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40acd8c9-075e-4674-bb37-684586c9504d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73e3ab8f-9cb3-4b2b-9e77-149cd0961956" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40acd8c9-075e-4674-bb37-684586c9504d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:href="cpix-20220331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40acd8c9-075e-4674-bb37-684586c9504d" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8e95c472-9d7b-4a6a-bc08-a048f6e9ed6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8e95c472-9d7b-4a6a-bc08-a048f6e9ed6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_e765e828-f8f2-4ce4-8703-8e0bf221b23c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_e765e828-f8f2-4ce4-8703-8e0bf221b23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_6b647743-8096-40b7-a68e-14d506fd875e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_6b647743-8096-40b7-a68e-14d506fd875e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9f8c2520-0ea9-470b-95e9-0a85f0faac86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9f8c2520-0ea9-470b-95e9-0a85f0faac86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_e3239653-c327-4647-820c-f3a98a0f3b56" xlink:href="cpix-20220331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_e3239653-c327-4647-820c-f3a98a0f3b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4e8db747-7159-4a58-966e-1cfc9c2dd935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4e8db747-7159-4a58-966e-1cfc9c2dd935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8f62d730-9feb-42e3-a048-dc6e42f707c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1e167e8d-387b-4d30-a022-efacb78dc172" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8f62d730-9feb-42e3-a048-dc6e42f707c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_7c130a37-7267-4786-9b9a-5c8b3721e5da" xlink:href="cpix-20220331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_7c130a37-7267-4786-9b9a-5c8b3721e5da" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_0039730b-fc33-4149-9607-90010e7bac92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_0039730b-fc33-4149-9607-90010e7bac92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_7154ea4b-8699-4908-b8fa-0589cec184d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_0039730b-fc33-4149-9607-90010e7bac92" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_7154ea4b-8699-4908-b8fa-0589cec184d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_91fe21ce-4567-4085-b426-73fa0cfa2218" xlink:href="cpix-20220331.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7154ea4b-8699-4908-b8fa-0589cec184d4" xlink:to="loc_cpix_PinnacleBankMember_91fe21ce-4567-4085-b426-73fa0cfa2218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b00de137-a882-4137-b78d-87d3ad1f5fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_us-gaap_DebtInstrumentAxis_b00de137-a882-4137-b78d-87d3ad1f5fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4aaad100-14e5-44f3-b8db-1291fc17474d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b00de137-a882-4137-b78d-87d3ad1f5fa8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4aaad100-14e5-44f3-b8db-1291fc17474d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1c61e1c2-8341-4cea-b48f-88dcbc887933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4aaad100-14e5-44f3-b8db-1291fc17474d" xlink:to="loc_us-gaap_LineOfCreditMember_1c61e1c2-8341-4cea-b48f-88dcbc887933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FifthAmendmentMember_2ac97fde-3a80-4cba-a3d4-1701d73b0c87" xlink:href="cpix-20220331.xsd#cpix_FifthAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4aaad100-14e5-44f3-b8db-1291fc17474d" xlink:to="loc_cpix_FifthAmendmentMember_2ac97fde-3a80-4cba-a3d4-1701d73b0c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4431fc02-f3b9-4b5a-8e57-5acb53614828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_us-gaap_CreditFacilityAxis_4431fc02-f3b9-4b5a-8e57-5acb53614828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7fa2213e-8228-45d1-807f-c1d4ac2a07e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_4431fc02-f3b9-4b5a-8e57-5acb53614828" xlink:to="loc_us-gaap_CreditFacilityDomain_7fa2213e-8228-45d1-807f-c1d4ac2a07e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_85c265db-aca0-4e50-8466-fb7f0234f829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7fa2213e-8228-45d1-807f-c1d4ac2a07e9" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_85c265db-aca0-4e50-8466-fb7f0234f829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1c537c37-c6a1-4802-b513-7d4ce266e6ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_srt_RangeAxis_1c537c37-c6a1-4802-b513-7d4ce266e6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_554377bc-4c64-482c-bc9e-e3bf0f7f3073" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1c537c37-c6a1-4802-b513-7d4ce266e6ac" xlink:to="loc_srt_RangeMember_554377bc-4c64-482c-bc9e-e3bf0f7f3073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1ead5683-0a6f-40ac-9cfa-c6c08a3cb012" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_554377bc-4c64-482c-bc9e-e3bf0f7f3073" xlink:to="loc_srt_MinimumMember_1ead5683-0a6f-40ac-9cfa-c6c08a3cb012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c043dc79-47ef-42db-8f19-2f5cb4409660" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_554377bc-4c64-482c-bc9e-e3bf0f7f3073" xlink:to="loc_srt_MaximumMember_c043dc79-47ef-42db-8f19-2f5cb4409660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f95845b4-7c99-4389-a5a6-77b8a5b1cba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_us-gaap_VariableRateAxis_f95845b4-7c99-4389-a5a6-77b8a5b1cba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c77b5720-3934-4190-a0d9-00cfe5e09262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_f95845b4-7c99-4389-a5a6-77b8a5b1cba9" xlink:to="loc_us-gaap_VariableRateDomain_c77b5720-3934-4190-a0d9-00cfe5e09262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f6eff7c9-728d-4368-8646-f7d3e28bb46b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_c77b5720-3934-4190-a0d9-00cfe5e09262" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f6eff7c9-728d-4368-8646-f7d3e28bb46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5d57b063-f0b9-4a63-ab84-64519c63241b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5d57b063-f0b9-4a63-ab84-64519c63241b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6be373a7-c0c8-4faa-9852-606592175ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5d57b063-f0b9-4a63-ab84-64519c63241b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6be373a7-c0c8-4faa-9852-606592175ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_6eeb604f-9bb1-487b-8de2-9dffbcccf1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6be373a7-c0c8-4faa-9852-606592175ecd" xlink:to="loc_us-gaap_ConvertibleDebtMember_6eeb604f-9bb1-487b-8de2-9dffbcccf1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7e45d909-9da6-4ce3-8128-71dc2edf705d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_srt_CounterpartyNameAxis_7e45d909-9da6-4ce3-8128-71dc2edf705d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6272847-6c67-4dd2-afaa-5eab3557dd4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7e45d909-9da6-4ce3-8128-71dc2edf705d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6272847-6c67-4dd2-afaa-5eab3557dd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember_d54c6eef-d7d6-40db-af48-70a7a38f34d1" xlink:href="cpix-20220331.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6272847-6c67-4dd2-afaa-5eab3557dd4e" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdMember_d54c6eef-d7d6-40db-af48-70a7a38f34d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_3f763c37-e9ea-4b7d-a904-125a0b6f266a" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_374593eb-9150-411a-821a-22cfaaeb9946" xlink:href="cpix-20220331.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_374593eb-9150-411a-821a-22cfaaeb9946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_d6d37e8a-9a82-4c9b-a069-2b95781239a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_d6d37e8a-9a82-4c9b-a069-2b95781239a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7353925a-0a32-47ec-9ae3-cd6c83516823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7353925a-0a32-47ec-9ae3-cd6c83516823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e472a13-9747-4784-9e70-f0f20395286e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e472a13-9747-4784-9e70-f0f20395286e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_1931fe47-e5ce-40a4-9806-77ee7865b6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_1931fe47-e5ce-40a4-9806-77ee7865b6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_aa6f4c34-a18c-4d55-89aa-88522a7c3eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_LongTermLineOfCredit_aa6f4c34-a18c-4d55-89aa-88522a7c3eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_7b4ae229-286f-4bd7-bf9e-58f6901f41f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_7b4ae229-286f-4bd7-bf9e-58f6901f41f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8a46e0d2-8f51-47e4-be80-9c4c26296b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0975b75a-2a47-4e83-aaae-dff99c599ba5" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8a46e0d2-8f51-47e4-be80-9c4c26296b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4f526cef-50eb-4ea8-9d58-c63aeed5c928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_95a40439-8445-43b9-bb2a-ed487488e2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4f526cef-50eb-4ea8-9d58-c63aeed5c928" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_95a40439-8445-43b9-bb2a-ed487488e2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20220331.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0d486be1-baaf-454b-9fd8-4912180570b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_16e90639-dcf9-4bdc-84d0-e4e386ccee21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d486be1-baaf-454b-9fd8-4912180570b5" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_16e90639-dcf9-4bdc-84d0-e4e386ccee21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4e6f0917-882d-4d1a-90b3-749775cb6342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_16e90639-dcf9-4bdc-84d0-e4e386ccee21" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4e6f0917-882d-4d1a-90b3-749775cb6342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e911e6a7-2529-472c-8227-51f7c370e5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4e6f0917-882d-4d1a-90b3-749775cb6342" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e911e6a7-2529-472c-8227-51f7c370e5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_495b0e64-c4d7-41d6-9a9f-ece9474e3c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e911e6a7-2529-472c-8227-51f7c370e5e3" xlink:to="loc_us-gaap_DomesticCountryMember_495b0e64-c4d7-41d6-9a9f-ece9474e3c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_cc84651b-2505-4886-8074-787bf9609b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_16e90639-dcf9-4bdc-84d0-e4e386ccee21" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_cc84651b-2505-4886-8074-787bf9609b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_49e0912b-5dfd-4b2f-93d5-efb7fb6ba236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cc84651b-2505-4886-8074-787bf9609b6e" xlink:to="loc_us-gaap_OperatingLossCarryforwards_49e0912b-5dfd-4b2f-93d5-efb7fb6ba236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20220331.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ddddeb0a-9280-4307-ad2e-25346ba86b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_194e5e3e-07f3-4bdb-bbbc-29d5af498cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ddddeb0a-9280-4307-ad2e-25346ba86b55" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_194e5e3e-07f3-4bdb-bbbc-29d5af498cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20220331.xsd#AdditionsandReturnsofProductRights"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_6c2e38ef-65fb-40a1-b0aa-4d86c2485c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_eca45ceb-2238-46e0-9ad3-f20af00e1816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_6c2e38ef-65fb-40a1-b0aa-4d86c2485c95" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_eca45ceb-2238-46e0-9ad3-f20af00e1816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20220331.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8ab2ccf7-e9c1-4099-a99b-cd5890730d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_c589e297-9acd-48c7-be7e-554a0fdf51b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8ab2ccf7-e9c1-4099-a99b-cd5890730d53" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_c589e297-9acd-48c7-be7e-554a0fdf51b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1fd95148-ccc0-40c7-9448-419800ffb51e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8ab2ccf7-e9c1-4099-a99b-cd5890730d53" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1fd95148-ccc0-40c7-9448-419800ffb51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_be67a3fd-f6d0-4099-8834-dfdbc5f09498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_be67a3fd-f6d0-4099-8834-dfdbc5f09498" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6e6d8c25-76b2-46e9-a45a-b9b7b0714e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6e6d8c25-76b2-46e9-a45a-b9b7b0714e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a32eddc7-aa38-49e1-9e09-5ca53c518f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6e6d8c25-76b2-46e9-a45a-b9b7b0714e35" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a32eddc7-aa38-49e1-9e09-5ca53c518f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_e7c71264-9113-460f-93d4-2060e2a8e38a" xlink:href="cpix-20220331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a32eddc7-aa38-49e1-9e09-5ca53c518f86" xlink:to="loc_cpix_VIBATIVMember_e7c71264-9113-460f-93d4-2060e2a8e38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_93563ecf-7af6-45c4-95b6-e07ab6136dc8" xlink:href="cpix-20220331.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a32eddc7-aa38-49e1-9e09-5ca53c518f86" xlink:to="loc_cpix_MethotrexateMember_93563ecf-7af6-45c4-95b6-e07ab6136dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_528c3333-6107-42ad-a113-a12203519cc3" xlink:href="cpix-20220331.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a32eddc7-aa38-49e1-9e09-5ca53c518f86" xlink:to="loc_cpix_SancusoMember_528c3333-6107-42ad-a113-a12203519cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_82570244-07cc-4f07-8821-3f9b0ac5b6e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:to="loc_srt_CounterpartyNameAxis_82570244-07cc-4f07-8821-3f9b0ac5b6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8965666-0ce7-4c90-8607-ff930b7bb1e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_82570244-07cc-4f07-8821-3f9b0ac5b6e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8965666-0ce7-4c90-8607-ff930b7bb1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_e010ae08-8bb9-4817-9810-89118d07239d" xlink:href="cpix-20220331.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8965666-0ce7-4c90-8607-ff930b7bb1e8" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_e010ae08-8bb9-4817-9810-89118d07239d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember_f342e59c-81f3-4599-a1b0-2fdc831db98f" xlink:href="cpix-20220331.xsd#cpix_KyowaKirinMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8965666-0ce7-4c90-8607-ff930b7bb1e8" xlink:to="loc_cpix_KyowaKirinMember_f342e59c-81f3-4599-a1b0-2fdc831db98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_03f7c917-799d-4e51-a5bf-5eb6296160f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:to="loc_us-gaap_AwardTypeAxis_03f7c917-799d-4e51-a5bf-5eb6296160f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9b5ca9b-e070-4014-8793-8fca03fd3ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_03f7c917-799d-4e51-a5bf-5eb6296160f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9b5ca9b-e070-4014-8793-8fca03fd3ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e88a79ff-838d-469b-abba-859019b92334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9b5ca9b-e070-4014-8793-8fca03fd3ea1" xlink:to="loc_us-gaap_RestrictedStockMember_e88a79ff-838d-469b-abba-859019b92334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6bfb72e6-d3c7-49af-ba65-48487500a17a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6bfb72e6-d3c7-49af-ba65-48487500a17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_718e4484-f10d-47af-ba82-17d793896c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6bfb72e6-d3c7-49af-ba65-48487500a17a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_718e4484-f10d-47af-ba82-17d793896c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_03bd2325-3627-4df2-b14c-6ab9d677f6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_718e4484-f10d-47af-ba82-17d793896c6c" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_03bd2325-3627-4df2-b14c-6ab9d677f6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_19741a9f-55bb-4eba-953a-0837ecced466" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:to="loc_srt_RangeAxis_19741a9f-55bb-4eba-953a-0837ecced466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd3b109e-b55e-4f88-aba7-053f836e7762" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_19741a9f-55bb-4eba-953a-0837ecced466" xlink:to="loc_srt_RangeMember_dd3b109e-b55e-4f88-aba7-053f836e7762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c791286-98d9-4548-ae5e-c19f023400c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dd3b109e-b55e-4f88-aba7-053f836e7762" xlink:to="loc_srt_MaximumMember_9c791286-98d9-4548-ae5e-c19f023400c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d692161-2d29-4345-a444-ff44859415ee" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8cc8ff1f-4c0b-4f82-b740-1c2cadf4f2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8cc8ff1f-4c0b-4f82-b740-1c2cadf4f2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_36cb9d8f-3c9c-4c63-960d-4f8b9b134dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_36cb9d8f-3c9c-4c63-960d-4f8b9b134dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_f140d39c-233b-4c84-8168-b1c63cdb44c0" xlink:href="cpix-20220331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_f140d39c-233b-4c84-8168-b1c63cdb44c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsThreshold_568ac77c-9887-43ba-96a1-9ecbb460f62c" xlink:href="cpix-20220331.xsd#cpix_TieredRoyaltyPaymentsThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_TieredRoyaltyPaymentsThreshold_568ac77c-9887-43ba-96a1-9ecbb460f62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_da59ee16-dfa6-4d33-be01-b23284c6e979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_da59ee16-dfa6-4d33-be01-b23284c6e979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_bcc208f6-212e-4ee0-ad18-32b9fe291dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_bcc208f6-212e-4ee0-ad18-32b9fe291dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7cbc9254-ee8d-4ebd-becf-e332c0d232f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7cbc9254-ee8d-4ebd-becf-e332c0d232f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a72a3fbf-4a3e-4108-851f-f3990147bcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a72a3fbf-4a3e-4108-851f-f3990147bcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ef83b48c-7e52-4245-b4ff-e032cde9779e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ef83b48c-7e52-4245-b4ff-e032cde9779e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_f71cee9e-66b3-4859-b76b-c1dce0f2daae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_f71cee9e-66b3-4859-b76b-c1dce0f2daae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_eac2a4c4-eb52-43ea-a8e5-6e959d8fd1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_eac2a4c4-eb52-43ea-a8e5-6e959d8fd1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_9e908a25-ff8a-4510-82fa-6ae5b1f6f664" xlink:href="cpix-20220331.xsd#cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_9e908a25-ff8a-4510-82fa-6ae5b1f6f664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_edb53fb0-a5a4-495b-a880-8fc39a6c5de4" xlink:href="cpix-20220331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_edb53fb0-a5a4-495b-a880-8fc39a6c5de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_32cb1cb6-6f97-40ab-a08c-835ebb6b8420" xlink:href="cpix-20220331.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_32cb1cb6-6f97-40ab-a08c-835ebb6b8420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_716e3b0f-300b-4ef1-a959-3973f9024075" xlink:href="cpix-20220331.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_716e3b0f-300b-4ef1-a959-3973f9024075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_505c578d-4752-4803-be78-7287bf75acd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_505c578d-4752-4803-be78-7287bf75acd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_201eba71-d03f-46f3-bada-b02dfdd091b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_201eba71-d03f-46f3-bada-b02dfdd091b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_48ff346c-a024-4465-b46e-250a108e6285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_Goodwill_48ff346c-a024-4465-b46e-250a108e6285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7ca0f1a4-9717-4e05-98f5-24b095eaade3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7ca0f1a4-9717-4e05-98f5-24b095eaade3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_1447bf30-ecca-44ff-aac6-a54907a1d4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_1447bf30-ecca-44ff-aac6-a54907a1d4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationPaymentPeriod_88731633-ce53-4d82-a011-55743bae559d" xlink:href="cpix-20220331.xsd#cpix_FinancialConsiderationPaymentPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_FinancialConsiderationPaymentPeriod_88731633-ce53-4d82-a011-55743bae559d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationNumberOfInstallments_fbeaf646-5b95-4d46-b872-9131e09eda47" xlink:href="cpix-20220331.xsd#cpix_FinancialConsiderationNumberOfInstallments"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_FinancialConsiderationNumberOfInstallments_fbeaf646-5b95-4d46-b872-9131e09eda47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_d84c457d-b1e7-4659-a0ec-ce2ac63374f5" xlink:href="cpix-20220331.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_d84c457d-b1e7-4659-a0ec-ce2ac63374f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7ee17478-e248-4924-aba0-645e1e31c1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0761baf8-a4bb-46b3-90f4-a5427481de3b" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7ee17478-e248-4924-aba0-645e1e31c1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4a7124af-8986-4748-81f1-9ebb8af6091e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_652074f3-c680-4beb-8225-314886b2c759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4a7124af-8986-4748-81f1-9ebb8af6091e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_652074f3-c680-4beb-8225-314886b2c759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_89998546-da4f-4311-8744-db567b2298fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_652074f3-c680-4beb-8225-314886b2c759" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_89998546-da4f-4311-8744-db567b2298fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_985429d7-ec01-41e5-99a5-97120d15a295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89998546-da4f-4311-8744-db567b2298fc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_985429d7-ec01-41e5-99a5-97120d15a295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_6b2ac75d-7ec2-47ec-a6fd-e03697a7fedf" xlink:href="cpix-20220331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_985429d7-ec01-41e5-99a5-97120d15a295" xlink:to="loc_cpix_VIBATIVMember_6b2ac75d-7ec2-47ec-a6fd-e03697a7fedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8aa2136a-6192-4313-bb89-2f6bcdbfa56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_652074f3-c680-4beb-8225-314886b2c759" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8aa2136a-6192-4313-bb89-2f6bcdbfa56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_733372c3-7d7f-48d5-a930-d0b278517a93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8aa2136a-6192-4313-bb89-2f6bcdbfa56c" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_733372c3-7d7f-48d5-a930-d0b278517a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_17d7b808-8b2a-4aa7-a3be-2d721c15bbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_733372c3-7d7f-48d5-a930-d0b278517a93" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_17d7b808-8b2a-4aa7-a3be-2d721c15bbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_15469ef9-6935-4d7c-8039-8ba6d9358d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_733372c3-7d7f-48d5-a930-d0b278517a93" xlink:to="loc_us-gaap_PaymentsForRoyalties_15469ef9-6935-4d7c-8039-8ba6d9358d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76d3a43e-1f4a-4d67-b3ea-ccee0bdc8c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_733372c3-7d7f-48d5-a930-d0b278517a93" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76d3a43e-1f4a-4d67-b3ea-ccee0bdc8c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_c5f95d80-83a4-443d-ae51-03d5079a1f0f" xlink:href="cpix-20220331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_733372c3-7d7f-48d5-a930-d0b278517a93" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_c5f95d80-83a4-443d-ae51-03d5079a1f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c66e9ef2-1f1c-4f9f-b2f8-a714c3f79c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_733372c3-7d7f-48d5-a930-d0b278517a93" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c66e9ef2-1f1c-4f9f-b2f8-a714c3f79c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="simple" xlink:href="cpix-20220331.xsd#AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2884bb3c-813a-45e0-a57e-8dac0e2234a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a35f3e9-2541-4a86-bdf3-a619ecd17719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2884bb3c-813a-45e0-a57e-8dac0e2234a4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a35f3e9-2541-4a86-bdf3-a619ecd17719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_de167165-510c-4bf3-87b7-95b9dc24e262" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a35f3e9-2541-4a86-bdf3-a619ecd17719" xlink:to="loc_srt_CounterpartyNameAxis_de167165-510c-4bf3-87b7-95b9dc24e262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6b0cd0f-b7cc-49c0-96cc-7fcaa44cb7e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_de167165-510c-4bf3-87b7-95b9dc24e262" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6b0cd0f-b7cc-49c0-96cc-7fcaa44cb7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_f4d839ee-881b-450b-ad5b-8d9bf402b37e" xlink:href="cpix-20220331.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6b0cd0f-b7cc-49c0-96cc-7fcaa44cb7e5" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_f4d839ee-881b-450b-ad5b-8d9bf402b37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d1c894ab-83da-4ff2-83e9-6f81f1a8faec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a35f3e9-2541-4a86-bdf3-a619ecd17719" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d1c894ab-83da-4ff2-83e9-6f81f1a8faec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27bcb5f6-45ba-41a2-a47d-c8ac324029fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d1c894ab-83da-4ff2-83e9-6f81f1a8faec" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_27bcb5f6-45ba-41a2-a47d-c8ac324029fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_015f73db-04c8-4278-b360-d69f2d4c3d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d1c894ab-83da-4ff2-83e9-6f81f1a8faec" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_015f73db-04c8-4278-b360-d69f2d4c3d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !5 7,# 2(  A$! Q$!_\0
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MCBNAO4445YQT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4UM<1M%+&T;X9&!##_CW]":ZJU&E5K2JJM&S=^O?T,*52I3I1INF[I6Z$_\
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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MLXO"GW[ZZ90I4PCOU7(F(>'IRB0^W*#1HT</_3-) >&?^@/'<8DRGSU[1N]
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M*9VLB'UH2D)9XGFR6?D8#'W2ROC2)T^>D!WP?ZX==THU""*H!O>'U(_Z&QE
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M'7#0KAKRN7__?E!0$&& WAR552U=#IV9/)>7865RK\D9;&]X;HF8MB9.1""
MVR2PR94K%_<P1,=+)**OF]-4K%C1X*,F;)W*Z$>,0Z-,&HY0$R,1_2S"H"9\
MM/; T_(Q4JI4J7"V*U>N5 ^M@2<<-&B0,O,,22C%R.5P8N@G?OSXW&U\++$E
M\9W=03O"2UQKEBQ9Z"GJUZ]/_,(ED,'* ARY6;-F]#LXPSIUZNBK0>$)$R;0
MROH_6D+8Y>_O7Z]>/70KGJ_8'E0/09D(&EDC3AJ/O@V[-)*P.@0)"=<334.\
MF^+EJ<JD&1QR1&^T-^N)? A<Q8G(/3A4^?+EN5*N-\29?4J<)G'"D=I]D8K
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MO_Q*#]V'2):$,L6MLY;.B&_EW@KBR'0B?*5L$*9'WB*0QD8^1@3^]UNX=O%
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M&6[(J2T*/7OV5(M:YZ^__I+CJ,9Q;J%:(^S;MT\]F4;BQ(E=..GJ?<!49OB
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>\41,99J8>"+_ \_?!14==]1D     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
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M$HLP)5+V@!8GDIVI\6(Y*KO#$@3MY25M*VGU#LO1:_<:B]C+0LG!2W:T*'O
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MUP[)CA^[DWJ)CDO$:"1>L32FM7N-BAB-PXDE)6B\:!\B1E,:*K)$2].#P?/
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M-^9O)$1,M.@A*M8SSSP3(Q.KYM=??SW5>=1@G*09NO[PX8<?(M'+M!N#CE6
M=O!AB9T]D.R<3N(52*,DD]0^V,LC1HS E%M-5;0UB$4[.>KI^XE??/$%4@;6
M")P4.!$4=Y3PV<ZO5^6AAN&%:>V]]]X;/WX\AA=*>N0@C)M''GD$\S &!P^X
M:OL) "]\ F,;#]*/XUUSS36H#K TV[=O7RT]ZX^8&/?(K<V;-Y\Z=6H%?57^
M /U4%0]-#,K9LV?74;++TI>'OOWV6YPDR'$8FF^__3:\^ &%&KKX@GZZS52=
M<49NA0L63L><99PC9XJZY#7Z*@[CQ!(MBJ:>+EU5T,N^40YT[MP9NP@69 0<
M%)[,K'$2PS///(,!T[)E2QP%GIEX?VI=/EFZ\(+S=OKTZ9CV<! KDY_<E#+O
MYF.03YX\&8M0-(J4AX2+>>OEEU_FJ05[==&B16>==18^JLK_89TL74A!FD.6
M?."!!U  \BPH8OM!QS",,3%/FC1)!JRE]ZIU[-@Q2_-Q%5WO1E$))886*@]^
M.^R@08/0G-K)XMAZMM$K^"FY7X<9 MM^)/^=&D[C-:9%!I%8 F=O\F17DZSU
M>$?SS^)4YM]DE(AV<M10'3=__OSAPX<C51VA1]A5#M(^!62I9D%.V;1I$Z9Z
MY YD-Z0,9)PKK[QRUJQ9*U:L0"VP;-DR?H[T"/VB"B,;"L+)#NXH3S#+??#!
M!VBT@MX2@0WG/%B=_$YHLV;-L+SEYOAL1!6 4Y2+D0Q5(O@4:S',TE@3U28O
MV($ *VM\A-[*G*4ZXXR<X'A/<K[+Y#_$Q^G@"#TD56O,S$XLT:)H.)>AK>7+
MEY]^^NF8#W#Z89&.=1S_=A?78MHM#MY2E(JGGGHJLAY?J^*86IH/IP8L13%+
M85[))F\*43+OYM][[[W_^M>_,!5A('WSS3>8SP8.'(@,SL>QBFX%H*3B-S#*
MGO!!P8(7 X8?#,!Z,R;9P?'--]]$HP\]])#,XV@1K;=ITX8[SQM50Z^90-\P
MHV_;M@V^8\>.O?766\N8[#!+8:JNS'_TQ&F\QK3((!)+X.Q-GNRX/*FEXHY?
M'H>BILB8$^WD@'C[]NU88Z+@XCDV2Z2J['  4$%@E3IDR!"42!,F3$!>0[7(
MKP"HH??>8&@BB532JR8XUU33.R1$!\/4T:L*,'LC/>$TYBFZAKXCS:G_"'T]
MGDL_3+]8SV[>O/D@?1,6]BU;MF!BGS=O7BT57Y7T<U:8BK_[[KOJY+U[570A
M!D.9WSB4";W.#SN*WR]P^^VW8P/YU1V\#YTCA]VU:Q=.'J0&%8=Q8HD61<-Y
MI)JF,:QAL<<JZ4H%7][--FY!#5]L)N97E$M(6X\^^BA6%3QXM#2?>EI&C!HU
M"JF'[Q)DDT>1I,R[^3B(=]YY)ZI4-%I)/]>)C,-S&T\MZ  $6!TC \I3 /L!
MFXQ^8B6+TP35'S\Z(V+[P6'%:$$%AR&-UIT=#6$2A1$"SG=96ME@<8UA@VER
MS9HU&(=SY\Y%\E5951Q;SS9Z!3_128HM'3=N7)\^?6+VE7!-APPBL03.WN3)
MSH%]@5.H7[]^.-GX8E,=7>>2TY&DCLC0PP<X5#@J*+DQ E)E20G//"B.>-@U
M))4%]X'/@?ONN^^..^[@3,1A@^=&(7#'"!LP8,""!0OJZ9'7>@&?/+S5//JA
M1*,5]$U8_'?;MFU(?TA,5;2"?O755Y'I^&V [,5Q\,<GGWR"48LD:"4[UM?0
MQ([=CH2"L^B<<\[!RH7GFUJZ(PPXN6/ECH"085>C&JVB-:\,Z*A/WC6R8\<.
M#&ZDAG???;>6X$VNH<D#)W 5?:V=.T_3QR]/J_'!Q<Q70>_[//GDDS_\\,-W
MWGD'ZSB4V/+HZ[8)/IWX4/(<4$-SZF'ZHAA:7+)D"9(.-@1I!?%1*XT9,^9K
M>G\R3V"5HK:J3QZ6Y#]6KER)_?#BBR]RNN$^.#'CW>%H'<M8E$XC1HS ]-RE
M2Q=L8"6M8YAJ^C$ 9+2E2Y>Z_9"E@GKAPH5(KY=>>BFF80P ''<^3;)4[W.0
M.AJN/$/ !>D;%0 6L*A#<60__?13;#M/KH?IY9J=.G7B!PSXLB,VOWOW[IA.
M<#9A/^,C= ^'VYK;++S;GJ5[+%CX\[)=?N3%!4F+#I00%)3R(]DE@V.&-1T.
M)P8?#WW^UPEDSWAD\+_(<3CA,1KX%/7JG=%"BJ5>&C$$,5+Y=JIPS2'%#480
M=))K*#G36J AI DL*["-G MPDF!5\OKKKZ,;&,TX8W'N\?A6^PH"+'BG3Y]N
M]9;W,(8@5N[()BASUJ]?_^"##[9OWYY/(4Y)G(EP$J*RP!(,U2). '[S#Y]C
M+J#L-GR19Y%-KKON.BR%SCCCC*>??II3=I8*4F2<K5NW8GKC=PYR\JJBBT=\
MGN._%?2*%"16'-]6K5IA 3MQXL0*>B"1LP GFD*<H(Z2767R1"2B(<VAI$)V
M0]Y!IN/S'.MB%(RH=+!8QG%!BZJVXK8R=,T4<\]--]V$K:NUOYCLM1^F]QW]
MY2]_P4&9-6L6DA<G&B>HHR<!T8W9LV=GDPD/?^S<N;-KUZXXZ$A & Q8?:-8
MXU^TX:VKH8J^DBZ#'"10HT'#/U9;2=\+1I\QER/^(?H=#/[A%RP+> ) H7?)
M)9=@]^) XZ#C^/+;55%FHLK+;8.!VUZ)%&!?80RCS%RW;IUUU+1_TR-;/ZK)
MKI*^.?C00P]A_W[SS3=UR9U0)Y ]<]D0&JQ!,"/AF''AX-4[HX442[TTXOP\
M[;33N$80KCFDN,$(@@YC1OV*WE<A[5YXH&-0(C]6$YA^+[C@ GY  8D)@[@Z
M^?%ON>T\#2 /XJRN,5Y'SA46SC><2)AC,!;QWX<??KASY\Z</3GU5-##MSC#
M!P\>C/3ZPP\_0  7KA&\LTL=70-ZY)%',+AY#8[,\O>__QU5!I]L?.!0J?WU
MKW_%IE$:__F\K4H>-LP2J"EP2N/XHI+ZTY_^A&R+\H33>H8N]5JG#<>OI L.
M_,@NSEC$0<]1-]UXXXU\$X!#U=+73I%Y,0/AT_'CQV,G'Q!?-^2BB96<(Q -
M+FF3'5R0K9#WL3>P Y'O.$\Y035=-T2BP7[#8*M+[MU/FS;MRBNO1/Y%K]!)
MI/[FS9L/'3J4O^G%&YNE^8EWXY-//HG2[/[[[^<"'$<0RAX]>F")BB%11;>8
MOOCB"XP-5/'8(@3$WY@&./MCIR'EX8AC:L?)N'SY<K$1?MSV2J0 C3[UU%-\
MZUG.(A+MW_3(UH]JLJNB+V;AW+[WWGL'#AR(\XJ'HQ/(GF63NTBH=#!NWGSS
M30QHN%OCSQDMI%CJI1$G+089AH(\PR52W& $P5#&Q,YGM;1[@0;C;]BP8:-'
MC^8B!4L2] 'G/'94NW;M^*=,7.IW+6;I$@Q:08) 3G%V216M3U%'_^YWOWO_
M_??YMZ"PY,3.Y[..SQR<HOR^$/2$JQZ,6IQ+R!=<E;B KMMPQ"H/YP_6GI6T
MGH47SJ5FS9IA886U;34M+7&(D4!1KV'I-'_^_'>)M]]^&^45ZL?[[KL/-<[_
M_N__XLS'V@W3PRVWW(+D"!<4F)"AP]8%4XP$# EDVRE3IF =C52.G88S[;''
M'D/KZ#8VA%,#)Y0J6MFA/^^]]QZ&$Q:86->[FHN372VM@E&*HC-\R]X:G V^
M?0(^^^PS] 0)%T&P:2@GC^0_05)/7S- #S&?+5NV+$.%)'IRZJFG8N_QXAI'
MX<X[[T3-?LXYYR 98<F);F/W8A):M&@1QLGYYY^/N1^Y^R#=*>:CC#^PNU!)
M8&?^\Y__1 >0\;$S^8A@;R,;LJPFN4F%@#BY4)4C+8J-\..V5R(%"(Y>8?5=
MX?NA*$;[-SVR]10O[]0?VUB.SH*!A8.!O5Q#RR@WO\E]5$E/EF$TX&!C-/,,
M5F44&@T1W9-BJ9=&C'6,PD/TVC*OP(*OI-0D5^MP'O)IIG4%\ F)B7KX\.&<
MSI#FD..01#!OJU]T;Q#=KB/0Z,LOOXSE4I:6JQFZDN4T&5K9H5+HV[=O+95R
MV*4(CLF&3\(C]#0U:CTLG%%HU"=LV;+EK+/.@JR"'ECAJJ>.OI_ :1?=0S;D
MGSJ2.1WY$:43DB"VHH:N-.&,0MF"4^X/?_C#?_[G?_[7?_W7_R/P7YRT6(5A
M[>8R"URP".K=NS=2QN]___OSSCL/T5 F8Y=B&Y'+,!*PKL=R#$LP%))(!VW;
MMD7Z7KAP(4:(E1DE: BK"A1W:!WI !4T6M^?O/ 2=1E:1"[FO& =09Z),\G7
M8'BW;-NV#6D%\];(D2/YRX*5R5UOZ5A-E]O&CAV+#4$60VI#58MC=)A^DS!#
MTP\Z,V[<.*1+A$+6PUSUF]_\YK>__2VF#<P'_"9D=[ 4M72_'AN"'(K=B(:\
MJ<?I^6_]<5'< &N@<YDW$R4DBE,,,*[KM0_A'&/0SCZT#Z%%"4<UV4EPC'%*
M8)E6(WYL6.XC/K6P[R##V<@G%9]7.E8<N0X17CL.&^92S)"RAI(""Q[Z5?1%
MI5:M6J&XJZ4O9FA= ?7T[#&\,(@K:5&_8,$"K"QPSK=LV?*[[[ZK%+\2*>%D
M!SUF;)SS6[=NK2 :\I,=P,*<+\!A[R&SG'SRR:CRJF@!BQ,,F0B;S.>/ZQ4^
M0M'TCW_\XZVWWJI/;N#4T&,Q>_;L08) ID"^X/*P+O_Y%12D.'N1IQ"!OW^.
M7B%KXS@B':!=I#_TEO/L87H^G,\6/DLKJ50Y1* RPGH0JZTA!,Y;5*#( C-G
MSIP]>S9_/SJ;7'S,V*^3D=0DB^C5JU<C>Z(.0M^P_L4LA3V)X.XWL"MIY9@[
M5 )._34T55<D]T.P^,6,!0N.(%:R*$X/T7=1:_._)%-%)3_6T9A@L&F<&;D6
MKJ/K=YSWL:MON^VV]NW;HX)&'%Y[<D"9/2TXR2+[8(OT+B"T@R"H<0).]-A\
M3'ZH$K"&^+D>L;]LZQQCT,X^M ]A:8Y9LCM"RRLLP5"X\93.LZ5TQ)F DQ.5
MR!%ZY*TN>>I5QXI#1FXPCBA:09<V;=J425G9<;T#]XD3)Z+NP%F4);2N $Y8
M0X<.Q2G'$;#B0(277GKIIIMNRM+#&:XG"MYI<$'A@S'-!:D\X3DAGG+**9CG
M.55!AN7>KEV[L&^1>G Z<6*MRW__>S7=%$+IT:9-&YR'+I7 "S747_[R%W28
MRS'^R+581<\_\XV+/__YS__]W__]6P+I#\O2"GK8D#>9DV]%\@MJG)?YY.&D
M7TD++LZ5G)I9R1F!,SN?TC7)=Y!E3RQXL%71=2XT@6D&ZW>D&Y11V"B40A]\
M\ %?+?DY@QH7(CC3<2>1ME#$(7.A$H<%LSCV)PHQ+-(Y;<G<Q)N IB&;-V\>
MI@1,:>Y^';?(5-+/C>-X(8=B4&%,<H<YN8N^^$&[V'7(E<B_>A<0VD$0U$@!
M)@F,$)PU#](/]]12J6N5BLXQ!NWL0_L0EJ91R<X2*+L7'LI+ER[%:8#"K3JY
M6/YS84WP@,;1NN>>>W@H\W /)CO5D&7W4DF_I_G99Y_)\<3]J4MN$?#?[M]Z
M.JY5=$D(G1PQ8@36':@7>.SF0@O8RX7"6@:;N6+%BBJJ<'$.].S9<\R8,:_0
M:ZR*;&]M\J0%UF7(62BIY JB/OG. $Y@Q#Q,]PVPSKKSSCNQXN,GJ'OTZ+&-
MJJVJ_*]#5=$*=_WZ]<@".-G0$Q1T.#]1AJ#<FS!A C\'QWFGKF"*X@WAH8__
M\M4B9!"^%L$G=ATM?WBOUE'ZX[+%[1;.X[7)[Y<[(V\4Q^<464FWC%FC]U$!
M/)!8S''0I67+EB&M8([!3'#SS3=C=VW<N!'[\P!]K86WRW4,%NP*[//%BQ=C
MMH 7DAT_MG:07D. 3U&.??GEE]Q_%Z&!"BXN73D9<<[-)(\E<-\X/S+X+\X1
M# ^LWU$P8D_RWG!C3^$:.D0W9-$]GG>=W>T'9XFG/AGS[K_H(28VOLIYF%XA
M557T4K4X#F&TLP_M0UB:1MV@L()*E,;AABPF_-Z]>R/?86#Q8:ZAA08&P9MO
MOMFV;=N//OJHUGCAA!>IE&)EES@-3DB<V_QJ"O=IEAZ#XBL[E<F[P_A,SB07
MYG@0H^=(4IBKD2.0':J-[WBP%V\LO+"!**"PN*ND>XN//_XX$B[&-R;,JOQK
ME!9H?=&B13?>>..6+5OX1.(Q5TVE!]9*J-%0@$"#M<9CCSTV;-@P?O\/-LH%
MD5WETZR*GMCHW+GS7__Z5_Y6+_+XJZ^^RCE+ZF/P-N0U2GN3PD>PGK(>M@N+
MOH<>>@A9#[L+VXOCB$R!W(>*#UD>BVBL3%$H]>_?OTN7+LAQ.&JHN; <KJ9R
M5>8::Q.D(*BIIPQ>2=<]4?BC5]===]WSSS^/_QZF'S.J3:9_G@9X*#+\*?(C
MYC-D;3=6=6.$\[*HIVJTEA)Q#=7%?+9NV+"A5:M66/CS ]O21;=Q%)'=D#TY
MELDNFURLQ:R(<8;) 5,B)\$:*N-Q]N)$Y0=3I:]N(Q^IE&)EES@-.G#ZZ:=O
MW;HU(V;C(_3>UVW;MB%9?/SQQYSI>$'!2:&.%C6<N['VQ$G2M6M7G ,R2(-H
MA3<\0S,Y_D!^Q+E4F;P5"NOZ#ATZW'KKK5547M7:RUA''55)DR=/QJF(W55-
M<'_P[_;MVS'B3SOM-"R:_O:WOS5KUJQOW[[+ER\_1.\N=T%D5_DHU"9/I:#$
M>^ZYYUY__75WCLEB(1)O0UZCM#<IG.;JZ)6+2"7(7#P@L6=P&B-3X%@@]Z'0
M[M2I$T8C1BGFB9DS9V)O<"G'DU]-\G64X"9(05#CC@)//)@^GWGF&>1?E.?C
MQX_'/%1%93(G,AZ'SI?_BTH"&9GKP6JJFG5CA/.RJ$]^"BI#CT9BJW?MVH4E
M%VH1E"E<!,1L_M%!=D/VY)@E.SX\?#;BWW7KUB%!<&IC"\Y&C+]-FS8=HL>=
MI*]N(Q^IE&)EES@-A@6J&!YA[E,,&MB1@) O3CGEE/GSYU?2(ZS58G'-F0M=
MO?#""S$6!PT:M&3)$JO;/!5STN3?W$0V.9)\0>V^^^Y#93=ERA0>7M9L+(%R
M[]Z]R-&H!W%R8N:OH+NH1^A".]96B/_WO_\=0Q-E';_@@*]Y%4EVW'2&:D_.
MN9C,?\[HOA,[!F]#7J.T-RE\%+ M"Q<NQ%% 7;R?P!ZKIF*-/^45(A^.&O'E
MXL-T=Z6.JBH>S,%-D(*@ABL[-\PXRZ!,>^FEEP8.'-BB10O,D3B:%<DU37E0
MN,,XB2"#GD^W;-ROV1;"LT(US= 8!N^^^RZR/P8;9O1#]$5R7HQ+%]W&441V
M0_:DV#4[B_Q0.;2.T**$VN3[R1GZKBCV(PJ0T:-'8_W/53H.9+=NW; 3#Q2\
MV"L87!(4UR4+$/R+0=^]>W?..U+PP@LOG'KJJ5A$((M==MEE?"D'4RL_/\G#
MJ)JNPEQSS370#!DRY+777E/)CL\9SG2U-%=_]=57[=JU>^JIIWAAR*D$RR7,
MQHL7+ZZF5;"5,259NKX)Y5;ZQ@*R[3OOO//==]\A+-;";[WU%OJ,DH3?9<9Y
MF7,6;W@A?'9EDR]XU=!72FOIBJH[^;5/"-=;_8&/TL1IP=[@L[1/GSX8>YRP
MJNA+<KSA=50K\?;6$KQ/>"?PZ&49HWN6X%JT[!+W*>_MNN2]6QF:7VN3UR^N
M6+%BQ(@1R#C(.Q@SJU:MPEJ2NY%)KD)@(8+E-K_UVAUQ/G;U5.6YAGASZL77
MYC@4=Z">-A]Y%C/]U5?__./<<^;,X0>>.0E6%=R!+=P<RRCM%DKO" H:RICL
M]&<%2'$0)(M''GD$!P\K!2P&4>X=I->!6,M8:;0(BMUXQ>&\^^Z[^9Y:)G\9
MB[(.66S;MFTXWO_\YS\/T9M7L-+!,.*K[U7T#5#4H5===156/1B%+[[XHLH+
M-<D+$:KHLMJR9<NPI4BC7#IQ L+?DR9-XL?0N0_6&++ /L1I<,LMM^ $;M6J
M%9H8/'CPJZ^^>DC\.)83R\A6\*# 0CIZ?8."GPHT7K1/-'P@D!'^]*<_8:YU
MZ4SK"M ]2+ $0;O$*Y!&R;???HLTAU4M)C,,T=Z]>S_YY)-+ER[=O'GS 7HE
M'Y8CO#RO)'A.Y<J41S[#8Z,N>>DL#]0*^AWN#S_\$,MVC.K++[]\P( !+[_\
M,H)SA*Q1A4B\ FF4=@NE=U@"X9KCUY7LL/OV[-F#J@2'#5D#HY#OT-4:U8TT
M6@3%+M,!?FVD2G;?TSL7GWGFF7W[]J$6.^.,,_AB#<8-BB8,,AQ^+LU>>>65
MUJU;8UB@O,(0J4V>EN!YLC)Y>!T5UJ.//GKII9>B?,/?7%Q4)R^&PC*V?__^
MK@,N5S)N<RQX*-?0"_*V;=N&^'RAK5Y,VDXL(UO!@P(+Z>CU#0I^*M!XT3[1
MU-+R'V4OY@,> %S+:%T!N@<)EB!HEW@%TBBIH8L5.-88I9A]L31!:L,BMWGS
MYA=<<$'GSIU_][O?(4/A5/KFFV\XP?&T6BW>Y)JEVR"8R)':D#JQ['WBB2<P
MAJ^XX@H$P>(#RRQ8,)?SR*])[H;'S,1>@31*NX72.RR!<,WQZTIV65J.(7>T
M;=MVVK1IV-<H20K?=9,J>%#,QZR2OLB)4H@O\,LI"ZN#BRZZ"..@DAY,1Z\X
M?>!?%)[\#0'4H1@-*$@[=NR(8@K]1UG**88S:0U]N0*Y<OKTZ8B $M)]IXH_
M9?#WXX\_?OOMMW-B*NRVVQP+'H5<;'),+ANY)YQ\G3@F>%!@(1V]OD'!3P4:
M+]HG&NRHV;-GGWKJJ1LW;N2E(B_'M*X W8,$2Q"T2[P":93P\:VDNUM\$;:2
M'M#;23\M\/SSSX\9,^;FFV_&P.;W-K9ITP8K7V1#U/XWW703!BH_/' 6@54+
M_N;K,+-FS<+B8RM]*:TZ>4\,U\)<?W"5(#LC-B*'5R"-TFZA] Y+(%QS>%[Q
MI"4%>,726,3NA=,!9QRD-E1&$R9,P,Y%E8>R''L?QVPOO=&_CJY'-!34.VGA
M.%SL\-4NC!+D*91O]53/RX4STERS9LWXBZ)(4C@]JNCQJ+KD G:&7E6$4K]%
MBQ9GGWWV^>>?CZKMX8<??O/--Q<M6H3D=>^]]]YZZZWGG7<>AA'2)5_IX[S#
M:8@WORYYN(R#\S:J+74[5B(%',3]RTUP*PU)9I=Z"V]PT688Z2A]E=U+:6*)
M%OG Q(8S?-2H47S>NMVE8Q':V4<JL<+KZS5*ZI('%7G$NF-=EYQ3U;2 Q:($
M0_2SSS[#"G?)DB4OOO@B5B%86& T?O311\B,V[9MV[5K%^9U?D$LIS,^+[+)
M!=RZY-79W&+Q<]#;<Z]1VBV4/A4NR,]W8ZW/++QB:2QB+X2'5R5=*L:,],8;
M;V#F^?+++S/T2GOL].7+EV->NNZZZYY^^FFD/-[764H*LDCQHAM+X-%01<]V
M8 F =I%/NW?OSD]C5%.%[\1(<UA68Z"@C,?<N'W[]@PA-354V*.'??KTP9KW
MG'/.0;X>.W8LRCT,J=6K5_-WN7D>KC-J!Q>M"-J'"&J40&)IA'>)6 &5W8L(
MDT.+$K2.T"(?J'JNO?9:'F;:OP#EJS^VL1PMNY=48@L5I&1T7,+2!(W2'H/R
M#>(<?Q7)KHK@-XYU[MQYQ(@1^^F+V5FZN,"?\EMQ4.A]^NFG7+17YK]JS8MN
M+,%E*VX",4\ZZ23^[GHFJ?B<&&U===554Z9,F3QY\@TWW)"E*VLJ(6;H$8W[
M[[\?*UF</^@JW_KD"?8(?7^@DJ[I<J.ZHX2+5@3M0P0U2B"Q-,*[1*R RNY%
MA,FA10E:1VB1CUZ]>O7OWY_O^&O_ I2O_MC&<K3L7E*)+520DM%Q"4L3-$I[
M#,HWB'/\M20[I(,N7;J<=MIIEUUV&;(>?^TF([Y-44-?[42YA!4BEH0K5ZX\
M3#\)[!KRHAM+J*9;$ B[>?-F9#$48G/GSL5_.<W5T#,Q3HP.W''''>C8!1=<
M@(3(Y3VG6JF!U[AQXZ9.G8IHCSSR2";YL6=.=GRGI8J>A\H87^%TT8J@?8B@
M1@DDED9XEX@54-F]B# YM"A!ZP@M\E%%]] KZ/DU[5^ \M4?VUB.EMU+*K&%
M"E(R.BYA:8)&:8]!^09QCHU-=HVGCM[=BK4AJJ'KK[]^XL2)E72[)TNW"#BA
M<)W%J[^OO_[ZEEMNP5)Q^/#ARY8M.TQO]*PCN%[C=:*[;%%/L("KJCJZ]+!C
MQPXT]YO?_.9/?_K3JZ^^NFO7+GZ_.>LYY;FK%1]^^"&*NT&#!E71-]4YV7&T
M;'+1#7;D1%1V2'8OO_PRYS7>"H;#UA5<,DNU8W.'06!IE-V+)7;VDK$"*KL7
M$2:'%B5H':%%/GB<\&'2_H1V$&@IX15(8Q&[Q&DLL?XX#A7DUX_> $*+HBDE
MV3F48PR%OO7T+HT5*U9<>>65??KT0:E51;<1ZXP+6YQ$D)BPL&W?OGW;MFT?
M??31=>O6(5WR53]^KIVS5;6XW0G[$?HF /[>L&%#APX=?O_[WV/AC$3&KWU'
M0->KNOP'CKA>0W&W?OUZ_D([EP-\GF 3]NW;AW5KSYX]4?WQ+TAPTG0!&WS;
M7MSN<(*TE"5(V?EU]LJ+[&I,;TL6*[3TUX3NJ\#2>.U>H\)I4J&C)!S[9(>T
M@DS1M6O7 0,&\!L::@DKV=73LK<Z^>'W-]YX XY(0RC3[K[[[L6+%W_SS3><
M*SD3<7:KI;7P#S_\@*PZ>O3H,\XXXX]__./--]_,7]=_^^VW87GII9=<K[+)
M*S?@A9C-FS=_\<47L4J]_/++WWGG'2[NN)4,/:^ -+IITR84IT.&#+GBBBNP
M*.:JP05L\&U[<;O#"=)2EB!EY]?9*R^RJS&]+5FLT-)?$[JO DOCM7N-"J=)
MA8Z2<.R3'=+*"R^\T*9-FQMOO/%=^H4J7F]:%[;JZ>ZMO!961S^TN&#! A2&
M[8GNW;MCD8M%Y8P9,QYXX('ITZ>/&3,&BU"D(11H2$F3)DU:OGPY:C0N!E&4
M(=DA@NL58AZA+^4@#S9KUFSRY,GX[\Z=.Y%8\5^DRZ5+EZ)1OO.P:M6J"1,F
M7$CP$]%SYLSA%;$+V.#;]N)VAQ.DI2Q!RLZOLU=>9%=C>ENR6*&EOR9T7P66
MQFOW&A5.DPH=):%8LE/VLN""<T%40;\5@.R 9#=PX$"^1< 4J>PXE%/R?_EB
MW/[]^[%$1?GV\,,/(]DAYDTWW80_4&J]]=9;:]>NY3=H<SYE]QJZX<N5714]
M-U=-CU#NI]?/(G^A .0K='7T)"!J22Q^D?+P$;)GRY8MSSWW7#2$%>[@P8,_
M_?33SIT[SYPYD_6Y+;=WK&5W.$$,VCE!ZYJ&F$:5QHLE]MJ=T4**%5J:CU8;
M>/4BC!\I5FAI2K%%N1PM++UE#V(Y>HU!&IOLG-C"TE?1VRZ1W9Y\\LGSSCOO
MHHLN6KUZ=97Q'5B)%#B-M-115<CW6^5E.WFO0,*:JZ^^>N+$B>ZB'G(B2L(S
MSSP3RU*LLEU6Y25V)?T^QE=???7%%U_@WQT[=O!5/*1%Y-G;;[]]ZM2I?'\C
MO^]' [5U^N,F)E7K2BRQ-%Z[,UI(L4)+;;2G0$N; -VD0$MMCIIC4*\$$BTE
MO!IEE'@=CUFRXP2$)63;MFU1(O7HT8/3DU<LD0*GD9;ZY/Y:)7W!GI,.5W-2
MYN#,.&W:M/_[O__#HA5=P@H7]2#JM4<>>60__=X=*^N3%33?).%'2?AQ:&YH
MV+!A6(DC/Z+$JZ;OG.7W_6B0OW'^?=ATI&I=B266QFMW1@LI5FBIC?84:&D3
MH)L4:*G-47,,ZI5 HJ6$5Z.,$J_C,4MV?$5LS9HUYYQSSNFGGXZRKH)>R^45
M2Z3 ::2%UX_N[@0_[9&A+UU(F8.+M:U;M[9HT>*TTT[[\Y___+>__:UUZ];H
M4B51F[R&@),=ZSF!\G^SE%A1W&$QNVK5JNG3IW/NKHYX+K_LY&^<?Q\V':E:
M5V*)I?':G=%"BA5::J,]!5K:!.@F!5IJ<]0<@WHED&@IX=4HH\3K6+9DE];.
M[_Q#$73&&6=@W<>%4KDJ.XG\J#C(O]NW;U^[=NWFS9NK"UX](/];".?!?OWZ
M+5FR9-*D22>==!(_[E>\VPJE<6A=4;1S@B40KF5 !9=H:9PXTNXE1NP5.$>)
MTDB\&N$:1CIZ?95 HJ4VEF.DW>$$%D&]$EBDU1<G]DW%RDU_'"%05-/WO=JT
M:=.I4R=^DJ/(%?U4R AI@]31<\+U=-="?U843G;\[,L;;[R!#'Z8?G_'"6)Z
MI30.K8O&&T0:I;WL!!M2 HF6VFA/@9;:I'6T]%YC#-(QZ)M*++$<(^T.)[!(
MI5=BB9827H$T*ISFF"6[!OK.5I9^VIE7@H4K3>T3AXR0-DB][Z5O,63I.[8S
M9\Y\_/''-VS8@&2WJ>CO,0K7'$KCT+IHO$&D4=K+3K A)9!HJ8WV%&BI35I'
M2^\UQB =@[ZIQ!++,=+N< *+5'HEEF@IX15(H\)I/,M8B17+V>,%"K[RQ?5=
M;?).0;7JU#Z$%,2@_8M2'_'2-R_\K8]9LV8]\<03!PX<N/CBBU>M6J4*54FJ
MX$XLT2*!5^,U2GL,J1RE6!$IB$%["F(T7D3X'%H40OL7H!T$6EI4+/'JO<82
M[ Y+$+1; HN@/BAH$)K89/?K07?1A_9I'#JZ#[Y9\?###T^;-@TY[L(++URT
M:%$)R4XT&T Y2K2T?)3<BG1TOLHHR?<NAO84Q&@<(J0?2^\UQB =%5I:($YE
M]QJEW4+I'98@: \*TMHM@<1I3B2[,#JZ#ZX'GWSRR7OOO1=9KW7KUB^\\,*)
M9.>0CLY7&27YWL70GH(8C4.$]&/IO<88I*-"2PO$J>Q>H[1;*+W#$@3M04%:
MNR60.,V)9!=&1_?!*]_Y\^??====^*-___Y(?">2G4,Z.E]EE.1[%T-["F(T
M#A'2CZ7W&F.0C@HM+1"GLGN-TFZA] Y+$+0'!6GMED#B-(U*=JG$/Q7H'5I'
M6!IE#V(Y.KL7)0["MW%?>^VU,6/&X(^A0X?>?__]ZDD:B=60Z$( Y1A$^Q-:
M)-!2PBN01FF7>#7**,GW_@6O1ADEEJ,7)Y9H40CM7Q3M7 Z\P;W&(O8@EF/0
M'A1$VE/A@GB2G?LL2%I'I7=H'9%6XS7&V+U88LO.-Y17K5K5M6O7RLK*$2-&
M=.O6#<:@8]E1#3FTCM B@9;:E.PHB0D2HTE%,)H4%$&[Q6$%4?8@(F2.H$ B
MQ0JO(-^[%-(&5'HOEMC93R0[/Y;8LF/I6EU=O7GSYLZ=.Q\Z=&C&C!GGG7=>
MD5NZSEYV5$,.K2.T2*"E-B4[2F*"Q&A2$8PF!470;G%8090]B B9(RB02+'"
M*\CW+H6T 97>BR5V]A/)SH\EMNS\Z,SAPX=;M&AQX,"!U:M7GWWVV?AOT+'L
MJ(8<6D=HD4!+;4IVE,0$B=&D(AA-"HJ@W>*P@BA[$!$R1U @D6*%5Y#O70II
M RJ]%TOL[*7\E*+#<E3V(")DCK0:KS'&+E&:(,ZQCE[U?N3(D8LOOAC_[MZ]
M^[333OOBBR^LR,Y>%E1P+]J'T"*!EN:CU0(MC<,*HNQ>1!@_VL%'*K$BE:\E
MMNRI\ 9Q1@LI5D0*TJ*C&*326V)G+^5'LH/DMY6'EMJ4W=&R2Y0FB'/DKUX@
MW[5NW7KOWKU[]NQIUJP9ZCL1NPFQ>A5$.4JT-)]4XABL@#%V9[208H66%HCU
MQT51OEXLL=?NC!(I4'@UPC6,='2^RBC)]XY%1S'0;D108'$BV>6A-$&<8X;>
MG%Q963EX\."//_YX__[]%UQPP9HU:_Z_]LY>MZFN"\*WQ)U00DG!%8 0HD%0
M$%%P 2"!A"CXD6B@3<L=4%#24A$1D,GW(N+7LI7E.7/6[+76.=O.^TE^"HKQ
M,[-/M>4DQ('M':*>*H2*"*M#2G(&-9C)+52@3+ ZDOGE)M1U4;*;6XB@0+@.
M5&.P:%T*D6$["Z\(N+8F%!2'RVX .2%6W%QVOW__/CHZ.CX^_OGSY\V;-S]^
M_ C;.T0]50@5$5:'E.0,:C"36ZA F6!U)//+3:CKHF0WMQ!!@7 =J,9@T;H4
M(L-V%EX1<&U-*"AF?<\.X16!Z\/,%A304;D2%%6_S>:R.ST]??CPX?OW[U=O
M\>[?O__APP=XKAC:Y)<UO8H(JT-*LH)&$.6XN84*E!5*KN8AJNCF%B(H9)A<
MS% :+\GG"=^$#+-^&HO0B,+U828&BVZ7!(35-:& H(S\67\2\J]?OYX\>?+N
MW;O56[Q;MVZ]>O6*^TUHDU_>,?L_?6\GJH/<4($R^FZ8 8O8=4,%RHJ2?"Y\
M-VSD+B97Z;)SN.QJ3X(RLOD\Y+]__[Y^_?K9LV>;R^[%BQ?<;T*;_/*.V?_I
M>SM1'>2&"I31=\,,6,2N&RI05I3D<^&[82-W,;E*EYW#95=[$I21S:^+K>ZX
M-V_>/'[\>/4E[>W;MY\_?\[])K3)+^^8_9^^MQ/506ZH0!E]-\R 1>RZH0)E
M14D^%[X;-G(7DZMTV?EO?<\.0\R1T"%!X?HPLP4%Q>933U:7W?'Q\:-'CQ:+
MQ>K?ER]?\E83VN27ARA9Y:&@\I#N196[D(QD' ,FM[ $N Y48["(73=4H*PH
MR>?"=\-&[F)R%7?'#1OLZK+CET>X,H:8EU CF=Q"! 7E;'Z#XNSL[.O7KS=N
MW/C^_?N]>_>>/GW*7C_44ZD\%%0>,KFH* V2C+"Z)N,8);D774[L,C(9/!UA
M;Q[5\<-EYS\)@H)R-N_L-C^3O7+ERLG)R8,'#]Z^?<M>/]13J3P45!XRN:@H
M#9*,L+HFXQ@EN1==3NPR,AD\'6%O'M7QPV7G/PF"@G(V;^O^6?\)VFO7KGWZ
M]&GUSF[U)2U[_5!/I?)04'G(Y**B-$@RPNJ:C&.4Y%YT.;'+R&3P=(2]>53'
M6Y>=REU(5I1\F!]P#G\O<2QO^_7<0@0%Y=CSK+ASY\[=NW>O7KWZ^?-GMX@A
MYB74".6&$E2.F..2D5W'#<<Y8DY&1D(?)K=4'3?,Y$@H9, 11 E0W>(*&&*.
MD..B9)@)H*+"_-9?%U,=%Y(57&L665VS><ENEK%L">6*DJS D2]?OER_?OWH
MZ.A_%W]=>X,K8]X%&C?8:U+J9F37<4,BX[BH(N4&5&NX(QAF<B04,N (H@2H
M;G$%##'/X!8QQ+P$C2#F_/]==G3'C665*TJR D=67\E^^_;MQX\?ZF]^8XAY
M%VC<8*])J9N17<<-B8SCHHJ4&U"MX8Y@F,F14,B (X@2H+K%%3#$/(-;Q!#S
M$C2"F-/ZW=AAQ7<,DA5<:Q9=QRX[RET9<X2<$.ZO8>F"U1NZDY.3T]/3Q6*!
MN2K"I$-)7HY\0PDJ1\QQ81M03B,DR$%<0155;IB@4'X89G*$'(.])ER^0 E0
MW4)."/='N#*&F)>@$<2<UF4WF>%9P3C)B'+<W TQ1Y1#N0'5+2P!K,Z@^[(:
M5'D(%1%6AY3DI?#=L)$CH8"@G/$G0P<9[.68,T)=0PE0O4S44QTNNX%#N0'5
M+2P!K,Z@^[(:5'D(%1%6AY3DI?#=L)$CH8"@G/$G0P<9[.68,T)=0PE0O4S4
M4QTNNX%#N0'5+2P!K,Z@^[(:5'D(%1%6AY3DI?#=L)$CH8"@G/$G0P<9[.68
M,T)=0PE0O4S44SG_]02!A0!N JP.81M0CIN[(:$<E1NA0+BRC93H,H*HP4QN
M(8("P>H0M@7*=T.%&C%,0%@"6!U2DI<C/X3[&E54.4*.H80P#P65EU CS@<!
M(-N!"&X"K/8C/ 4%Y2"AC$(#5QXN71K5IRK)D\%3"%8UF6+&,4A&6!U2DI<C
MWU "5 -44>4N)7F9\)6@\BX<+KL!H8Q" U<>+ET:U:<JR9/!4PA6-9EBQC%(
M1E@=4I*7(]]0 E0#5%'E+B5YF?"5H/(N'"Z[ :&,0@-7'BY=&M6G*LF3P5,(
M5C698L8Q2$98'5*2ER/?4 )4 U11Y2XE>9GPE:#R+@27'6(=#-W_WTML3_-@
M&V!U!!<N4$(U-T(A@XTH0I\$A%5-M5B2)X.G$*QJ,D5R#/;6L 2P.J0D+T>^
MH02H!E Q T\T1UA=$SHD*+@VA&V!^<YEI[;&N?W.UN9#>L$-GA+!%L&J1A5G
MYD8H**R8(>R2@+#:C_V?0K#:C]V=@LM=QKL,JA&5*P%A=4W&,4HR0D6%^1TN
MNS]__BP6B[.S,W#[/#&K&E6<F1NAH+!BAK!+ L)J/_9_"L%J/W9W"BYW&>\R
MJ$94K@2$U349QRC)"!45YG>X[#;WW>K-';A]GIA5C2K.S(U04%@Q0]@E 6&U
M'_L_A6"U'[L[!9>[C'<95",J5P+"ZIJ,8Y1DA(H*\V===N?Z>W:NC+D2$%8U
MJC@SGX\M9W"[%"K:(U5HQ(4[3;A<@;<TF2(YAA*@NH4<0PE0G0@-*K@V1,F4
M(TF!8.D"]M8H1^5*"&E]ZDD7Z#Q^>20@K%X2U:<JR2&XAH/5O(0:<<,,6,S
M_1R9D= )A>7(,90 U0[0.,+JD(R<<4I,7L-BM6O@PN&RBZD^54D.P34<K.8E
MU(@;9L!B!N[GR(R$3B@L1XZA!*AV@,815H=DY(Q38O(:%JM= Q?^!0<KY\^,
/V$OE     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
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DA%D19D68%6%6A%D19D5\ ^1+''+;+;\$     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_2.jpg
<TEXT>
begin 644 image_2.jpg
MB5!.1PT*&@H    -24A$4@  !G(   %W" (    >L$)N  "  $E$051X7NS=
M"5Q55YXO^GWO^WQNO_OI3[_J[O?Z];VWNKHK7?6I[GZWATJE*DFE*HF55,4A
ME4DSF<3,B<:H<4 $$51DD$%F05 0!!%0!%3 651$Q1E%!2<T<< Y1HE$Q+=D
MMZ=.UH+-6OOLO?8Z^_R^G__'3P*LL_][G;777OM_]CE'NP<           ""
M-/H'            T!^4U0           (2AK 8          " ,934
M      !A**L!           (0UD-          ! &,IJ            PE!6
M P          $(:R&@          @#"4U0           (2AK 8
M " ,934           !A**L!           (0UD-          ! &,IJ
M        PE!6 UIW=_>,F*IQDXOH7P          P ,HJP&MJ^ONIV/S1X[+
MIW\!           /H*P&M,[;=WXQ*.*S"07T+P          X &4U8#6WG[C
MSQ\=\_G$0OH7          #P ,IJ0*NHW/=?'OX$934           ,HJP%M
M\K0R[>>?C$%9#0        "@;RBK >VW+T3]EX<_'1.$;P(%         .@3
MRFKP/0</GOW;WTSXKP^/1%D-         ,  RFKP/=.CJ_[LD<_^#Y35
M       ,H:P&?W+K5N?@UQ+^VR]&H:P&         & ,937XDZJ5^__ZU^/^
MSU^.1ED-         , 8RFKP)Q^/R?MOOQCUWW^%LAH         0#]05H/_
MM&??Z7]^=NJ?_VHTRFH          /U"60WNZ^[NCIA5^6>_'/T7CX[!FT !
M         /J%LAK<MZWA^#_^;LH/'AV#LAH           ^4U>#^K6IC)A7]
M]U^._JO'QZ*L!@        #  V4UN+=TV>Z_>'3,7_]ZW%\]/NXO'OT<934
M        @'ZAK!;HVB_<>'A0Q%\]/O9OGQC_E_?O5D-9#0        "@?RBK
M!;3.VW<^'I/WYX]^_L/?3OR;7W^!LAH          ">4U0):Y.R5?_;(9S]Z
M<N+__,T$E-4          /BAK!:@NKN[8^)6_>7C8W_T5-"/GYJ$LAH
M    @!"4U0)48O+J_^NQ,3]^.NBG X)_]"3*:@          8E!6"S@W;MR>
M/JOBKQ\?]Y,!P?_T3,A/!DQ&60T         0!3*:H'ER.'SPS_*_,%C8_[E
MF9!_^T/8SWX7C+(:         ( )**L%D/D+-C_U8M0/GYSXBX'3'AD8_K]_
M'XJR&@        " .2BK!80M6X^]\7[&__SMQ'_[0]@3ST]_='#$?SP7AK(:
M         (!I**NYW)DS5\=,*OK)[Z;\TS,AOWTA<L"+LYYX?OHO!X>CK 8
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M934SKE_OR%^X]=,QN4->C1L[*7])R=;3;5^UM[>?:ONJN?D$B::F8RBK 0
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M-935          "LX[:RVJJ:IN=>B7UI^)SL^>N6E&Q=5+BEJ!AE-935
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M5D-9#0        ! #K\LJW5W=P=/+?G)[X(GAA9E9*Z9DU*=G%J-LAK*:@
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MK_=18_<KUC:6U0H*M_UX0/ S+\<.?G"WVLMO)P]Y+?Z'OYWXP6<+;MRX33<
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M3;W*&O^4I0?=/N )W:I&_I@<[^J': 5!VJ@66G_2C1UE;L8@AR?G$2IMZC/
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MV:.XN'C>O'F1D9&)B8GD5Y<O7Z:W!!#8OOGFFYDS9\;&QN[=NY?^'0
M  !81%Y9[=Z#&]96KUZ]>_=N$V6UY<N7+UNVK+R\G/Q;7%R<FYL;%Q<7%165
MEY>W?__^[[[[CMX>0* BQ\[$B1/)H43_ @         L(K6L1E165F9G9^L?
MKV:NK+9TZ=+2TM*RLK*2DI+BXN*%"Q<F)R=/GSY]]NS9Y"\O7+AP^_9M>JL
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M4UF-/'A65E9F9N;<'NGIZ<G)R7%Q<;-FS8J(B(B.CDY+2R,/M6?/'MS"!@
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M3",@$$3HBX!1:?+?I"[YI_>NG)RAJLZN<[Z?M9<+D\JIVKMVU=[UJSKG (@
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M:H:$^R;6,[;0D'Q?XY\;&Y]83_Q<_-=XS<8:,CMU2PQB@T4+R[L'
M]^D5JPDU-349&1D+%R[<O'DSL5KC6*TA*5/SM:3[$9NH0DH]49TI]QEU;"PU
M-36M$=$4F?=EU1.OL&+%"GG?        X#[M8C7ATT\_34I*JJBHV+AQ([&:
MO[&:P4C6#$:X-K61OPW9_B9E2Z\G7HI8#0      P L=8[6[=^_NW+ESTJ1)
MRY<OKZJJ(E8C5@,      -"-CK%:77VRMG[]^BE3IJQ8L6+=NG7$:L1J
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M/7OV)"8FSIHURWA@C5B-6"V2_?G,U:<[3?UMVXGM>V3^^(FH\B7[Y"4
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MM)=ZYW3LF=6A1^9SG5-_^E3TF=-7Y44! (@,556?BI*6M3XN>;E4C%_)?P
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MYX"9KP^?-VAX8?\A^>:Q6M\93[\TM>4+*>?.7Y-?16/6#DOBQ*T^<&[3A7H
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M%GN+U?KE=ND[X[=M$OL/+I!?47MV#$OJO$>3*TEIJ^R;^SJV(ILT&Q;4F3W
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M%7[':J^]W;G/C!\^-NK=C6X]E5LX+'VP^XSZ@0Z>H*,*"TD;9M_LP;$562N
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MYA4//E83#27J*"KNBMN#ZL'>U!Q4;1D?\R-U:N[EX\-\WQX=7#7[P+@ OG-
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MG+K_0 1][R<      &&&6 TFB-5LBM5FS*Q*RUK=KFM:QQY9APY?D-L=
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M^\0V_^F%Y)BXQ1<N_$5N00      $.Z(U6""6*VI6$V4/7N.9N>NZ] ]H\?
M66O7'I+;#@      1 9B-9@@5E-CM1T[/MFSYVCERCVB%J*^63E5UZ_?EAL.
M      !$#&(UF"!6:QRK?;COF/COMFV'XY(6_ZIU_)NC2T^>J)&;#
M1!AB-9@@5C-BM4.'3AX^?&K7KB-S"S>W[9KV8L^L;=N.?UO[O=Q>       @
M\A"KP42$QVJ?'CDMECQU^OQ''YT0K]^S_XP6'9+G%6V7FPD      $0P8C68
MB.18[?BQL^(G8LF%"[>_.C3_T1=2TK+6\S%J      ! 0JP&$Q$;J]74U%RX
M<''1XIV#AA4\\>+D\7$5APY?D%L'      " 6 VF(C!6NW3ITI4K5\1+#1R:
M_\0+*2E3*C_\\*S<+@       /<1J\%$1,5J-34U7W[YY9HU>\7FM>R8/"5U
M]<&#G\LM @      \+>(U6 B[&.US\]>N'CQ4DU-S:5+E\2?B\U[LM/DY,F5
M)T_4R&T!      !@AE@-)L(X5CMU\MR]=WV>_^+3(Z?%*X@M?*+3E%GYU5]=
MO2FW @      0-.(U6 B_&*U@_N/'S_ZYR^^N/C9D3,;-GPD7KQ#]PQ1EBW_
M2*X\      " #XC58"*<8K5]^XY]=N3TZ5/GQ/_.+=@T^*V"YSJG#GFK>.W:
MC^5J P      ^(Q8#2;"(U;;O>O(X4].'=A_0BPC7KS3*YG=!\S,FK[AZ)%+
M<H4!      #\1*P&$ZZ.U39NW+]M^^&]>XXN7;Y+O$ZG5[*Z])TQ;L*B-:L/
MWKKUK5Q5      " @!"KP83K8K7ERW>M7+5GW=I]F[<<W+#AH]2,E5WZ9C_2
M-N'U$<6+%NT^?O2R7$,      (#@$*O!A#MBM05;[V=JNY<N>W_I\EW3TBM[
M#LS];9N$[@-F%I7L.';DTLV;M7+=        K$"L!A,ZQVIS"S>5E+ZWL&S[
M@H7;BHNWS,ZO$LMWZ9O]R^?C7NR5/7ONUE.GK]36?B]7"0      P%+$:C"A
M6ZPV/6=-WJP-<^:^6UQ275"X.7O&VDE3EP\=5=RE3_9C+Z2\W#LG.W?CB>,U
M<C4       !L0ZP&$YK$:M/2*[-RULQ\>X,HTS)63D@H'SJJN%N_&>V[I;_P
MRO0A;Q47E^PX=>J*O/4       #V(U:#B1#&:G%)BR=.7CHMO3)C^NJDR4M'
MC)W?]XVW._;(>*)32L<>64-'SL_*WK!Y\Q&^TQ,      (06L1I,.!ZKE8Z=
ML# VL3QA4L7X^++71Q3T')CW_,M3'VF7V+%GUJ"WBF?/J5ZYZL#1(Y?D#04
M      @18C68<")6>ZM@\,AYPT87CQI7.G1T4:]79[;KEO:KY^/^N=7X3KVR
MAX]]9\'"7;MVG3IUZLIM'DP#      #Z(5:#"3MBM5X#\_J\/JO_D/R!0_-?
M'3KWM6%SN_3-?KK3Y']Y=OR#3T>_U#LG:<K*Y2OVGSIUY>J7-_DJ3P
MH#EB-9BP-E;KUN]>IB9*SX&Y7?O-:--YVL/M$A]J-;YUE[2D*2O75WUR[OPU
M'DD#      #N0JP&$Y;$:B^^DMFE3W:7?CDO]YXN_K=EAZ1?/A_[>*?)@]XL
M$J]_[OPU>:T       #N0:P&$\'':IU>R1+E^<[WOG;@%\_%MNV6/BJFK&+)
M/K[!$P      A =B-9@()E9KUS6M;=>TEAV3?_Y,],-M)PZ/6K"P;/>%"W^1
MUP$      .!FQ&HP$5BL]F2GR<^]//7AMHEBL8X]LC*F;]B[YXS\T@
M &&!6 TF HC5'GLA^=>MXW[XV,C.O6<LK]S/1Z<!     (#P1JP&$[[':O_6
M)J%%NXF_;ATO?OMPVXGE%7N_NGI3?CD      ("P0ZP&$[[$:O_R[/A?MX[_
MU?-Q/WDBZF=/14],J;QQHU9^(0      @#!%K 83S<9J/Z^/U1YZ.OI'?QK5
M]_7\_0<_EU\"       @K!&KP83W6.W!I^\]K2;^_8OG8_/F5,M_#
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M^:<       "XCU@-        \!NQ&@       . W8C4       # ;\1J
M    @-^(U0        "_$:L!        ?B-6 P       /Q&K 8       #X
MC5@-        \!NQ&@       . W8C4       # ;\1J        @-^(U0
M      "_$:L!        ?B-6 P       /Q&K 8       #X[?\#24]-*U^W
..27$     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_2a.jpg
<TEXT>
begin 644 image_2a.jpg
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M]N#\U2Q!&U^')\5814D;VRYN9G):/ORV\W1W>T-XLQ@?UX&C_9,DB9#7+]E
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M69)SDB=T=^R-7;RW\BV(P_IN;5>0K#!TB'%E,@<ZC',1JD&+?U)^]D%OQ4U
M0[#KZ>VS%0QYP#+65W\F0:3#W'8@)4E2R#<CT0^'I@=9].E^L/!1\V7).O$.
M%V5<GPR!]K8Z'.D_LBU9\6]E'[%9K@0: DK0RF0L$?QL96T\F8:;B:<@)4EB
MR;?DUN!+P0,5#3+M$RSL"I*-!+N]\?U)A-);O[U^EH&5I6N"E3B:*R&;E8V7
ML7U6@_^,GO!/C$MA,@U:VJ)HM"Q)&N2[<FODD['^[9"/T1#!DOS,?8;1/J\<
M?>*#LZCVMAJLXB@C9X=E:.)W\!?/6=XL.L.#ZK,Z$(VXL2R9 &TLG<23@TDR
M2KXW]X4_'!L_(L5GU(U7\IYY ^OT9<D6LM4GH;SVK8/PLX(C<U*/2[P,6'QU
M+QR4)V.SY.$!O93''1*FM [=XWYF2Y-U\AVZ+_PUP<]%%JVZA8O^R='D7Z;M
M=&]H*RY$3%K90ED)UG-.L#Q>IZR9X_)$G'&405#(M=-N-\<>"J/J))DBWZ0[
M8C\BN[XIQ<?Z^Z!*$X;B'%$F6QCM-HYRJ"IQ0#.K+?6S@G,N79.AB8X&:Y#%
MV+A=L]5@+'LL/X&4#&'+$9GVO"=H%S<P>YAL)U^I^R(?%_Q471BQ&B(X>U>0
M',%0V_$"#%4E+=#,:C]'6]U2MOP!3^0KCZ Z>_4G8U>+2$&RT'#*EDQ@RQ'A
M8-*">T6=^Q=)DNWDBW5'\$&1 3\GF"X/EN!3&-0G6YCN]G1API37'B^_I15G
MNA?'28'N2K9@S67Q=B_5)44B5> /$)Q&3.P@:2%'\#J3?\$D.8A\O6X'?VC*
M0"+3P&?(BE?RGE%VK3,99:+G$R5)%>>U'[IKCMA)@:+IRJ:!<QGPD^E&MBQ2
MUM!:3)#JDM9M+T]I$;K$/Y/D:/(]NQWXN."C4YZ+7Y\M#AHB5IR3%4K/ASJ/
MDCRR=9PVHL^:,/A*/UM UI=5$7]V$#=6BGYBWFG^>U'&B*@N@/@@R*E$D*9E
MHY+/DR_<C<#WA;\XX$TZ"!Q&?8)5T_[)%KIM+P?$,OF93( >VF9RBN-5?*4U
MKS(TX\-,*@,\F7^5AQ&<0I:TN#:8=(-WAEO-S<'/)/DP^=K="/DB;_SZR.=,
MTPU&E7%]LAV_^>4MLAH;2>*TNEHH\5:6Z9ITP4H</:<P%GWYR<^/@<5WYY5%
M!JLLU5JVG?"\'F@%]X3'2?(5\N6[%_C<X!O$P6GXBZ8YEZ >SD%]LA?_9$M6
M*'%DM28)X#00$9L2')-"*RY8'^L)3>3G)RE+C4S-BT1)I+!*==YUV\L@S4%;
MLC/)U\E7\"[(%[G\!*H>9,('^FY57)D<3?4(_IW]BQ)!BG\F0]A^(LY9'U_F
MI!A>B0QD7'[*X+M@P7@ZE+T 1%07 %52#EL.WHJ__E*',59UDGR#?!'O G]T
M^#.T_C$Z^KOV^G(>8IY$\,\7!V1EK7'2!<VL]JT5M]A#86R<]7)\F%3B&-N?
M)P$K[\(;M)L=XE^_:OVIIFZ";/S.K4C.3+Z1MT ^1O)<!%9#;L$%L&U7G!R'
MW_QR3*":XF#2!4VSW<//;E=;#@7Q<9XV"*K.IZ*L/[).* 75Q2B%MKP5OS;H
M))XKO4V2H\E7\_K()\D&%YG[S 7U6&=0GQR'<PHXIO(4&2*M\L0B+6VENI3F
M2XD,6E8L@[(E/B>C"^:&\',4[IB-(WL3T(I[;C_Y1?(%O1W;OU#%9,AM5!G7
M)\?AG 5.OYHM.*G$TKI6W3X72F'5!&.VJ@:9EY_&#V++1%ASW*THN2I>R[1J
M6_$+PUM&5Y/DY.1K>@OD>X2?Z]^I\K$;_>05<;=DSCPY#N<@<$S\Y*P-)@[\
MYG>;B7$UQ4'^:<4.4G4<NR:2W47<RJ28&H-16N4<GW/^+;#-^VPYN0SYLEZ?
MZA=JUZ>*#377)BB>,T\.I7H6.":@"M)H(C&@AZU^2J3:6]3:<L;/ O@$]1/
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M)I;2KFYCISG.6< LTW.AO.7 <8R+?G%J9J_;.9&F?6;+AYI_!>D;-CBQ4S@
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MBJT-;7!C0WCV?XW>Y+P7K,VAR")/Z&$N@P^#)94%R/(8429)DB3)%O*/RF^
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M[XGD7.1_/$Z2)$F2Y(OD/T&2<X'_;)S_/DZ2*S'W_PA=F]*3;,OER2/^.?+
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M$6BV-U3WPM<X*<:1.:D(*'<<?(&?O3G9E$OAO.BX!J*Q$9NJ9AE'V8H7_*S
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!@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664995605176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cumberland Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,766,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140665001040152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,266,785<span></span>
</td>
<td class="nump">$ 27,040,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">14,635,435<span></span>
</td>
<td class="nump">6,877,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">9,878,680<span></span>
</td>
<td class="nump">8,429,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">3,561,027<span></span>
</td>
<td class="nump">3,339,969<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">45,341,927<span></span>
</td>
<td class="nump">45,688,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">10,593,792<span></span>
</td>
<td class="nump">9,048,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">409,121<span></span>
</td>
<td class="nump">442,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">34,479,356<span></span>
</td>
<td class="nump">23,954,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,932,876<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">761,177<span></span>
</td>
<td class="nump">1,024,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,178,857<span></span>
</td>
<td class="nump">3,419,908<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">96,697,106<span></span>
</td>
<td class="nump">84,459,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,447,505<span></span>
</td>
<td class="nump">9,640,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">766,488<span></span>
</td>
<td class="nump">969,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">12,343,405<span></span>
</td>
<td class="nump">8,668,303<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,557,398<span></span>
</td>
<td class="nump">19,278,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">22,712<span></span>
</td>
<td class="nump">90,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_OtherLongTermObligationsExcludingCurrentPortion', window );">Other long-term liabilities</a></td>
<td class="nump">11,323,593<span></span>
</td>
<td class="nump">7,488,844<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">55,903,703<span></span>
</td>
<td class="nump">41,857,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">48,046,764<span></span>
</td>
<td class="nump">48,452,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (deficit)</a></td>
<td class="num">(7,023,853)<span></span>
</td>
<td class="num">(5,638,600)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">41,022,911<span></span>
</td>
<td class="nump">42,814,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(229,508)<span></span>
</td>
<td class="num">(212,328)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">40,793,403<span></span>
</td>
<td class="nump">42,601,978<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 96,697,106<span></span>
</td>
<td class="nump">$ 84,459,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherLongTermObligationsExcludingCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Long Term Obligations, Excluding Current Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherLongTermObligationsExcludingCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140665000914200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">14,730,760<span></span>
</td>
<td class="nump">14,742,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">14,730,760<span></span>
</td>
<td class="nump">14,742,754<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664995641368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 11,175,045<span></span>
</td>
<td class="nump">$ 10,537,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">2,211,885<span></span>
</td>
<td class="nump">2,417,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">4,614,429<span></span>
</td>
<td class="nump">3,787,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,745,136<span></span>
</td>
<td class="nump">1,257,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,302,349<span></span>
</td>
<td class="nump">2,230,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,593,245<span></span>
</td>
<td class="nump">1,168,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">12,467,044<span></span>
</td>
<td class="nump">10,861,459<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(1,291,999)<span></span>
</td>
<td class="num">(324,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">16,041<span></span>
</td>
<td class="nump">5,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(119,575)<span></span>
</td>
<td class="num">(24,417)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) from continuing operations before income taxes</a></td>
<td class="num">(1,395,533)<span></span>
</td>
<td class="num">(343,291)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(6,900)<span></span>
</td>
<td class="num">(7,458)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</a></td>
<td class="num">(1,402,433)<span></span>
</td>
<td class="num">(350,749)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">495,410<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,402,433)<span></span>
</td>
<td class="nump">144,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">17,180<span></span>
</td>
<td class="nump">22,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (1,385,253)<span></span>
</td>
<td class="nump">$ 166,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</a></td>
<td class="num">(0.09)<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</a></td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- basic (in shares)</a></td>
<td class="nump">14,691,623<span></span>
</td>
<td class="nump">14,974,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in shares)</a></td>
<td class="nump">14,691,623<span></span>
</td>
<td class="nump">15,244,146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664994373560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (1,402,433)<span></span>
</td>
<td class="nump">$ 144,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">495,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(1,402,433)<span></span>
</td>
<td class="num">(350,749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,653,746<span></span>
</td>
<td class="nump">1,227,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">159,901<span></span>
</td>
<td class="nump">162,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Increase (decrease) in non-cash contingent consideration</a></td>
<td class="nump">370,464<span></span>
</td>
<td class="num">(280,020)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy', window );">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</a></td>
<td class="nump">222,209<span></span>
</td>
<td class="num">(76,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Decrease (increase) in noncash interest expense</a></td>
<td class="nump">2,183<span></span>
</td>
<td class="nump">13,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(7,758,089)<span></span>
</td>
<td class="num">(171,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">2,271,484<span></span>
</td>
<td class="nump">1,868,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="nump">239,862<span></span>
</td>
<td class="nump">507,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">4,461,389<span></span>
</td>
<td class="num">(1,311,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(371,214)<span></span>
</td>
<td class="num">(299,937)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities from continuing operations</a></td>
<td class="num">(150,498)<span></span>
</td>
<td class="nump">1,290,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">495,410<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(150,498)<span></span>
</td>
<td class="nump">1,785,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(26,986)<span></span>
</td>
<td class="num">(19,458)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Note receivable investment funding</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisitions</a></td>
<td class="num">(13,500,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(14,912)<span></span>
</td>
<td class="num">(98,883)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(13,541,898)<span></span>
</td>
<td class="num">(318,341)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(15,000,000)<span></span>
</td>
<td class="num">(15,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash payment of contingent consideration</a></td>
<td class="num">(501,505)<span></span>
</td>
<td class="num">(995,277)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(580,130)<span></span>
</td>
<td class="num">(302,802)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">3,918,365<span></span>
</td>
<td class="num">(1,298,079)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(9,774,031)<span></span>
</td>
<td class="nump">169,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">27,040,816<span></span>
</td>
<td class="nump">24,753,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 17,266,785<span></span>
</td>
<td class="nump">$ 24,922,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664994388936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2020</a></td>
<td class="nump">$ 46,873,394<span></span>
</td>
<td class="nump">$ 49,121,523<span></span>
</td>
<td class="num">$ (2,131,013)<span></span>
</td>
<td class="num">$ (117,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">162,960<span></span>
</td>
<td class="nump">$ 162,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(303,088)<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">144,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,828<span></span>
</td>
<td class="num">(22,167)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,084,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2021</a></td>
<td class="nump">$ 46,877,927<span></span>
</td>
<td class="nump">$ 48,981,395<span></span>
</td>
<td class="num">(1,964,185)<span></span>
</td>
<td class="num">(139,283)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">14,742,754<span></span>
</td>
<td class="nump">14,742,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2021</a></td>
<td class="nump">$ 42,601,978<span></span>
</td>
<td class="nump">$ 48,452,906<span></span>
</td>
<td class="num">(5,638,600)<span></span>
</td>
<td class="num">(212,328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">159,901<span></span>
</td>
<td class="nump">$ 159,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(174,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(566,043)<span></span>
</td>
<td class="num">$ (566,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (1,402,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,385,253)<span></span>
</td>
<td class="num">(17,180)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2022</a></td>
<td class="nump">14,730,760<span></span>
</td>
<td class="nump">14,730,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2022</a></td>
<td class="nump">$ 40,793,403<span></span>
</td>
<td class="nump">$ 48,046,764<span></span>
</td>
<td class="num">$ (7,023,853)<span></span>
</td>
<td class="num">$ (229,508)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664999733432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products.  The Company's primary target markets are hospital acute care, oncology, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be served effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital, oncology and field sales forces in the United States.  We are continuing to build a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2021, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 (the &#8220;2021 Annual Report on Form 10-K&#8221;). The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland has faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our clinical studies were impacted as fewer patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020, 2021 and the three months ended March 31, 2022,  we carefully monitored our supply chain, including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance during the pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Segments</span></div>The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664999813560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350,749)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,385,253)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,828&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,691,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,974,663&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,691,623&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,244,146&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and 2021, restricted stock awards and options to purchase 131,225 and 215,600 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664999780584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,097&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994,378&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052,243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,264&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450,263)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,618&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,537,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omeclamox-Pak revenue for the first quarter of 2022 and 2021 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  In the first quarter of 2022, the amounts noted were normal adjustments by channel partners.  Net revenue was impacted by product return adjustments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to Vaprisol, we are in the process of transitioning to a new manufacturer and expect FDA approval later this year.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.04&#160;million and $0.1 million for the three months ended March 31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664999765800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2022 and December 31, 2021, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.6 million and $1.4 million, respectively.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at March 31, 2022 and December 31, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consigned inventory represents Authorized Generic inventory stored with our partner until shipment.   </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  For the Sancuso acquisition, Cumberland acquired $3.0 million of work in progress non-current inventory.  At March 31, 2022 and December 31, 2021, total non-current inventory, including Vibativ, Sancuso and our clinical trial drug ifetroban, was $10.6 million and $9.0 million, respectively. The Company had $0.2 million and $0.5 million of Vibativ finished goods included in non-current inventory at March 31, 2022 and December 31, 2021, respectively.  The Company also has obtained $0.2 million and $0.4&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at March 31, 2022 and December 31, 2021, respectively. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022 and December 31, 2021 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,004,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,374,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,338,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,472,472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,478,449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,593,792)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,048,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,878,680&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,429,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664999787928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The Company's operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at March 31, 2022 is 0.8 years.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company will lease approximately 16,631 rentable square feet of space (the &#8220;Leased Premise&#8221;) at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise will serve as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of five years each, and will commence on the earlier of November 1, 2022, the date on which Cumberland takes occupancy of the Leased Premise, or the date which Cumberland receives a temporary or permanent certificate of occupancy for the Leased Premise.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,200&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the Broadwest agreement, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at March 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730,829&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664999653256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EquityAndDebtAbstract', window );"><strong>Equity and Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY AND DEBT</a></td>
<td class="text">SHAREHOLDERS&#8217; EQUITY AND DEBT<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2022 and March 31, 2021, the Company repurchased 174,149 shares and 91,724 shares of common stock for approximately $0.6 million and $0.3 million, respectively.  At March 31, 2022, approximately $4.2 million of common shares was left to repurchase under this program.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's March 2022 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  These purchases began in April 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sales</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021.  On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19 million.  The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. The Company did not issue any shares under an ATM during the three months ended March 31, 2022 or March 31, 2021.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants and Incentive Stock Options</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and March 31, 2021, the Company issued 65,225 shares and 35,850 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  During the three months ended March 31, 2022 and 2021, the Company also issued 166,350 and 172,350 incentive stock options, respectively, to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March 2032 and 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement (the "Pinnacle Agreement") to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $15&#160;million to $20&#160;million. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment ("Fifth Amendment") to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original Pinnacle Agreement was dated July 2017.  Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement.  The Fifth Amendment extends the maturity date three years through October 1, 2024.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at March 31, 2022.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  The parties have agreed on a process to determine a new interest rate benchmark at the point the LIBOR rate is expected to be discontinued over the next 12  to 24 months.    </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the Company had $20.0 million and $15.0 million, respectively, in borrowings outstanding under its revolving credit facility.  The Company was in compliance with the Maximum Funded Debt Ratio financial covenant as of March 31, 2022.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the line of credit are collateralized by substantially all of our assets.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span>. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of a $0.2&#160;million convertible note, which was funded during the first quarter of 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license product candidates from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies Inc.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EquityAndDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity and Debt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EquityAndDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664999791880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXESAs of March 31, 2022, the Company has approximately $56.6 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2022 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664999600488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text">COLLABORATIVE AGREEMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664999761368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ADDITIONS AND RETURN OF PRODUCT RIGHTS</a></td>
<td class="text">ADDITIONS AND RETURN OF PRODUCT RIGHTS<div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% of on-going net sales of the product after the $2.5&#160;million threshold is met. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,384,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $6.4 million was accounted for as $2.3 million of other current liabilities and $4.1 million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2022.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that took place in late 2021 will result in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment is payable during 2022 and is included as a current liability at March 31, 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has approximately $2.6&#160;million in net intangible assets related to RediTrex at March 31, 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso Acquisition</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2022, Cumberland acquired the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $13.5&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $3.5&#160;million based on the attainment of various approvals and sales performance. The Company believes that $1.5&#160;million of the milestone payments will be earned and paid.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Cumberland has agreed to pay a royalty of up to 10% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a preliminary valuation of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was funded by cash and the Company's revolving credit facility.  The Company is working with an outside consultant firm to finalize the Sancuso valuation of the transaction which will be completed later this year.  The estimates of fair value for the more significant assets and liabilities assumed were prepaid expenses $0.3&#160;million, inventory $5.2&#160;million, goodwill $1.0&#160;million, intangible assets $12.1&#160;million, milestone payable $1.2&#160;million and contingent liability $3.9&#160;million.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability earned and accrued in operating expenses is paid to Kyowa Kirin quarterly.  The contingent consideration liability of $3.9&#160;million was accounted for as $1.3&#160;million of current liabilities and $2.6&#160;million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2022.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ethyol and Totect </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland received $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $3.0 million during 2020 and the final four installments totaling $2.0 million during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discontinued operations.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from Ethyol and Totect met the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company did not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.829%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140665077559368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664999815688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of numerator and denominator</a></td>
<td class="text">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350,749)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,385,253)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,828&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,691,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,974,663&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,691,623&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,244,146&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140665077808344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of net revenue</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,097&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994,378&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052,243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,264&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450,263)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,618&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,537,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664999756312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022 and December 31, 2021 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,004,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,374,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,338,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,472,472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,478,449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,593,792)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,048,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,878,680&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,429,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140665077648040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Lease Position</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,200&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the Broadwest agreement, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at March 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730,829&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock', window );">Schedule of Rent Expense and Sublease Income</a></td>
<td class="text">Rent expense and sublease income were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Rent Expense and Sublease Income [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664999618376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,384,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Dissolution Payments</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company did not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.829%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664999620072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140665000874312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">$ (1,402,433)<span></span>
</td>
<td class="num">$ (350,749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">495,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,402,433)<span></span>
</td>
<td class="nump">144,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">17,180<span></span>
</td>
<td class="nump">22,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (1,385,253)<span></span>
</td>
<td class="nump">$ 166,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">14,691,623<span></span>
</td>
<td class="nump">14,974,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of other securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">269,483<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">14,691,623<span></span>
</td>
<td class="nump">15,244,146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140665000543160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock available for purchase through restricted stock awards and options (in shares)</a></td>
<td class="nump">131,225<span></span>
</td>
<td class="nump">215,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664994205512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 11,175,045<span></span>
</td>
<td class="nump">$ 10,537,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,945,097<span></span>
</td>
<td class="nump">2,994,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,397,209<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,501,434<span></span>
</td>
<td class="nump">5,052,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">959,634<span></span>
</td>
<td class="nump">1,539,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(117,000)<span></span>
</td>
<td class="nump">1,134,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">111,090<span></span>
</td>
<td class="nump">117,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">22,737<span></span>
</td>
<td class="num">(450,263)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_RediTrexMember', window );">RediTrex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">59,226<span></span>
</td>
<td class="num">(32,252)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">295,618<span></span>
</td>
<td class="nump">182,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 40,000.00<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_RediTrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_RediTrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664992356056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Obsolescence and discontinuance losses</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">10,593,792<span></span>
</td>
<td class="nump">9,048,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Inventory, Finished Goods, Net of Reserves</a></td>
<td class="nump">5,338,469<span></span>
</td>
<td class="nump">4,939,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember', window );">Ifetroban Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664992356792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 15,004,954<span></span>
</td>
<td class="nump">$ 12,374,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">129,049<span></span>
</td>
<td class="nump">164,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">5,338,469<span></span>
</td>
<td class="nump">4,939,088<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventories</a></td>
<td class="nump">20,472,472<span></span>
</td>
<td class="nump">17,478,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">less non-current inventories</a></td>
<td class="num">(10,593,792)<span></span>
</td>
<td class="num">(9,048,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories classified as current</a></td>
<td class="nump">$ 9,878,680<span></span>
</td>
<td class="nump">$ 8,429,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140665001069432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 15, 2021 </div>
<div>ft&#178; </div>
<div>renewalTerm</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Present value of remaining lease payments, percent</a></td>
<td class="nump">7.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Future minimum sublease income under noncancelable operating subleases | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet of office space</a></td>
<td class="nump">25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember', window );">Wet Laboratory and Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet of office space</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseLeasedArea', window );">Leased area</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">157 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember', window );">Wet Laboratory and Office Space | Broadwest Lease, Five Year Renewal Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseNumberOfRenewalTerms', window );">Number of renewal terms | renewalTerm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseLeasedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Leased Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseLeasedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cpix_BroadwestLeaseFiveYearRenewalOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cpix_BroadwestLeaseFiveYearRenewalOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140665001078968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Position (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 761,177<span></span>
</td>
<td class="nump">$ 1,024,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">766,488<span></span>
</td>
<td class="nump">969,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">22,712<span></span>
</td>
<td class="nump">90,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 789,200<span></span>
</td>
<td class="nump">$ 1,059,693<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664995563336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Lease Liabilities at March 31, 2022</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 730,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">92,477<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">823,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">34,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 789,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140665077761640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Rent Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 285,963<span></span>
</td>
<td class="nump">$ 227,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 161,804<span></span>
</td>
<td class="nump">$ 178,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664994242440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt - Shareholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 27, 2021</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>May 13, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (566,043)<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,225<span></span>
</td>
<td class="nump">35,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember', window );">Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,350<span></span>
</td>
<td class="nump">172,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock awards, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,149<span></span>
</td>
<td class="nump">91,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (566,043)<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Common shares left to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664991317960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt - Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember', window );">WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Initial investment in joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Minimum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Maximum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Fifth Amendment | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Additional borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Additional Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_FifthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_FifthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664994416680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 44,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 56,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140664996263864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 03, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,932,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_FinancialConsiderationPaymentPeriod', window );">Financial consideration, payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_FinancialConsiderationNumberOfInstallments', window );">Financial consideration, number of installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment', window );">Financial consideration received in exchange for product license rights, installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Financial consideration received in exchange for product license rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Discontinued operations income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember', window );">Kyowa Kirin | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum', window );">Sales milestone payments, maximum</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected', window );">Sales milestone payments, expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember', window );">Kyowa Kirin | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent', window );">Tiered royalty, percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Other Payments to Acquire Businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Percentage of tiered royalty payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsThreshold', window );">Tiered royalty payment, threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,384,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,515,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Vested common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Net intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Unvested restricted shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Other Payments to Acquire Businesses</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FinancialConsiderationNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Consideration, Number of Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FinancialConsiderationNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FinancialConsiderationPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Consideration, Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FinancialConsiderationPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Intangible Assets, Installment Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_KyowaKirinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140665001214936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Change in Consideration (Details) - Vibativ<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 6,515,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="num">(501,505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="nump">370,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 6,384,586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140665000440488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Dissolution Payments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 11,175,045<span></span>
</td>
<td class="nump">$ 10,537,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">495,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 495,410<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>cpix-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20220331.xsd" xlink:type="simple"/>
    <context id="if17ad389803849e8845be7075058d029_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if88ebbbeffcb449c948e6a903954c826_I20220509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="ieb034453f7ac43e19ed1e1d5524e4104_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8f233a458221495a93adac84dff7b497_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i644ff4fff14b4f54ad5cdf6cc770dece_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2c89fbd5ff1649de916ca18e3a139199_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibedb5ab4be9f4828b6ff4f2b9053cd4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idff02794c5744302a7a96ca85b2b2f66_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifb20159ba2734e579f3392f2e79daeab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1d0083118644bf1b61cd8ab51f0651c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie296e6d816494ea481965188b1bfd3f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i17901c1bb2d74608877a7c878cad3111_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i56165262ecf84c87b423cb5447374724_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id350bef77d574d008a405bc73ebfe1fe_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if554e0ab48004252b12642dddb138333_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i446d1255167148e999d79f66391e2f66_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i97cd8436b20f43fca8ed1adbd8f5dc98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i429817e1a880442a9a593ae8851d641d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09d5c2c85fad488185d55a2c1dacd727_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i315c01ee2f6d43d9856f494cb2c0a31d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i715fd504c0c84828baacf0d421460e91_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if31eafab8bfe4d1b94fb61717226d991_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1cde581e0d7e4fa0be8fb69e2e2b1b22_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icf07c0fa3a084e55ab5d2d0e826c062b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie877302447534894b2d5513d38b31fbb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib1b5c64a6e224a7291d17215b8e20cac_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ice443517d3bd4eacb0f21f2731ff3c9a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i29eb8f904a99423e9e75afb35fc798bb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0f7afb68d83b46cf9e1efc1a40f6f60d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2d669dc1bc564b61a9673076b557bba0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7edbe25bc59c416088d0b62c3c7ba86d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i200c0ccbad3548a4ab7da1ea2e3a57f0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1dc6fa5f3f3948bab15a2a93c882cb38_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0e515d306ed64aeb9f21e8890cae9d55_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie4604540a3e34ae8969cd1ce548e7c56_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib7faae5cf158490da1a4081a5c49115b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id911eaa5894443c2a98fbc046aa0ba09_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia78b359fdf784449a00e7aa9d754ce29_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icdccc9e2bb3149a6a0c56fbbbec9dd0b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i796c57f0f1b3412d8d803b33df824490_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0bd2dd746ac5484bada9868db377c71a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c714cbee7e14e928534563714a191c7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i52b835511e1b4d32814daf525c7b851d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibad57998d50b42e28e43f57e0458042e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0daea624eb8d4452969618186921bc8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i098351aedd7d43fe971148fc9b861a98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae86c13d2edd4a3bb59c24847ec261c4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i84c1a7a949634b2ca9c4f2cac3729504_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2325bc53765d4db18477773f3a908aeb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f1903407422459a9d2afe8a574e9574_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8c5daecc32784c3b84e2034c8b84fb28_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9e9d6ba88f264e658e866ce6a611c696_I20211115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="i7e0ddb33c8e14da08e5d4bf80bbf83c4_I20211115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cpix:BroadwestLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="i6f9bbd3fc1b64e3aaff098e2d4118248_I20100513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-05-13</instant>
        </period>
    </context>
    <context id="i08bc631bb3a84b3e911db80c62f763aa_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i289b83d4e5d54057a0a8a4e6c2f1c792_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i61780641954246b1a1327370732b7ffa_D20211227-20211227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-12-27</startDate>
            <endDate>2021-12-27</endDate>
        </period>
    </context>
    <context id="i252b48b488b0434e85d14e8d2b0c2868_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i91438a451f684b24a2fca503fc14d053_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i393e64896f1e48d1a056d5ef7f775821_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if18a26b0f0ee4feca8ce62bae76cfdec_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i75376963bb5c44dd95c8a7c842962c8d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i30c0769f6c3c4e2da21df888867dc1bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:FifthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1994f4e6e7b4be9b7830b35c2aac539_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="i2a86b88298df427db4bc3b73b915632f_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="i27af9c4796d34881a155e56ca9fd7685_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="i8197f941295d4acd903690460d5fb886_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic80f9798db0747c1acdd1be19fd4f610_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i47ad0a97e0314f8eba21273d51757cd8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i42ffe35d0bb445bca3edfba518ae51db_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i99eb7be3baca40ca8e4e084c3136775c_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i65fbb43d257d44b79182efae8d2e0fd5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4ef7c1987e104296b100805721e7adc8_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i93eb9b844c7244b59e4acf2535ce2a3d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1bf6dd4ac05d40108e2514911c613b85_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="ic73781ab99bd43f2bb632a84368ba389_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i9a90c1c0e8b64d6ebbf750ff29642e7a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i38e26d699b094a1ca3994c9d4c08e244_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="if4192a5594914fce8a1e18207ab24bd1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i390596c6353c4e4383db5ca0102868d7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i33b531a22e104cd8907be7f1309ea431_I20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="i411fb7851cc645fda84082a006d9aae8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8840d2d783664d03833988394492a1b2_I20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="i90ce8664b55e4a05a9829ae3b930adff_I20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="i636282a040df4f679c7f36b32d67a813_D20220103-20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="i10cdce073f8047ab9cded3432889dbae_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i882c40446970433c9806df95c94da0c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iad75b7bb8c1f44d99624874d167e93a3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i973592a5bcc6433aaf22a683d9a22dd5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9c0e77e71ede43e88dd6fd578f76e2e6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i703c37c87b3b4ae1a94069c964a3f5b7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>cpix:Segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="renewalterm">
        <measure>cpix:renewalTerm</measure>
    </unit>
    <unit id="installment">
        <measure>cpix:installment</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80L2ZyYWc6MjM2NzAwZThmYWU0NDY2NGEzY2YwNjAxMzg4MGYwY2MvdGFibGU6MTE2NTk0ZDE5NjY2NGQwYTkxOGU1NTkzMWQzMGE3MTkvdGFibGVyYW5nZToxMTY1OTRkMTk2NjY0ZDBhOTE4ZTU1OTMxZDMwYTcxOV81LTEtMS0xLTIzMzcy_5fd9c0a6-5b6c-4ef0-98ef-73da2529a40f">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80L2ZyYWc6MjM2NzAwZThmYWU0NDY2NGEzY2YwNjAxMzg4MGYwY2MvdGFibGU6MTE2NTk0ZDE5NjY2NGQwYTkxOGU1NTkzMWQzMGE3MTkvdGFibGVyYW5nZToxMTY1OTRkMTk2NjY0ZDBhOTE4ZTU1OTMxZDMwYTcxOV82LTEtMS0xLTIzMzcy_975a576e-1498-4904-b21d-48bfd55a83c4">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80L2ZyYWc6MjM2NzAwZThmYWU0NDY2NGEzY2YwNjAxMzg4MGYwY2MvdGFibGU6MTE2NTk0ZDE5NjY2NGQwYTkxOGU1NTkzMWQzMGE3MTkvdGFibGVyYW5nZToxMTY1OTRkMTk2NjY0ZDBhOTE4ZTU1OTMxZDMwYTcxOV83LTEtMS0xLTIzMzcy_c4e5f167-ef54-4cc7-83f9-c88094fa193d">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80L2ZyYWc6MjM2NzAwZThmYWU0NDY2NGEzY2YwNjAxMzg4MGYwY2MvdGV4dHJlZ2lvbjoyMzY3MDBlOGZhZTQ0NjY0YTNjZjA2MDEzODgwZjBjY183OA_c76ca47f-b7c2-41b5-85f5-fbea1597e3ff">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80L2ZyYWc6MjM2NzAwZThmYWU0NDY2NGEzY2YwNjAxMzg4MGYwY2MvdGV4dHJlZ2lvbjoyMzY3MDBlOGZhZTQ0NjY0YTNjZjA2MDEzODgwZjBjY183OQ_d8cf48e6-7d1c-4c91-88a0-060e926717f5">0001087294</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTc4_3a910e92-a874-4374-9a24-f45b30069e82">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6MGFlNDljYjUwYzNiNDM3ZGE4YmNjYzU1ZTgwYjFjYTUvdGFibGVyYW5nZTowYWU0OWNiNTBjM2I0MzdkYThiY2NjNTVlODBiMWNhNV8wLTAtMS0xLTIzMzcy_6881eee8-6cde-42d6-8682-08c716de00c3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xMzA_47765a2c-15d9-40c8-bcaf-90379a0ff953">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6M2MzZTIwNWVkMzI3NGIwZDlhOWUwZWZjOTQ2NTE2ZDcvdGFibGVyYW5nZTozYzNlMjA1ZWQzMjc0YjBkOWE5ZTBlZmM5NDY1MTZkN18wLTAtMS0xLTIzMzcy_b681a900-ac96-4b3c-aac2-822b75c9877d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTc0_08d4e48a-ca70-4ede-82c2-ec62f5944618">001-33637</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTgx_34b89e78-6ac3-4bfc-a63a-a271623b3bdb">Cumberland Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8wLTAtMS0xLTIzMzcy_e313a7a9-5343-4a5e-bf01-87e49e3a57e6">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8wLTItMS0xLTIzMzcy_6d660aaa-1a2c-425d-b3f5-9d77029fbe1a">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8zLTAtMS0xLTIzMzcyL3RleHRyZWdpb246YTE0MWZjOGJmYmEzNDNhMWJmMTBlNTg2MmIzMmE3NTlfNQ_b18ec93d-9809-4ab2-ab85-88f67d278d3e">2525 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8zLTAtMS0xLTIzMzcyL3RleHRyZWdpb246YTE0MWZjOGJmYmEzNDNhMWJmMTBlNTg2MmIzMmE3NTlfOQ_5acee415-b07f-4c93-9b3a-9f15ee96a64a">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8zLTAtMS0xLTIzMzcyL3RleHRyZWdpb246YTE0MWZjOGJmYmEzNDNhMWJmMTBlNTg2MmIzMmE3NTlfMTM_dcb516dd-e90e-48ab-a7af-090c2480abb2">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8zLTAtMS0xLTIzMzcyL3RleHRyZWdpb246YTE0MWZjOGJmYmEzNDNhMWJmMTBlNTg2MmIzMmE3NTlfMTc_f3d1e39e-dd15-4109-88f5-ebc09a07fd83">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6ZmUwYzE4NmNmZWZhNDc3OThmYzJiYzViNDMzMjE1MWIvdGFibGVyYW5nZTpmZTBjMTg2Y2ZlZmE0Nzc5OGZjMmJjNWI0MzMyMTUxYl8zLTItMS0xLTIzMzcy_ee342a80-3acc-4b3c-a4c3-eb9b9facc6c6">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTc1_cc162360-b798-42f7-9235-773e5d3d572d">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTc2_493c73d5-030b-4d82-83eb-186777d77266">255-0068</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6NzEzNTg4NjRiNWI5NDEyYzk5Yzg4YjdjZGQ2NGIxZDQvdGFibGVyYW5nZTo3MTM1ODg2NGI1Yjk0MTJjOTljODhiN2NkZDY0YjFkNF8yLTAtMS0xLTIzMzcy_12fbdf17-d3f1-43e1-9493-604e604ba828">Common stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6NzEzNTg4NjRiNWI5NDEyYzk5Yzg4YjdjZGQ2NGIxZDQvdGFibGVyYW5nZTo3MTM1ODg2NGI1Yjk0MTJjOTljODhiN2NkZDY0YjFkNF8yLTItMS0xLTIzMzcy_dbfe46a3-549b-4f4b-9049-81aeac4809a4">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6NzEzNTg4NjRiNWI5NDEyYzk5Yzg4YjdjZGQ2NGIxZDQvdGFibGVyYW5nZTo3MTM1ODg2NGI1Yjk0MTJjOTljODhiN2NkZDY0YjFkNF8yLTQtMS0xLTIzMzcy_af582e1b-741b-4069-808a-701a58954e09">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTc3_07268e6e-23dc-48bb-8165-c67ae3c30f97">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTcx_7a250d74-e21f-4f6c-bf0b-9818d550e893">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6NDQxMzYzZmUyNDIyNGIxNGJkZjkyZjdhNmMzODQwOTkvdGFibGVyYW5nZTo0NDEzNjNmZTI0MjI0YjE0YmRmOTJmN2E2YzM4NDA5OV8xLTAtMS0xLTIzMzcy_3ceb769b-9917-447b-a5a3-2c442a761cff">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6NDQxMzYzZmUyNDIyNGIxNGJkZjkyZjdhNmMzODQwOTkvdGFibGVyYW5nZTo0NDEzNjNmZTI0MjI0YjE0YmRmOTJmN2E2YzM4NDA5OV8xLTUtMS0xLTIzMzcy_b66de79c-49a7-4137-bfba-8166164d81b7">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGFibGU6NDQxMzYzZmUyNDIyNGIxNGJkZjkyZjdhNmMzODQwOTkvdGFibGVyYW5nZTo0NDEzNjNmZTI0MjI0YjE0YmRmOTJmN2E2YzM4NDA5OV8yLTItMS0xLTIzMzcy_8dee71ec-c8e0-458f-bd21-9450da136724">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTcy_b91918ea-867e-46dd-b329-b9c530e59677">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if88ebbbeffcb449c948e6a903954c826_I20220509"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xL2ZyYWc6NTE2YjgyYzVkNTAzNDljMTkxZWNhMzRiN2IzYjJmMDEvdGV4dHJlZ2lvbjo1MTZiODJjNWQ1MDM0OWMxOTFlY2EzNGI3YjNiMmYwMV8xOTM2_6b4e095a-1479-4475-b3c1-db84c78458ed"
      unitRef="shares">14766492</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMy0xLTEtMS0yMzM3Mg_8cca0f5e-30bd-4a68-9122-8e6a9c9998f0"
      unitRef="usd">17266785</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMy0zLTEtMS0yMzM3Mg_58bd1f3d-a928-4d9e-b2a8-7275fbf71428"
      unitRef="usd">27040816</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfNS0xLTEtMS0yMzM3Mg_3959dabd-3c92-4e2a-b428-275036d78899"
      unitRef="usd">14635435</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfNS0zLTEtMS0yMzM3Mg_67c17f33-6ad1-4928-8f0c-f4b398d8b458"
      unitRef="usd">6877346</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfNi0xLTEtMS0yMzM3Mg_05b27725-bc49-42fa-ba7f-2d13e6a9992c"
      unitRef="usd">9878680</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfNi0zLTEtMS0yMzM3Mg_e7178dca-924b-47cc-9898-1d45dbab0182"
      unitRef="usd">8429882</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfNy0xLTEtMS0yMzM3Mg_3cfc146b-a73a-46ed-9fe3-ab1c2a575b64"
      unitRef="usd">3561027</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfNy0zLTEtMS0yMzM3Mg_0844e8e7-0a99-48c6-8492-a3e1b66d9197"
      unitRef="usd">3339969</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfOC0xLTEtMS0yMzM3Mg_cc4e6165-18ce-44fb-991e-2908bab2738d"
      unitRef="usd">45341927</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfOC0zLTEtMS0yMzM3Mg_13cb60be-2ba3-4084-b50d-c19d02ca55a5"
      unitRef="usd">45688013</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfOS0xLTEtMS0yMzM3Mg_e0975b68-b678-486e-84af-520244a1cddb"
      unitRef="usd">10593792</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfOS0zLTEtMS0yMzM3Mg_6f5a6075-59b5-466f-a5f0-e0eb6dafdf48"
      unitRef="usd">9048567</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTAtMS0xLTEtMjMzNzI_9fd8c862-977c-45f3-ae3f-a568ac31b5a9"
      unitRef="usd">409121</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTAtMy0xLTEtMjMzNzI_5482f006-9daf-4e6c-93e8-7eae63db9fd1"
      unitRef="usd">442635</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTEtMS0xLTEtMjMzNzI_7a1cbeb0-ebc8-4bd6-a3ca-5c68b765996b"
      unitRef="usd">34479356</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTEtMy0xLTEtMjMzNzI_a0099788-a762-4f22-8018-e6dc0d0d14fa"
      unitRef="usd">23954475</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTItMS0xLTEtMjMzNzI_40dc8eee-5637-4a8d-b085-8eb4906b3400"
      unitRef="usd">1932876</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTItMy0xLTEtMjMzNzI_d00e4fba-f530-44af-b823-78938a93863b"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTMtMS0xLTEtMjMzNzI_544a9768-6e8f-4f0e-bb03-2237d301c2c2"
      unitRef="usd">761177</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTMtMy0xLTEtMjMzNzI_5fdef202-dfc1-4d8e-a473-000a7281df65"
      unitRef="usd">1024200</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTMtMy0xLTEtMjMzNzI_8a50daf5-f64a-4c9f-8246-e2bfaf5dbbd8"
      unitRef="usd">1024200</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTQtMS0xLTEtMjMzNzI_28410087-5507-42d6-a35f-73f483c89861"
      unitRef="usd">3178857</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTQtMy0xLTEtMjMzNzI_3dcda24a-267f-4022-8d97-e37cbaf8089f"
      unitRef="usd">3419908</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTUtMS0xLTEtMjMzNzI_1bd19d27-f7e4-42ea-9914-4d1f2c31c112"
      unitRef="usd">96697106</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTUtMy0xLTEtMjMzNzI_d95b8f85-9173-4f82-ae66-f35f1d19c0ea"
      unitRef="usd">84459798</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTgtMS0xLTEtMjMzNzI_34d3000e-6541-4cbf-ae22-c66baa167356"
      unitRef="usd">11447505</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTgtMy0xLTEtMjMzNzI_848b81b3-ebb4-4494-8b04-cf9d0b16ce27"
      unitRef="usd">9640980</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTktMS0xLTEtMjMzNzI_11a58c38-7098-4cf9-8477-e10f513335b9"
      unitRef="usd">766488</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTktMy0xLTEtMjMzNzI_47dcec09-9bcd-4d06-abb6-359b2949c82e"
      unitRef="usd">969677</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMTktMy0xLTEtMjMzNzI_ceccbe19-e4da-4ad8-9d53-bbd7b8f1b82b"
      unitRef="usd">969677</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjAtMS0xLTEtMjMzNzI_d0203267-adb3-41c0-bf51-97fde7e41b1e"
      unitRef="usd">12343405</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjAtMy0xLTEtMjMzNzI_6ee7ebd1-d74c-4719-a47d-cb457614b9e2"
      unitRef="usd">8668303</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjEtMS0xLTEtMjMzNzI_e9c7fb67-b6e2-4fa0-906f-461fd50946bd"
      unitRef="usd">24557398</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjEtMy0xLTEtMjMzNzI_6fdfe7fa-50c5-4642-81c6-b868554859f7"
      unitRef="usd">19278960</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjItMS0xLTEtMjMzNzI_7f88d0a8-b5f7-47af-bec2-b495ee348a17"
      unitRef="usd">20000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjItMy0xLTEtMjMzNzI_e40c1958-8cfa-4876-bcad-166f3c0e7ef2"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjMtMS0xLTEtMjMzNzI_b97cc6d4-42fa-4fdc-a454-29257c133fec"
      unitRef="usd">22712</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjMtMy0xLTEtMjMzNzI_4418b772-efef-4aee-b316-006e5dc37f97"
      unitRef="usd">90016</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjMtMy0xLTEtMjMzNzI_b3e1eb15-f394-468a-bdf8-0aae1ef1e270"
      unitRef="usd">90016</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjQtMS0xLTEtMjMzNzI_9e9fe7bd-3d2b-4cc3-9e66-314fbe5cc55b"
      unitRef="usd">11323593</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjQtMy0xLTEtMjMzNzI_6b82a70e-3720-49b1-96f0-d48bc0c91ff2"
      unitRef="usd">7488844</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <us-gaap:Liabilities
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjUtMS0xLTEtMjMzNzI_f16126b2-b47c-4d7d-88c4-7771c4a8923d"
      unitRef="usd">55903703</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjUtMy0xLTEtMjMzNzI_56c73add-7811-48bd-bcfe-7be178ba0f4b"
      unitRef="usd">41857820</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjYtMS0xLTEtMjMzNzI_de5907b2-f242-483b-8050-be25bb014d5b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjYtMy0xLTEtMjMzNzI_3f665f4b-9253-441d-ada8-ab67aed7400c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY18xNw_d83304e6-7c01-4966-abb0-293f332ca896"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY18xNw_ec70afa5-0f1c-4523-ab4a-ad8e23ccebe3"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY18zMQ_bf4657bb-7d96-48ba-840a-26b6c719a205"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY18zMQ_c1d32118-0bbf-4c49-97b0-30b7cde60fc2"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY181Mw_210106f1-4ea6-47e7-8c78-c84950ac7f68"
      unitRef="shares">14730760</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY181Mw_4050a7e4-55e3-48cd-ac58-a5a665b079cf"
      unitRef="shares">14730760</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY182MA_82650b84-f2ba-4684-9c7b-763f04c848b9"
      unitRef="shares">14742754</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMC0xLTEtMjMzNzIvdGV4dHJlZ2lvbjozN2ZkYjA1MjEzMjc0OTFkOGYxMDZjZTM2MTMwYjZlY182MA_f12c0592-7354-43fa-9a3c-91c5a12c1824"
      unitRef="shares">14742754</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMS0xLTEtMjMzNzI_d2dcab0a-303f-4add-81e0-440a9a287da8"
      unitRef="usd">48046764</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMjktMy0xLTEtMjMzNzI_5f7a433c-678e-4402-8fdb-6a0acc54d39b"
      unitRef="usd">48452906</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzAtMS0xLTEtMjMzNzI_2ceee3c7-bf88-42b8-8406-d2a1aff95474"
      unitRef="usd">-7023853</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzAtMy0xLTEtMjMzNzI_f9d9fb2e-4f01-469a-908e-db6a079749a9"
      unitRef="usd">-5638600</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzEtMS0xLTEtMjMzNzI_9ef8a504-dd45-4467-b0fb-ca472d2b7fbc"
      unitRef="usd">41022911</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzEtMy0xLTEtMjMzNzI_29b8fc8c-2560-4375-af6d-97315e35593f"
      unitRef="usd">42814306</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzItMS0xLTEtMjMzNzI_cdea89cf-4c3c-4a06-82eb-798f5dd980a8"
      unitRef="usd">-229508</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzItMy0xLTEtMjMzNzI_94c68ae5-bbc3-4ea7-b4b5-0149f16476d5"
      unitRef="usd">-212328</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzMtMS0xLTEtMjMzNzI_671956bc-8c40-47e9-8037-e9b48f4f5a9d"
      unitRef="usd">40793403</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzMtMy0xLTEtMjMzNzI_6e4149b7-3b5d-455e-85ac-10e5b6016510"
      unitRef="usd">42601978</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzQtMS0xLTEtMjMzNzI_d06983f6-8449-484b-a019-7952a87dc6b8"
      unitRef="usd">96697106</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xNi9mcmFnOjM1YTYyMGI1NWUxYTRiYmY4Njc4YmExMGM2YzdiODNhL3RhYmxlOjZkZDE1ZGU4MGE3ZjQzOThiNjc5ZDQyMjE4NGIzOTg0L3RhYmxlcmFuZ2U6NmRkMTVkZTgwYTdmNDM5OGI2NzlkNDIyMTg0YjM5ODRfMzQtMy0xLTEtMjMzNzI_63cc0b19-31d4-4ae6-a22e-ada19b8d2340"
      unitRef="usd">84459798</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMi01LTEtMS0yMzM3Mg_6e275429-c3df-4b27-985c-794d29917aea"
      unitRef="usd">11175045</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMi03LTEtMS0yMzM3Mg_cbfce169-1185-414a-9c34-971e102e72bb"
      unitRef="usd">10537159</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNC01LTEtMS0yMzM3Mg_c0440576-cd7a-4389-b0cc-ac9e782138da"
      unitRef="usd">2211885</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNC03LTEtMS0yMzM3Mg_6b36a5d3-1674-4dae-aec4-cd193803b27d"
      unitRef="usd">2417329</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNS01LTEtMS0yMzM3Mg_165e1b6d-e9cd-4313-93c4-a3b717f95dd8"
      unitRef="usd">4614429</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNS03LTEtMS0yMzM3Mg_de6feec4-e964-4591-a4a7-7be741a2749c"
      unitRef="usd">3787340</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNi01LTEtMS0yMzM3Mg_5aa5d2af-d775-46c5-b420-57ec230ff2d3"
      unitRef="usd">1745136</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNi03LTEtMS0yMzM3Mg_9056a6a8-4808-4b67-8d39-6c77d75ce251"
      unitRef="usd">1257367</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNy01LTEtMS0yMzM3Mg_a5d5dc53-d207-47e2-a08c-01ec2b4b9193"
      unitRef="usd">2302349</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfNy03LTEtMS0yMzM3Mg_780de144-8953-477c-a9b0-dd749356a42b"
      unitRef="usd">2230509</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfOC01LTEtMS0yMzM3Mg_4a644832-59ba-41fe-837c-f6f9639bac42"
      unitRef="usd">1593245</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfOC03LTEtMS0yMzM3Mg_fa38d890-7c78-487e-939a-cb78a79be9bc"
      unitRef="usd">1168914</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfOS01LTEtMS0yMzM3Mg_f384f70d-fea6-40b0-8391-62d9f655d7ad"
      unitRef="usd">12467044</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfOS03LTEtMS0yMzM3Mg_ed45f087-0d91-4d7b-95fc-aeb420ed3fbc"
      unitRef="usd">10861459</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTAtNS0xLTEtMjMzNzI_8aaa5fed-ffa3-4fe8-9aec-fb9b7503bef2"
      unitRef="usd">-1291999</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTAtNy0xLTEtMjMzNzI_7f7c85c8-b276-432c-b377-6a32ca260f6b"
      unitRef="usd">-324300</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTEtNS0xLTEtMjMzNzI_e5b2096f-cab0-42a9-ac6a-ce52317a345a"
      unitRef="usd">16041</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTEtNy0xLTEtMjMzNzI_9d64e3f4-faa7-4b88-af67-44dcae1d9fa6"
      unitRef="usd">5426</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTMtNS0xLTEtMjMzNzI_2bf3158b-e67f-4152-859d-efa885edde4f"
      unitRef="usd">119575</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTMtNy0xLTEtMjMzNzI_26089730-fe8c-45bb-acf1-62fdb5432629"
      unitRef="usd">24417</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTQtNS0xLTEtMjMzNzI_f3623599-fe2c-4032-a828-8414aceee476"
      unitRef="usd">-1395533</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTQtNy0xLTEtMjMzNzI_383b2977-95e8-4468-b004-9bca4b196fdd"
      unitRef="usd">-343291</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTUtNS0xLTEtMjMzNzI_44400ef6-0bd8-4c9d-ab19-096b9ad02b19"
      unitRef="usd">6900</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTUtNy0xLTEtMjMzNzI_ff12372a-6095-4233-a43e-ccf58e148a30"
      unitRef="usd">7458</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTYtNS0xLTEtMjMzNzI_e16771ea-1f72-40f2-9cbb-b700bb4beeb9"
      unitRef="usd">-1402433</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTYtNy0xLTEtMjMzNzI_d538414a-a6eb-40bb-a03c-58c11776bdf2"
      unitRef="usd">-350749</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i644ff4fff14b4f54ad5cdf6cc770dece_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTctNS0xLTEtMjMzNzI_37660da1-e720-440b-b27a-0d3f909bae4e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c89fbd5ff1649de916ca18e3a139199_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTctNy0xLTEtMjMzNzI_47f6dff7-ea4a-4e0f-9347-01f1570319b1"
      unitRef="usd">495410</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTgtNS0xLTEtMjMzNzI_f9cafc37-cd39-476f-8e48-097f96023c4e"
      unitRef="usd">-1402433</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTgtNy0xLTEtMjMzNzI_629108db-6a72-494f-acc0-9dc48131b227"
      unitRef="usd">144661</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTktNS0xLTEtMjMzNzI_ee9111ca-f780-466a-8b74-497ec5cbbba9"
      unitRef="usd">-17180</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMTktNy0xLTEtMjMzNzI_b5f2aa2c-3bcd-45f5-a778-7f77d4ee4561"
      unitRef="usd">-22167</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjAtNS0xLTEtMjMzNzI_d47ce715-7315-416e-9f2b-346787b1d82f"
      unitRef="usd">-1385253</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjAtNy0xLTEtMjMzNzI_f9f2e69f-f791-4990-b09b-74273cfec55c"
      unitRef="usd">166828</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjItNS0xLTEtMjMzNzI_91900bb6-ac37-449e-9488-d06c389d3e5e"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjItNy0xLTEtMjMzNzI_6e9a0ba7-cb19-41da-b3cb-f2a47a7bb021"
      unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjMtNS0xLTEtMjMzNzI_5bb7b451-48ff-48e7-9e1d-0ac17c168ff1"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjMtNy0xLTEtMjMzNzI_41a8ba4e-5efa-4140-9532-5091f0a11d90"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjQtNS0xLTEtMjMzNzI_2745c57b-9566-4e89-a7b5-1f8c8092058d"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjQtNy0xLTEtMjMzNzI_2f2b9fe5-29af-45b6-ad88-19ef178bc238"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjYtNS0xLTEtMjMzNzI_38ad84c0-b180-4d07-b009-b3c817bb1d51"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjYtNy0xLTEtMjMzNzI_76486850-ef77-4fa1-abed-e5315d817309"
      unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjctNS0xLTEtMjMzNzI_a66eaeb2-3810-4ff6-b631-6843d83fa93c"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjctNy0xLTEtMjMzNzI_fafaa495-3117-41d2-8a9a-21a442603508"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjgtNS0xLTEtMjMzNzI_d02c4391-ac77-4318-85da-15415fce9750"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMjgtNy0xLTEtMjMzNzI_678d83db-a7f5-4ea5-b6d2-2c7ce1aef86f"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMzAtNS0xLTEtMjMzNzI_03c21247-7439-4fc0-8c40-8c657597cfa6"
      unitRef="shares">14691623</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMzAtNy0xLTEtMjMzNzI_a7d7824d-e641-4a2e-84d3-0a37e4253a0d"
      unitRef="shares">14974663</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMzEtNS0xLTEtMjMzNzI_62d62e1e-5d57-4b99-9eb6-adc2215f3c4d"
      unitRef="shares">14691623</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8xOS9mcmFnOmYyYTM0ODI5MmE1NzQ0ZDRhZjQ1YmMzZmI5NTRhOTFmL3RhYmxlOmEwNDQ3OTVhZDgwYjQyN2NhNTViNmJlNmM4YmUwMGU1L3RhYmxlcmFuZ2U6YTA0NDc5NWFkODBiNDI3Y2E1NWI2YmU2YzhiZTAwZTVfMzEtNy0xLTEtMjMzNzI_5994851d-a842-4f3d-b9ef-0ca12abf9025"
      unitRef="shares">15244146</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMy0xLTEtMS0yMzM3Mg_648c4565-9eb3-492c-a4e0-f401c4fd29b8"
      unitRef="usd">-1402433</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMy0zLTEtMS0yMzM3Mg_46c818fc-17c4-4744-abf7-6233a3a3f307"
      unitRef="usd">144661</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfNC0xLTEtMS0yMzM3Mg_9aafd138-4e05-4979-a8ab-be9670dcad98"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfNC0zLTEtMS0yMzM3Mg_07ab9ef4-a926-480b-bf6c-b7607c45e752"
      unitRef="usd">495410</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfNS0xLTEtMS0yMzM3Mg_4a6042cb-6f47-484e-a07b-3e042744c5f7"
      unitRef="usd">-1402433</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfNS0zLTEtMS0yMzM3Mg_7dbc6b58-3065-4f53-96ed-2d90afbace99"
      unitRef="usd">-350749</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfNy0xLTEtMS0yMzM3Mg_620ef460-0237-4b63-8366-e74d97c2c7e5"
      unitRef="usd">1653746</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfNy0zLTEtMS0yMzM3Mg_b82c4b75-e228-4ed1-b013-e0128520f72f"
      unitRef="usd">1227607</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfOC0xLTEtMS0yMzM3Mg_ceda5a50-b9e6-4a47-b620-40fd63b3e3e6"
      unitRef="usd">159901</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfOC0zLTEtMS0yMzM3Mg_6807f60d-d15d-4138-9c23-3f55bac33cd0"
      unitRef="usd">162960</us-gaap:ShareBasedCompensation>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfOS0xLTEtMS0yMzM3Mg_d48c8b94-9e3d-4cbf-ac07-361763529e8e"
      unitRef="usd">-370464</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfOS0zLTEtMS0yMzM3Mg_88b2cd55-ae01-4531-a81f-72bc2081dda6"
      unitRef="usd">280020</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTAtMS0xLTEtMjMzNzI_23173c42-4d80-45e3-9c03-053453baaee7"
      unitRef="usd">-222209</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTAtMy0xLTEtMjMzNzI_cec9896f-cd4f-4f64-a362-c2a1ec13d86d"
      unitRef="usd">76300</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTEtMS0xLTEtMjMzNzI_122248ba-b8b9-414f-9a8a-00685e725e90"
      unitRef="usd">2183</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTEtMy0xLTEtMjMzNzI_c5d49518-714d-4981-8194-3b1141a4b791"
      unitRef="usd">13833</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTQtMS0xLTEtMjMzNzI_2cbeeb01-9444-49bc-94a9-7055677c8f36"
      unitRef="usd">7758089</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTQtMy0xLTEtMjMzNzI_fd68a66c-12f0-45f3-8a5d-e471b83cbc9c"
      unitRef="usd">171584</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTUtMS0xLTEtMjMzNzI_1bc70e14-c1ba-4798-ae17-9916852f6d04"
      unitRef="usd">-2271484</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTUtMy0xLTEtMjMzNzI_f7f39ce3-e4a4-4701-ad2a-16ec65c10796"
      unitRef="usd">-1868350</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTYtMS0xLTEtMjMzNzI_2f83c137-18a3-423f-866f-c28bc56eb0df"
      unitRef="usd">-239862</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTYtMy0xLTEtMjMzNzI_d1e6777b-d143-41fc-9f62-444e8618f46a"
      unitRef="usd">-507102</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTctMS0xLTEtMjMzNzI_34bceb5a-91f4-4336-812b-7334cb115cf4"
      unitRef="usd">4461389</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTctMy0xLTEtMjMzNzI_7a20c812-6c08-4a6f-a71b-89ef6d211f5d"
      unitRef="usd">-1311123</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTgtMS0xLTEtMjMzNzI_000893ee-bc76-43e1-b5db-a5582ed55964"
      unitRef="usd">-371214</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTgtMy0xLTEtMjMzNzI_fdb638f4-e11a-4d59-ad53-d5216e2f9012"
      unitRef="usd">-299937</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTktMS0xLTEtMjMzNzI_91fe0995-ce1d-47f2-9860-1c84d6475ca7"
      unitRef="usd">-150498</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMTktMy0xLTEtMjMzNzI_4701f449-31c7-4cef-91ba-b3552a5d935e"
      unitRef="usd">1290139</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjAtMS0xLTEtMjMzNzI_b66f5944-e413-4bf9-8125-701e42e6f2f7"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjAtMy0xLTEtMjMzNzI_a97a5810-fe26-4db4-8c2e-91db95b462ff"
      unitRef="usd">495410</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjEtMS0xLTEtMjMzNzI_872bb16c-4a38-4128-87d2-cca00daa7a1b"
      unitRef="usd">-150498</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjEtMy0xLTEtMjMzNzI_7a779cdc-b2cd-4475-9ec7-bb114b92437d"
      unitRef="usd">1785549</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjMtMS0xLTEtMjMzNzI_dbf34d5c-f897-473a-b4e4-54057c9a7abc"
      unitRef="usd">26986</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjMtMy0xLTEtMjMzNzI_3fd72162-7877-4ed3-aaaa-6bfdca0a73d2"
      unitRef="usd">19458</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjUtMS0xLTEtMjMzNzI_401872ee-878b-4564-af54-361fefee0afd"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjUtMy0xLTEtMjMzNzI_04c4246e-2f4d-440a-9b0b-60241c1fe4bd"
      unitRef="usd">200000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjYtMS0xLTEtMjQ5NzU_21cc3fc2-ba03-4b90-9a01-e6a09c5b2893"
      unitRef="usd">13500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjYtMy0xLTEtMjQ5NzU_3754baa3-2f41-41f0-a628-3833d98d3a13"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjYtMS0xLTEtMjMzNzI_08c0812b-5a41-4d55-b62a-70e20f9b480a"
      unitRef="usd">14912</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjYtMy0xLTEtMjMzNzI_62ae80a6-3363-48e2-b4c4-af2857762649"
      unitRef="usd">98883</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjctMS0xLTEtMjMzNzI_e05db191-20b9-4d2d-a750-8f5eb3d6945f"
      unitRef="usd">-13541898</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMjctMy0xLTEtMjMzNzI_1d60514a-0571-4279-8f79-2a89788df9de"
      unitRef="usd">-318341</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzAtMS0xLTEtMjMzNzI_740a0f1a-4eac-4f7e-920f-eb8d89aef4c1"
      unitRef="usd">20000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzAtMy0xLTEtMjMzNzI_5f3c19fe-9d18-46f3-b7e7-d23ac28f5232"
      unitRef="usd">15000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzEtMS0xLTEtMjMzNzI_116ab87c-8e18-4d47-af37-068b681be286"
      unitRef="usd">15000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzEtMy0xLTEtMjMzNzI_c63a4fce-f5f4-4b11-8b54-519f64d8d110"
      unitRef="usd">15000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzItMS0xLTEtMjMzNzI_63956c06-41c3-4289-83b2-d596c4d282b8"
      unitRef="usd">501505</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzItMy0xLTEtMjMzNzI_8b3df205-fdc3-452b-a6b8-153de2d73d14"
      unitRef="usd">995277</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzQtMS0xLTEtMjMzNzI_a0b3da1f-3d1d-4849-9774-a68758f03440"
      unitRef="usd">580130</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzQtMy0xLTEtMjMzNzI_791eb824-1999-40e7-8cfb-d159af39f353"
      unitRef="usd">302802</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzUtMS0xLTEtMjMzNzI_cf212e92-4f35-4338-a8f4-c0f676a29f87"
      unitRef="usd">3918365</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzUtMy0xLTEtMjMzNzI_6ed57a59-21a7-478b-b9c4-e6261fc308a6"
      unitRef="usd">-1298079</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzYtMS0xLTEtMjMzNzI_29153ff5-2ccc-4aca-955b-40652107123b"
      unitRef="usd">-9774031</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzYtMy0xLTEtMjMzNzI_5f342f0b-2d9f-459e-aacc-efbab5501250"
      unitRef="usd">169129</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzctMS0xLTEtMjMzNzI_62a0d9b4-af3d-4ef2-8464-95f1166af76f"
      unitRef="usd">27040816</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibedb5ab4be9f4828b6ff4f2b9053cd4b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzctMy0xLTEtMjMzNzI_7fa4ced9-2b93-493d-be77-7f21957e867f"
      unitRef="usd">24753796</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzgtMS0xLTEtMjMzNzI_93c04fac-3b88-46be-a0ce-9c43f3f0246e"
      unitRef="usd">17266785</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idff02794c5744302a7a96ca85b2b2f66_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yMi9mcmFnOjEwZTk4MTMzNmM3MTRiYWZiODFmMDUxMzUxNTg3YTZjL3RhYmxlOjY5M2JlZTVlOGYzNDRhZTE4MmE5ZjAxZTNjYzA2YjI5L3RhYmxlcmFuZ2U6NjkzYmVlNWU4ZjM0NGFlMTgyYTlmMDFlM2NjMDZiMjlfMzgtMy0xLTEtMjMzNzI_8e6df392-7aed-433c-a4f8-539db300e058"
      unitRef="usd">24922925</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifb20159ba2734e579f3392f2e79daeab_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMi0xLTEtMS0yMzM3Mg_1b68654f-e8b7-439f-8574-d07430792094"
      unitRef="shares">14988429</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb20159ba2734e579f3392f2e79daeab_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMi0zLTEtMS0yMzM3Mg_6894126e-8489-49ec-990c-f9f51e79a443"
      unitRef="usd">49121523</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1d0083118644bf1b61cd8ab51f0651c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMi01LTEtMS0yMzM3Mg_7dacbae6-3289-4db2-b4c3-b000a78999e3"
      unitRef="usd">-2131013</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie296e6d816494ea481965188b1bfd3f5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMi03LTEtMS0yMzM3Mg_8e1d19d9-2cda-4c9b-865b-77071d303043"
      unitRef="usd">-117116</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibedb5ab4be9f4828b6ff4f2b9053cd4b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMi05LTEtMS0yMzM3Mg_72585d0b-8f40-47b4-ba93-9ec9795d1962"
      unitRef="usd">46873394</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMy0xLTEtMS0yMzM3Mg_d783e853-de85-4413-ad82-3bb670fb0996"
      unitRef="shares">187759</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMy0zLTEtMS0yMzM3Mg_ab24f539-5076-49d3-acfe-c54ab42a59ea"
      unitRef="usd">162960</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfMy05LTEtMS0yMzM3Mg_808347cf-007e-4854-a1f4-ccb5f51d3efe"
      unitRef="usd">162960</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNC0xLTEtMS0yMzM3Mg_deeeb198-4d64-493f-a03d-69a9c0036276"
      unitRef="shares">91724</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNC0zLTEtMS0yMzM3Mg_146ab648-4887-46a0-8554-1c8711b989f7"
      unitRef="usd">303088</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNC05LTEtMS0yMzM3Mg_183d411e-5d24-491b-943e-f5d2d4724399"
      unitRef="usd">303088</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i17901c1bb2d74608877a7c878cad3111_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNS01LTEtMS0yMzM3Mg_cb2199d8-9202-4c70-861f-59fb83ccaa15"
      unitRef="usd">166828</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i56165262ecf84c87b423cb5447374724_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNS03LTEtMS0yMzM3Mg_6b926014-75f0-4598-a80f-d5e5cc28aa43"
      unitRef="usd">-22167</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNS05LTEtMS0yMzM3Mg_1f28a636-8240-4eec-9db1-3e78ef1ea7ac"
      unitRef="usd">144661</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id350bef77d574d008a405bc73ebfe1fe_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNi0xLTEtMS0yMzM3Mg_66a79d98-45cd-4b79-80d4-8b5c7d43ee11"
      unitRef="shares">15084464</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id350bef77d574d008a405bc73ebfe1fe_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNi0zLTEtMS0yMzM3Mg_2806c0b5-a282-40b6-8a39-c03b54928b2d"
      unitRef="usd">48981395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if554e0ab48004252b12642dddb138333_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNi01LTEtMS0yMzM3Mg_0f9b190d-a79d-4cc7-839e-118b96953da8"
      unitRef="usd">-1964185</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i446d1255167148e999d79f66391e2f66_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNi03LTEtMS0yMzM3Mg_d3bcd8fb-cdc6-4dcc-8bc1-b3631e14cd52"
      unitRef="usd">-139283</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idff02794c5744302a7a96ca85b2b2f66_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOjQ2YzlmZWU2MmFiMzQxMGVhOGJiOWRmNWRkMmM4MGUzL3RhYmxlcmFuZ2U6NDZjOWZlZTYyYWIzNDEwZWE4YmI5ZGY1ZGQyYzgwZTNfNi05LTEtMS0yMzM3Mg_0f859525-1119-4960-990d-7b9e1db30a40"
      unitRef="usd">46877927</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i97cd8436b20f43fca8ed1adbd8f5dc98_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMi0xLTEtMS0yMzM3Mg_5c94cf90-9ec3-4ceb-a6b6-99faaff79b70"
      unitRef="shares">14742754</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i97cd8436b20f43fca8ed1adbd8f5dc98_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMi0zLTEtMS0yMzM3Mg_8f4f02cb-d466-4580-9769-e3a5ebd0f672"
      unitRef="usd">48452906</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i429817e1a880442a9a593ae8851d641d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMi01LTEtMS0yMzM3Mg_78ffa789-faa7-418f-aec4-ff1b8ff67ada"
      unitRef="usd">-5638600</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09d5c2c85fad488185d55a2c1dacd727_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMi03LTEtMS0yMzM3Mg_fde019a4-beab-4680-901e-0c138533c1e5"
      unitRef="usd">-212328</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMi05LTEtMS0yMzM3Mg_6845a75f-018c-4f8e-90a4-4b0ea46399bd"
      unitRef="usd">42601978</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMy0xLTEtMS0yMzM3Mg_5e3a2ce9-025d-4c97-9c9e-fed0b7ac214a"
      unitRef="shares">162155</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMy0zLTEtMS0yMzM3Mg_0b629f99-7b8a-4b57-b41b-1f9e0f0ef124"
      unitRef="usd">159901</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfMy05LTEtMS0yMzM3Mg_735a38c2-8817-432c-9469-c4c1a145b2d8"
      unitRef="usd">159901</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNC0xLTEtMS0yMzM3Mg_1e874a68-856a-4474-a646-41a5ccac7081"
      unitRef="shares">174149</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNC0zLTEtMS0yMzM3Mg_39c6c449-2be6-442f-9961-a9e6d06bc44d"
      unitRef="usd">566043</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNC05LTEtMS0yMzM3Mg_78ecf884-61e8-48ec-902b-9fa994144d3e"
      unitRef="usd">566043</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i315c01ee2f6d43d9856f494cb2c0a31d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNS01LTEtMS0yMzM3Mg_e16d10d2-6b9e-40a0-8bd1-62ca8e709520"
      unitRef="usd">-1385253</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i715fd504c0c84828baacf0d421460e91_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNS03LTEtMS0yMzM3Mg_c56ecbfc-2ecf-4167-86d9-b897dc08292b"
      unitRef="usd">-17180</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNS05LTEtMS0yMzM3Mg_c51a560f-a456-4ffe-82c9-af99d9535966"
      unitRef="usd">-1402433</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if31eafab8bfe4d1b94fb61717226d991_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNi0xLTEtMS0yMzM3Mg_821bf56e-11e5-4ed7-baa4-21463fca6d54"
      unitRef="shares">14730760</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if31eafab8bfe4d1b94fb61717226d991_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNi0zLTEtMS0yMzM3Mg_88a66238-d961-4193-aa71-f607047ee6d8"
      unitRef="usd">48046764</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cde581e0d7e4fa0be8fb69e2e2b1b22_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNi01LTEtMS0yMzM3Mg_42ff4642-0be0-4b5e-83be-a584354cd937"
      unitRef="usd">-7023853</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf07c0fa3a084e55ab5d2d0e826c062b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNi03LTEtMS0yMzM3Mg_73dcf55c-2da2-4bf8-94b3-6f9a825570ba"
      unitRef="usd">-229508</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8yNS9mcmFnOjQ5OTY1ZmFlZTdjODQ2YzhiYjJkMGVkOWI1NWI5NDE1L3RhYmxlOmU0ZWRhMGM5NGQ3ZjQ1YzNiNzQ0NDRjZjM2NjFiNTlhL3RhYmxlcmFuZ2U6ZTRlZGEwYzk0ZDdmNDVjM2I3NDQ0NGNmMzY2MWI1OWFfNi05LTEtMS0yMzM3Mg_6dc170f9-de1a-49b3-ba9c-30290ffa7daa"
      unitRef="usd">40793403</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zMS9mcmFnOjFkNWQ0ZmY1MjNjZDRjMTk5Nzc0N2ZkNTBhYzU5ZDQ0L3RleHRyZWdpb246MWQ1ZDRmZjUyM2NkNGMxOTk3NzQ3ZmQ1MGFjNTlkNDRfMTAwMzM_6736a951-fb36-4417-a411-48170dc2e7af">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products.  The Company's primary target markets are hospital acute care, oncology, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be served effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital, oncology and field sales forces in the United States.  We are continuing to build a network of international partners to register and provide our medicines to patients in their countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2021, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 (the &#x201c;2021 Annual Report on Form 10-K&#x201d;). The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Totect&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout the pandemic, Cumberland has faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our clinical studies were impacted as fewer patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020, 2021 and the three months ended March 31, 2022,  we carefully monitored our supply chain, including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance during the pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#x2019; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Policies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zMS9mcmFnOjFkNWQ0ZmY1MjNjZDRjMTk5Nzc0N2ZkNTBhYzU5ZDQ0L3RleHRyZWdpb246MWQ1ZDRmZjUyM2NkNGMxOTk3NzQ3ZmQ1MGFjNTlkNDRfMTAwMzU_8e5bf0eb-d5b3-49fc-9d8a-246a2a256a9a">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zMS9mcmFnOjFkNWQ0ZmY1MjNjZDRjMTk5Nzc0N2ZkNTBhYzU5ZDQ0L3RleHRyZWdpb246MWQ1ZDRmZjUyM2NkNGMxOTk3NzQ3ZmQ1MGFjNTlkNDRfMTAwMzY_96da59db-d802-4bf1-b00b-91ef0092b1d9">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zMS9mcmFnOjFkNWQ0ZmY1MjNjZDRjMTk5Nzc0N2ZkNTBhYzU5ZDQ0L3RleHRyZWdpb246MWQ1ZDRmZjUyM2NkNGMxOTk3NzQ3ZmQ1MGFjNTlkNDRfMTAwMzE_4a8e3fdf-416d-488f-a208-18907162335e">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zMS9mcmFnOjFkNWQ0ZmY1MjNjZDRjMTk5Nzc0N2ZkNTBhYzU5ZDQ0L3RleHRyZWdpb246MWQ1ZDRmZjUyM2NkNGMxOTk3NzQ3ZmQ1MGFjNTlkNDRfOTIyNQ_a200cfca-fad7-4f58-af3a-19d8a7455340"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RleHRyZWdpb246NGViMGQ3YzdlYWU4NDUwOTkzYWEwNTI1ODExZTA0NTdfNDI0_5b960598-3c1f-4731-aec1-720d07df8693">EARNINGS (LOSS) PER SHARE&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,402,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(350,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,402,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,385,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,691,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,974,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,691,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,244,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022 and 2021, restricted stock awards and options to purchase 131,225 and 215,600 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RleHRyZWdpb246NGViMGQ3YzdlYWU4NDUwOTkzYWEwNTI1ODExZTA0NTdfNDI2_9aecfe8a-8d98-4c9f-99c8-6b18bd6e65f2">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2022 and 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,402,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(350,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,402,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,385,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,691,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,974,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,691,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,244,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNC0xLTEtMS0yMzM3Mg_e16771ea-1f72-40f2-9cbb-b700bb4beeb9"
      unitRef="usd">-1402433</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNC0zLTEtMS0yMzM3Mg_d538414a-a6eb-40bb-a03c-58c11776bdf2"
      unitRef="usd">-350749</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i644ff4fff14b4f54ad5cdf6cc770dece_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNS0xLTEtMS0yMzM3Mg_37660da1-e720-440b-b27a-0d3f909bae4e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c89fbd5ff1649de916ca18e3a139199_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNS0zLTEtMS0yMzM3Mg_47f6dff7-ea4a-4e0f-9347-01f1570319b1"
      unitRef="usd">495410</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNi0xLTEtMS0yMzM3Mg_0dfd9f6f-15c5-4b29-b65f-ca3769a327ad"
      unitRef="usd">-1402433</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNi0zLTEtMS0yMzM3Mg_a9fc1e9f-1769-4516-8200-123616e1d1d7"
      unitRef="usd">144661</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNy0xLTEtMS0yMzM3Mg_ee9111ca-f780-466a-8b74-497ec5cbbba9"
      unitRef="usd">-17180</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfNy0zLTEtMS0yMzM3Mg_b5f2aa2c-3bcd-45f5-a778-7f77d4ee4561"
      unitRef="usd">-22167</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfOC0xLTEtMS0yMzM3Mg_d47ce715-7315-416e-9f2b-346787b1d82f"
      unitRef="usd">-1385253</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfOC0zLTEtMS0yMzM3Mg_f9f2e69f-f791-4990-b09b-74273cfec55c"
      unitRef="usd">166828</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfMTAtMS0xLTEtMjMzNzI_03c21247-7439-4fc0-8c40-8c657597cfa6"
      unitRef="shares">14691623</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfMTAtMy0xLTEtMjMzNzI_a7d7824d-e641-4a2e-84d3-0a37e4253a0d"
      unitRef="shares">14974663</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfMTEtMS0xLTEtMjMzNzI_d3ed46d0-cd4b-49bb-b67b-4def6e4d1b46"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfMTEtMy0xLTEtMjMzNzI_480670ed-d9e6-4570-9e93-5de77c7dd586"
      unitRef="shares">269483</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfMTItMS0xLTEtMjMzNzI_62d62e1e-5d57-4b99-9eb6-adc2215f3c4d"
      unitRef="shares">14691623</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RhYmxlOmI3OTk5ZTg5MmRhNzRjZWQ4YmRkMWYwNjJiOWMwYWRjL3RhYmxlcmFuZ2U6Yjc5OTllODkyZGE3NGNlZDhiZGQxZjA2MmI5YzBhZGNfMTItMy0xLTEtMjMzNzI_5994851d-a842-4f3d-b9ef-0ca12abf9025"
      unitRef="shares">15244146</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RleHRyZWdpb246NGViMGQ3YzdlYWU4NDUwOTkzYWEwNTI1ODExZTA0NTdfMjQ4_e6c8de21-5d51-4dc1-a06d-8443880edfde"
      unitRef="shares">131225</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNC9mcmFnOjRlYjBkN2M3ZWFlODQ1MDk5M2FhMDUyNTgxMWUwNDU3L3RleHRyZWdpb246NGViMGQ3YzdlYWU4NDUwOTkzYWEwNTI1ODExZTA0NTdfMjU1_239aa2e5-4cd6-40ba-9e27-8e3f87e8775c"
      unitRef="shares">215600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RleHRyZWdpb246ODRkODlkMzgyM2VhNGRkNjhhM2U0ZjQxZWY1MDg3OTFfMjY5OA_d12dcaa1-e78d-4487-9ce2-d3c67175895d">REVENUES&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,052,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,175,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,537,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Omeclamox-Pak revenue for the first quarter of 2022 and 2021 was the result of Cumberland currently being out of commercial inventory of this product.  The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.  In the first quarter of 2022, the amounts noted were normal adjustments by channel partners.  Net revenue was impacted by product return adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With regard to Vaprisol, we are in the process of transitioning to a new manufacturer and expect FDA approval later this year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#x2019;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual payments associated with the partner&#x2019;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#x2019;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.04&#160;million and $0.1 million for the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RleHRyZWdpb246ODRkODlkMzgyM2VhNGRkNjhhM2U0ZjQxZWY1MDg3OTFfMjY5OQ_ac3aaae9-ef6d-4f3d-be34-8976945c15b1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,052,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,175,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,537,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie877302447534894b2d5513d38b31fbb_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfMy01LTEtMS0yMzM3Mg_3c5e52c7-e967-4103-8181-92a83018f2ca"
      unitRef="usd">3945097</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1b5c64a6e224a7291d17215b8e20cac_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfMy03LTEtMS0yMzM3Mg_169027b9-9b9c-4766-8f48-529df28ed99e"
      unitRef="usd">2994378</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice443517d3bd4eacb0f21f2731ff3c9a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNC01LTEtMS0yNTAxMA_3446f4b3-e0b6-46c8-966b-d7a3a7d9d398"
      unitRef="usd">3397209</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29eb8f904a99423e9e75afb35fc798bb_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNC03LTEtMS0yNTAxMA_e30105a7-20e0-4519-8eb0-be52e7ce21d7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f7afb68d83b46cf9e1efc1a40f6f60d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNC01LTEtMS0yMzM3Mg_3d9db5e7-499f-4ce4-96b7-05ed116eb0c8"
      unitRef="usd">2501434</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d669dc1bc564b61a9673076b557bba0_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNC03LTEtMS0yMzM3Mg_5e26fb59-307d-4c9f-849e-83e0bbc6c049"
      unitRef="usd">5052243</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7edbe25bc59c416088d0b62c3c7ba86d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNS01LTEtMS0yMzM3Mg_1667540c-6548-41f0-83f0-be3f8ba9a07c"
      unitRef="usd">959634</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i200c0ccbad3548a4ab7da1ea2e3a57f0_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNS03LTEtMS0yMzM3Mg_b5fcea1b-ff3c-4669-b847-1ecb0a7ae953"
      unitRef="usd">1539496</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dc6fa5f3f3948bab15a2a93c882cb38_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNi01LTEtMS0yMzM3Mg_6d53e13f-ce01-4792-ab75-71253823d4c6"
      unitRef="usd">-117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e515d306ed64aeb9f21e8890cae9d55_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNi03LTEtMS0yMzM3Mg_cc9e1969-570a-4209-bbd2-61b6510859b2"
      unitRef="usd">1134264</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4604540a3e34ae8969cd1ce548e7c56_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNy01LTEtMS0yMzM3Mg_5fdfca3a-7090-4ccb-a0d4-f7c52aab15e8"
      unitRef="usd">111090</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7faae5cf158490da1a4081a5c49115b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfNy03LTEtMS0yMzM3Mg_40fcda26-bb51-47c6-a22e-649c7403d452"
      unitRef="usd">117191</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id911eaa5894443c2a98fbc046aa0ba09_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfOC01LTEtMS0yMzM3Mg_fad626d7-456e-4409-9a80-85a810210f5a"
      unitRef="usd">22737</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia78b359fdf784449a00e7aa9d754ce29_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfOC03LTEtMS0yMzM3Mg_7fafdd7d-3ae4-4e17-8b44-e3188490acc9"
      unitRef="usd">-450263</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdccc9e2bb3149a6a0c56fbbbec9dd0b_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfOS01LTEtMS0yMzM3Mg_a162c339-7ae7-4842-8ebf-7745592f6dd1"
      unitRef="usd">59226</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i796c57f0f1b3412d8d803b33df824490_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfOS03LTEtMS0yMzM3Mg_c6f506cb-b837-4b04-a45e-7023b2100020"
      unitRef="usd">-32252</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bd2dd746ac5484bada9868db377c71a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfMTAtNS0xLTEtMjMzNzI_38930a09-c254-4c7b-a52a-ef35e480c1ad"
      unitRef="usd">295618</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c714cbee7e14e928534563714a191c7_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfMTAtNy0xLTEtMjMzNzI_6fb43b11-2616-4bba-a745-54a2c4fdcb94"
      unitRef="usd">182102</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfMTEtNS0xLTEtMjMzNzI_328c3285-00e8-49d6-857a-c04990b42e33"
      unitRef="usd">11175045</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RhYmxlOjQwMDU2ZTgwYzdjZDQyZGZiZjhiM2YxMDY2OGJjNTg3L3RhYmxlcmFuZ2U6NDAwNTZlODBjN2NkNDJkZmJmOGIzZjEwNjY4YmM1ODdfMTEtNy0xLTEtMjMzNzI_ab54795f-72e9-4e5f-a52a-c12208d2d907"
      unitRef="usd">10537159</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52b835511e1b4d32814daf525c7b851d_D20220101-20220331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RleHRyZWdpb246ODRkODlkMzgyM2VhNGRkNjhhM2U0ZjQxZWY1MDg3OTFfMjYwMg_e9a155ed-50b1-469d-9d0d-91a6fec0986f"
      unitRef="usd">40000.00</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibad57998d50b42e28e43f57e0458042e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl8zNy9mcmFnOjg0ZDg5ZDM4MjNlYTRkZDY4YTNlNGY0MWVmNTA4NzkxL3RleHRyZWdpb246ODRkODlkMzgyM2VhNGRkNjhhM2U0ZjQxZWY1MDg3OTFfMjYwOQ_46ab326c-c3af-4452-b93c-884129de879d"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMjE2NA_51bd96c2-96b6-473b-a231-7f2175a7de70">INVENTORIES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#x2019;s warehouses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2022 and December 31, 2021, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.6 million and $1.4 million, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for the purchase of the active pharmaceutical ingredient (&#x201c;API&#x201d;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at March 31, 2022 and December 31, 2021.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consigned inventory represents Authorized Generic inventory stored with our partner until shipment.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  For the Sancuso acquisition, Cumberland acquired $3.0 million of work in progress non-current inventory.  At March 31, 2022 and December 31, 2021, total non-current inventory, including Vibativ, Sancuso and our clinical trial drug ifetroban, was $10.6 million and $9.0 million, respectively. The Company had $0.2 million and $0.5 million of Vibativ finished goods included in non-current inventory at March 31, 2022 and December 31, 2021, respectively.  The Company also has obtained $0.2 million and $0.4&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at March 31, 2022 and December 31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2022 and December 31, 2021 the Company's net inventories consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,004,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,374,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,338,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,472,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,478,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,593,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,048,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,878,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,429,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTAzOQ_a37739e9-2cd9-49f6-9cd2-285e724f2789"
      unitRef="usd">600000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTA0Ng_f5ac7df4-c458-46ea-9578-f3eb1691406b"
      unitRef="usd">1400000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNoncurrent
      contextRef="i0daea624eb8d4452969618186921bc8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTYzNQ_f8963c04-4e12-4e23-823e-578ddeb7b3fd"
      unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i098351aedd7d43fe971148fc9b861a98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMjE5OTAyMzI1OTA4Nw_09410ee7-1851-48c6-8433-7892479bc5ed"
      unitRef="usd">3000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTgwOQ_e33dd526-5d85-41ff-9346-79d64d9dc368"
      unitRef="usd">10600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTgxNg_298f2828-a475-48d0-aefd-7d8e936df6d7"
      unitRef="usd">9000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryFinishedGoods
      contextRef="iae86c13d2edd4a3bb59c24847ec261c4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTg1MA_ff46b76c-bce3-465d-a321-8324ee4000eb"
      unitRef="usd">200000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i0daea624eb8d4452969618186921bc8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTg1Nw_24bd3273-ca3c-47d3-9b7f-b84da85efa72"
      unitRef="usd">500000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNoncurrent
      contextRef="i84c1a7a949634b2ca9c4f2cac3729504_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMjE5OTAyMzI1OTE4Mw_40f5ac44-f633-4d04-a42a-f8f16cd7510e"
      unitRef="usd">200000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i2325bc53765d4db18477773f3a908aeb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMTk3OQ_2ca93532-112f-4a9b-ac13-9aadf57b6893"
      unitRef="usd">400000</us-gaap:InventoryNoncurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RleHRyZWdpb246ZmZkN2EwZDkxMmNiNDE4ZGFjYjQwNzMwNTRiOTBkNDBfMjE2Nw_3cade9f6-631a-4140-a32c-b69adb1d3301">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2022 and December 31, 2021 the Company's net inventories consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,004,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,374,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,338,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,472,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,478,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,593,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,048,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,878,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,429,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfMi0yLTEtMS0yMzM3Mg_192991da-23a2-4eb5-a2bb-2bd2f8794d2d"
      unitRef="usd">15004954</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfMi00LTEtMS0yMzM3Mg_ba65153b-a1f1-408a-8b3d-282b50d2706b"
      unitRef="usd">12374983</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfMi00LTEtMS0yMzM3Mg_bec3db18-6b4e-45ad-9515-8ed6332fbbaf"
      unitRef="usd">12374983</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfMy0yLTEtMS0yMzM3Mg_0c80250d-fe73-43c5-adfd-a54848e790ab"
      unitRef="usd">129049</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfMy00LTEtMS0yMzM3Mg_8c4e84d2-ed9b-46f8-a2eb-2878197ae00f"
      unitRef="usd">164378</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfMy00LTEtMS0yMzM3Mg_eec3829d-0b90-46fb-a04a-81a1798a89d7"
      unitRef="usd">164378</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNC0yLTEtMS0yMzM3Mg_494dc18f-4186-44b7-a78f-8b6245be7166"
      unitRef="usd">5338469</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNC00LTEtMS0yMzM3Mg_0e0c9367-eeb0-418f-a317-84592d7d62ec"
      unitRef="usd">4939088</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNC00LTEtMS0yMzM3Mg_a935b94b-f48b-43ba-a4c8-a113af9de855"
      unitRef="usd">4939088</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNS0yLTEtMS0yMzM3Mg_91e79dff-d75b-4f68-a673-159dfd441716"
      unitRef="usd">20472472</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNS00LTEtMS0yMzM3Mg_f2c88b57-80c0-48dd-b564-27c0e07005bd"
      unitRef="usd">17478449</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNi0yLTEtMS0yMzM3Mg_63a0f892-ccbd-497c-a116-4091f1201908"
      unitRef="usd">10593792</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNi00LTEtMS0yMzM3Mg_a47740c9-dacb-4086-8702-9a58737394b3"
      unitRef="usd">9048567</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNy0yLTEtMS0yMzM3Mg_7430fca0-73c4-44da-8c3c-5152ef260c38"
      unitRef="usd">9878680</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80MC9mcmFnOmZmZDdhMGQ5MTJjYjQxOGRhY2I0MDczMDU0YjkwZDQwL3RhYmxlOjhhYjk2M2Y1MjkwYjRlYjlhOTVkZTUzMDk4NDgxMjBmL3RhYmxlcmFuZ2U6OGFiOTYzZjUyOTBiNGViOWE5NWRlNTMwOTg0ODEyMGZfNy00LTEtMS0yMzM3Mg_8f7e70e3-486e-4b6d-8d73-2672feb1beb8"
      unitRef="usd">8429882</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTk4MA_46120881-db5b-42aa-9cbb-865bfb806a8f">LEASES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The Company's operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at March 31, 2022 is 0.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company will lease approximately 16,631 rentable square feet of space (the &#x201c;Leased Premise&#x201d;) at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise will serve as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of five years each, and will commence on the earlier of November 1, 2022, the date on which Cumberland takes occupancy of the Leased Premise, or the date which Cumberland receives a temporary or permanent certificate of occupancy for the Leased Premise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding the Broadwest agreement, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities at March 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i2f1903407422459a9d2afe8a574e9574_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfOTQ_b656207f-f0cd-4aa1-bd30-7fb774ea4399"
      unitRef="sqft">25500</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i8c5daecc32784c3b84e2034c8b84fb28_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMzAw_0a1c1ee2-27de-4a32-83c2-6f0dd09e5066"
      unitRef="sqft">14200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTI0OA_c21f3341-147d-4231-becd-f1f5365a0898"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTMwMw_594a24b5-b992-46fa-ae58-eb99653002b4">P0Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <cpix:LesseeOperatingLeaseLeasedArea
      contextRef="i9e9d6ba88f264e658e866ce6a611c696_I20211115"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMzg0ODI5MDY5OTk4NA_50f581aa-4181-43da-98a7-1b0a3dd2fbde"
      unitRef="sqft">16631</cpix:LesseeOperatingLeaseLeasedArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i9e9d6ba88f264e658e866ce6a611c696_I20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMzg0ODI5MDY5OTk5Mw_e51c1949-94b3-4239-a2c2-0e4a4e782534">P157M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cpix:LesseeOperatingLeaseNumberOfRenewalTerms
      contextRef="i7e0ddb33c8e14da08e5d4bf80bbf83c4_I20211115"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMzg0ODI5MDY5OTk5MQ_9b793344-5a27-4005-ba3c-44598919c2ab"
      unitRef="renewalterm">2</cpix:LesseeOperatingLeaseNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i7e0ddb33c8e14da08e5d4bf80bbf83c4_I20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMzg0ODI5MDcwMDAwNA_0997d34c-9284-479f-821e-c3706ef7a7c4">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTk4MQ_98e31e05-3450-4c44-84ae-6c517deb8458">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2022 and December 31, 2021, the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding the Broadwest agreement, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYzMWVhYTkzZjk4ZTRmOTViYmVjMzJkODc2ZTY1NjE0L3RhYmxlcmFuZ2U6NjMxZWFhOTNmOThlNGY5NWJiZWMzMmQ4NzZlNjU2MTRfMS0yLTEtMS0yMzM3Mg_544a9768-6e8f-4f0e-bb03-2237d301c2c2"
      unitRef="usd">761177</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYzMWVhYTkzZjk4ZTRmOTViYmVjMzJkODc2ZTY1NjE0L3RhYmxlcmFuZ2U6NjMxZWFhOTNmOThlNGY5NWJiZWMzMmQ4NzZlNjU2MTRfMS00LTEtMS0yMzM3Mg_5fdef202-dfc1-4d8e-a473-000a7281df65"
      unitRef="usd">1024200</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYzMWVhYTkzZjk4ZTRmOTViYmVjMzJkODc2ZTY1NjE0L3RhYmxlcmFuZ2U6NjMxZWFhOTNmOThlNGY5NWJiZWMzMmQ4NzZlNjU2MTRfMS00LTEtMS0yMzM3Mg_8a50daf5-f64a-4c9f-8246-e2bfaf5dbbd8"
      unitRef="usd">1024200</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfMS0yLTEtMS0yMzM3Mg_11a58c38-7098-4cf9-8477-e10f513335b9"
      unitRef="usd">766488</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfMS00LTEtMS0yMzM3Mg_47dcec09-9bcd-4d06-abb6-359b2949c82e"
      unitRef="usd">969677</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfMS00LTEtMS0yMzM3Mg_ceccbe19-e4da-4ad8-9d53-bbd7b8f1b82b"
      unitRef="usd">969677</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfMy0yLTEtMS0yMzM3Mg_b97cc6d4-42fa-4fdc-a454-29257c133fec"
      unitRef="usd">22712</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfMy00LTEtMS0yMzM3Mg_4418b772-efef-4aee-b316-006e5dc37f97"
      unitRef="usd">90016</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfMy00LTEtMS0yMzM3Mg_b3e1eb15-f394-468a-bdf8-0aae1ef1e270"
      unitRef="usd">90016</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfNC0yLTEtMS0yMzM3Mg_f5b25531-2d23-49bf-83bc-c942878952f6"
      unitRef="usd">789200</cpix:LeaseLiability>
    <cpix:LeaseLiability
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjk2M2Y3NWEyYmFjMDRjZjY5OGMwZTQyOGExOWIwZDRjL3RhYmxlcmFuZ2U6OTYzZjc1YTJiYWMwNGNmNjk4YzBlNDI4YTE5YjBkNGNfNC00LTEtMS0yMzM3Mg_871361d3-191a-413a-87b1-5358a965dcf9"
      unitRef="usd">1059693</cpix:LeaseLiability>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTUxMA_8b6ffaa8-4300-4d8c-a099-d88585b64c7f"
      unitRef="usd">100000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTk3OA_6b836a50-f8d4-4af6-adaa-874261851c07">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities at March 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOmNkNmQ5NzVjOTEzNzQxM2Q5YjAyMDFmMmUwNjNjOWY2L3RhYmxlcmFuZ2U6Y2Q2ZDk3NWM5MTM3NDEzZDliMDIwMWYyZTA2M2M5ZjZfMi0yLTEtMS0yMzM3Mg_5e53f39f-e550-4b31-8747-d0e822200c97"
      unitRef="usd">730829</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOmNkNmQ5NzVjOTEzNzQxM2Q5YjAyMDFmMmUwNjNjOWY2L3RhYmxlcmFuZ2U6Y2Q2ZDk3NWM5MTM3NDEzZDliMDIwMWYyZTA2M2M5ZjZfMy0yLTEtMS0yMzM3Mg_228ac672-454d-4592-bd03-50f408c454b3"
      unitRef="usd">92477</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOmNkNmQ5NzVjOTEzNzQxM2Q5YjAyMDFmMmUwNjNjOWY2L3RhYmxlcmFuZ2U6Y2Q2ZDk3NWM5MTM3NDEzZDliMDIwMWYyZTA2M2M5ZjZfNS0yLTEtMS0yMzM3Mg_b3d0c460-c1bb-468c-8c2f-ac891496af75"
      unitRef="usd">823306</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOmNkNmQ5NzVjOTEzNzQxM2Q5YjAyMDFmMmUwNjNjOWY2L3RhYmxlcmFuZ2U6Y2Q2ZDk3NWM5MTM3NDEzZDliMDIwMWYyZTA2M2M5ZjZfNi0yLTEtMS0yMzM3Mg_03e52a9c-15df-439a-8aa3-3ed804a03067"
      unitRef="usd">34106</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOmNkNmQ5NzVjOTEzNzQxM2Q5YjAyMDFmMmUwNjNjOWY2L3RhYmxlcmFuZ2U6Y2Q2ZDk3NWM5MTM3NDEzZDliMDIwMWYyZTA2M2M5ZjZfNy0yLTEtMS0yMzM3Mg_9d28f7a9-8c12-48c3-aa0c-f76bb53aff43"
      unitRef="usd">789200</us-gaap:OperatingLeaseLiability>
    <cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RleHRyZWdpb246OTE0ZDdlYTEyYTIzNDBkMmE4ODM1OTZlMWE0ZjJlZGJfMTk3OQ_fe0d18e3-edcf-4d41-8bdd-d30cd64adc59">Rent expense and sublease income were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYwYThhYWRkMmZiYjQ4ZTU4NjA2YzJkZTI2NWUwMDUxL3RhYmxlcmFuZ2U6NjBhOGFhZGQyZmJiNDhlNTg2MDZjMmRlMjY1ZTAwNTFfMi0yLTEtMS0yMzM3Mg_de928ce5-f246-4516-ad68-17c0cdc2301a"
      unitRef="usd">285963</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYwYThhYWRkMmZiYjQ4ZTU4NjA2YzJkZTI2NWUwMDUxL3RhYmxlcmFuZ2U6NjBhOGFhZGQyZmJiNDhlNTg2MDZjMmRlMjY1ZTAwNTFfMi00LTEtMS0yMzM3Mg_35051850-e98e-48b4-8140-feb2cc73f9ce"
      unitRef="usd">227395</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYwYThhYWRkMmZiYjQ4ZTU4NjA2YzJkZTI2NWUwMDUxL3RhYmxlcmFuZ2U6NjBhOGFhZGQyZmJiNDhlNTg2MDZjMmRlMjY1ZTAwNTFfNC0yLTEtMS0yMzM3Mg_c09ea5a6-e951-4f99-b919-74eb2a6ed344"
      unitRef="usd">161804</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i39347f75e40346e69c4ebd653eeb4a19_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80My9mcmFnOjkxNGQ3ZWExMmEyMzQwZDJhODgzNTk2ZTFhNGYyZWRiL3RhYmxlOjYwYThhYWRkMmZiYjQ4ZTU4NjA2YzJkZTI2NWUwMDUxL3RhYmxlcmFuZ2U6NjBhOGFhZGQyZmJiNDhlNTg2MDZjMmRlMjY1ZTAwNTFfNC00LTEtMS0yMzM3Mg_421782da-6ddc-42ec-bc20-67e47c2cf3ef"
      unitRef="usd">178029</us-gaap:SubleaseIncome>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzg0ODI5MDcxMDA5Mw_6f74fec7-e3df-4e0b-9ea4-a68bbad1d88d">SHAREHOLDERS&#x2019; EQUITY AND DEBT&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2022 and March 31, 2021, the Company repurchased 174,149 shares and 91,724 shares of common stock for approximately $0.6 million and $0.3 million, respectively.  At March 31, 2022, approximately $4.2 million of common shares was left to repurchase under this program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share purchases and sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the Company's March 2022 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  These purchases began in April 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allowed the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021.  On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19 million.  The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. The Company did not issue any shares under an ATM during the three months ended March 31, 2022 or March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Share Grants and Incentive Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022 and March 31, 2021, the Company issued 65,225 shares and 35,850 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  During the three months ended March 31, 2022 and 2021, the Company also issued 166,350 and 172,350 incentive stock options, respectively, to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March 2032 and 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement (the "Pinnacle Agreement") to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $15&#160;million to $20&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 28, 2021, the Company and Pinnacle Bank entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment ("Fifth Amendment") to the Revolving Credit Loan Agreement to renew the Revolving Credit Loan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The original Pinnacle Agreement was dated July 2017.  Beginning on August 14, 2018, and continuing until October 7, 2020, the Company and Pinnacle Bank entered into a series of amendments to extend and update the Revolving Credit Note and Revolving Credit Agreement.  The Fifth Amendment extends the maturity date three years through October 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The current pricing under the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at March 31, 2022.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  The parties have agreed on a process to determine a new interest rate benchmark at the point the LIBOR rate is expected to be discontinued over the next 12  to 24 months.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022 and December 31, 2021, the Company had $20.0 million and $15.0 million, respectively, in borrowings outstanding under its revolving credit facility.  The Company was in compliance with the Maximum Funded Debt Ratio financial covenant as of March 31, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the line of credit are collateralized by substantially all of our assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;WHC Biopharmaceuticals, Pte. Ltd&lt;/span&gt;. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of a $0.2&#160;million convertible note, which was funded during the first quarter of 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license product candidates from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies Inc.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i6f9bbd3fc1b64e3aaff098e2d4118248_I20100513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMTMz_937cf292-900e-4b03-b8ab-7a86ebe754cb"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i08bc631bb3a84b3e911db80c62f763aa_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMjk0_bf4b6cd2-00da-4c4a-a450-87505deaeecb"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNDAw_3ee178c5-a7e1-4f31-853d-74d9eb89070f"
      unitRef="shares">174149</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNDE0_6d11f282-2308-4992-bb83-ef3dd7f6b9a5"
      unitRef="shares">91724</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i03f7d2e9439043fe9f1d3eb19be57df4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNDcz_81fe3749-155b-455f-82ac-8c4a78b2b9f8"
      unitRef="usd">600000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iea59a32900ab4fcc8438ebf4b0afba7a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNDgw_0662ec59-d165-417d-afed-981c818b73f1"
      unitRef="usd">300000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="if31eafab8bfe4d1b94fb61717226d991_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNTIw_bd0c55d6-445a-4f17-be38-07103c487f98"
      unitRef="usd">4200000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="i289b83d4e5d54057a0a8a4e6c2f1c792_D20171101-20171130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMTA1OA_ffee0f2f-581a-4154-8302-b7c6428140c7"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="i61780641954246b1a1327370732b7ffa_D20211227-20211227"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMjE5OTAyMzI2MzQxMw_09e31d4b-b301-471f-8ed2-2237810a10a4"
      unitRef="usd">19000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i252b48b488b0434e85d14e8d2b0c2868_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMTk0NA_bb4675ae-91f5-4d7b-a2ff-45f70cfb5e44"
      unitRef="shares">65225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i91438a451f684b24a2fca503fc14d053_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMTk1OA_a6477777-a5c4-44ee-9802-2e7b28b61529"
      unitRef="shares">35850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i393e64896f1e48d1a056d5ef7f775821_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNzI2Nw_3f14adc6-5212-469f-aa8d-ad206b6ddb38">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if18a26b0f0ee4feca8ce62bae76cfdec_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMjI0Mw_4610bcc7-7418-4438-b965-469a77f4ab16"
      unitRef="shares">166350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i75376963bb5c44dd95c8a7c842962c8d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMjE5OTAyMzI2ODMwMQ_7f55bc64-f733-4d36-9584-e740333d7de0"
      unitRef="shares">172350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <cpix:LineOfCreditFacilityAdditionalBorrowingCapacity
      contextRef="i30c0769f6c3c4e2da21df888867dc1bb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzg0ODI5MDcxMDA4MQ_14a3be68-886e-457c-9436-e6405a74f47b"
      unitRef="usd">15000000</cpix:LineOfCreditFacilityAdditionalBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="i30c0769f6c3c4e2da21df888867dc1bb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzg0ODI5MDcxMDA2OA_01798f09-182f-4f70-9723-cb1610c9f932"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie1994f4e6e7b4be9b7830b35c2aac539_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzgyMg_ff2a25b6-2f05-4d92-97fa-9435228863dd"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2a86b88298df427db4bc3b73b915632f_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzgyOA_b75d8ef1-6f49-44f1-bd0a-8a16e05d0728"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i27af9c4796d34881a155e56ca9fd7685_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzg2Nw_f9578051-07f7-4d9d-994e-8effa39caec5"
      unitRef="number">0.009</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8197f941295d4acd903690460d5fb886_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzkzMw_326edca5-073b-4f6b-a73f-0e8d18f10b33"
      unitRef="number">0.0365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="ic80f9798db0747c1acdd1be19fd4f610_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMzk2Ng_3e045b49-7eaf-4c2b-a5d4-0544d7c745f0"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LongTermLineOfCredit
      contextRef="i47ad0a97e0314f8eba21273d51757cd8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNDExMQ_ff359313-f5fa-4ac9-b9d8-a0ab3a8cc2f8"
      unitRef="usd">20000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i8f233a458221495a93adac84dff7b497_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfMjE5OTAyMzI2ODM2OA_e40c1958-8cfa-4876-bcad-166f3c0e7ef2"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i42ffe35d0bb445bca3edfba518ae51db_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNjg2OQ_e6fee356-bcf0-4d0f-83c4-7e081607e223"
      unitRef="usd">200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i99eb7be3baca40ca8e4e084c3136775c_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80Ni9mcmFnOjE5YjQyMTIyOTVhMzQ1M2I5ZDBiMTE1MzM1YzU5YTU4L3RleHRyZWdpb246MTliNDIxMjI5NWEzNDUzYjlkMGIxMTUzMzVjNTlhNThfNjk1MQ_5fe8db77-78cc-4bac-86bc-f3d6b41cf186"
      unitRef="usd">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80OS9mcmFnOjJhNjVlOTc0MmYyNzQwYzY5MmUyN2MyODQwNzI1ODUxL3RleHRyZWdpb246MmE2NWU5NzQyZjI3NDBjNjkyZTI3YzI4NDA3MjU4NTFfNjM1_5413ba6d-ab6b-4597-9637-7e2ecb843756">INCOME TAXESAs of March 31, 2022, the Company has approximately $56.6 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2022 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i65fbb43d257d44b79182efae8d2e0fd5_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80OS9mcmFnOjJhNjVlOTc0MmYyNzQwYzY5MmUyN2MyODQwNzI1ODUxL3RleHRyZWdpb246MmE2NWU5NzQyZjI3NDBjNjkyZTI3YzI4NDA3MjU4NTFfNjI_6877a3bf-72a7-463a-b5ef-4bd39522ec68"
      unitRef="usd">56600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ieb034453f7ac43e19ed1e1d5524e4104_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl80OS9mcmFnOjJhNjVlOTc0MmYyNzQwYzY5MmUyN2MyODQwNzI1ODUxL3RleHRyZWdpb246MmE2NWU5NzQyZjI3NDBjNjkyZTI3YzI4NDA3MjU4NTFfMTMz_d12c878b-c46e-43fd-a442-964ad1131ab0"
      unitRef="usd">44100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81Mi9mcmFnOjI5OWIyMDY0ZDg5ODQwZWJhZDRjYjJiNjc4ZDU2Zjc2L3RleHRyZWdpb246Mjk5YjIwNjRkODk4NDBlYmFkNGNiMmI2NzhkNTZmNzZfMTAyNw_15c58536-054e-4f6f-af69-3b8091228b11">COLLABORATIVE AGREEMENTS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNTg0Mw_32c94e88-8f2b-469b-9fa4-76d301972ad0">ADDITIONS AND RETURN OF PRODUCT RIGHTS&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% of on-going net sales of the product after the $2.5&#160;million threshold is met. The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,515,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(501,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,384,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liability of $6.4 million was accounted for as $2.3 million of other current liabilities and $4.1 million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RediTrex&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#x2019;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  During December 2020, Cumberland introduced RediTrex and the launch that took place in late 2021 will result in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment is payable during 2022 and is included as a current liability at March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has approximately $2.6&#160;million in net intangible assets related to RediTrex at March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sancuso Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 3, 2022, Cumberland acquired the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#x2019;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#x201c;CINV&#x201d;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product &#x2013; including its marketing, promotion, distribution, manufacturing and medical support activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $13.5&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $3.5&#160;million based on the attainment of various approvals and sales performance. The Company believes that $1.5&#160;million of the milestone payments will be earned and paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Cumberland has agreed to pay a royalty of up to 10% of on-going net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a preliminary valuation of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition was funded by cash and the Company's revolving credit facility.  The Company is working with an outside consultant firm to finalize the Sancuso valuation of the transaction which will be completed later this year.  The estimates of fair value for the more significant assets and liabilities assumed were prepaid expenses $0.3&#160;million, inventory $5.2&#160;million, goodwill $1.0&#160;million, intangible assets $12.1&#160;million, milestone payable $1.2&#160;million and contingent liability $3.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liability earned and accrued in operating expenses is paid to Kyowa Kirin quarterly.  The contingent consideration liability of $3.9&#160;million was accounted for as $1.3&#160;million of current liabilities and $2.6&#160;million of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ethyol and Totect &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland received $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $3.0 million during 2020 and the final four installments totaling $2.0 million during &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as discontinued operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exit from Ethyol and Totect met the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company did not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incur expenses associated with these payments from Clinigen. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i4ef7c1987e104296b100805721e7adc8_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfOTcx_81b58010-04c5-45d1-987f-7d26b54b0451"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i4ef7c1987e104296b100805721e7adc8_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMTAxNA_46a86c56-9b4c-4ac7-81d6-cd7432d70c06"
      unitRef="usd">5000000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="i4ef7c1987e104296b100805721e7adc8_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMTExNw_0a59ff18-c72e-45ca-8993-8e63f27ecaa8"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <cpix:TieredRoyaltyPaymentsThreshold
      contextRef="i4ef7c1987e104296b100805721e7adc8_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDgwNQ_d24cd94c-55dc-4d97-805a-ed59a6de375d"
      unitRef="usd">2500000</cpix:TieredRoyaltyPaymentsThreshold>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNTg0MQ_cdcc8e36-31db-4889-b1d5-e67597a74a40">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,515,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(501,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,384,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0daea624eb8d4452969618186921bc8f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjc0ODFkODNmOWIyNTRlMjg5MDg0YzI0ZjVmYTViYjVmL3RhYmxlcmFuZ2U6NzQ4MWQ4M2Y5YjI1NGUyODkwODRjMjRmNWZhNWJiNWZfOS0xLTEtMS0yMzM3Mg_590efa4f-9a27-4551-8d78-3878133a6106"
      unitRef="usd">6515627</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="i93eb9b844c7244b59e4acf2535ce2a3d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjc0ODFkODNmOWIyNTRlMjg5MDg0YzI0ZjVmYTViYjVmL3RhYmxlcmFuZ2U6NzQ4MWQ4M2Y5YjI1NGUyODkwODRjMjRmNWZhNWJiNWZfMTAtMS0xLTEtMjMzNzI_ecc27e4f-f03a-46c4-acb7-50d7569afd9a"
      unitRef="usd">501505</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i93eb9b844c7244b59e4acf2535ce2a3d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjc0ODFkODNmOWIyNTRlMjg5MDg0YzI0ZjVmYTViYjVmL3RhYmxlcmFuZ2U6NzQ4MWQ4M2Y5YjI1NGUyODkwODRjMjRmNWZhNWJiNWZfMTEtMS0xLTEtMjMzNzI_8fedbcb4-2612-4889-b278-ef3f73104c05"
      unitRef="usd">370464</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i93eb9b844c7244b59e4acf2535ce2a3d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjc0ODFkODNmOWIyNTRlMjg5MDg0YzI0ZjVmYTViYjVmL3RhYmxlcmFuZ2U6NzQ4MWQ4M2Y5YjI1NGUyODkwODRjMjRmNWZhNWJiNWZfMTItMS0xLTEtMjMzNzI_b4297138-f8be-41f7-ba93-8a28280310e3"
      unitRef="usd">0</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iae86c13d2edd4a3bb59c24847ec261c4_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjc0ODFkODNmOWIyNTRlMjg5MDg0YzI0ZjVmYTViYjVmL3RhYmxlcmFuZ2U6NzQ4MWQ4M2Y5YjI1NGUyODkwODRjMjRmNWZhNWJiNWZfMTMtMS0xLTEtMjMzNzI_34fc124a-5f00-41fe-aabf-9e6aa57d4ac9"
      unitRef="usd">6384586</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iae86c13d2edd4a3bb59c24847ec261c4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMjE5OTAyMzI2MTM5OA_ddba7c18-c1d9-454c-b8ab-5211302a2b18"
      unitRef="usd">6400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="iae86c13d2edd4a3bb59c24847ec261c4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNDk0NzgwMjMzNTkwMQ_3da4c273-4863-409b-9dbc-e3abc2d7f9f2"
      unitRef="usd">2300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="iae86c13d2edd4a3bb59c24847ec261c4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNDk0NzgwMjMzNTk0Mg_d0ac1316-46f4-4690-b4de-50ec5e268462"
      unitRef="usd">4100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i1bf6dd4ac05d40108e2514911c613b85_D20161101-20161130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMjQxMQ_241edaff-8277-4407-ba73-4f06b34081e9"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i1bf6dd4ac05d40108e2514911c613b85_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMjQ0OA_aef21c2b-4b80-4a19-b4a8-c7ddcbb4866e"
      unitRef="usd">900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ic73781ab99bd43f2bb632a84368ba389_D20161101-20161130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMjQ4Nw_80e3deed-a524-4946-8730-6c3aa31563ca"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ic73781ab99bd43f2bb632a84368ba389_D20161101-20161130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzA5OA_ccff8dd8-79a6-41a0-a399-e459cf0ea9a6"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i9a90c1c0e8b64d6ebbf750ff29642e7a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzIxNg_221e015b-1449-4784-8792-259e6f96e9a2"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i38e26d699b094a1ca3994c9d4c08e244_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzI3Ng_1dbbff5b-7491-4529-8516-832d1e4aaf26"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if4192a5594914fce8a1e18207ab24bd1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzQzMg_2219a51e-ef44-4ca2-aa1a-529b9449b0bf"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i390596c6353c4e4383db5ca0102868d7_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzU5Mg_424c4bbe-c594-424b-bdaf-ce444c616c7d"
      unitRef="usd">2600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <cpix:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i33b531a22e104cd8907be7f1309ea431_I20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDgxOQ_a5a40de3-9921-45b8-bf8b-1eec8761dcbe"
      unitRef="usd">13500000</cpix:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum
      contextRef="i33b531a22e104cd8907be7f1309ea431_I20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDgzNA_c3d63a95-30d4-40d4-b109-f4a43af6a061"
      unitRef="usd">3500000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected
      contextRef="i411fb7851cc645fda84082a006d9aae8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDg0OA_8ecc3e01-a958-43d6-9c05-e27561a4d142"
      unitRef="usd">1500000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected>
    <cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent
      contextRef="i8840d2d783664d03833988394492a1b2_I20220103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDg2Mg_b580aacd-cfbf-4efc-a573-bf1d960407b2"
      unitRef="number">0.10</cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i90ce8664b55e4a05a9829ae3b930adff_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDg2Nw_9e1b3607-b46e-42e2-a3e6-6f004a68a7fa"
      unitRef="usd">300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i90ce8664b55e4a05a9829ae3b930adff_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDg4MQ_2521a590-4b40-4c8c-9d79-373ed210da73"
      unitRef="usd">5200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:Goodwill
      contextRef="i90ce8664b55e4a05a9829ae3b930adff_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDkwOQ_1f0f0258-c009-4bc4-b696-42df154b3e00"
      unitRef="usd">1000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i90ce8664b55e4a05a9829ae3b930adff_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDkyMw_98edcd09-9f49-457a-8188-effe8c2afe0e"
      unitRef="usd">12100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i636282a040df4f679c7f36b32d67a813_D20220103-20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDkzOA_596359fa-e24a-4d51-a187-9c84b2a94718"
      unitRef="usd">1200000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i90ce8664b55e4a05a9829ae3b930adff_I20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDg5NQ_d42eb2ca-565a-4e8c-ba1b-b699925212f4"
      unitRef="usd">3900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i10cdce073f8047ab9cded3432889dbae_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDk1Mg_5c081507-b0aa-4217-8937-01767825cf83"
      unitRef="usd">3900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i10cdce073f8047ab9cded3432889dbae_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDk2Ng_dfa00e60-4ff9-4101-8711-f16b89543d5f"
      unitRef="usd">1300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i10cdce073f8047ab9cded3432889dbae_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDk4MA_9affe093-ffd0-4eb5-88f6-8e014298756e"
      unitRef="usd">2600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i882c40446970433c9806df95c94da0c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNDgwNA_493372a8-659e-4b6e-991f-8bbc484bd7b5"
      unitRef="usd">5000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <cpix:FinancialConsiderationPaymentPeriod
      contextRef="iad75b7bb8c1f44d99624874d167e93a3_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMTAxMQ_fcab91da-af88-4086-a883-1703a97994b1">P2Y</cpix:FinancialConsiderationPaymentPeriod>
    <cpix:FinancialConsiderationNumberOfInstallments
      contextRef="i973592a5bcc6433aaf22a683d9a22dd5_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMDk5NA_1ec1f0c0-0089-4fb0-989b-49794eb8002d"
      unitRef="installment">4</cpix:FinancialConsiderationNumberOfInstallments>
    <cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment
      contextRef="i973592a5bcc6433aaf22a683d9a22dd5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNDk4Mg_1aad7f7e-3d44-43a2-85f5-7f4e7ffc8f6a"
      unitRef="usd">3000000</cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment>
    <cpix:FinancialConsiderationNumberOfInstallments
      contextRef="i9c0e77e71ede43e88dd6fd578f76e2e6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfMzg0ODI5MDcxMTAxMg_fdce952e-4482-43d4-b9bd-413876deadb9"
      unitRef="installment">4</cpix:FinancialConsiderationNumberOfInstallments>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i703c37c87b3b4ae1a94069c964a3f5b7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNTAzOA_341b176c-3716-427e-a020-a4d6fbfd3f4c"
      unitRef="usd">2000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="if17ad389803849e8845be7075058d029_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RleHRyZWdpb246YWNmYjUwMmE0YjhmNDQyZjlkZGIxODdiYzYzZmYzODlfNTg0Mg_3659e092-0f92-4d67-ae7b-df0c3ac44f8a">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company did not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incur expenses associated with these payments from Clinigen. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i644ff4fff14b4f54ad5cdf6cc770dece_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjllYTY4NGEyNDc0MzQwZDg4ODQwNjExMTUwOTcxMzBhL3RhYmxlcmFuZ2U6OWVhNjg0YTI0NzQzNDBkODg4NDA2MTExNTA5NzEzMGFfMy01LTEtMS0yMzM3Mg_37660da1-e720-440b-b27a-0d3f909bae4e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c89fbd5ff1649de916ca18e3a139199_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjllYTY4NGEyNDc0MzQwZDg4ODQwNjExMTUwOTcxMzBhL3RhYmxlcmFuZ2U6OWVhNjg0YTI0NzQzNDBkODg4NDA2MTExNTA5NzEzMGFfMy03LTEtMS0yMzM3Mg_47f6dff7-ea4a-4e0f-9347-01f1570319b1"
      unitRef="usd">495410</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i644ff4fff14b4f54ad5cdf6cc770dece_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjllYTY4NGEyNDc0MzQwZDg4ODQwNjExMTUwOTcxMzBhL3RhYmxlcmFuZ2U6OWVhNjg0YTI0NzQzNDBkODg4NDA2MTExNTA5NzEzMGFfNi01LTEtMS0yMzM3Mg_1911ffd5-908c-4afc-b1ce-26adfadbf75a"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i2c89fbd5ff1649de916ca18e3a139199_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmExZDM2ZmMyYTMxMzQ0ZWZhNjc0ODVlYmE1ZjE2MWJmL3NlYzphMWQzNmZjMmEzMTM0NGVmYTY3NDg1ZWJhNWYxNjFiZl81NS9mcmFnOmFjZmI1MDJhNGI4ZjQ0MmY5ZGRiMTg3YmM2M2ZmMzg5L3RhYmxlOjllYTY4NGEyNDc0MzQwZDg4ODQwNjExMTUwOTcxMzBhL3RhYmxlcmFuZ2U6OWVhNjg0YTI0NzQzNDBkODg4NDA2MTExNTA5NzEzMGFfNi03LTEtMS0yMzM3Mg_aac22bd8-32a6-41f9-9317-bb53b8533c24"
      unitRef="usd">495410</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M*;)E*6H<M*X5M,'-%8L3L2+S?;:0J8NO06 Z>_@3(ZD+ L7=^Y@C<O<2K9F
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MC4Z1])!]>\M3L",3$C\3GL0%]&/0ZG!#*[,42)P[Q0Q/*= EEZ5I.D,>9*1
MXJ? (?W[C'=FC1.YD]"@(J5VRCM$*;2=X<R'!#)2'TG/2ODU;Z"U/R/E1\HB
M?LJZ%2V,@9EAN] @_5;O** -!X\[S6/S2I<0=B"ZMH2!)WGH2$'43T%?&30V
M_9>ZUX"FCIV:A:5#_2K14]@C)5$_)?4Y;Y ;P&=L2JF#AZ( D$53!1R"61:1
M9*:[H2,/4?\^#:R^;V&?(SMKB[H&XTO]C<"92-3>;2UABX&I97*'( U@)SW3
M!].CCY-^/GNA!W!EE5,3F[=H!GD>6[9W$1S)TB"9:0+H2''T51] 71\YC(::
MI,V%9NI#7NGD<.KB8+0L2<* 3C_5."1Q#!5\3I61^N@KJ,^%%^4*/; -;QK3
M"*\1]!]<.#]:4,?V, G"(,73IL,E&2813;)X1I&1%JF?%KV*,+WE\JH0VU^A
M$Q+'T#1.5; E29@1DI%HHL+JZ%"D9NW&G!5)9':#W1G#\'0XC[HQIS"3Y[?X
MXJX[51JGZ0ZY/N4M>$BBBJUARN!= I9MNW.C[D:)G3EZ>1!*B=I<;ED.M4T+
MP/NU@&ZMO]$+#*=WU_\#4$L#!!0    ( ,Z(K53&<4B6F@0   ,3   8
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MQ/IN'3#.!;4BF1W#AI02'KH#(7@G<_B\3C8KDOY&^TF673\C3KW"QV$$6$#
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MXVO^N#+@JX$>P'V:O.8O=$#WZ[AG_P-02P,$%     @ SHBM5-5W(\[& P
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MW8>[GS?$Y:^;#7%Y^P";]^N'VU-<_D\H^*U!J)6@QT2A@&5;@?0X2B5++M"
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MI?.5*+$-XC8;0),V/"SY-+?#L X0AL\YP?\^S#:3*V[)82P34%(L W8V6 F
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MKG.RKH#Q#QI)1R%X+_J]P\9!4H"%4;W0Q6F^4)S<LL>>&(<M:[O;VO9[P\W
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MTU5*U-I=5)M[NMZ,'P!<$"L64.ZK_,!8;U+II&92&RE<;N1?3S(P(6A3*F;
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MRX#KEZ$G_1A4CR1W?3#=V_@2G2O<&OK>3F,5DG7\*-VL-I_TQ_%+]EH\_G\
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M/AF'_7'#5X5+M_,-P<F"Z"X,+N0T&09!J#'W@4'PZP%/4>M Q#+N-YQ)'S(
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M#!T.WA\D8+ONV0T\-;%C+<AS_XN?%?]PT(8-O%X0^>T@!.A_8;/?4$L#!!0
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M<1TOP/.5M:&[X /Z+X,7_P-02P,$%     @ SHBM5&"!:!]> P  8P<  !D
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M!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R%5-]/VS 0_E=.$=)
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M,3^XTEQ1^1B+!:BR=2V5H#KD<CWYE_Y_ZCNVI:=F47,F3!O>51CQ0Z-5CL;
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MTN=F9]MVV$Z\J4,+VAA/#2T,2_J"0,L':']KC#]/F*#[)IG_ U!+ P04
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MJ:/HT3./[I[O\_(&)Q%)XG@>/N_':,(P3J,\F8UVW_%/1_[I6?XK;@:NK+I
MM0=*]QA$!QR/+9)9FN!HFF(V4LQ^+L13Y+*CK4_$\=@0)TF6X6F.^<@QO\CQ
MJB=YC1Q)1"VDV;7A%8=,"R.K^;JS="T8L@I))5W8M1+"W1$N+=/,V,FXY\>,
M<UP<QO[8BA"<Y=.RBE%6\9.W^U (K+60V8U+/XT2%=.3&HJ):QX7*4D/C^?8
M$&=908II';-1Q^SLDU\QJ2 17WKT.'K-P-'9P'SQI895-_09GLR&]0$P"(JN
ML516[E!_^Z4@&/_N*A8OW>T8C*93<C1Q+[,9SLAAA"8M9SG<X7@Z2'BOKN +
MR4!TKD(C5M=0LI&JD;(-5!?#RDYSRT'A)1WX8I:8,"'9+"E.T2>O],G_=BB5
MDPHI[Y(<\L/',F&9DB0!\P-=X5[EATJT\0V1@9?42=L7U7%V;+K>^E;C8/[>
M-6.^HWB%Z3LY*)D;+@T2K ;(Z#8'6KIOCOJ!55O?7ZR5A6[%?S;04#+M#&"]
M5LJ^#-P&8XNZ_ ]02P,$%     @ SHBM5.O(;AA; @  404  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&ULC53;;MLP#/T5PD\ML-6WI!L*QT"3=MB
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MCBBCLW<D2@\-/&RL:GT/;)6ECO++FF8>:F= ]SNE[&'C'$Q3-/\-4$L#!!0
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M'ES< S+1YP%"J$NN;X@Q\2'TA\F!:2)@;R)W:_UZD'!E.P_ 5#[@T>C U#[
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MEZJ) ZX-U/Z<,?DZT6U"VQ:._P!02P,$%     @ SHBM5//,_W+" @  OP<
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MJFP C"^E-!\=>XBW=_;D+U!+ P04    " #.B*U4L*NP 9D#  ":"P  &0
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MFF8NWR?\Y+ SO3%Q3A9*/;C@RW(21$X0""BM8V#X>H0I".&(4,;?EC/H/NF
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M9I[47;3'8IC%\7"8AX_]^ARFQ1%-\89V>7NBTTYT^B[1Y59KD)8(SA9<X &
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MD3)J]5&:KEJ_,JS:^NY9*8N]Z)<%3DO0+@#WUTK9H^$.:.9O^@=02P,$%
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M5L[\TIE6U=7XH^?[ENL,S=5NM5KL',NQ^OW&;H^MV[!U.]G.8D@6Z!F65&=
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M2S*IAT74$I;B)>J=C(-?JG10/@RXF%)+:8JS]9;KA=2*OS#-L:.Q):SG'.X
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MV%,214GB1@!S*X@B#(&G$4<P!: !0Z*H.P</SJ-@<TX%V]]'9K\ 4$L#!!0
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M   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V$UNPC 0AN&K1#X
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M>[9=DUJ5S<&?=?_ 9U]02P$"% ,4    " #.B*U4!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,Z(
MK50V"?19[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( ,Z(K5297)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ SHBM5*D1MV1'
M!0   !8  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( ,Z(K50,+E%;*08  )T7   8              "
M@8H-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #.B*U4
M'078N7\"  #0!@  &               @('I$P  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ SHBM5&(A4"C^!0  %1D  !@
M     ("!GA8  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M ,Z(K53<HIBVXP8  ,D;   8              " @=(<  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " #.B*U4QG%(EIH$   #$P  &
M            @('K(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ SHBM5+-&!'"3#P  *2<  !@              ("!NR@  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( ,Z(K535=R/.Q@,  %<(
M   8              " @80X  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " #.B*U4]RKDDUL'  "E$   &               @(& /
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ SHBM5 V;=65?
M!@  G@\  !D              ("!$40  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " #.B*U4K)$&4CH'  !^$0  &0
M@(&G2@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,Z(
MK53Q+CCN=@D  /08   9              " @1A2  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ SHBM5,XX(#47 P  S@8  !D
M         ("!Q5L  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " #.B*U4]@#"T>\#  " "   &0              @($37P  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( ,Z(K509/NC>^PT  - H
M   9              " @3EC  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ SHBM5"G*]BM "   )10  !D              ("!:W$
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #.B*U48(%H
M'UX#  !C!P  &0              @('B>0  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( ,Z(K51CIX[M% ,  "@&   9
M  " @7=]  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MSHBM5%W;Q6S0 @  ]@4  !D              ("!PH   'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " #.B*U4T>F4[0T$  #T"0  &0
M            @(')@P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( ,Z(K53M9/\5H ,  )\(   9              " @0V(  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ SHBM5.TGDDXF @
MH 0  !D              ("!Y(L  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " #.B*U4&^U:[7D#  "N"@  &0              @(%!
MC@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( ,Z(K53K
MR&X86P(  %$%   9              " @?&1  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ SHBM5/)9/J3D P  !!$  !D
M     ("!@Y0  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,Z(K51]%9!/8@(  / %   9              "
M@3FE  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ SHBM
M5 RXHU!% @  BP4  !D              ("!TJ<  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " #.B*U4HX?O8^(#  #]#@  &0
M        @(%.J@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( ,Z(K51S[)\S[@,  )P1   9              " @6>N  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ SHBM5$]MF!L3 @  $ 4
M !D              ("!C+(  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " #.B*U4LNJB0Z\&   6(   &0              @('6M
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( ,Z(K51L^;4'
MT0(  /<&   9              " @;R[  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ SHBM5%=OQP>C @  %@<  !D
M ("!Q+X  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #.
MB*U4=^I]TA$#   L$0  #0              @ &>P0  >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( ,Z(K527BKL<P    !,"   +              "  =K$
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,Z(K53?$3BD:@,  /,8   /
M          "  </%  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #.B*U4
MF3ZBA'P!  "6%@  &@              @ %:R0  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " #.B*U4JF<489@!   +%P  $P
M        @ $.RP  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     +0 M #(,
(  #7S      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>94</ContextCount>
  <ElementCount>199</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity</Role>
      <ShortName>Condensed Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Shareholders' Equity and Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</Role>
      <ShortName>Shareholders' Equity and Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127109 - Disclosure - Additions and Returns of Product Rights</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</Role>
      <ShortName>Additions and Returns of Product Rights</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - Additions and Returns of Product Rights (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables</Role>
      <ShortName>Additions and Returns of Product Rights (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails</Role>
      <ShortName>Organization and Basis of Presentation Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual</Role>
      <ShortName>Earnings (Loss) Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Leases - Lease Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases - Lease Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Leases - Rent Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails</Role>
      <ShortName>Leases - Rent Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity and Debt - Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Shareholders' Equity and Debt - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails</Role>
      <ShortName>Shareholders' Equity and Debt - Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Change in Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Dissolution Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cpix-20220331.htm">cpix-20220331.htm</File>
    <File>a2022q1-exhibit311.htm</File>
    <File>a2022q1-exhibit312.htm</File>
    <File>a2022q1-exhibit321.htm</File>
    <File>ajkazimi-2022.htm</File>
    <File>cpix-20220331.xsd</File>
    <File>cpix-20220331_cal.xml</File>
    <File>cpix-20220331_def.xml</File>
    <File>cpix-20220331_lab.xml</File>
    <File>cpix-20220331_pre.xml</File>
    <File>jamesherman-2022.htm</File>
    <File>johnhamm-2022.htm</File>
    <File>leopavliv-2022.htm</File>
    <File>pinnaclebank-cpiamend7tolo.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="370">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>65
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 94,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 318,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 20,
   "keyStandard": 179,
   "memberCustom": 18,
   "memberStandard": 16,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Inventories",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Leases",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Shareholders' Equity and Debt",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt",
     "shortName": "Shareholders' Equity and Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Income Taxes",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Collaborative Agreements",
     "role": "http://www.cumberlandpharma.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127109 - Disclosure - Additions and Returns of Product Rights",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights",
     "shortName": "Additions and Returns of Product Rights",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Revenues (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Inventories (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Leases (Tables)",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - Additions and Returns of Product Rights (Tables)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables",
     "shortName": "Additions and Returns of Product Rights (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails",
     "shortName": "Organization and Basis of Presentation Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Earnings (Loss) Per Share (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual",
     "shortName": "Earnings (Loss) Per Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Revenues (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ie877302447534894b2d5513d38b31fbb_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Inventories (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Leases - Lease Position (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases - Lease Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Leases - Rent Expense (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails",
     "shortName": "Leases - Rent Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Shareholders' Equity and Debt - Shareholders' Equity (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails",
     "shortName": "Shareholders' Equity and Debt - Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "i61780641954246b1a1327370732b7ffa_D20211227-20211227",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Shareholders' Equity and Debt - Debt (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
     "shortName": "Shareholders' Equity and Debt - Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "i42ffe35d0bb445bca3edfba518ae51db_I20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ieb034453f7ac43e19ed1e1d5524e4104_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
     "shortName": "Additions and Returns of Product Rights - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "iad75b7bb8c1f44d99624874d167e93a3_D20190101-20191231",
      "decimals": null,
      "lang": "en-US",
      "name": "cpix:FinancialConsiderationPaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "i0daea624eb8d4452969618186921bc8f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
     "shortName": "Additions and Returns of Product Rights - Change in Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "i93eb9b844c7244b59e4acf2535ce2a3d_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
     "shortName": "Additions and Returns of Product Rights - Dissolution Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "i644ff4fff14b4f54ad5cdf6cc770dece_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ifb20159ba2734e579f3392f2e79daeab_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statement of Equity",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
     "shortName": "Condensed Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "ifb20159ba2734e579f3392f2e79daeab_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Revenues",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20220331.htm",
      "contextRef": "if17ad389803849e8845be7075058d029_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 36,
   "tag": {
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acetadote",
        "label": "Acetadote [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Lease Position"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_BroadwestLeaseFiveYearRenewalOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Broadwest Lease, Five Year Renewal Option",
        "label": "Broadwest Lease, Five Year Renewal Option [Member]",
        "terseLabel": "Broadwest Lease, Five Year Renewal Option"
       }
      }
     },
     "localname": "BroadwestLeaseFiveYearRenewalOptionMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Caldolor",
        "label": "Caldolor [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ClinigenHealthcareLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinigen Healthcare Limited",
        "label": "Clinigen Healthcare Limited [Member]",
        "terseLabel": "Clinigen"
       }
      }
     },
     "localname": "ClinigenHealthcareLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected",
        "terseLabel": "Sales milestone payments, expected"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "terseLabel": "Sales milestone payments, maximum"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "label": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "terseLabel": "Tiered royalty, percent"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_EquityAndDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity and Debt [Abstract]",
        "label": "Equity and Debt [Abstract]"
       }
      }
     },
     "localname": "EquityAndDebtAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "cpix_FifthAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fifth Amendment",
        "label": "Fifth Amendment [Member]",
        "terseLabel": "Fifth Amendment"
       }
      }
     },
     "localname": "FifthAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_FinancialConsiderationNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Consideration, Number of Installments",
        "label": "Financial Consideration, Number of Installments",
        "terseLabel": "Financial consideration, number of installments"
       }
      }
     },
     "localname": "FinancialConsiderationNumberOfInstallments",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_FinancialConsiderationPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Consideration, Payment Period",
        "label": "Financial Consideration, Payment Period",
        "terseLabel": "Financial consideration, payment period"
       }
      }
     },
     "localname": "FinancialConsiderationPaymentPeriod",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cpix_IfetrobanClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ifetroban Clinical",
        "label": "Ifetroban Clinical [Member]",
        "terseLabel": "Ifetroban Clinical"
       }
      }
     },
     "localname": "IfetrobanClinicalMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Stock Options",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "label": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "negatedTerseLabel": "Decrease (increase) in cash surrender value of life insurance policies over premiums paid"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_IncreaseDecreaseInCurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IncreaseDecreaseInCurrentOperatingLiabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInCurrentOperatingLiabilities",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kristalose",
        "label": "Kristalose [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_KyowaKirinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyowa Kirin",
        "label": "Kyowa Kirin [Member]",
        "terseLabel": "Kyowa Kirin"
       }
      }
     },
     "localname": "KyowaKirinMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LesseeOperatingLeaseLeasedArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Leased Area",
        "label": "Lessee, Operating Lease, Leased Area",
        "terseLabel": "Leased area"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeasedArea",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "cpix_LesseeOperatingLeaseNumberOfRenewalTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Terms",
        "label": "Lessee, Operating Lease, Number Of Renewal Terms",
        "terseLabel": "Number of renewal terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalTerms",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Additional Borrowing Capacity",
        "label": "Line Of Credit Facility, Additional Borrowing Capacity",
        "terseLabel": "Additional borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_MethotrexateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Methotrexate [Member]",
        "label": "Methotrexate [Member]",
        "terseLabel": "Methotrexate"
       }
      }
     },
     "localname": "MethotrexateMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omeclamox-Pak",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherLongTermObligationsExcludingCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long Term Obligations, Excluding Current Portion",
        "label": "Other Long Term Obligations, Excluding Current Portion",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLongTermObligationsExcludingCurrentPortion",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products",
        "label": "Other Products [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Bank",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Intangible Assets, Installment Payment",
        "label": "Proceeds from Sale of Intangible Assets, Installment Payment",
        "terseLabel": "Financial consideration received in exchange for product license rights, installment payments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssetsInstallmentPayment",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products.",
        "label": "Products [Abstract]",
        "verboseLabel": "Products:"
       }
      }
     },
     "localname": "ProductsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_RediTrexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RediTrex",
        "label": "RediTrex [Member]",
        "terseLabel": "RediTrex"
       }
      }
     },
     "localname": "RediTrexMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_SancusoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sancuso",
        "label": "Sancuso [Member]",
        "terseLabel": "Sancuso"
       }
      }
     },
     "localname": "SancusoMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "label": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "terseLabel": "Schedule of Rent Expense and Sublease Income"
       }
      }
     },
     "localname": "ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ShareholdersEquityTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholders Equity.",
        "label": "Shareholders Equity (Textual) [Abstract]",
        "verboseLabel": "Shareholders' Equity (Textual) [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityTextualAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Percentage of tiered royalty payments (up to)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_TieredRoyaltyPaymentsThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered Royalty Payments, Threshold",
        "label": "Tiered Royalty Payments, Threshold",
        "terseLabel": "Tiered royalty payment, threshold"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsThreshold",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaprisol",
        "label": "Vaprisol [Member]",
        "terseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_WinHealthInvestmentSingaporeLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WinHealth Investment (Singapore) Ltd",
        "label": "WinHealth Investment (Singapore) Ltd [Member]",
        "terseLabel": "WinHealth"
       }
      }
     },
     "localname": "WinHealthInvestmentSingaporeLtdMember",
     "nsuri": "http://www.cumberlandpharma.com/20220331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r66",
      "r68",
      "r106",
      "r107",
      "r217",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r216",
      "r235",
      "r256",
      "r258",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r400",
      "r402",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r216",
      "r235",
      "r256",
      "r258",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r400",
      "r402",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficeBuildingMember": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]",
        "terseLabel": "Wet Laboratory and Office Space"
       }
      }
     },
     "localname": "OfficeBuildingMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r174",
      "r252",
      "r253",
      "r367",
      "r399",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r174",
      "r252",
      "r253",
      "r367",
      "r399",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r216",
      "r235",
      "r254",
      "r256",
      "r258",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r400",
      "r402",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r216",
      "r235",
      "r254",
      "r256",
      "r258",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r400",
      "r402",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r67",
      "r68",
      "r106",
      "r107",
      "r217",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r179",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r51",
      "r358"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r24",
      "r37",
      "r180",
      "r181"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r80",
      "r97",
      "r229",
      "r340"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Decrease (increase) in noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r97",
      "r190",
      "r192"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Square feet of office space"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r103",
      "r154",
      "r164",
      "r170",
      "r183",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r315",
      "r320",
      "r330",
      "r356",
      "r358",
      "r371",
      "r386"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r65",
      "r103",
      "r183",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r315",
      "r320",
      "r330",
      "r356",
      "r358"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r261",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r255",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r255",
      "r257",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r297",
      "r299",
      "r300",
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liability recorded"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r96",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration included in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r298",
      "r301",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Additional liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r298",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r298",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Noncurrent portion of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ADDITIONS AND RETURN OF PRODUCT RIGHTS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Net intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r22",
      "r47",
      "r99"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r93",
      "r99",
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r93",
      "r331"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r15",
      "r93"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r308",
      "r309",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATIVE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r58",
      "r197",
      "r376",
      "r391"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r36",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, End of Period (in shares)",
        "periodStartLabel": "Balance, Beginning of Period (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r36",
      "r358"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r216",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r82",
      "r367"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r102",
      "r108",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r341",
      "r372",
      "r373",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r213",
      "r230",
      "r231",
      "r339",
      "r341",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Convertible note"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r56",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate spread"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r57",
      "r102",
      "r108",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r97",
      "r152"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r14",
      "r77",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "terseLabel": "Discontinued operations income"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r79",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r122",
      "r124",
      "r127",
      "r128",
      "r129",
      "r133",
      "r134",
      "r328",
      "r329",
      "r381",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r79",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r124",
      "r127",
      "r128",
      "r129",
      "r133",
      "r134",
      "r328",
      "r329",
      "r381",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r71",
      "r72",
      "r73",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r136",
      "r184",
      "r248",
      "r249",
      "r267",
      "r268",
      "r269",
      "r283",
      "r284",
      "r327",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r403",
      "r404",
      "r405",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
        "negatedLabel": "Increase (decrease) in non-cash contingent consideration"
       }
      }
     },
     "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r191",
      "r368"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r188",
      "r189",
      "r358",
      "r370"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r76",
      "r154",
      "r163",
      "r166",
      "r169",
      "r172",
      "r369",
      "r378",
      "r383",
      "r397"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r103",
      "r112",
      "r154",
      "r163",
      "r166",
      "r169",
      "r172",
      "r183",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r314",
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) from continuing operations",
        "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r74",
      "r79",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r124",
      "r127",
      "r128",
      "r329",
      "r377",
      "r379",
      "r381",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r74",
      "r79",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r124",
      "r127",
      "r128",
      "r129",
      "r329",
      "r381",
      "r392",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r17",
      "r20",
      "r289",
      "r393"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r14",
      "r17",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r77",
      "r79",
      "r125",
      "r127",
      "r128",
      "r381",
      "r393",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r125",
      "r127",
      "r128",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r276",
      "r277",
      "r279",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r274",
      "r278",
      "r280",
      "r285",
      "r287",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r105",
      "r120",
      "r121",
      "r153",
      "r273",
      "r286",
      "r288",
      "r398"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r75",
      "r151",
      "r338",
      "r340",
      "r382"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r42",
      "r186"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r23",
      "r62",
      "r358"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Total inventories classified as current",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "less non-current inventories",
        "terseLabel": "Non-current inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r43",
      "r186"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r62",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Obsolescence and discontinuance losses"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r84",
      "r150"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Initial investment in joint ventures"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Future minimum sublease income under noncancelable operating subleases"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r53",
      "r103",
      "r165",
      "r183",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r316",
      "r320",
      "r321",
      "r330",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r41",
      "r103",
      "r183",
      "r330",
      "r358",
      "r375",
      "r389"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r55",
      "r103",
      "r183",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r316",
      "r320",
      "r321",
      "r330",
      "r356",
      "r357",
      "r358"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r52",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Current borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r52",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r52",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r57",
      "r198",
      "r199"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r57",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Loss Contingency Accrual [Roll Forward]",
        "terseLabel": "Loss Contingency Accrual [Roll Forward]"
       }
      }
     },
     "localname": "LossContingencyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r60",
      "r103",
      "r183",
      "r201",
      "r205",
      "r206",
      "r207",
      "r210",
      "r211",
      "r330",
      "r374",
      "r388"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r93",
      "r95",
      "r98"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r93",
      "r95",
      "r98"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by (used in) operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r20",
      "r69",
      "r70",
      "r73",
      "r78",
      "r98",
      "r103",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r126",
      "r154",
      "r163",
      "r166",
      "r169",
      "r172",
      "r183",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r329",
      "r330",
      "r380",
      "r394"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to common shareholders",
        "totalLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r70",
      "r73",
      "r120",
      "r121",
      "r318",
      "r323"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net (income) loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r249",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r154",
      "r163",
      "r166",
      "r169",
      "r172"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Maturity of Lease Liabilities at March 31, 2022"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease noncurrent liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r350",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Present value of remaining lease payments, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r349",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r21",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r64",
      "r358"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r28",
      "r54",
      "r358"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Other Payments to Acquire Businesses"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Cash payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "negatedLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r86",
      "r303"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Cash paid for acquisitions",
        "terseLabel": "Payment to acquire business upon closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Note receivable investment funding"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Financial consideration received in exchange for product license rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r20",
      "r69",
      "r70",
      "r73",
      "r92",
      "r103",
      "r112",
      "r120",
      "r121",
      "r154",
      "r163",
      "r166",
      "r169",
      "r172",
      "r183",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r314",
      "r317",
      "r319",
      "r323",
      "r324",
      "r329",
      "r330",
      "r383"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r49",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r30",
      "r31",
      "r194",
      "r358",
      "r384",
      "r390"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r30",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r272",
      "r366",
      "r412"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r38",
      "r249",
      "r270",
      "r358",
      "r387",
      "r406",
      "r407"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings (deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r184",
      "r267",
      "r268",
      "r269",
      "r283",
      "r284",
      "r327",
      "r403",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r148",
      "r149",
      "r162",
      "r167",
      "r168",
      "r174",
      "r175",
      "r177",
      "r251",
      "r252",
      "r367"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Net Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r2",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r16",
      "r18",
      "r19",
      "r20",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Dissolution Payments"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of numerator and denominator"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of net revenue"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r29",
      "r44",
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r261",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r144",
      "r146",
      "r147",
      "r154",
      "r155",
      "r166",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Restricted stock awards, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted in period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r259",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r59",
      "r71",
      "r72",
      "r73",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r136",
      "r184",
      "r248",
      "r249",
      "r267",
      "r268",
      "r269",
      "r283",
      "r284",
      "r327",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r403",
      "r404",
      "r405",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r136",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r35",
      "r36",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Unvested restricted shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r35",
      "r36",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r59",
      "r248",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Vested common stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r35",
      "r36",
      "r249",
      "r260",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "verboseLabel": "Repurchase outstanding common shares"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Common shares left to repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r35",
      "r36",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of shares (in shares)",
        "terseLabel": "Repurchase of shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r35",
      "r36",
      "r248",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common shares",
        "negatedTerseLabel": "Repurchase of shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r36",
      "r39",
      "r40",
      "r103",
      "r182",
      "r183",
      "r330",
      "r358"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r72",
      "r103",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r183",
      "r184",
      "r249",
      "r267",
      "r268",
      "r269",
      "r283",
      "r284",
      "r312",
      "r313",
      "r322",
      "r327",
      "r330",
      "r332",
      "r333",
      "r337",
      "r404",
      "r405",
      "r419"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, End of Period",
        "periodStartLabel": "Balance, Beginning of Period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r234",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY AND DEBT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r348",
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive effect of other securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r123",
      "r129"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "- diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r122",
      "r129"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "- basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11374-113907"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r413": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r414": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r415": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r416": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r417": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r418": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001628280-22-014372-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-014372-xbrl.zip
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M(OTK%F1X)$C.W<YM<[ZW/*]W)ANOO:\(SM77YE/I?C30<4]RIFSC1?HE>JT
M\9=5Z @@G)G-*G>\>Y]_NI\!V!\D'/\?4$L#!!0    ( ,Z(K52W]+P3>0@
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MGK^4.@MV*>G;&E@\Z4695)F0$NR)J42'A']+>RPL,)/_)"CLQ)#M>0WAY@_
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M;67)_T>O!$&'\W:)06-K++ZS!+SAIH[IO/+OA_JH"FJ"H[R= TQ74N<!/E"
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M;09;8U,:CG.HM08H!4 I9@X8$AA03H@HCF \TDNK' ,D>!S!U /L8+ICPF
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M,N"-A4I'E'22%"<R,\#6>YGH(B/NQTY::G:0G0R"E*6A_-10QH(OWA.*M82
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MV"XR/XY0J2O-^"Z^HJV-N-W5"7P3E'43I[SSUTK497#G@5XK GY\2G=$ZB(
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ML#3\\R'?WGAE5NZ\4!90I2/R(2* "4:G4#]'G#J)C'A8:?B%&]TW[_:T7S'
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M03%*!DR(IBSMMTX5TXIHIZVD+@1AJ!(Y1B&$2XPJ&$9=C6$4D\:A0!S0"DM
MG?+ 8"V!P((%$P2B:2T\%E5(856F]::%P:B?<,)1)"<VUO\8UI[KS"EY(W-
M8M<&&Z;U*MWHFT>S-DU?K;1]_U[_!#^N%^X<*^8:4*=$^D8=OW/=[W7?'SJ)
M)8Y."T?KNQ-<CRBFG(XTCUB% ?58 Q.A$T08A80[(:52^09 G+ J)4_F>C^
MAEEQO8?Z^*_>EJ=$CDI;?B9;'N=$7%@D B& :X< 3<0H>FH6!&J(DDX:FFIO
M\*H4HDKHDRG1%$WY]83)MMIGT0PZW<Q/!,8>!$0/=4#G&HBF1"I&?7T9\:<$
MGJD!3S9!(B S6 C,@+%4 8I#)!%:!( =(BEFI!2V2ZLJ H^L<@D+Y(M->S;H
MU9ONE#A$:;HS,MUQSN %$M)9#12F!E!A+5!228 <9<YH U$J92&K%$?SE9/[
M?Q8VC+) 48F/77^B,Y?/KG7R?</MK>G3,CHQ8R*QG3I]+>_KTH^9-B9-SC\1
M&RRBW  MB :4>P=4\ 1H@RS63###Z=(JJ3*.JC!5V2F,'U.&)(I))TH#GJD!
MCY,**"GUT@L (_<'5%H.)%48Z C!AG.G4%I21:J$J*KBJD &/,U !!%%)A6-
M3E\WIT$D'I/DMI@@-:TYD!*?9H%/V^L3!,-:ZCGB#"!I/: T&* 4\@ K**//
M@P61;FF5LBJAJ*J>SC >:R)S%,UXQ68_K>F2TNQG9/;CM 01:S@TT<Z-)H!&
ME@(,@U&CD7(06\V89KG9<RFK$)%Y,?N%SQ:O=]I@Q%2R)TZ@O JW:>H3*)VV
M+0%JR@ UF8SAH4K!#0D,%S+Z3=Q'OTD'P**T*-7(.F>65A&L,D6J0CTY&EM&
M/HIKPE.?2"E->!8F/)&#$9CF4## E&& <AZ 9@$"#[WA3@<7J$Q3H9#**N-%
MBET^TX+#EYQ&Z9S$MESF\RAI@=))*@CPZ_F=KV(^=TI,8M3W'YNZW5]KN\U1
M]Y?SN]/,DV^L)2P:T(KCVE7]:NNK"DY:R3%00EA 62! >Y)0B4MM"3)Q:(E.
M#U15E%8@%V9ZM\S,*":A*"WYV2SY\K8E,RIQ@) #%7D$H)Y;H(B70'CM.7$F
M6CJ*EDQQRM4ND"4O?'ABJ]W7[<,LE6D9S*.4:T:>@U.\R^(C_(?LS+OO$AA$
M4TLLFBH6;4ZP"J&1-5&.P!LK 36. TVL!LQR:01G2G&SM$IHE0I5):Q(N>9E
MI**8Q*(TYV<TYS%JH2%42D@)M(B> @UIL3]$$GCN+'30(1KTTBHF5<6221=I
M%=C"ARW>=SKN/&LVRQC%C/G$J*-+J)D>U&Q-, <*G97>>\ X$8!JZ8"!D@'I
MXU@!N2$TU<]%545P58HBK=LO(Q+%) ZEW<[$;L<H@H/0TV T"(Q 0-.TI)&8
M "$5D5%TDI/(^*7$U:A?!;+:A8\^;)_X5*V\?5AI>MWSE;Q/0"> TYXO%X@\
MTP*1D0P^)!'LI+9LA[W>P'TI<6EZN%2;X!,L0I$27 +N98BN"_3 1*$"C(EP
M!"*++5Y:%1Q5D2C2=&L9AB@FFRA-^?E,>7R"(S@?HI" "Q8!ZJ0'F@H"HHII
M@25R@;-2)5Z52DC-H-.!@<"I!M2J "2F''AL0OS9&>-D\A8AIE5\!^\L$. O
M?* J7V0WA95$BSU,37])<IG9-PLL^C3!-+&,\H%2 ,:@ !3G<UXL $$"E<1*
M)3E*JQJ1D%7)IK5HJ(Q<%="(I[\LN33B&1GQ&*$@SCJ-(Y? 7$1W$::9+J<$
M\$18HX.$4H5DQ!2IJH*R0$8\S7HG\[ T^6XB\;.W?=IZQ#DNV_WH]U\8,)[J
M\NL2?:>'OGL3% H9AY3# @3A::107J>%U_&30P%;@FP<,Y=6%:]R):H(3BMM
MJ# +KQ_3G@?O25 BWVM%OJFN0"^1;ZK(-SY]JIB103*@D"" !HF!]IR#$#U(
M%$'10J^75B6M4J:J0CV9>#X7\KV&;>H^;*V]W?JPU=C:W,WW1=W\M+?5V)_2
MMG4D=KSKG*;D\0+O6_?05B[\;/MHX[IFIDW6S/J9+W>O6X"RW-<;?YSHRU2Q
MOMRT[I5L"#7E_4L^#M2GK.8S=4IU..%,$NI(U",/.*,(4&M"I%08 \NYT1IQ
M01A?6D6H2JFH,EBD)7'E-G4E*CWC3BPE*LT0E<8S%J@T$AD"O#$44*HHD 92
M8(-RT"!N/1:I  BGL*H*M1?"ZRFH/IXR:R=)?9DR^ZPILQ^&/7]98M34,>K;
M9!@>:28MD4! )2-S"@I(*@3P" :&""',J)0SRZM43BL25>;,%M"69Y(@6=KR
M3&UYC&]0X:RW4 %EK /400ZT,1P0I@Q65%F)?:D3KTLGHD)8$T=FX*G3@&HG
M@7*, &.<,#(@([%)TZR1A=ZQ)J) @/]Z I#;M_;U>2H1?15)>-/,I/WPO<-+
MA)HV0AU/5J5S, H&<P&TBZXR118"$ZDG4"(X+Z+X#(JC%L)50DF5+F+LKK3C
M6233EG8\8SL>8QK<1VLU#@$GJ 541,ZA(R,%UE F.*)&^7S[0,YEE<!I5=0O
M6K1K'M)IIQSC>L7[?DR)=Y10-4NHFBQ9YY45P43*8;A/-:XT! KR "A'P3&H
M*#=N:173*F.B2N8G ^L%@F*OV/BG1%9*XY^Q\8_SE.""%T$#!FTJRT\QD,AR
M8"27C%')5!#1WU!5+&15\2=/RRU8^N7+D9<=?]9IGN53=?%8I1,JMNM=5E;L
MGSD]Z;0/&[[;^A#;LAW6\TXO,6IZ&#59&4\$*1W4$A@61/2E4H4M;S&(PPKS
MGE"I4<0H#%.!K8(5V2IC(@6E&:41S]J(QXB&I] BQ220-K(-*D7D&%8[@#@/
MQ$(O?,"1:+ "&O'"Y^Z/I_VTK]?<EYD_+Y_Y4U9 F 5"31;,,TI8RUU:?IL0
M*C@+XD!# 5:8"8L("=Y&FH&K I4;#"ZP-<\VSZ.TYAE9\WCZ#T72"(&!#SX
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M[_,+Y;S!\X+TM\E92*\00E:#("0$E',-I$E;UROA+;/&&)UF(445R2*YN65
MJW DJ[3W0MK[&"DS+&"ML07$I.W566! "R%!E+UPU'O*.%I:Q;B*RLT&BQ'6
MFB!=\5@K&G/O2'?]4:<9^>[<\JW9IG?<)=@7Q>/_GMDT^R/LZ=5&^FZ-1.4H
M,[51YGBRIJNCPGJ!&! D_J&(>Z "-B!2"R&%04[BD*__E*R*V2O*;2L![W4
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M5%#&#/PO,BS3RF)*TUA4[G63IG$3';SBT(,KR?\S6R"]#WIT^UW$RWY6P$K
MU,ZK.<JDC8F>,(6 )PF@3%(CHXQ%-NA"8N^,UZHY*N 9*/>B:<;ME;LA(G?2
M\%DB@J5):0Y /S0M$%<8E#L6#EE98* F(DA!UUYP+=J<X"72\&<<<:I"DZYW
MR<&BMV(G=]^>NWS0MA1QG5^?(@=W=$9I;-_U^NF#C:E:R0>]G5XW-;3?ZT '
M#[?2^D 8#!LX7!@<[L\1'FX*S*FSJ(A< ASR@ R6%K$ 'X.7YD24"XT1K<3.
M_@9&'H0B-3"RJC RRZJDMZZP0B&&"_";HF!(%^"34J^QB: [0>NU%TS@MN1+
M?SS(\XGY;/@OH\&PRH(:]EK] 'KCRDYH=6_ P=(WT_TNK26?]'O?RI2P8<\6
MOYB\+.O%][XDS.0RSYK-< (SI<S2;YFN;YGC!,,_J@_"]Y.4;G<79KZ"AO,1
MXX;3XH#?.R%;Q*[?F))*8_P69OPN66>E.$1>8(1I*E)O"X84*PH4)/=:.NID
M2#LIVD"-P/S=>2/%\BVV-KI]7V'#1K<?6+=GB:U5U'$K!0J4IE4!3Y#%A*&
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M2' LI-/ ?:U;>T&+ME;SU5,?)=6T22E?OJ2M1K>70K=GN"R+7E)24"25E*F
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M=6$'D6R;OCL:GT)"[K+V^M/3QI])V==+EVP]$]B&**47DJ<=LX9C89UDP<9
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MS&LEBL@U=Y8Z;!CQO[;M5R3&ONOW8CG\"\"LL>8+L^;[<\G_@12>8$]1875
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MM"2/N>9Y+ORR\UQ^FM%2_#2AI4E(FN$+Q2HF)*W&V3[TWL_V>5VOT+P+_7U
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M-E<WY"'WI^K/,6Q1E["X#BFY[ADC3])M>J"HQE6XU:#5XM!J:XZ8%-07-)
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MN/@@Y/J(5:VZ2M@3HS-(7QE"D\:VW&4^"/ 2.^%[-H =8UL@)I@G:<:.C?D
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MZ&+ZP/8/I^.,Z=,+(>04VJH#_^T+3FJ.O84RNQ=#\S5%E(:=R0+%S,!/!YW
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M^I#<X2_*_QM,"&P?VP7\R5F(GXW_\^(HB5^"'E@FHLS21*E8<\)#"WK :D5
MKW,2IF&4*/"!+#82"\-F0K^;4VU#*?Y\-_/C6G2;S?PHFWG)SN=49$D2$F.-
M!:/.&)(Q&I,@B$VD%4MLFFRDXE>3B@QTL\EH1"Q+ >=C(4FFK2"!E/"&I29,
M C#U@V9 XQ?<$/#%)  [OOGO.-V:/RC_E9F.-X3&#V>.5Y7+L_B\0>6'0N45
M/;EME(51Q"@)=<@(3S-+!,L442D/12+2*+3QJ]?PR\JLH9M1^-G1O&^@; -E
M/\[LW$#9XT+94@ID0EE,-2,TI<A;PR01249)Q"(ATQ@\#YNZ%,@H;<8I>SE@
MME9FX[.CF=J]0(+6FIQQRMPC3X;&L?0U&VK<'WMZ]H8=C\9#T^CG@[P_[B/I
MYH1 L>@;V*4PO[Y)HQPHXRD*IUR,]<>150.LVG*!@^J_'MU^(2OY-HKAO,OY
M=\4EV"G>F -/NJ#7@X3X94+"=U  ?+IH;1^+++962D$X"P+,<U=$!FE*M!"1
MB+*8J\0B-]L*"BJ0Z)YCM*PY-S+CZ41'7? ,3[I32M&R809.3A>(B-U79PE:
MW\W+Z (_Y"TB6MWJ-\<)5+-$%<.5[(&.&M9<*&Q,BG0; T\K\KMC55U1^#_M
MPC#+<_Z([!4WD<I,E%U+PG3!O[\ZEP7;WSZ.,\%B&07$"@QR2QL3L"500?$P
MIB*B*DB6N"Q>3$)ZDFQ%T6/D>"?!]3=]UCG>UX=ZGK2/R'4)SWZC(M8L98(O
M,YDNH,[3Y$7_B+C9ZMF:GOGZ1AYWRHE^^;P!#Y43']YQ4GZ^LZX'.KB^40?7
M%J>G =9(_?<N1YORR/']_O3>:+_]M=W_&+6O_CD%K7W5OOIXT0H_@A>Y?=G:
M>==O]3^=MT_;I_N?C\)%;_0H_!A^V?D*GFPK@C'"V':OONST\M;.WGGK,]RG
MLPV>;BOZ<OK%MI9[9$<&5I:EEI@(V:LR1E'9)T0'1H2PK('"0["$!4T1IO?R
M11\W7^E[DW>>-8*Q34K.SX)L.V/3AAMWSDWOFVDYXM4-KCT8KBUGZH2AD"I.
M0L(CKN%'&I),!XQ$@>6!4/"J:QX>-OF#\79L4&W=X]R%F,13H]S&LOLA^+?!
MNX?"N_9R<5;&=*!X'!!%LPS35A01*K1$*I%2GL;2)M&KUR)D318LYZT\XX3T
M%Y_ @MOCC\9>U5'H87W2#3Y]+SY]&DR;=.VZ4/9V'__:@-6#@=6RTQDP$X4R
M581&VA+.4DF$E(PPHT7 90 0!4XGXTUZ5ZS:V&!K;,&_%QN*+?6(>WI*S5\R
MK>51IV:C%M9*L]X _X,!_[)7GNI0P+*E8)M2<,V%8D3*0!&;Q%D6,6DM9_=-
MXWO,S?,P*3&+#;[O1/[%GU/2S &J#W-Q9@:^8Q2V4#T9N,:8KANF:Q8";ROL
M?37;8ZIJTN:[(KNVE[ZW2]5NIFHO4\(G7)?D'LQLAAVS,$,"'G(H'?TS#@@;
M@\*=);8#447_K' =0. V)W#%(5P1TR*DQBP(_)[+WJE&O'5C[YKO[99QJ+I&
MCWNFP.Y%HUU_2QC,897\L^=2A3;9!A^/K0DT%881HQ68@9I3(C*MB6:!TC&7
M6D6IQ_Y\,#9Z&S&9R5 9*S.KTI K;44BDBBU(E-!F-B +68GS$DJBL1BRM9R
MEXK%;7ISCYC5NU6L.ASV6JYZ'M_(UBW[K<_T@G(LHF0K9.S!<RR"K3A)7@[I
MW\M("'F($OOTA7+&=;I#8ZH.>)A8!WIJDCYREU2)QZ$KN-8JN24'XQE.])J)
M&&L]\2\W<P_#9/AB A.SROHI0A"_0"CAYPP)W,MF7SLV4-GPOT!DX/3H_*C3
M[1Y]/@#;_4M^=/J1?^E\XNW3[?#HZJ^O7SI[8?OSI_/6SJ>+96+P-]W]]^^Z
M7]Y_O/S2_RMO[W1[[<Y)V-K!<1_T6J=']$MG^[S=>;<J#TF;-!3*1,0B'3B/
M*&8>QX+01($SH$(64 F0**)F&M^U)N8%4&MLD.DG12:6,I[8)#(\ .O=Q*GB
M)M-QQ(S)N*0>F6B-3'2#3$^.3(OU>@R4"!510$PJ#.$BXT10'A!KLE"IA-E4
M&>3\29HLC9X1,JTF=*/1#V=TFS')%Z*O=[3M'_>>/[UU?3@?^7IV9WR;P[P5
M<_#3*,*'-M'GP^D;#?A0&G %^88*4B,C&8,&C"CA-DU)EM*4)&#*A#(VFG'^
MZC6-:5,$_$><VCW4\=P&]3:H][+,_PWJ/1KJ+=$#AC01H98DUEH1'AI%,A4&
M)$X,3U2H+#,64"\1S>#.E5%/BGI+20FS)Y*S5?KSK\\<?5:[@>-AXEE1YOB!
M/X;&<V1,SQ#_-5]'7#U5,/V*S,JB-QY=_Y4?7WJ\.M^!!@O5Q#,_<;AN?TFJ
M66Q5*!D%A6BLC!,N(I/)R()NS.PQCU_57^H.IT[-B2'9T,BO1%IXPC]D[UQ>
MEJ_^/7_8G _J$468"7+=A-UX*$U#I[;\@V3#?[]>]5 S%X/94@16 &7ZCW+<
MATM=_KE&A[H??%CB5NBW^/?'RNJ88.^H4%^[10]V:+G[OV-'R3DR.WFI>D4Y
M'CZ;;(YV7N,M\A!]O&QU]B[W._]TX3ZT%>Y%7W;>Y*W.+@6<HT=7GZ(CP-/%
M;(Y6IP=XN7?1.MV+VI]WK]H[GZZ.3GM?6^_AM<ZGJ];5/Z?M3J_;[G1MZ^H$
MQKT7M7;416MG.VJ='\<VX=:HA!B&";XFR B8D)S(6&29U%0+H1<S.R0/0Q&D
M-&*!X#P6:2A2QA0+I3(6OKR8V7'XG^V#W?_L?]C9/3C\O_]' %K_V=C]^&FO
M<]38;N\T=G;?=&[.Y5B9BW'[*.9';;,,[.$H8PH^#JI=4BEXHJD![8 M E9N
MSRI#Y/&VBKOB'_D(H%.M 6^'761L&9JS\5!UY\@"7@J+T]LQ-H#K88)/19+;
MNVQT77)8N?!PC;-A<3*4_<:HF'UU?(8OW(6"*;9IEFEF%<UB;IB4U@:I,*'F
ME(J0"\Q#!82.*)LUZ?;:[U8"R\%D*'_[\6V/1]UBB#EUOB*!O@P*IA^./IW6
MU7'*$F7#-"1I$!C"L4-[)F1&$BEB S@?<95Y+7X=_U)A&_FHQ$S"?H'2"RO2
M@ 4IQW(P0L$X&(,51@''J*AS&0^-0CX2)!_9O8"5&YR8QK9R.8@4S/ZMQMZ@
M\9<$=!E>-D 2TJ;[UMNB#_OC\K_+QIM"#C5^>B<?&C4JAB4@')IE>=G%M,GN
MM%'?7<0R$)F*&<TR!DB4,9-2JC,1J#BT20Q2ZL0R#NB\I[$1RP<6R].OP7%F
M>18K'9(@P+8QBDML%Q 0@6:'-M*8V\3R6MCJ@3YR(G(VS(MA0U:KXC19N=5H
M[(!H5IQVHQM2G:8,8G,OT3E9G1F%;EPKB0YGRT5A9#;1H4DY2P/.K$DM&,DF
MHVEFHD1;?DO4[W:IU/Y!_W9YPX?5$%Z"5_RC!;*]LWU^S(P!AU5%1"8&(WG(
M]A$Q31*N4Y.)-$@"Y]/R)N7+/JU7I:43E[N)@9%1*ED(Z"PS;A782DP8W!V!
MM)E,Y"UAD(T8/* 8[ ;'L:;4AB(D(5BYA*=(CI )1HQE6B<VSE(9O7J=TF82
M+L=S:RD Q36G+2W"T+WY++\3*):)+6\2D'^P\&VCMU;+A[HZ%M0:EO"4T"C*
M"(\B2P0X0$2 !DM$%F:I%<AGN5R<.<=G>2<^T^]#B,WZ/]CZGYP?!W$<&A6E
M1-,X(IPFFDAK-$D%50*;IC!+<?V7$['J]6^"S5!B_4_^#9  [)'M17J^YG>
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M?NC5Y-J3-U[][L^+O^45]:,/]U;!ZPO7'/7=V%D/;NH/4)0:-A_(@<*NIZJ
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MA2'8+DQK,)6VDF5CZ5\(!7>3@E"*.!,B3(6V/$PTB()B6<*RE$8Q"^U&"IY
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M/Q368C&;;W79&,F+1I$!P,OI%2=0YP\R09!'W@"<,-C 1<_DI4\H<I9>?2T
M_,J\G)SA9.:R&.CF)"^TJF&KSD/!7.M5Y.Q5Z4=I;IVQI@L7( 6.O*BR5MP
M?!$=!AO<1&+\<:80KK&JI=-RI&BY!95U__WYM*KN=M4U1_53P'B0ZP=I@Y0<
M>;H?Y *;:>DP(P)UC>%O&4RAS4<N$WS^X'JVHG#)6+ZOJ>Q.*%^2J2P>W51^
MB\'UK/#%GS/5RL_.<J:MB:N\%^U_WKML[1P%7W9.(@1A_.R7G8/3H]._<K@?
M_[+S*?QRJL(E4#[]"F[VWGG[].#K_LY7 .$W,*YW7]OOVWFKOQ>VK[I?VYTO
M_?;5%R0%O&R?']-(12)B,>:9&$Q:LD3:."4LP_9$82@R2A<-OS!**;5,)5D0
M\RRTPF88L=%1)D7 =;IH.[_=__!A^\W^P79G[Y_=QO;[@]W=UFZ[\[!V],I]
M?NM(G[R-4(Y174RGJ9@+/5NMFA7;AIS*;>E#^%C[[*SJ? #//W*1+>?HYQJK
MNJTO?'!4M,[I[^<E@O]\R'9%-,!K+ QM. 5:#"L=4O$>E[[P&M34$":E#MKJ
MB39Z5QESAWT\M'HSAIMB,M#V3 DVK,QOAV_V#OY]V.D<_#X3'ZY86YQ*FE><
M74>$6"43:5]%[H>U,$V3D$=S>O1H+I0YFU&("]\Y\TP%,*'*P-]Z0I&([+U&
MYYVAN6B" G#PWS?&9RBI88XQ=.GK!Y3"@-STT'3[\&VC4YP!FHE -)_9 <H<
M($X/WLI''N6-8]J:/PPHZ_G&DVIG:J$1YCF04?D:"8+OMDS5CPV,/KR:#XW-
MV%^NC@<_["5L>@I[_?;:0E9F$!BWLF=P-Y -;:Q3YZHH4;0J[>XT/A:=N"/;
M8F"J78Q'NCCX(0:?AY.\M:')^QGL1_]Q'(0?E/O25@-NNWC5R7!O$'1WMPEI
M:CZ8 H-C89HYRYF,VO$B51M\(O7.PCNIB/E<&S.%%<:.6P'MQR$6S8_=Z+Z/
M-N&:-J!WL'&B53;.2G-F5;;8+]U=-'R)F7U/0*Y_L]&:/KK16BM.4(!9/G ;
MY?G9J^TZB-!_=_JEOT=;._#^^SW^Y?0C!A.B+^\/\E;GA!WU6Z$;Q=5)M&BO
M'GUN]X]./YW#_8*CTVZ_O8/!A-[7+^_W+O9W='YT=73UI7]TM;_3L^W.2>"2
M[%7*85:)L&&&!$H92:WD)(DU"VB:A%('B_9J'*B,IH9E& RV<9B%69RR--11
M!-\-Z:*]NKVSL]?9VV\?N@Z?![N=3P?MQOZ[QM\'^SN?WG8:!WOO_W.;];K2
M'+U]( N&=JI8I.)(PO]Q$68"+',F0FDHE90[*%R]/9+GG?WS3YXARKZXN'G%
M#3=+SB_FX]FX2:M<^*6\&S!RAO*;RXR;I+ T?GLU?=F7C/O,#5]O?-(K,K"G
M,6D/U&A>I7R@;5)-X4Q8U!<28WJ%S_I @[LZ]&["&X.QE6KD'P!M@*$Y&8.N
M*X9@LF ^H.])L:I30 9V 7:.F-S2NRPCQ[[4;+PK"E\GO3,<GRS9^J_>[6S#
M<[F8[3=GHYP:Y9J"-S##C>2#FMB\\C8:(\P\JGG5E1F.)!@=N&#%&.N"E;.\
M,4QF/5/Y;&BX6Y3N^)14D^@'AN>NN7M6,O-\TTN=#<RX7PS GJ]R75P!ES-H
MON8^8\#]@J?PRIW23F_NN>NUAB5RUE7#V9(X]/?@,!%O)<#3S=Q-CKK%B4&N
MK=G%*\J:U-[E!,)J:W>\JW,+)O"X-X+M0-S<N 'U,<BI8<8)W#EWZ8(O,4ER
MQA-V1T'>ES)Z1AK@ZE5DWV5 9;57J:;:$<U2_.I03_-.T0L3030I;ZF=74],
MOV@WXR=\Y'C!='7)F&#*SY!"S+ =N8+]>6_542DYTG\PJC&SJ?(PX:IW2E(R
M-E$T%8FA ;+V96!;P>,D(35@7RA'Z$Q%W61#+#796#KCJCCYRDZQ[?=&;668
M\CTR]K^(HXL?;G7L=]3%L:!9),!B(P%7$>&1I@06QI)$AW$6\2S@$;TFX7X^
MGZ0J=4(EX2@N[+*(8W;2TPJ*XV>\05HV@K)*4%J=[8OV]C&/I8A5%),TXPIK
M,Q(BJ(Z)T@EGH4X"%<2O7J]*T9^7%/@7TWT&TP@5@!1X]KW+29\FFF[-5X@N
M8JDORZM.ET Q%9>R-[J<=N.X6R'I=\I9.,<*ULE1MQWX$=6R-ELI^DR*09]
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MZ&O.ERH<X(47(B=5=]:-N*S,VMKY&K2O3LZ=^NE\/6]]/&9:<A4FC' 1PX\
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M79/*YC1X)NO>O>BH_R5A%D@F\4Q\YDN-MP5\Y<-(O\ 3Q'HB\G(F_.5Z)0Q
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M0&IK5Z/Y.N7N]SZHJ^H*_2?_]@]7$9J@9L!HD7]O8TBMHR':Y\>IH1F+L5R
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MWQN'F&B&*N]0]<RPP *R^I*'AZJ^)!8KE.X#SJ7 .VCCZFO]8\OQJ,C[_?'
ME5TZ;HWE['.;9_X&51'T1+RJK%]L#GP"2^N++]GOC<8VR/40I&CW0L*6R-RD
M'!A\$<7Z$FD(\$$F(][>/9B;A2KZXJJI,6Y3CKI]^0+K"&8J6$ <7>(TED:[
MC&K7N!>P;IH3?_=BD&OJ/B9)]EN'6PWBOCY3$W#NRP+0U!K*$^-K^<Q%7E:.
MI!W**63 5BO'9[[.;SQL3-G]JIIJL)^Z#5W G+DA]"Z7*Z)[EUL-S'R>J<L>
M&=GW?69+7]6X\"!@4<&Z@:!\@SE"A[@R_*8UG/"$J[J\-R=;=^[%H3D9.T2]
MQ([7@S%6,+N>7TU?G+#8!]M71)H7*''[LP7KLS+DICQ'0S6WCE"A K^:6V%@
M3HI1[J"NGL(Y>?1-J.L)4@69]@J7=7OITB_TBB6H5AQUI;\!^*]FA.4UN,=Q
M;5 K-2L9*;VLU<!=CD!=XCC/AN9,#JNW,7>^'&?]O"PGE?OE2%I;3LL+',T
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MC\NFSOM'IY:2::4@>79!0HU:%+4D +[)<(K1N1$XW)KAD >7(:H#$A;\$$L
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MGWTQN66I%6,@.40W)6L'HVK?B\L_5+EO1;N@U#QZ>*A5:@T<NM$!9R4$\3?
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MRRA^>?*1'Y/1J8&'72N/*>?'9-3UIK&M\9,_ZSJ_LIJ[ 28Q"'9LM"*1!.8
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M5HR%,9:<RN*QF(E#B8V=60CO@[]\5&LD)T>D=#5X:\ B$J7=##PA\QZEX9
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M)2/QBU>2< #LW+4NC'J<[0-KE8ZQF]F3(T/]R,^HH=>P%6>W>KB#.A83E'+
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M#J/+V^JC[>[7J[;(\ZK7#=_L5&X7.BSZ6#T=4KDM=5C;FXH\HDQ2?Q<5U=!
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MJ 6HEH95C&6!7WG+V#0$#_=@B;-[_IZ133SJU=.&/,*D)ZFB3?.=\H;/EKC
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MT] 0AO2SFD[/0/[8JUK\B%^:,YV'>'RV#_ELC9/ 3!')U,*<5$\8UE??28;
MO$I(=E1AHQ>9;8IP5\5XXW-^KQJ\/W6)^>3HV_YA_6F"S#-F"RU'S1BHF#/%
M1\: 9H%G8;,+I4T29"NX8_+TFC#OLEIM+]3AW,*K04YLQ(*>*XBZ?Q<-:7U?
M6 ;D7(2B>4BQ3;79-8#&Y,K="8>&$,Q#-,<3/@*#3"!&;)(O3]%=&V7)H[#"
M(Q3%#2CC.$2F"[B</$8FM97ZKVN4SY[S!@_#M 97M<E+1QSY7PS+"7<Z)LM]
M;?)7.[MZ\I:9R6 "K?GD?&Q51K ]Y@=IGF_#P5N9Y^'$.YB-WG12?B5%\.XC
MSC[@+XOYZJ";R")-SL4 =[F^ODY9J'LJ(.B+<"HXI]J<O]@6\8.T\LVIN*MH
M-W0#3C^O7R+!^/F[_P=02P,$%     @ SHBM5!,2X&(?+0  _=(! !4   !C
M<&EX+3(P,C(P,S,Q7V1E9BYX;6SM?5MS&\FQYKM_A59^W;+J?G%X?(+2S'BY
M1S-22/+,V2=$7;)$A$&T#AK42.?7;Q8N%"\@V4!W 21DATU3)-C]5>9759F5
M69E_^X\OYY-GGV'6CIOI#\_97^CS9S"-31I//_[P_)\??B;V^7_\_4]_^MO_
M(N2_7KY[_>S')EZ<PW3^[-4,_!S2LS_&\[-GOR=H__4LSYKS9[\WLW^-/WM"
M_K[XHU?-IZ^S\<>S^3-..;_YV]E?#<O4^<P)!,>(E(82*Q0E61GEDZ8B:/^_
M/_XUJ\C *D-\@D@DMX($7_Y &9>M95):NGCH9#S]UU_+E^!;>(:#F[:+?_[P
M_&P^__37%R_^^../OWP)L\E?FMG'%YQ2\6+]Z>>KCW^Y]?D_Q.+3S#GW8O';
MRX^VXTT?Q,>R%__UR^OW\0S./1E/V[F?QF\OP->G^>4?7D6C7BQ_B1]MQW]M
M%W__NHE^OE#/@T-X=N<GRK_(^F.D_(@P3@3[RY<V/?_[GYX]6TK.S^*LF< [
MR,]6W_[SW>EMI./I_$4:G[]8?>:%GTP0\>()\Z^?X(?G[?C\TP36/SN;0;X3
M_7K(!90J</Y<GO:B-Z8S!#*+%P$(_A2FA> #8MST]/Z8+Y]%$F1_,9D/B/CV
MLP?%VYS[\9 "OO7H = N'D3.X3S ;$BHUYY[!><:Y$V$Y9&XC.*G)WZ:/IWY
MV;G_2VS.7RQ@OFJF"8<.";]IF\DXE77V_1R_EH6WR3_]]\5X_O5A_/'3^ LI
MJRX5RWG^YXY/OC("I,IX.BZKSVO\Y^KQ!67%L<"7.>!?I>?/QNF'YV,.6?KL
M:;8T2D:%"PJW!4=M-E(&[48=WU$&M1[6I(G77CDI2VQSR8F)#S!9_'1TT9*/
MWG\:73X/Y0"G^&T[$E0Y2G4D246%6Y<6Q%LAB5 L(& 5(&U@5+MF:/9M6'!J
M]0KD%F<O8#)OUS\IRF.$LM4R_>>[L2Q5MOOH3J<1M_,6?H3E_Y].W\^;^*^S
M9I+0-%@*\%TSF?S<S/[PLS2BC"L/+N%V;"1NPI+AT#DEVH+A/%EE6:HR]"V!
M7I?+-S*?S-826JT-.RX>Q>(9E"?S9G^*69(#Q_?\63/#Q_WPG/;ET:OF_+Q9
M0GR/*P&T;R[FQ?8IYN0H^V@IEY'8K !M.(/8. 14-:3,# LQU"'-?:CVSY"J
M*FTJZ>,V5UA?KMP>-4IF<E&@O6UF"QW,Y[-QN)C[,($/S:\-^B73.8H:G_CQ
M=#H'',]\%)+@SC#$[E4B$F@DSJN,- "(&@4%W%1:A8? ?]S\.X".;S.5#\+4
MT[:]@/3CQ:Q@A]FX2<L9M?CZTB_,C_-/:(<L?+61IRXG[S-11N.BGT4B@7E-
MM,1E7^ (6-#U:+D=V.^ @Q6U=YMPHA+A?O.3"[@#L7).4&XE<1$8D=8I8D6F
M)!E!61*,*NKWR;=[L'Z7=!M*=[?9)@=AVSOX=#&+9P7;[5DRHCESE1(0[2G.
M!RL-L8ZB'4M#Y&@L,.$J;K+W8OL.V#2<;FZS1]5DSX+T(Z:TU]HX@IP.1"8T
M-FT4:';J&&B0)@>N]DZ>!;3OESO;:^8V=71?ZKR=-7D\?]VT[<A%XW1V.$0:
M?$&B2# !B/ ^!B<-C[;.6<HW#,=-AAUE?5OKINH9@0S2!B> 1!9IP99)2($3
MZW&05#&>J3OP&<'!/%V31% F!!(B+N]21X9BB0%'$D R!TE ?#*>;H\3V _E
M+2.:@D SW9"0A4$JXP+FC!%$,_0,=?3"02V#]RJ. 5>-*T&TZN>*/82YZ2CH
MV3(D\M<X:7"C^>'Y?'8!WWZ(7( O\Y\FBQ?^\+R%C^6;P?BPI&2QJ)LI_K,]
M^3)N1Z!LT$$JDI+$E<XP7.1B0GUZ,"@SYSQ4/IS?!&M MMP3WKR'/3NH^R[F
M]!9[A3/%&YA^7.S#G4"-;@1<!^7$1EA#VAMWA8WO84)_]36U9+\W8EACJ&!1
M$ZK*,8_CGGC &9%U.?<Q/M/(GSHAKL7E#\^';41>@0=7S+Q?%M;Y2&;%DT&C
M6H'4:%6A[6FI,83R)'*VLN0AU;8X?[F2.;!/!V0 %=T=<-I!OA4BDN]@CF."
M]).?3=$8;5>H7!#"1%1*= 55C"6?3&O"!0=KC4TITBI:WXSG&%0_@*0K3/C-
MOL@*FU*"T4P-NKZ RQO/G 3%%2D&M(O2BU3)H[H/U3%P83"IWQG-^]N+&^)!
MO^A??3.OWL%GF%Y ^V.A\J3=)<7JYB,&S*6Z%]W-I"G#-$H79UAF,F9OE60L
M 4H8-6<@CVX^K*=Y-9TC@WX?)SB=Y@91EU&N7O$S\NTG1#>;^LFKBW;>G,/L
MFQ-+:30J*4UPB4!7Q$1+7-#HF7BKN3>>)R?JF&"[0NZ_(RTE?Q+:^<S'^0BB
MRX()19!&&;TQ;G"B24; 4\.R$E[[.L&5FT@.L/+LA3>W=ZH>&AC01BFK1SF8
M31=Q_@V,-NB/LRR(21&71^"9.*4R$290H1630N2'5J&-3]Z_>OL)NAE*2A7,
MBBL<?54V.H3T^WA^MN;I3U]6YZ,G;0OXW_3!?QE1IL (38FTVB'D&$@(S!$>
MG/+9 620->?Y-F#WQY4!U+MY>E?338U<N'@&Z6(";_*V*V+[\NNE\*;I/<P^
MCR.TRV,^*1CZZ)(2)SF.#)UVXKF3A!L=K ]&25?'R:DRG'V=M!]F3SH\ PY]
MKM_.YNMUX,UL-8S%(92T.#LI.,)0P#A!.8K5,4V\80!&RQ!2[D)C?,$5"N._
M;M+W+@0'.[4_/">: 74SX+IY!<_5 :X\URZ@MCGOWX8XM^'L]YQ_&$W=5OM
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M:K-L+^W'<O-WXZ'5XLX9FNU&T$!R%*)</W+$:6J(HY11,,%']WT$R ?2=]>
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MC<2 XD1R64KT9IPG%.=)0J/ N#J;:V>(1T2J.FJYS1];B3^_^<D%7,.9#8L
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M87!II'=T9TO*/[LFW]NA6;][W5U3?GJN33G#_ ]3@$0[ZJ8PR1?]XI6;]SS
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M"7]>TJ@3OM'8XPG??+'[X4P>:?(UN5G*^<M<FJH8IG1Q3"FD$>8 Y16#((X
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MX+K0>K]I\"; 8I4>'L%7Y^[WJW?J5@EEV@K.(LFPH)K2<>)S@$0H >>! #R
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MF_:FK/ZOX^EZ^M119F>M,=5DK+_ ?5/P0^F ?:OB/SZP3,T@YC1*N )1)#E
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MU(AGJV)+BK$ V7*?OU?H!J89!]3<=_6M@>AW6_^RV''W]:UA.-G8M[^S;47
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M1Z*H>?C(%-%LXBDY7+B^9?Q%:M)BLM=O>JBSZZ4TKL^SV>/\HK(9Y1@I'S/
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M]$",=*(\U("X'39W ;/Q[+G5@\<[BNYB]\')=*<'=716_YJNUNN9KY2?(*R
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M7H13S^,Z%SY@G/D<7B]?XXJXE3RO\VL\K?9TU"5)]3R%RFS#H27Z2E* >)X
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M'<@4%$_&*U1M#I^?2.BX!S ]('00%?X3M)9Y$59GO\P6?[3I+'/]]-,VEGF
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MC$I6&-GFL.MQNL8]9#@""7?-PH#B_SX,Q>'%U+=^OX'1:%A"?0<PTLJ0DD[
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MWJ.E)\@<JN-'')<#!#ZVJ_++M*S/GI$\<I7)E@%!GIHM&4$&QXB!&.JP8;+
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MY%F)VF9/,@LA"R1,2D58H1A0MSD!&(3\XPNZ;NKK>IC(KE,S[E7U&!"8+77
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M90JIZY4"^LJUW%JZF*(IELPHDH@") /M,DL>DI)D3*%1V=T9@YV&)W\Y4O[
ML=Y6;1- YH![ )LWN'U;2+87V^UZ$7?;:MKO>]IN^O7^5)+^8?MKQX4I3N7(
MN$Z>:>D\B\IREFTH,NND<FASY?9J(DR8(NL2%(^CXO8W0(X?U&^1G)Z__N7_
M4$L#!!0    ( ,Z(K535-F^G&1H  &",   4    :F%M97-H97)M86XM,C R
M,BYH=&WM7>MSV[:6_[Y_!6ZRMTUF)-ERWDYN9AS;O4DW33-)NIE^ZD D)"&F
M"%V M*+^]7L>  A2DN,TK66YFTD<BR+Q.#C/WSD G_WCY.?C#[^^/173:E:(
MM[^\>/WJ6-SJ[^U]O'>\MW?RX42\_/#3:W%_L#\4'ZPLG:ZT*66QMW?ZYI:X
M-:VJ^>'>WF*Q&"SN#8R=['UXMX=-W=\KC'%JD%?YK>?/\ K\5#)__E_/_M'O
MBQ.3U3-55B*S2E8J%[73Y41\S)4[$_V^O^O8S)=63Z:5.-@_.! ?C3W3YY*_
MKW15J.>AG6=[_/G9'G7R;&3RY?-GN3X7.O_7+?U0W;]_H Y&ZO%#^.7A4,IA
MINZI)RI[^%#);/3;$ :Y![?S,ZY:%NI?MV:Z[$\5]G\XW-\?[#^>5T\7.J^F
M^/&?M^C>Y\_&IJR@0PL-\*^QG8W?K?14J<]57Q9Z4AYF,!ME;UW4[E4^Q=^%
M9S-3&'MX>Y_^/,5O^F,YT\7R\/L/>J:<>*,6XIV9R?+[G@-FZ3ME]9AO=/IW
M=3@\ !K2QP43]CZT4^A2)80&ROXD;385CWJT[I>9R:?:57J\O,14+DV<=I-7
M3@$[$#]*;/"ELM":N/Y#/GAP\$!\5*X2IV4NCLY56:N>>%_K2HDG#_:O_P3>
M2#<]UT4!H_[P1HA[CP[V[_WQ48]D=C:QIB[SOI_ &/Y QU<U';&99^8RST'?
M]@LUK@[O/83F5J?#EW29@Y(X[.--6UJ6=^J[VP\>/_WN]O#A_IJ?I[-Y899D
M3,RX+3/2B=//*JLK?:[$_^I,B;=6.8TSZHDWDBV9.,HR6*7*"0EL>SS5:@R&
M!QK5LH0G?AZ/X4$KCNO92-D"[WD[E=!\IJ#=3!9.O"JSP9^EI*Z=4)PH:<6/
M9EKV_H *VI$YGH['*B,F^5&6M;1+,633TQ/55#M1J KLI) 3JQ0QVIUJJL1W
MMQ\?'.P_/0I7Z?/PZ5VQ !TBU#GR&3 0W@I/SYB_,E/FY$(Y 9H!&EU,-9BZ
MI:GYL9$2BA@:?*+1\DM<UQH(,JTLEW$8KTKL#=G=$JNC>$ _,(_YW.BRHIG\
MF2("[>-P_#AZ=+.!*U9,C,GIX[DL:CDJ5'MD/7K.JDSI>47WN1K;U$# )3;+
M1(*5@,84D 54:VD6A<HG*N>'Y])6&CB"U@AG-39%81:.5,>-9=SA8)-6#&._
M^E&QW<A59GAQ#XG/\:Y;SY$U5.GH^F![0T3;^*'A5&8:)RH#;.D'J$@D_RY\
M=$?>W<1(Z^DTETLB$&@5*9PL4&>.I--(+RM@%.>@$9R8*PN?9ZC+I(.?>#O^
M!25;"(M41IVQ,&(*3&(5ZX@2AE<M^WBYFIK:X;4<5D%:)^[\]\&3@]X^1F/[
M=WLX#-(F&AJU$$G"'?"K^@\V/X-93XLE7'"5+ K4=@X'@-IB^)?PWJ/!X\O(
MQ]QP$'UH52%1[SZMS/RP?W^ :W6N+.EWSQ9(-A8=5VU57G))BAB"Y:F X:DR
M![> 2(R7T58.A/@!UI[N6,)2D%Z&-1F#\>NU#-Q<ZOS;.2=7:%5AI&0H$\.#
M+*!AK9T!SLBURZQ"<H,$/WDJYM:@80:K,34+=:YHF!*-#LQO!#1G4PDL/I-G
M.-0E,PX;:_(&WJ.O /<,06IX3IF",8IZC@_2F-KV5C4>*LX1NP*Z.%"!0KPQ
MU4)74V#1$CURF@?<I"9@H2<]48+]Q,NZ7-.W+* WX&F+EA$,.BP*$ .&3E]0
M4Q+6%4<((ZJM6C<B4'&Y AKI$3P+W80>[K$YAY:C@S.X(*+8>0TXVJ@!?TU]
M,QBJ1HU#.A!%5<^1&5$!P;)Z#@2:Y]&/4_!<J<;(D4!K\+V  QN>?6&DS9'4
M)QK\G\I8-V#;Q"YC7##J5Q>Z6I*.;/K&M0JCFT#+-A$(8G9'SJ;WS;IC$G/P
M+5T/1^9J$%SZ"*R_Q.8@E"*.&ELS$Q50&V=-_VM6HXUP=7R_[]VZB=U<YLDN
M9!Y/SL@[00D$?34R9>UPL296SGI>X9$V\5J0O&R@^4P!L4$;$$M 9*Y!E:$^
M-*-/'+^P@YXL! 8#PT=/8?V!,\ *IBU"3Z!=6 %$58K/?YE'.\L-+'L$\R .
MXLD$CFPX!/4\-AZ^<34-FE@J97?26G,(+3*R[!W:M&[EJ,!_%Z@\,[D>Z\"U
M:(BP"_K?<VW'+G3F$BEV!0P<8!C"N-$#>+ 6B=D65^=?5HD4LT'D* 6L 2,P
M%X2LX%V#RP#S,-D9.&^U=34^A!:++PHSY]@X";7?_WQT%QCL/3*7@P:5V\1#
M<&?D?V82I\CD I?[M=<E8MXXXBP)14CMM>)QN!?8%2RF7  7J!P&X"49=&6U
MEE\Z;-5K:)/G/FG"K1'O!MD'7Q5T>L]WNWYBVJ*)!H:@3$DD32/L%\S*73RM
MC:S9S7NL.JW=3$C$/4U5F=GA?O.(' %MZFKUD6](GO#/J6U$::+Z(W"KSOKD
M<1[*8B&7[M:?E]"Y>59+;93OT\^9FI-OV)*@X!L>]%K^-D@ENIBF0M8MM/3^
M$;K\P=2IS\B6Q*FUM6Q:\/NZ+)1S]&L0E[8;,;<:FEA878%[2ZB18HUAE9Z-
M0(.HV ^9']_1%?@:+7R<5/>V\BY;1%*>MC()!X^"_5H/_QPUFO"M#ZRV&=0.
MQ$EM0]"%!H/@13/F:)6Y&OVVDG++.7,=,RDX'3,0D,B$37!'1A&#.Q(#QBXX
M1PTM>.YTC1QXNY0Z>F =8AB,<44&I,SI&XP4V8WWXM3N?V[ :UJN^F9D.M?>
MRG.T:(30*.2(G&!H[4?,9L2+:H@@PA0X#.$@LA. XPRP3SECU#B2<@9=T"QP
M7BF=8/X:(>)Q"%RSPC@5^@S>6S1BS2@6L&*1FC<WPKBW8T!ODI0#=^DCN#7;
M%72,J5,H Q$3-%@MU 3S#JDIH_F 7VKR$-_#2$I,! 'W<\H(E(>Q'',L@R8)
MF(L#^:G=.LPERG$2/SG"M_RC,4Q7FO(G)'^V)6,8[@2P226Q/77 3AH8RZF>
M"X]N4>!./:-!U0BM5B*3-8J9Q2F#PO'80P.$T?"]V7?B?D\\Z(F'/:S,>-P3
MPWWX-R2Z#0](=P*9F(*N!@5VWB2_$DCLHJ$:NP9UNK%"+>[OF%0?FW),J4$M
M$8G:LD@? 9_%-"!QH2[)B'+XA4(L"[ Q.80\YU(7P2\E>UL#BV>])/LJ,S*"
M/3&5&+/QI[S'P@(]^2O!8&>&?,]+"#=?@+!UGH2JW>!QA/5OX G#B(P]$S,%
MXID[ZAT,'2'#5DUJ$!5C4?8Q'\U?<X*UT0KTC<>T8;B5KZ_K6&B)P7BSF+W&
M1$,W%!H&LP]W5A;-ME,8V>((IXKZ9*W1Q)19(9W38_;_"VBF*)9K'F_4[*@U
M/-^9JZS.*G@R'5]P8C8N=Z*XO<K,";6!=@Q#9?X3JG6'ZXJ1.OH8O,3DF("G
M!4L0X%T@DRE5&%D(9.:UA;@6V$1QB.39 3PT31!7PQ<7+;,/RC-MP=%"[-_[
M>@D[HC]6 Q=8$ HR3UY1AW&SAY60@)()X>L:89+@AJ647$.TX)>!/<"4/(_=
M^,!J=1R4%_'39IZTG.E?)0&)1EY38MY'>G@G^(2Z:,5\[2AOC@;#N<1>?!&!
MC .C"3=$N,'&X\&.&8\36!1$H;6/'5[-"&6^!E%@*PRD- =JS\#]:3E.N[P%
M,W\;1*O7U7JHR*T!/E<5RD@JA02Y0UO&ZZU(IA[<=HYM&TS1.#.N%C@@#WC#
M)?@--1;>Z2T&Z\6$LHTE@*&2L*'N4^>J,'.O^ZC?A79>#7B%A_-#_>>=1;[+
M^6PI.6TQZ[60RTUV;0YZB"KS+*&1E)L*.I!)DM<9C/(.K';!.8R"R>R+FDYX
MJ#274-FT8H(P!0?1*BINPH$B>)K% G+HJ?+H%64AV@V I:\S5F^@C&.69H;?
M)]_-K<S034[,94PHX.HJ6ZT)OQ$XYK*DRC3J&Y]/)^<AA0(8:UR3Y20+1TJ1
MF--<U.R94G-Z8B8AI)&X,"&8IZHS#(]A&7)&D"D-4^$BP*>@=2U*+8/3[,&#
M(DT'V M*GPDS1L(AY[DS5653_"VW<@%#96ZW:FXLNPN:X =NG0E'50!^OKA>
M,QQ"WIECVU/ #U;A]$)J<QVY*=B!!U",79=(Z)Y,2O9 ?"%9WERM3!O5Q&;(
M@!$#P7<( OE5 1\+ZYRKJ37UA (I?!)<M\*'BCX-WU[B]GBF?J@M)N#I(LP)
MW=55% /<^L 5$B_! GI!$'="VA;E.U=CRN"%2@4E?AF\'R1[*%[+A;N;3IYG
MOD)U&H!_")4,"9=+JOE21<9WD<; B)2<9Z\66A,+ 6>GSL+7XV Z>XU%QRHC
M:Y:R( _">V \AG9E8X(VK_#MG^X";#<U<OW3'U?N"3W<,4_H+06?=/D:A- !
M[$TEW!L=YPUT$Z#EC:?D(=O5"+A1^>0D@&Q23!O\J=QXU(QT18X^QKB#;1D;
ME%+C+(R[=U!!S7BL"RW9#GE+ 5[+!FO)E5#H+^ "N&D[XDGMCJ]E"+8W*"\V
M/.L24I>-4Y*1]&*SX]IZG=8D;S' Q+)LU8+O[G3\ED!3$+\&->QZJG=)I3?+
MC' _6"\5ULY#< W5$E\IA)#!&.@R*^I8J,8&)&R]2&[LTO_&1F&/=DSUO :&
MGEP'S?-KS+ A\CQNHU,^0P3NE4I40 X&36CT.P7*N+(-PW/4,U,YZ@*L^1U?
M+!)X0Y =$.$*W'J^AR >B'-,V9(*O)P54E- 4$0:@BLGL;QXC80W>!06O=0E
MZGO522-07-7M,>0B+MWA&NWTM5HI@#.D@ J?Z@37V!FD22$7-U> '^^8 -,.
MBDI? PFF:F_'LHC [1?PDN"^'P633=%+"%K0;"\X."&D-?$NT$&@!# GA[$;
MKK<&'AU=OKLTJ0]BV=L $(/=+2?@3$=L UV7"+-C^'^NJV6_'PPQS,$L2BPC
MIP*VJ2ER_( !#5TUO#>J1S)9%Y5$_R@%7?I]79Z;XAPUC634:";M62]@(P$Z
M0J"'@L88AYNY+B^H7^1M6LWFKI_#2+03PFE@"BZ-7-=IVJ=)86DDA\I7'+8[
M76K?I3F.$(F VQ/8?H2:"MHK*%P^PUEW&TL=GK7^9NIJ:N]WK%\GG"M<*#TB
MX<L-N!PI\ZIV!'(V4SU6?BA9Y['00JX$I:L3]2E3Q ,P<8$+$B$*!9XS#A^5
M,>T%;*P"EKA&,\2><$A(= /R! 0B: .^0H*68BPS<N<:.]4B120"A?S8A8?;
M<ZJ]*$B(DL:YS/M2]D+BGBA?B8S]-C*S=@2#=+?5EQC4$XD&W"W51;,4:I4C
MAD?AQ\JD.6'#[.!U!,HYBIIR#<N[R/,NE325 *>)K%SVL4148-0=!A^(GU%C
M4,*[J:T94QY$V8R*7A_\DR2H2$(?#%;"+A%?!XM.-Y?-CMEC"$6EG *[H^^"
M[\">/M;;E&$[IP.2XZ)#$^IS-I7@3-$L[FAX @A/K%8)Y)"*]&_8GG4'M/_=
M5-.YA*4I_T)6(*!6R8T!LHJNG1(S)4L*!<=,-*K  GV*^;FXX044J9Q8.9_Z
M[44760/B@0ZQDYU'E!Q<J]PCT] X>$L/%49X]@9N@Z])<T3\MLD04KL;K!#K
MBU0ODFI+<@."_;7U"3H:#X>TW9A*>&( ]3 2CCT@RHB[BEK;AB(5_7(5P-+L
M,/IXC=0C^L]J5=:M=K07:9/!)+WA$XV-"FTIZ1 U-C$OC<!'NN3HNG3? R)9
MV93% H1,(]*8UU@G/=..MB> H^N?YO4>DZK>1,AD3TW<MAT(%CB3*8-,N0)"
MDTQA%2!EI2MKBH(F$S[0NM-(?%Z7Z]S]UZOE/C?6FWZR<]YT.2XTUW$=XVJA
M1;T&D;%5(7%&N1II:7-%*RV)6@>\ ,]Q'5@='@9?,QIUM@T\/=)WV-Y$L7#Z
M:)-C4)!F;6<]5DIV;L+^_+@!'T09D7=7^:R>)C8G(@8^[VP9?*W/%&47EU<Z
ML<O,*^RZ,'61H[MV3@0AU42W:A!7;5MISDZM;F._R0M)"^?^+A#8<'_'A/X]
MUCY[X[-M_/VK0EIR)AK#%'T*.IM@\];<_\]7W0@YN^",AB:K3 5Y"-P1BV_V
MV2*HFF".R&IYDSBE4@I9L$,X;^WD:^HVHA9F]PBUY@2\^M\;W\QCF]& !'6M
M\A6_*)B9*00!(Z5*GRJ*8UVIK(3F:0#-OH"(B4H7B."#F5C<$W1U4I9, Y5D
M(A*LXZR$A:,\5>ZQ ZJT0-O$\4JG/]JRGU"_&7C:?13V_&)I]TIU!5Q8V=*X
M+9C!)6KT+X 85E&%M,._\5$$ZP4=J&AK_&5*1<S(SP[=M, E<-G'VB2M87_!
M*M%C$.WW' 0,I>U'M9Q#N"NP^@UV<W;MK*5WJJHMH</AD-1M1S:_?/4!*2EH
MG^;W+,]M3>52NYJ!4!#G$92U572T+8CQ"2PB&-5Q:Q"% :0F5XHY-U=]1J2[
MA[5V$D4#+_6G9N$KWT,5)Z4=-0%@W4KN=27VZ<0L5FH2N!A/?DM*Y3V><7,%
M\6#G!)&!M6N *R3GYK$/XZT#1;XHC@WPUH[C?:#;0Z@43QS)Y0Q,\PHF&<XO
M@,#9-#LIP&/,<.N*:A58QCQ !!X1<I:+II$RU+#VNL>:\#UX2"""^M8J!#BQ
M-W13&>RS"H]18@625ER6L604RZQ+B1+E93&!G9N)^V-%</>.'J/SB^DCE%6J
M">8"4'CL4UWR"9+@]6@U9DW25,0PBMRY*?'3T(E#%=2:)'E+;'TCC=@]#0?T
MI-N:=.47.903);-V4X(XJ$82'DDJAB,UL!Q78P(C+0)?(4<OY%41##G7ABN\
M.K>D<]BTBQI+W$EASTRI*6V2>*(N;$FFNQWN@$I+CR1$I;942^=92(P5ZF[R
M&&EAPH1:AQ_]/?84#G=MI_ +.C!ZC"&-/U[4PXFT;*]\J?4V=2?#*ZP_+7G2
M:>SJ-PG'X]M VI(3<+1C#X<2F3$-B=_$M)0_D0[CS[HH^KQ-%YUP1409=/8/
MJ'/#AU-:$BG>#S)6M%T*3Y@IFQT6_1C<8YOT#1);>6)7W]U^<O"4%7@\<" *
MGJ\-]$&I^HRX;=Q>PO%M<F931P%PH\G^?BQJ=!A(>K<O)5%R6A^?D OMJRK-
M^X)B.\58T*>T?+J.<E5-!2?1C.C/[Q0 @D9D&I-DGI-(@^6*(6,^(XK.Q/6'
MJV'5.>.[_CJ5.*J<-G B\DWW^7)T/(_+;W+S=2P3@^<<42%M<R87\4HS8ZK
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M]"NP_AP?)W/FJ+$UN:B VKAJ^E>S&FV%:P'[?>]6+>SN,D]R+?-X<C:\$Y1
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M=B-9N>EMD:C K!<8?"!^0HU!*?FV^F=,F1IE$ZHF/O@G25 6N3[HK(3C-[[
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M/NGAOUZN'+NS;L_3K7-[BG&FN23P%'<+H<\M"&%8%7*PE/:3EHX7=3+<:!X
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M>W^#]]YL)^QZ%$4D;Q? ND!L$OK2O0@A:4!95(J($GH.]CMQ&V[%OD)-8/V
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MW=!,_BP!@;9Q*'X,(YJK@2M63(S)Z>.%+%LY+E5_5"-ZSJI,Z5E#][D6V]1
MO 4VRP2"58#&%) $5&IMYJ7*)RKGAV?2-AJX@=8'9U28LC1S1RKCSC+MWO8Z
M;1C&?OVC8GN1J\SPXAX3C^-=]YXA:ZC:T?7MS0T1;>*'CE.9:9QH#+"E'Z B
M<?RK\-$#^7 =(ZVFTTPNB$"@4:1PLD1].99.([VL@%%<@$9P G0$?*Y0CTD'
M/_%V_ L*MA06J0S"7: ^F@*76,5*HM!%L]@J4!LU4],ZO);#,DCKQ(/_/C@\
M'.UB$+;[<(3C('6BH54+ 23< ;^J?V'[%4Q[6B[@@FMD6:+N<C@"5!=[7X7Y
MCK8?7T5 9H9CYV.K2HE*]TEC9L=;!]NX6!?*DG+W?(%T8]EQS48%)I>DB94$
M10S#4W4.+@&1&"^CH=P6X@=8?+IC 4M!BAG6I #+-^I9MYG4^9>S3J[0I,)(
MR4HFE@=90,-:.P.<D6N7687D!A'^_HF868-6&<S&U,S!JM$P)5H=F-\8:,YV
M$GB\DN<XU 4S#EMJ<@7>HZ, ]^R!V/"<,@5C%.T,'Z0Q]8VMZEQ3G"-V!71Q
MH .%>&V:N6ZFP*(UNN(T#[A)3< \3T:B!@.*EW6]HF]90F_ TQ9-(UAS6!0@
M!@R=OJ"F)*PKCA!&U%JU:D2@XW(%--)C>!:Z"3T\8GL.+4?O9ON24.+6J\#Q
M6A7X2^J8P5 U:AQ2@BBJ>H;,B H(EM5S(- \CTZ<@N=J52!' JW!\0(.['CV
MN9$V1U*_T.  -<:Z;39.["_&!:-^=:F;!>G(KF]<JS"Z";1L$X$@9G?DI'GG
M;#@F,0/'THUP9*X%P:6/P/H+;$Y6S%&%-95H@-HX:_I?LQKMA&O@_'WK5DWL
M[C)/=BGS>')&W@E*(.BKL:E;AXLUL;(:>85'VL1K08E!!-"\4D!LT ;$$A"2
M:U!EJ _-^#<.7CC 2!8"(X&]HR>P_L 98 73%J$GT"ZL *(JQ><_SZ.#Y0:6
M/8%Y$ ?Q9 )'=AR">AX;#]^XE@9-+)6R.VFMV:P$(XBT&M"F=RN'!?Z[0.7*
MY+K0@6O1$&$7]+_GVH%=&,PE4NP:&#C@+P1MHP=PN!*"V117YY]7B12T@:,F
M!:P!0R^7Q*O@7H/+ /,PV3DX;ZUU+3Z$%HLO"C/CF#*)L]^_.7D(#/8>F<M!
M@\JMXR&X,_(_,XE39'*!R_W:ZQJA;AQQEL0BI/9ZP3C<"^P*%E/.@0M4#@/P
MD@RZLEG)+P.V&G6TR7.?*^'6B'>#[(.O"CI]Y+M=/3%MT40#0U""))*F$_9+
M9N4NG]:?S='#+,FRKSO,FT2<U#2-J8YWNT?D&$C:-LN/?$&JA7].;2>!$[4U
M!F_L?(L<U6-9SN7"]8?V1>F?&VRUU%KY/ON4J1GYACT)"K[A_JCG;X-4HHMI
M&F3=4DOO'Z'+'TR=^H1L29S:6LNF!;]OZU(Y1[\&<>F[$3.KH8FYU0VXMP0;
M*=885NEJ#!I$Q7[(_/B.KL'7Z 'CI+HWE7#9()3RI)="V#\*]FLU_G/2:<*W
M/K#:9%"[+5ZT-@1=:# (7S0%1ZO,U>BWU912SIGKF$G!Z:A 0"(3=L$=&44,
M[D@,&+O@U#2TX+G3=7+@[5+JZ(%UB&$PQA49D#*G;S!29#?>BU.__YD!KVFQ
M[)N1Z5QY*\_1HA%"HY C<H*AM1\QFQ$OJB&""%/@,(2#R$$ CC/ /F5E6K13
MD905=$&SP'FE=(+Y:\2(BQ"X9J5Q*O09O+=HQ+I1S&'%(C7O;H3QZ)8AO4DV
M#MREC^#6;%;0,:9.H0Q$3-!@]5 33#RDIHSF WZIR4-\#R.I,0L$W,_Y(E >
MQG+,L0B:)& N#N2G=:LPERC'2?SD"-_RC\8P76E*H)#\V9Z,8;@3P":5Q/;4
M 7M;8"RG>B8\ND6!._6,!E4CM-J(3+8H9A:G# K'8P\=$$;#]V;?B8.1.!R)
M[T98D/%X)/9VX=\>T6UOGW0GD(DIZ%I08!==YBN!Q"X;JK$K4*<[*]3BX)9)
M]:FI"\H+:HE(U(9%^@3X+.8!B0MU34:4PR\48EF"C<DAY+F0N@Q^*=G;%E@\
M&R6I5YF1$1R)J<28C3_E(Q86Z,E?"08[,^1[7D&X^0*$K;,D5!T&CV,L>P-/
M&$9D[+FH%(AG[JAW,'2$#%LU:4%4C$79QV0T?\T9UDXKT#<>TX;A-KZL;F"A
M)0;CW6*..A,-W5!H&,P^W-E8--M.862+(YPJZI.U1A=39J5T3A?L_Y?03%DN
M5CS>J=EQ;WB^,]=8G37P9#J^X,2L7>Y$<7N5F1-J ^T8ALK\)U3K#M<5(W7T
M,7B)R3$!3PN6(,"[0"93JS"R$,C,6@L!*K")XA#)LP-X:)H@KHXO+EMF'Y1G
MVH*CA=B_]_42=D1_K 4NL" 49)Z\H@[C9@\K(0$E$\+7+<(DP0U+*;F":,$O
M WN .7D>N_&!U?(X*"_BI\T\:3G5OTP"$HV\I<R\C_3P3O )==F+^?I1W@P-
MAG.)O?@L AD'1A/NB'"'C<?A+3,>+V!1$(76/G9X61'*? .BP%X82&D.U)Z!
M^]-:G'Y]"V;^UHC6:*CU4)%; WRN&I215 H)<H>VC-=;D4PCN.T"VS:8HG&F
M:.8X( ]XPR7X#346WNDM!NO%A+*=)8"ADK"A[N-R'J_[J-^Y=EX->(6'\T/]
MYYU%OLOY;"DY;3'K-9>+=79M!GJ(2O(LH9&4FPHZD$F2MQF,\@&L=LDYC)+)
M["N:DLHC%\J:EDP0IN @6D7%33A0!$^S6#<./34>O:(L1+\!L/1MQNH-E'',
MTE3X??+=S,H,W>3$7,:$ JZNLLV*\!N!8ZY+:DRGOO'Y='(>4BB!L8J6+"=9
M.%**Q)SFLF;/E9K1$Y6$D$;BPH1@GDK.,#R&9<@90:8T3(.+ )^"UK4HM0Q.
MLP</BC0=X"@H?29,@81#SG/GJLFF^%MNY1R&RMQNU<Q8=A<TP0_<.A..J@#\
M?'&]*AQ"/IACWU/ #U;A]$)J<Q6Y*=B!!U",W9!(Z)Y,:O9 ?"59WEUM3!_5
MQ&;(@!$#P7<( OE5 1\+"YR;J37MA (I?!)<M]*'BCX-WU_B_GBF?J@])N#I
M(LP)W;5-% /<\< 5$C^"!?2"(!Z$M"W*=ZX*RN"%2@4E?MY^OYULG7@EY^YA
M.GF>^1+5:0#^(50R)%PN*>=+%1G?11H#(U)RGKU:Z$TL!)R#.@M?CX/I[!46
M'<N,K%G(DCP([X'Q&/IEC0G:O,2W=RS'\9\\QI(G]-TM\X3>4O!)EV] "!W
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MO,NZ(0YNI,=89R&H""F4CXIS%P#AE(E&/H5U<KJ#+>N_K=;IT9=B_?O=SOD
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M.1OM].23<,TD0=N L+4-82L3PE9S-PA7K:= ^#NY9RO@]K2-=8-7AW7KI&V
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MWC61$\)/^_C93U+-JNA/4*N/8;_]'U!+ 0(4 Q0    ( ,Z(K51>&&7'@0@
M .LP   6              "  0    !A,C R,G$Q+65X:&EB:70S,3$N:'1M
M4$L! A0#%     @ SHBM5+?TO!-Y"   Y3   !8              ( !M0@
M &$R,#(R<3$M97AH:6)I=#,Q,BYH=&U02P$"% ,4    " #.B*U4***]@#D%
M  ##&@  %@              @ %B$0  83(P,C)Q,2UE>&AI8FET,S(Q+FAT
M;5!+ 0(4 Q0    ( ,Z(K50K +!39AH  '"/   1              "  <\6
M  !A:FMA>FEM:2TR,#(R+FAT;5!+ 0(4 Q0    ( ,Z(K517 TX&>C,! "9X
M#  1              "  60Q  !C<&EX+3(P,C(P,S,Q+FAT;5!+ 0(4 Q0
M   ( ,Z(K51ZWR3JE L  !AR   1              "  0UE 0!C<&EX+3(P
M,C(P,S,Q+GAS9%!+ 0(4 Q0    ( ,Z(K52H*K62SA4  /++   5
M      "  =!P 0!C<&EX+3(P,C(P,S,Q7V-A;"YX;6Q02P$"% ,4    " #.
MB*U4$Q+@8A\M  #]T@$ %0              @ '1A@$ 8W!I>"TR,#(R,#,S
M,5]D968N>&UL4$L! A0#%     @ SHBM5" H*]**C@  $]L% !4
M     ( !([0! &-P:7@M,C R,C S,S%?;&%B+GAM;%!+ 0(4 Q0    ( ,Z(
MK52Z1:7^R58  &[' P 5              "  >!" @!C<&EX+3(P,C(P,S,Q
M7W!R92YX;6Q02P$"% ,4    " #.B*U4U39OIQD:  !@C   %
M    @ '<F0( :F%M97-H97)M86XM,C R,BYH=&U02P$"% ,4    " #.B*U4
M=7,!1'$:  "GCP  $0              @ $GM ( :F]H;FAA;6TM,C R,BYH
M=&U02P$"% ,4    " #.B*U4EHFA+1@:  #2C   $@              @ ''
MS@( ;&5O<&%V;&EV+3(P,C(N:'1M4$L! A0#%     @ SHBM5(<*VRJR#@
M9UL  !X              ( !#^D" '!I;FYA8VQE8F%N:RUC<&EA;65N9#=T
=;VQO+FAT;5!+!08     #@ . *(#  #]]P(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
